79th EAS CONGRESS

Transcription

79th EAS CONGRESS

FINAL PROGRAMME
CONGRESS ORGANISERS
The 79th EAS Annual Congress
1-3, rue du Chantepoulet; P.O. Box 1726
CH-1211 Geneva 1, Switzerland
Tel: +41 22 908 0488; Fax: +41 22 906 9140
E-Mail: eas2011@kenes.com
Website: www.kenes.com/eas
eas2011_final.indd 3
6/10/11 9:49 AM
June 26-29, 2011
CONTENTS
Welcoming Words
V
Committees
VI
Faculty List
VII
About EAS
IX
Acknowledgements
XI
About Gothenburg
XIV
The Anitschkow Award
XVI
XVII
Young Investigator Awards
General Information
XIX
Instruction for Oral Presenters
XXII
Instruction for Poster Presenters
XXIII
Overview of Moderated Poster Sessions
XXIV
Company Sponsored Educational Symposia &
EBAC Accredited Educational Programme and Special Sessions
XXVII
XXIX
Opening Ceremony
XXX
Social Programme
Hall Name Eulogy of Distinguished Scientists
XXXI
List of Official Congress Hotels
XXXIII
Caring for the Environment
XXXIV
Venue Floor Plans
XXXV
Exhibition Floor Plan & Exhibitor List
XXXVI
Exhibitor & Sponsor Profiles
XXXVII
Scientific Programme
1
Sunday, 26 June, 2011
Monday, 27 June, 2011
7
Tuesday, 28 June, 2011
19
Wednesday, 29 June, 2011
31
Poster Presentations and Moderated Poster Sessions
37
149
Index
IV
6/10/11 9:49 AM
FINAL PROGRAMME
WELCOMING WORDS
Dear Colleagues,
Welcome to the 79th EAS Congress in Gothenburg, Sweden!
The Congress is hosted by the Scandinavian Society for Atherosclerosis Research. All the
Scandinavian countries are represented in the organising committee, and have worked
together with the EAS Scientific Programme Committee to prepare a programme that
includes the latest developments in the field of atherosclerosis, and timely reviews
presented by outstanding plenary speakers.
Although there have been considerable advances in our understanding of this disease
in recent years, atherosclerosis remains the major cause of death in the industrialised
world. The EAS has been, and continues to be, a major contributor to developments
in the field. For EAS 2011 we have created a programme of interest both to junior and
established basic scientists and to clinical researchers and practitioners. Our goal is
to promote interaction between these different groups, to ensure that frontline basic
research is translated into disease prevention and treatment. There is also a special
focus on new treatment guidelines, and a major effort to present accessible, interesting
and interactive poster sessions.
You will find that the Gothenburg Convention Centre, located in the city centre within
walking distance of the major hotels, offers convenient facilities, allowing you to select
your favourite topics among the parallel sessions and visit the exhibitions.
Gothenburg is Sweden’s second largest city and is at its most beautiful in June. It is
located at the mouth of the Göta river on the west coast of southern Sweden and has
many attractions, including the picturesque archipelago, the largest amusement park in
Scandinavia, and numerous parklands and nature areas.
On behalf of the organising committee, we welcome you to the Gothenburg 79th EAS
Congress, 2011 - a stimulating meeting offering enjoyable and rewarding interactions
between basic and clinical researchers in the field of atherosclerosis.
Olov Wiklund
Congress Chairperson
Jan Borén
Congress
Co-Chairperson
Petri Kovanen
Chairman of the Scientific
Programme Committee
M. John Chapman
EAS President
V
6/10/11 9:49 AM
June 26-29, 2011
COMMITTEES
CONGRESS CHAIRPERSON
LOCAL ORGANISING COMMITTEE
Olov Wiklund, Sweden
Olov Wiklund, Sweden, Chair
Bo Angelin, Stockholm, Sweden
Jan Borén, Gothenburg, Sweden
Ruth Frikke-Schmidt, Denmark
Bente Halvorsen, Oslo, Norway
Anders Hamsten, Stockholm, Sweden
Eva Hurt-Camejo, Gothenburg, Sweden
Petri Kovanen, Helsinki, Finland
Lars-Bo Nielsen, Copenhagen, Denmark
Terje R. Pedersen, Oslo, Norway
Karl Swedberg, Gothenburg, Sweden
Marja-Riitta Taskinen, Helsinki, Finland
CONGRESS CO-CHAIRPERSON
Jan Borén, Sweden
EAS EXECUTIVE COMMITTEE
M. John Chapman, President
Lale Tokgözoglu, Vice President
Jan Borén, Treasurer
Petri Kovanen, Secretary, Scientific Committee Chair
Alberico L. Catapano
Olivier Descamps
Luís Masana
Rudolf Zechner
SCIENTIFIC COMMITTEE
POSTER AWARD COMMITTEE
Petri Kovanen, Finland, Chair
Ulrike Beisiegel, Germany
John Betteridge, UK
Jan Borén, Sweden
Alberico Catapano, Italy
M. John Chapman, France
Fernando Civeira, Spain
Göran Hansson, Sweden
Andrew Newby, UK
Gerard Pasterkamp, The Netherlands
Arnold von Eckardstein, Switzerland
Rudolf Zechner, Austria
Ruth Frikke-Schmidt, Denmark, Chair
Martin Adiels, Sweden
Marianne Benn, Denmark
Francisco Blanco-Vaca, Spain
Phillipe Costet, France
Ewa Ehrenborg, Sweden
Jörg Heeren, Germany
Dimitris Kardassis, Greece
Florian Kronenberg, Austria
Monique Mulder, The Netherlands
Guiseppe Norata, Italy
APPRECIATION AND THANKS
We would like to thank the reviewers of the submitted abstracts and The
Young Investigator Award Jury for their valuable help and assistance.
VI
6/10/11 9:49 AM
FINAL PROGRAMME
FACULTY LIST
M. Adiels, Sweden
F. Andreotti, Italy
B. Angelin, Sweden
M. Bäck, Sweden
F. Bäckhed, Sweden
P. Barter, Australia
U. Beisiegel, Germany
M. Benn, Denmark
C. Betsholtz, Sweden
J. Betteridge, UK
E.A. Biessen, The Netherlands
F. Blanco-Vaca, Spain
S. Blankenberg, Germany
G. Bondjers, Sweden
J. Borén, Sweden
I. Bosaeus, Sweden
B. Brewer, USA
W.V. Brown, USA
G. Camejo, Sweden
A. Catapano, Italy
M.J. Chapman, France
Y. Chatzizisis, Greece
R. Choudhury, UK
F. Civeira, Spain
P. Costet, France
M. Daemen, The Netherlands
G.M. Dallinga-Thie, The Netherlands
N. Danchin, France
G. De Backer, Belgium
U. de Faire, Sweden
P. de Groot, The Netherlands
J. Defesche, The Netherlands
E. Dennis, USA
O. Descamps, Belgium
M. Diamant, The Netherlands
E. Ehrenborg, Sweden
M. Eriksson, Sweden
B. Fagerberg, Sweden
E. Falk, Denmark
Z.A. Fayad, USA
R. Frikke-Schmidt, Denmark
C. Glass, USA
J.F.C. Glatz, The Netherlands
L. Grip, Sweden
H. Gylling, Finland
J. Haeggström, Sweden
B. Halvorsen, Norway
A. Hamsten, Sweden
G.K. Hansson, Sweden
L. M. Havekes, The Netherlands
J. Heeren, Germany
J. W. Heinecke, USA
M.L. Hellenius, Sweden
H. Hobbs, USA
M. Hofker, The Netherlands
S. Humphries, UK
E. Hurt-Camejo, Sweden
E. Ikonen, Finland
M. Jauhiainen, Finland
C. Jern, Sweden
L. Johansson, Sweden
D. Kardassis, Greece
M. Kaste, Finland
S. Kathiresan, USA
A. Kontush, France
P. Kovanen, Finland
F. Kronenberg, Austria
E. Larose, Canada
I. Larsson, Sweden
N. Leitinger, USA
M. Levin, Sweden
P. Libby, USA
T. LÜscher, Switzerland
R. Marchioli, Italy
L. Masana, Spain
L. Mattsson Hultén, Sweden
J. Mercer, UK
M. Mulder, The Netherlands
A. Newby, UK
L.B. Nielsen, Denmark
J. Nilsson, Sweden
G. Norata, Italy
B. Nordestgaard, Denmark
V. Olkkonen, Finland
S.O. Olofsson, Sweden
A. Olsson, Sweden
K. Öörni, Finland
G. Pasterkamp, The Netherlands
P. Pedersen, Norway
J. Perk, Sweden
S. Potteaux, France
G. Randolph, USA
Z. Reiner, Croatia
G. Riccardi, Italy
S. Romeo, Sweden
E. Ros, Spain
A. Rosengren, Sweden
J. Rudd, UK
B. Staels, France
P. Stenvinkel, Sweden
A. Steptoe, UK
E. Stroes, The Netherlands
K. Swedberg, Sweden
I. Tabas, USA
M.R. Taskinen, Finland
T. Tholstrup, Denmark
S.L. Tokgözoglu, Turkey
S. Tsimikas, USA
A. Tybjærg-Hansen, Denmark
T. van Berkel, Norway
A. von Eckardstein, Switzerland
L. Wallentin, Sweden
C. Weber, Germany
P. Wester, Sweden
O. Wiklund, Sweden
J. Wikstrand, Sweden
K.J. Williams, USA
S. Young, USA
R. Zechner, Austria
VII
6/10/11 9:49 AM
June 26-29, 2011
EUROPEAN
ATHEROSCLEROSIS
SOCIETY
Join the EAS and become a member of
the society that connects European
scientists and clinicians interested in
atherosclerosis research.
...advancing and exchanging
knowledge concerning the
causes, natural history,
treatment and prevention of
atherosclerotic disease
EAS membership has many benefits,
including member-rate registration fee at
EAS Congresses and educational
activities, eligibility for EAS grants and
awards, and on-line access to our journal,
Atherosclerosis.
You can find out more about the Society’s
activities, and apply for membership, via
our website:
www.eas-society.org
For more information contact Carmel
Hayes or Josefine Harbrecht at the
EAS Office (address below):
European Atherosclerosis Society
Kronhusgatan 11
SE-411 05, Gothenburg
SWEDEN
Tel: +46(0)31 724 27 95
Fax: +46(0)31 724 27 01
Email: office@eas-society.org
Web: www.eas-society.org
VIII
6/10/11 9:49 AM
FINAL PROGRAMME
ABOUT EAS
EUROPEAN ATHEROSCLEROSIS SOCIETY
The European Atherosclerosis Society was founded in 1964. Its goal is to promote understanding
of atherosclerosis: advancing knowledge of its causes, natural history, treatment and prevention.
An elected Executive Committee plans and runs a programme of activities – which include
a large annual congress, smaller scientific workshops, advanced courses, and supported
fellowships – all opportunities for professional interaction and education.
Membership
Membership is open to physicians and scientists who carry out research in both basic and
clinical science, in Europe and in neighbouring countries. Corresponding members, active
in atherosclerosis research, are accepted from around the world
Supporting Young Scientists
A major goal of the society is to support young scientists - their participation in EAS activities
will bring new ideas for the future. EAS activities provide them with opportunities to meet and
discuss with more-senior colleagues, and to present their own work. In selected cases, EAS
offers financial support, in the form of awards and grants for travel.
Advanced Courses
To fulfill its aims to promote education and training in the prevention and care of
atherosclerosis EAS has launched a series of Advanced Courses in Atherosclerosis. These
courses will each highlight a different aspect of basic science and research or clinical
prevention, diagnosis and treatment in the field of atherosclerotic vascular disease and
its complications. The courses are run by recognised experts and distinguished specialists
in the relevant research or clinical area, and are held in established centres of excellence
throughout Europe.
Consensus Position Paper Initiative
The EAS Consensus Panel, comprised of 18 internationally renowned experts in
atherosclerosis and cardiovascular disease, was convened in 2009 to consider the
evidence for non-LDL lipids as risk factors for cardiovascular disease. The resulting articles,
“Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high
risk of cardiovascular disease: evidence and guidance for management” and “Lipoprotein(a)
as a cardiovascular risk factor: current status” are available as open access publications by
European Heart Journal.
IX
6/10/11 9:49 AM
June 26-29, 2011
ABOUT EAS (cont.)
Collaborations
The EAS collaborates with other European and international scientific societies on joint
educational symposia, guidelines task forces and other projects of mutual interest within
the field of cardiovascular research.
Guidelines
EAS has pioneered guidelines on the prevention of cardiovascular disease with panEuropean campaigns in 1987 and 1988. EAS joined forces with the European Society of
Cardiology (ESC) and the European Society of Hypertension (ESH) to issue the first set of
joint European Guidelines on Prevention of Coronary Artery Disease in 1994. The current
revision of these Guidelines is available via the EAS website, www.eas-society.org.
Specific Guidelines are also being developed between EAS and ESC on Management of
Dyslipidemias. Publication is scheduled for June 2011, during EAS 2011, where they will
be presented during a plenary session, and covered in detail at a post-Congress satellite
meeting. These Guidelines will also be available at www.eas-society.org.
Journal
The society’s Journal ‘Atherosclerosis’ is a well-respected, monthly peer-reviewed journal,
available online at : www.atherosclerosis-journal.com.
Support
EAS activities are supported by the membership fees of individual members. EAS actively
includes companies in the society as corporate partners, who work with EAS to support
research and educational programmes.
For further information about EAS, visit our website: www.eas-society.org or contact the
administrative executive, Dr Carmel Hayes, at the Society’s Administrative Office at the
address below:
Kronhusgatan 11,
SE-411 05, Gothenburg,
Sweden
Tel: +46(0)31 724 27 95
Fax: +46(0)31 724 27 01
Email: office@eas-society.org
X
6/10/11 9:49 AM
FINAL PROGRAMME
ACKNOWLEDGEMENTS
CORPORATE PARTNERS
The EAS Executive Committee would like to express its sincere appreciation
to the following Corporate Partners for their continued support of the
missions and activities of the European Atherosclerosis Society.
The 79th EAS Congress would like to thank Volvo for providing a VIP
Limousine car service.
XI
6/10/11 9:49 AM
June 26-29, 2011
ACKNOWLEDGEMENTS
The EAS Committee would like to express their sincere appreciation
to the following organisations for their support in the 79th EAS
Annual Congress.
PLATINUM SPONSOR
GOLD SPONSORS
SILVER SPONSORS
SUPPORTERS
XII
6/10/11 9:49 AM
FINAL PROGRAMME
EXHIBITORS
XIII
6/10/11 9:49 AM
June 26-29, 2011
ABOUT GOTHENBURG
Gothenburg is located on the beautiful west coast of Sweden, easily accessible from around
the world. Being the second largest city in Sweden, Gothenburg blends a distinct feeling
of charm with the pulse of modern urban life. Meeting venues, hotels, restaurants, shops
and entertainment are all located within easy walking distance. The city’s spectacular
surroundings, closeness to forests and the sea, with its stunning archipelago, guarantee a
whole new meeting experience, far from that of traditional big-city meetings.
Easily accessible from around the world, Gothenburg is an excellent venue for major
events and meetings. Two international airports are located here and the city is a major
Swedish railway network hub. Gothenburg has a reputation for being clean, safe and
green with a relaxed and friendly atmosphere.
The Gothenburg archipelago is an extraordinary experience. Thousands of islands
lie scattered along the west coast all the way up to Oslo, Norway. You can find many
untouched spots, and explore charming fishing villages. With a public transport ticket
you can take the tram to the ferries, in 20 minutes, for a trip to the southern archipelago.
Gothenburg is a city full of contrasts, where trendy glass and stainless steel bars stand
beside beautiful 19th century buildings with splendid entrances, old wooden County
Governor houses and beautiful parks. A number of city tours are available, for instance a
dramatised city sightseeing walk with historically dressed guides.
XIV
6/10/11 9:49 AM
FINAL PROGRAMME
There are many attractions to choose from - Liseberg Amusement Park, the Göteborg Opera
House, Gothenburg Symphony Orchestra - Sweden’s national orchestra, the Art Museum’s
fascinating collections, Universeum Science Centre, the Museum of World Culture and a
wide repertoire of entertaining shows, sports, cultural events, fairs and exhibitions.
Gothenburg is a must for the gourmet as it is home to the highest number of first-class
restaurants per capita in the whole of Scandinavia - some with stars in the Guide Michelin.
The main culinary attraction in Gothenburg is the local seafood; prawns, lobster and
a wideselection of fish, ranked amongst the finest in the world. The city also offers
a considerable number of great restaurants offering cuisine from all over the world, at
reasonable prices.
In the heart of the city everything from fashionable boutiques and department stores, to
picturesque markets selling crafts, souvenirs and antiquities are located within easy walking
distance.
Gothenburg offers an exiting mixture of modern warehouses and specialist shops,
pedestrian areas, galleries and arcades - all guaranteed to make shopping a memorable
experience. Gothenburg has a long and successful tradition of trade and industry, and
some of Scandinavia’s best-known corporations such as Volvo, SKF, ESAB and Hasselblad
have their origins and head offices here. A significant proportion of Sweden’s exports and
imports pass through Gothenburg’s port, the largest in Scandinavia.
XV
6/10/11 9:49 AM
June 26-29, 2011
THE ANITSCHKOW AWARD
THE ANITSCHKOW AWARD IN ATHEROSCLEROSIS
RESEARCH, 2011
Professor Philip Barter
DIRECTOR OF THE HEART RESEARCH INSTITUTE IN SYDNEY, AUSTRALIA
The EAS is delighted to announce that the recipient of the Society’s
prestigious Anitschkow Award 2011 is Professor Philip Barter,
Director of The Heart Research Institute in Sydney, Australia.
Presentation of the Award and the Anitschkow Medal will take place
at the Opening Ceremony of the 79th EAS Congress, Gothenburg,
Sweden, June 26-29, 2011, where Professor Barter will present the
Anitschkow Lecture.
Professor Philip Barter
Professor Barter is a dedicated and outstanding scientist who has
made, and who continues to make, unique contributions to the
advancement of atherosclerosis research by active clinical and basic research, teaching
and national and international relations. He has a longstanding research interest in the
diagnosis, pathogenesis and therapy of risk factors of atherosclerosis. By combining basic
and clinical research he is an excellent example of a from-bench-to-bedside researcher.
Since the 1970s he and his coworkers have repeatedly made pivotal and pioneering
contributions to better understand the metabolism and function of plasma lipoproteins,
notably HDL. His more than 250 original publications and more than 50 review papers
have been cited about 15,000 times, and placing him in the top 1% of most frequently cited
scientists in the field of clinical sciences.
XVI
6/10/11 9:49 AM
FINAL PROGRAMME
YOUNG INVESTIGATOR AWARDS
Dr. Yiannis S. Chatzizisis, MD, PhD from the Cardiovascular
Division, Brigham and Women’s Hospital, Harvard Medical School,
Boston, USA
Publication:
Dr. Yiannis S. Chatzizisis
Chatzizisis YS, Baker AB, Sukhova GK, Koskinas KC, Papafaklis
MI, Beigel R, Jonas M, Coskun AU, Stone BV, Maynard C, Shi
GP, Libby P, Feldman CL, Edelman ER, Stone PH. Augmented
expression and activity of extracellular matrix-degrading enzymes
in regions of low endothelial shear stress colocalize with
coronary atheromata with thin fibrous caps in pigs. Circulation
2011;123:621-30
Award statement:
This study explored the local hemodynamic and molecular mechanisms that determine
the localized formation of thin-capped fibroatheromas in the coronary arteries of
diabetic, hyperlipidemic swine. The study demonstrated that: (1) arterial areas with
low preceding endothelial shear stress have reduced endothelial cell coverage and
enhanced lipid accumulation and inflammation, (2) they exhibit increased expression
of messenger RNAs encoding matrix metalloproteinase-2, -9, and -12 and cathepsins
K and S relative to their endogenous inhibitors and increased elastolytic activity and
(3) the expression of these enzymes correlates positively with the severity of internal
elastic lamina fragmentation. These results provide new insight into the hemodynamic
and molecular mechanisms of regional formation of plaques with thin fibrous cap and
indicate that the in-vivo understanding of local endothelial shear stress may allow
identification of a high-risk plaque in its early stages of development. Early identification
of a high-risk plaque may provide a rationale for selective local coronary interventions,
supplemented by an intensive systemic pharmacological approach, to avert future
acute coronary events.
XVII
6/10/11 9:49 AM
June 26-29, 2011
YOUNG INVESTIGATOR AWARDS (cont.)
Dr. John Mercer at the Division of Cardiovascular Medicine,
University of Cambridge, Cambridge, UK
Publication:
Dr. John Mercer
Mercer, J, Cheng, KK, Figg, N, Gorenne, I,
Mahmoudi, M, Griffin, J, Vidal-Puig, A, Logan, A, Murphy, MP,
Bennett, MR. DNA damage links mitochondrial dysfunction to
atherosclerosis and the metabolic syndrome (2010).
Circ Res ;107;1021-1031
Award Statement:
Many studies have found that DNA damage is increased in atherosclerosis, but
its role is unclear. Dr Mercer’s studies show that DNA damage directly promotes
atherosclerosis and multiple features of the metabolic syndrome. He also identifies
that damage to mitochondrial DNA and dysfunction may underlie both pathologies,
by damage to the vessel wall cells and systemic metabolic disturbance. The study
opens the way for agents that reduce mitochondrial reactive oxygen species and
protect against mitochondrial damage and dysfunction as potential therapeutic
agents in both diseases.
XVIII
6/10/11 9:49 AM
FINAL PROGRAMME
GENERAL INFORMATION
VENUE
The Swedish Exhibition Centre / Svenska Mässan
Mässans Gata/Korsvägen, Sweden
Postal address: SE-412 94. Gothenburg
Tel: +46 31-708 80 00 Fax: +46 31-16 03 30
E-mail: infomaster@svenskamassan.se
Website: www.svenskamassan.se DIALING CODES & IMPORTANT TELEPHONE NUMBERS
The International dialing code for Sweden is +46
The Gothenburg area code is 31
Emergency numbers:
Police - 112; Fire Brigade - 112; Ambulance - 112
REGISTRATION / INFORMATION / SECRETARIAT DESK
The Registration Desk will be situated at Entrance 5, Congress Centre Sweden,
for the duration of the congress and will be open as follows:
OPENING HOURS
Sunday, June 26, 2011
Monday, June 27, 2011
Tuesday, June 28, 2011
Wednesday, June 29, 2011
09:00 – 18:00
08:00 – 18:30
08:00 – 18:30
08:00 – 19:00
BADGES
On registering you will receive your congress kit and name badge.
You are kindly requested to wear your badge during all congress
sessions and events.
EXHIBITION HOURS
15:00 – 20:30
10:00 – 18:00
10:00 – 18:00
08:30 – 12:30
FOOD & BEVERAGE
We wish to thank
for sponsoring the coffee breaks on Monday 27th June
and Tuesday 28th June, and
for sponsoring the Welcome Reception.
XIX
6/10/11 9:49 AM
June 26-29, 2011
CYBER CENTRE
There will be a Cyber Centre equipped with workstations where attendees may check e-mails.
ABSTRACT MEMORY STICK
The congress abstracts will be published on a USB Memory Stick. You are welcome to visit
the EAS booth and collect it. If you would like to print any of the abstracts while at the
congress, please look for the printing stations in the exhibition area.
CERTIFICATE OF ATTENDANCE
The Certificate of Attendance may be printed from the self-service stations in the registration
area from Tuesday, 28th June, 2011
CME ACCREDITATION
An application for the CME accreditation has been made to the European Board for
Accreditation in Cardiology (EBAC). The EBAC works in cooperation with the European
Accreditation Council for Continuing Medical Education (EACCME) which is an
institution of the European Union of Medical Specialists (UEMS) www.uems. net.
Delegates are kindly requested to scan their name badge when they enter & leave the
congress area. EBAC Desk will be situated in the registration area (Entrance 5). For more
information please contact the information desk.
BANKING & EXCHANGE
The official currency is the Swedish Krona. Foreign currency may be changed at banks
during normal banking hours, at hotels, at airports and in exchange offices. All major credit
cards are acceptable in most hotels, restaurants and shops.
MAIL / MESSAGES / MEDICAL ASSISTANCE / LOST & FOUND
Please apply to the Information Desk.
LANGUAGE
English is the official language of the Congress. All presentations will be made in English.
CLOTHING
Clothing is informal for all occasions.
MOBILE PHONES
Please note that mobile phones must be switched off during all sessions.
XX
6/10/11 9:49 AM
FINAL PROGRAMME
SESSIONS
Please make sure to be in session halls on time as all sessions will begin as per schedule.
SMOKING POLICY
Smoking is prohibited at all times in the meeting halls, exhibit halls and restrooms.
Your compliance is appreciated.
LIABILITY AND INSURANCE
The Congress Secretariat and Organisers cannot accept liability for personal accidents or
loss of or damage to private property of participants and accompanying persons. Participants
are advised to take out their own personal travel and health insurance for their trip.
SAFETY AND SECURITY
Please do not leave bags or suitcases unattended at any time, whether inside or outside
session halls. Hotels strongly recommend that you use their safety deposit boxes for your
valuables.
PRESS
Journalists must register at the Registration Desk. Upon registration the journalists will
receive a press kit including the detailed press briefing schedule. Press releases will be
available to the journalists in association to the press briefings in the Press Briefing Room.
PRESS ROOM HOURS
12:00 – 20:00
08:30 – 18:30
08:30 – 18:30
08:30 – 12:30
CONGRESS ORGANISERS
The 79th EAS Congress
1-3, rue du Chantepoulet; P.O. Box 1726
CH-1211 Geneva 1, Switzerland
Tel: +41 22 908 0488
Fax: +41 22 906 9140
E-Mail: eas2011@kenes.com
XXI
6/10/11 9:49 AM
June 26-29, 2011
INSTRUCTIONS FOR ORAL PRESENTERS
SPEAKERS’ READY ROOM
A Speakers’ Ready Room will be available every day throughout the Congress for speakers.
If using a PowerPoint (or any other computer) presentation, please note you need to bring it
on a CD, a DVD or on a “disk on key” memory stick (using the USB port in the computer)
and load it on one of the congress’ computers in the Speakers’ Ready Room, at least 1 hour
before the start of the session. You may supply your own laptop computer as a back-up.
If combining video films with PowerPoint, please make sure to check it in the session hall
where your lecture is taking place during a coffee or lunch break prior to your session,
at least 30 minutes before the start of the session - even after checking it in the Speakers’
Ready Room.
Please note that the Congress’ computers in the session halls are being supplied
with Windows and Office 2007.
Important Note for Macintosh Users
In order to use MAC presentations on a PC compatible computer please note that
you need to prepare it according to the instructions below, before bringing it to
the Speakers’ Ready Room.
•
•
•
Use a common font, such as Arial, Times New Roman, Verdana, etc. (special
fonts might be changed to a default font on a PowerPoint based PC).
Insert pictures as JPG files (and not TIF, PNG or PICT - these images will not be
visible on a PowerPoint based PC).
Use a common movie format, such as AVI, MPG and WMV (MOV files from QuickTime will not be visible on a PowerPoint based PC).
You may use your own Macintosh laptop computer as a back-up. In such a case please
confirm that it has a VGA socket for external signal and come to check it first in the
Speakers’ Ready Room as soon as you arrive and later on in the session hall where your
lecture is taking place during the coffee or lunch break prior to your session, at least 30
minutes before the start of the session. Please note that VHS Video projection, 35 mm slide
projection and Overhead projection (projection of transparencies) will not be available.
XXII
6/10/11 9:49 AM
FINAL PROGRAMME
INSTRUCTIONS FOR POSTER PRESENTERS
Posters will be on display for the entire congress. Please check the Scientific Programme to
see the exact poster board number, date, and time of the poster discussion groups.Posters
may be mounted from Sunday, June 26th from 15:30. Presenters are requested to stand
next to their posters during the exclusive poster sessions on Monday June 27th from 12:30
- 15:00 and Tuesday, June 28th from 12:30-15:00. The organisers are not responsible for
any posters that have not been removed by the end of sessions on Wednesday, June 29th.
MODERATED POSTER PRESENTATIONS
EAS is proud to introduce moderated poster sessions, providing the unique opportunity
for convivial scientific discussions and exchange. For further details please refer to the
Overview of Moderated Poster Sessions on the following page.
ACKNOWLEDGEMENT OF POSTER MODERATORS
EAS is honoured and indebted to the distinguished scientists and clinicians who have
accepted to participate in the Moderated Poster Sessions at the EAS Congress.
MEET THE SPEAKER SESSIONS
Take the opportunity to meet the plenary speakers. At the Meet the Speaker Table in the
poster area the plenary speakers will be available for your questions:
Monday June 27, 2011
Tuesday June 28, 2011
12:40-14:50
12:40-14:50
Detailed time schedule will be announced during the plenary sessions.
XXIII
6/10/11 9:49 AM
June 26-29, 2011
OVERVIEW OF MODERATED POSTER SESSIONS
Kindly note that abstracts marked with a
have been selected for
discussion during the Moderated Poster Sessions.
Moderated Poster Sessions for the track
“Lipids, Lipoproteins and Lipid Metabolism”
Moderated
Poster
Session
Workshop
1
Metabolism of Atherogenic
Lipoproteins and their Role in
Atherosclerosis
Metabolism of Atherogenic
Lipoproteins and their Role in
Atherosclerosis
Cellular Lipid Metabolism, from
Uptake to Storage
Cellular Lipid Metabolism, from
Uptake to Storage
9
2
3
10
11
12
Day
Time
Posters
Moderator
Scientific
Page No.
Monday 13.50-14.50
1.01-1.07
Louis M. Havekes
37-38
Tuesday 12.40-13.40
1.73-1.79
Erik Biessen
47-48
Monday 13.50-14.50
1.49-1.56
Steven Humphries 43-44
Monday 13.50-14.50
1.97-1.103
Geesje M.
Dallinga-Thie
50-51
Mechanisms for the Protective Tuesday 12.40-13.40
Role of HDL
Mechanisms for the Protective Tuesday 12.40-13.40
Role of HDL
Reactive Lipid Compounds and Tuesday 12.40-13.40
Modified Lipoproteins in Disease
Processes
1.121-1.128
Theo van Berkel
53-54
1.146-1.152
Anatol Kontush
57-58
1.169-1.176
Eva Hurt-Camejo
60-61
XXIV
6/10/11 9:49 AM
FINAL PROGRAMME
“From the Vulnerable Plaque to the Vulnerable Patient –
Challenges for Translational Medicine”
Moderated
Poster
Session
Workshop
Day
4
Mechanisms for the
Progression and Regression of
Atherosclerosis
Mechanisms for the
Atherosclerosis
Mechanisms for the
Atherosclerosis
Consequences of Inflammation
and Immune Response in
Atherosclerosis
Consequences of Inflammation
and Immune Response in
Atherosclerosis
•Hypoxia and Angiogenesis in
the Plaque
Monday
13.50-14.50 2.01-2.07
Gerard Pasterkamp 69-70
Monday
13.50-14.50 2.25-2.31
Bente Halvorsen
72-73
Monday
13.50-14.50 2.49-2.55
Kevin J. Williams
75-76
Tuesday
12.40-13.40 2.73-2.80
Jan Nilsson
78-79
Tuesday
12.40-13.40 2.145-2.152 Matti Jauhiainen
87-88
Tuesday
12.40-13.40 2.157-2.158 German Camejo
89
5
6
13
14
15
Time
•Nuclear Receptors at
the Crossroad of Lipid
Metabolism and Inflammation
•Thrombogenic Risk Factors
for Atherothrombosis and
Acute Coronary Events
Posters
Moderator
Scientific
Page No.
2.160-2.161
89
3.197-3.199
116
XXV
6/10/11 9:49 AM
June 26-29, 2011
“Genetics, Risk Factors and Epidemiology- from Population to Patients”
Moderated
Poster
Session
16
17
18
19
Workshop
Day
Time
Posters
Moderator
Scientific
Page No.
Biomarkers - From Bench to
Bedside
Biomarkers - From Bench to
Bedside
Psychosocial, Socioeconomic
and Life Style Factors as
Determinants of Cardiovascular
Disease
Novel Genes Related to
Atherogenesis and Lipid
Metabolism – Do they Increase
our Understanding of the
Disease?
Tuesday
12.40-13.40
3.25-3.32
John Betteridge
94-95
Tuesday
13.50-14.50
3.74-3.79
Luis Masana
99-100
Tuesday
13.50-14.50
3.121-3.128 Anders Olsson
105-106
Tuesday
13.50-14.50
3.146-3.152 Florian
Kronenberg
108-109
“Diagnosis, Prevention and Treatment of Cardiovascular Disease”
Moderated
Poster
Session
Workshop
Day
Time
7
Healthy Diets and Functional
Food A Road to Prevention
Healthy Diets and Functional
Food A Road to Prevention
New Challenges and Targets
of Cardiovascular Prevention
and Treatment
Imaging Techniques in
Atherosclerosis, Diagnostics
and Progress Monitoring
Imaging Techniques in
Atherosclerosis, Diagnostics
and Progress Monitoring
Monday
13.50-14.50
4.01-4.08
Lars Bo Nielsen
117-118
Monday
13.50-14.50
4.73-4.80
Helena Gylling
125-127
Tuesday
13.50-14.50
4.110-4.117
Terje R. Pedersen
130-132
Tuesday
13.50-14.50
4.168-4.175
Lale Tokgözuglu
138-139
Tuesday
13.50-14.50
4.176-4.182
Felicita Andreotti
139-140
8
20
21
22
Posters
Moderator
Scientific
Page No.
XXVI
6/10/11 9:49 AM
FINAL PROGRAMME
COMPANY SPONSORED EDUCATIONAL SYMPOSIA,
EBAC ACCREDITED EDUCATIONAL PROGRAMME AND
SPECIAL SESSIONS
SUNDAY, JUNE 26, 2011
COMPANY SPONSORED EDUCATIONAL SYMPOSIUM
14:00 – 15:30, E. Nikkilä Hall
Atorvastatin, An Enduring Legacy
In Focus: Modifying CETP to Reduce Cardiovascular Risk?
EBAC ACCREDITED EDUCATIONAL PROGRAMME
16:00 – 17:30, T. Svedberg Hall
Effective Implementation of Evidence-Based
Cardiovascular Disease Prevention
MONDAY, JUNE 27, 2011
Nutritional Behaviour and Reduction of Cardiovascular
Risk: from Basic Science to Clinical Practice
New Advances in Cardiovascular Risk Reduction in
High-Risk Patients
XXVII
6/10/11 9:49 AM
June 26-29, 2011
Severe Familial Hypercholesterolemia, A Genetic Disease that Needs
Aggressive Treatment
TUESDAY, JUNE 28, 2011
SPECIAL LECTURE
13:50 – 14:30, C. Müller Hall
The Role of MTP in Lipoprotein Assembly and in The Development
of Novel Therapeutic Approaches
SPECIAL LECTURE
15:00 – 15:40, C. Müller Hall
C. Müller Hall
CETP Inhibition: The Next Frontier In Cardiovascular Therapy
Novel Strategies for Raising HDL-C: Pitavastatin in Clinical Practice
EDUCATIONAL SYMPOSIUM
The InterChol FH Symposium
In appreciation of Roger Williams and MEDPED
SPECIAL LECTURE
17:00 – 17:40, C. Müller Hall
Cardiovascular Risk in Diabetes:
New Therapeutic Approaches
XXVIII
6/10/11 9:49 AM
FINAL PROGRAMME
OPENING CEREMONY
SUNDAY, JUNE 26, 2011, 18:00
N.N. Anitschkow Hall
WELCOME
Olov Wiklund
Chairperson of the Congress
M. John Chapman
President of EAS
WELCOMING WORDS
Elisabet Rothenberg
First Deputy Lord Mayor of
The City of Gothenburg
Conny Brännberg
First Deputy President of the Regional Council
of Västra Götaland
WELCOME
Ruth Frikke-Schmidt
Scandinavian Society for Atherosclerosis Research
MUSICAL PERFORMANCE
GREETINGS
W. Virgil Brown
President of the International Society of Atherosclerosis
M. John Chapman
Introduction of the Anitschkow Prize Winner
Philip Barter
The Anitschkow Lecture
MUSICAL PERFORMANCE
Reception sponsored by Region Västra Götaland and
the City of Gothenburg
XXIX
6/10/11 9:49 AM
June 26-29, 2011
SOCIAL EVENTS PROGRAMME
FACULTY DINNER
20:00
The EAS Faculty are invited to a reception which will
be held in the River Café restaurant.
(By invitation only)
CONGRESS PARTY
19:30
Light dinner will be served at the Gothenburg Opera
with live entertainment and dancing.
The Poster Awards will be presented to the 20 finalists
of the Poster Competition.
Ticket Price: €50 and €25 for students.
Limited tickets are still available
XXX
6/10/11 9:49 AM
FINAL PROGRAMME
HALL NAME EULOGY OF DISTINGUISHED
SCIENTISTS
Nikolai N. Anitschkow (1885-1964)
Professor of the Department of Pathological Physiology of the Military
Medical Academy St. Petersburg, Russia
In 1913, experimental pathologist Dr. Nikolai N. Anitschkow showed
that simply feeding rabbits purified cholesterol dissolved in sunflower oil
induced vascular lesions closely resembling those of human atherosclerosis,
both grossly and microscopically. Controls fed only the sunflower oil
showed no lesions. It is fair to say that this paper marked the beginning of the modern era
of atherosclerosis research. Dr. Anitschkow was not only a keen-eyed structural pathologist
and a careful experimentalist; he thought in terms of function and time-related pathogenesis.
However, the landmark studies by Dr. Anitschkow were largely rejected at the time. An important
reason for this was that the findings were inconsistent with the prevailing view of atherosclerosis.
It was generally accepted to be an inevitable accompaniment of aging (the “senescence
hypothesis”). If the full significance of his findings had been appreciated at the time, we might
have saved more than 30 years in the long struggle to settle the cholesterol controversy.
In honor of Dr. Nikolai N. Anitschkow, the “Anitschkow Prize in Atherosclerosis Research”
by the EAS recognizes outstanding research in the field of atherosclerosis and linked
metabolic disturbances.
Carl Müller (1886-1983)
Carl Müller presented his landmark paper, Angina Pectoris in hereditary
Xanthomatosis before the Nordic Congress for Internal Medicine in 1937
and published in the Archives of Internal Medicine in 1939. He was the
first to pull together the evidence linking familial hypercholesterolemia to
coronary artery disease.
XXXI
6/10/11 9:49 AM
June 26-29, 2011
Esko Nikkilä (1926-1986)
Professor of Medicine and Head of Third Department of Medicine,
University of Helsinki, Finland Esko Nikkilä was Professor of Medicine
at the University of Helsinki from 1962 until his untimely death in 1986
in an automobile accident at the age of 60. Esko Nikkilä was an active,
innovative member of the Finnish scientific community, a member of
the Finnish Academy of Science and Letters, one of Finland’s leading
scientists, and an internationally recognised expert on lipid metabolism and diabetes.
He was one of the founding fathers of EAS and a regular participant in EAS meetings.
He was a mentor and role model for numerous investigators who now populate major
academic positions in Finland including the chairs of this EAS meeting. In 1953, Nikkilä
presented his studies on the lipid-protein relationship in normal and pathological sera and
the effect of heparin on serum lipoproteins”. He was a true pioneer discovering the role of
lipoprotein lipase and reporting that “the amount of cholesterol found in 1 lipoprotein is
considerably decreased in the majority of atherosclerotic sera”.
These observations, from the start of his exceptional career, stand out as signs of his
originality and excellence. HDL became the major focus of his interest and over the
years he carried out studies that step-by-step established the detailed mechanisms of
HDL metabolism in health and in disease. Esko’s career paralleled the major evolution of
arteriosclerosis over more than 30 years. He described the fenotype of FCHL patients 1973
in the Lancet simultaneously with papers by Goldstein JL et al. and Rose HG et al.
These basic discoveries made him one of the leading scientists in the field. He was a true
pioneer in studies of lipoprotein metabolism in diabetes and atherosclerosis and became
a figure of tremendous stature and great internationally respected eminence in lipidology,
atherosclerosis and diabetes. He had an admirable facility for tackling his research
questions at both the bench and the bedside. He was a valued friend and at meetings, he
could always be counted on for warm, sharp humour and incisive perceptions.
Theodor Svedberg (1884-1971)
Theodor H. E. Svedberg was a Swedish chemist and Nobel laureate,
active at Uppsala University. His work with colloids supported the
theories of Brownian motion put forward by Einstein and the Polish
geophysicist Marian Smoluchowski. During this work, he developed the
technique of analytical ultracentrifugation, and demonstrated its utility in
distinguishing pure proteins one from another.
XXXII
6/10/11 9:49 AM
FINAL PROGRAMME
LIST OF OFFICIAL CONGRESS HOTELS
Best Western Hotel Eggers
Drottningtorget, 404 25 Gothenburg
+46-31 333 44 40
Lorensberg Hotel
Berzeliigatan 15, 412 53 Gothenburg
+46 31 81 06 00
Elite Park Avenue
Kungsportsavenyn 36-38, 400 15 Gothenburg
+46 31 727 10 00
Poseidon Hotel
Storgatan 33, 411 38 Gothenburg
+46 31 10 05 50
First G Hotel
Nils Ericsonsplatsen 4, 411 03 Gothenburg
+46 11 63 7242
Quality Panorama Hotel
Eklandagatan 51-53, 400 22 Gothenburg
+46 31 767 70 00
First Hotel Avalon
Kungstorget 9, 411 17 Gothenburg
+ 46 31 751 02 01
Radisson Blu Scandinavia
Södra Hamngatan 59-65, 401 24 Gothenburg
+46 31 758 50 00
Flora Hotel
Grönsakstorget 2, 411 17 Gothenburg
+46 31 13 86 16
Royal Hotel
Drottninggatan 67, 411 07 Gothenburg
+46 31 700 11 70
Gothia Towers (Headquarters
Mässans Gata 24, 402 26 Gothenburg
+46 31 750 88 00
Scandic Opalen Hotel
Engelbrektsgatan 73, 412 52 Gothenburg
+46 31 751 53 00
Grand Hotel Opera
Nils Ericsonsgatan 23, 404 26 Gothenburg
+46 31 80 50 80
Scandic Rubinen Hotel
Kungsportsavenyn 24, 411 36 Gothenburg
+46 31 751 54 00
Liseberg Heden Hotel
Sten Sturegatan 1, 411 39 Gothenburg
+46 31 750 69 00
Vasa Hotel Hotel
Viktoriagatan 6, 411 25 Gothenburg
+46 31 17 36 30
XXXIII
6/10/11 9:49 AM
June 26-29, 2011
CARING FOR THE ENVIRONMENT
EAS and Kenes International are committed to integrating responsible business practices into
all of our operations not just by words but deeds. Responsibility to our clients, staff, environment
and social issues are paramount to all of our decisions, policies and practices.
It is our belief that by employing a Green Culture in the workplace we can duplicate this
culture, and the responsibilities it entails, through our core business clients and onsite
during our Meetings.
As part of this ongoing learning process we wish to share with you the eco friendly conduct
of EAS 2011.
Green print - The print materials of this congress have been printed on paper made of
50 - 100% paper waste or paper that is FEFC approved. The FEFC is an organisation that
certifies paper manufacturers which keep to sustainable forest management criteria.
Reducing print - This year the book of abstracts will be published on a USB Stick as well
as an online supplement of Atherosclerosis. If you wish to print any of the abstracts
while at the Congress, please look for the printing stations in the exhibition area where
you can print your choice of abstracts. In addition we have added blank pages at the end
of the Final Programme, which you may use for your notes.
Recycling - As part of our efforts we try to produce less waste. We will also recycle plastic,
glass, cans and paper. Before leaving the congress, please don’t forget to place your badges
in the recycle bin for badges. Organising green meetings all over the world is a real
challenge, as green is not only the onsite conduct but the suppliers we are using, the source
of the raw materials, the methods of production, management of waste, shipping vs. using
local products and fair management of labour throughout the supply chain. EAS and Kenes
International are committed to the process.
XXXIV
6/10/11 9:49 AM
FINAL PROGRAMME
VENUE FLOOR PLANS
EAS 2011
G1
1
H2
H2
N.N. Anitschkow
Hall
G2
G2
22
220
20
285
285
5
Plenary
G3
3
220
0
G
G4
260
37
370
70
G
H1
H1
24
245
45
F1
1
2 0
250
Passage to
Focus shopping
centre & parking
F
F2
260
2
60
F
F3
220
22
20
First Floor
F4
330
33
30
F
F5
330
33
30
Post Congress
Satellites
J1
F6
6
R2
2 0
220
72
R9
R10
Bryggan
R26
R21
R22
+
R23
E. Nikkilä
Hall
R11
Press
Centre
R12
Expo Hall
R7
R3
R25
+
R24
R4
R5
+
R6
Hotel
Gothia Towers
Meeting Rooms
T. Svedberg
Hall
F
Press Center
Speakers’ Ready
Room
V
Executive Lounge
320
500
C. Müller
Hall
Eat
&
Go
Ground Floor
320
C
Indoor passage
to Plenary
Indoor passage from Hotel Gothia Towers
Ho
te
lR
ec
ep
tio
n
Livingroom
Entrance
Eden
Restaurant
Hotel
Lobby
Hotel
Gothia Towers
Elevator to Heaven 23
Registration
Exhibition & Posters
XXXV
6/10/11 9:49 AM
June 26-29, 2011
EXHIBITION FLOOR PLAN
EXHIBITOR LIST
COMPANY
BOOTH #
AstraZeneca
33
Athera Biotechnologies AB
25
B. Braun Avitum AG
14
Cayman Chemical Company
12
Denka Seiken Co.,Ltd.
24
Elsevier
6A
35
Fresenius Medical Care Deutschland GmbH
29
Genzyme Corporation
6
International Atherosclerosis Society
15
Kaneka Pharma Europe N.V. (KPE)
26
Kowa Pharmaceutical Europe Co Ltd.
34
Mercodia AB
21
MSD
32
Raisio Group, Benecol Division
8
Randox Laboratories
22
Roche
1
Wisepress Medical Bookshop
7
XXXVI
6/10/11 9:49 AM
FINAL PROGRAMME
EXHIBITOR AND SPONSOR PROFILES
AstraZeneca
2 Kingdom Street
London W2 6BD
UK
www.astrazeneca.com
AstraZeneca is a global, innovation-driven biopharmaceutical company focused on the
discovery, development and commercialisation of medicines that bring benefit for patients
and add value for society in important areas of healthcare, including neuroscience, cancer
and heart disease.
Athera Biotechnologies AB
Fogdevreten 2
171 77 Stockholm
Sweden
www.athera.se
Athera Biotechnologies AB was founded in 2002 to exploit breakthrough innovations in
cardiovascular disease made at Karolinska Institute.
The mission of Athera is to address the large unmet need for anti-inflammatory therapeutics
in the prevention and treatment of atherosclerosis, cardiovascular disease (CVD) and
premature death.
Athera currently runs two pre-clinical biopharmaceutical programs aiming for future
treatment of acute cardiovascular disease. In addition, Athera has developed a biomarker
and companion diagnostic CVDefine® kit.
The biomarker, anti-PC, is linked to increased risk for cardiovascular disease and could in
the future be used for identification of patients that benefit from Athera’s novel therapeutics.
XXXVII
6/10/11 9:49 AM
June 26-29, 2011
B. Braun Avitum AG
Schwarzenberger Weg 73-79
34212 Melsungen
Germany
www.bbraun.com
B. Braun Avitum concentrates on treatment systems for hemodialysis, acute dialysis and
therapeutic apheresis. It provides new prospects for quality of life for patients with chronic
renal or metabolic diseases. The expertise of B. Braun Avitum is comprehensive, embracing
high-quality machine systems, consumables and a network of dialysis centres.
Cayman Chemical Company
1180 East Ellsworth Road
Ann Arbor, MI 48108
USA
www.caymanchem.com
High-quality biochemical research products are available from Cayman Chemical
Company including an extensive line of assay kits for measuring lipid mediators, oxidative
stress biomarkers, cyclic nucleotides, steroids, and nitric oxide metabolites. Products key
to atherosclerosis research include various agonists, antagonists, proteins, and antibodies
related to cholesterol trafficking, platelet aggregation, and inflammatory mediators.
Danone
15, rue du Helder
75009 Paris Cedex
France
www.danone.com
Danone is one of the largest healthy food companies worldwide with 4 expertise areas in dairy
products, bottled waters, baby and medical nutrition. Its mission is to bring health through
food to as many people as possible at all the ages of the life, in more than 120 countries.
Danone and its 80,000 employees are entirely focused on this mission and R&D budget
is dedicated to projects associated with nutrition and health. Its major research centres,
Palaiseau (France) and Wageningen (Netherlands) have established more than 200 external
scientific partnerships, to develop products with relevant, scientifically proven health
XXXVIII
6/10/11 9:49 AM
FINAL PROGRAMME
Denka Seiken Co.,Ltd.
3-4-2 Nihonbashi-kayabacho, Chuo-ku
Tokyo, 103-0025
Japan
www.denka-seiken.co.jp
Denka Seiken manufactures clinical chemistry and latex-enhanced serum protein reagents
for automated chemistry analyzers such as CRP, Lp(a), Myoglobin, HDL-C, LDL-C, etc.
Denka Seiken currently features a reagent that can quantitatively determines small, dense
low-density lipoproteins (small, dense LDL). The s LDL-EX “SEIKEN” is a homogeneous
assay consisting of two ready-to-use liquid reagents to be used on automated chemistry
analyzers. The test is fully automated and has within-run precisions of 1 – 2 %. Test result
is available in 10 minutes. The assay methodology correlates well with the traditional
ultracentrifugation method.
Elsevier
32 Jamestown Road
London NW1 7BY
UK
www.elsevier.com
Elsevier delivers reliable, relevant content, tools and support across the entire health
science curriculum in ways that help educators, their students and practitioners achieve
high levels of success.
Trust Elsevier to offer superior resources that expand your knowledge, foster communication,
enable individual and collective advancement in the healthcare field.
Visit the Elsevier stand 6A where complimentary journals will be available.
Elsevier, building insights, breaking boundaries!
XXXIX
6/10/11 9:49 AM
June 26-29, 2011
Administrative Executive Office
Kronhusgatan 11
SE-411 05 Gothenburg
Sweden
www.eas-society.org
The European Atherosclerosis Society (EAS) affords medical professionals access to the latest
knowledge in areas including myocardial infarction, cerebro- and peripheral vascular disease.
EAS organises educational activities - including our annual Congress and Advanced
Courses. The Society is also active in the development and publication of Guidelines
and Consensus Position Papers on atherosclerosis-related topics. The Society’s journal,
Atherosclerosis, brings together from all sources papers concerned with research and
investigation on atherosclerosis.
EAS also supports researchers and clinicians in the field of atherosclerosis with various
grants, awards and fellowships.
Fresenius Medical Care Deutschland GmbH
Else-Kröner-Str. 1
Bad Homburg v.d.H. 061352
Germany
www.fmc-ag.com
Therapeutic Apheresis is a division of Fresenius Medical Care, the world’s largest fully
integrated renal healthcare company. Therapeutic Apheresis offers the possibility to treat
therapy refractory patients.
In patients suffering from severe hypercholesterolaemia the only effective therapy option to
reduce LDL cholesterol and to improve the prognosis is LDL apheresis with DALI or MONET.
Pathogenic antibodies produced by the patient’s own body are involved in many diseases.
Clinical settings in which such harmful antibodies occur are various autoimmune diseases
or responses to transplanted organs.
Immunosorba, GLOBAFFIN in general are mainly “placed” for the treatment of various
autoimmune diseases and antibody mediated transplant rejections (e.g. DCM, Pemphigus,
MG, GBS, SLE, AHR).
XL
6/10/11 9:49 AM
FINAL PROGRAMME
Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
USA
www.genzyme.com
One of the world’s leading biotechnology companies, Genzyme is dedicated to making a
major positive impact on the lives of people with serious diseases. Genzyme has extensive
experience in the cardiovascular field, ranging from research in cell- and gene-therapy to
the commercialization of Cholestagel® (colesevelam), a therapy designed to provide an
additive reduction in LDL-C in adult patients with primary hypercholesterolaemia who
are not adequately controlled with a statin alone. The company’s commitment to this field
continues today with the development of a novel lipid-lowering therapy for patients with
severe Familial Hypercholesterolemia. Genzyme is a Sanofi company.
International Atherosclerosis Society
6535 Fannin, MS A-601, Suite A754
Houston, TX 77030
USA
www.athero.org
The International Atherosclerosis Society (IAS), incorporated in 1979, is a Federation of 62
national or regional societies, which promotes, at an international level, the advancement
of science, research, and teaching in the field of atherosclerosis.
The IAS endeavors to achieve these objectives by promoting the exchange of existing
knowledge; encouraging new research ventures and interdisciplinary approaches;
establishing visiting fellowships for young investigators; fostering the dissemination of
knowledge by organizing international symposia, workshops, courses, and meetings; and
through the association with a scientific journal.
We encourage you to attend the XVI International Symposium on Atherosclerosis in Sydney,
Australia from 25-29 March 2012. Please visit the Symposium website for more details –
www.isa2012.com
To know more on the IAS please visit the IAS website: www.athero.org
XLI
6/10/11 9:49 AM
June 26-29, 2011
Kaneka Pharma Europe N.V. (KPE)
Otto-von-Guericke-Ring 13
65205 Wiesbaden
Germany
www.kaneka.com
Kaneka Corporation Japan is touching people’s lives by enhancing its key of highly
innovative technology in producing building blocks for active pharmaceutical ingredients
(API), macromolecules, fermentation and bioscience. One of the main businesses of
the independent subsidiary KPE is LDL-apheresis, in which Kaneka is the pioneer. Our
regeneration plasma adsorber convinces by minimum of extra-corporeal volume, even
perfect for pediatric treatment, with maximum of possible effect. The direct hemoperfusion
column pleases by easiest handling and reduction of treatment time up to half, while
keeping performance on top-class.
New branches: Kaneka introduced the world’s only Ubiquinol (Kaneka QHTM), the
biological active form of Coenzyme Q10. Minimum invasive interventional cardiology
device will be available on the European market shortly.
Kowa Pharmaceutical Europe Co Ltd.
105 Wharfedale Road
Winnersh Triangle, Wokingham
Berkshire RG41 5RB
UK
www.kowapharmaceuticals.eu
Kowa Pharmaceutical Europe Co Ltd (KPE) is a UK-based specialty pharmaceutical
company part of the Japanese-based Kowa group of companies. This privately owned
company concentrates its efforts on the research, acquisition, development, licensing
and marketing of pharmaceutical products. Its primary area of focus is cardiometabolic
disease and the first product to be launched by KPE in partnership with Recordati SpA and
Algorithm SAL is Livazo® (pitavastatin), a potent HMG-CoA reductase inhibitor (statin) for
the treatment of primary hyperlipidemia and combined (mixed) dyslipidemia.
XLII
6/10/11 9:49 AM
FINAL PROGRAMME
Mercodia AB
Sylveniusgata 8a
Uppsala 754 50
Sweden
www.mercodia.se
Mercodia AB is a Swedish biotech company focusing on the development of immunoassays
for research within the field of metabolic disorders. Our assays are applicable to both
animal and human models and are used for research ranging from basic scientific studies
to large pre-clinical and clinical phase trials.
The company was founded in 1991 and is today a world-leading supplier of products to all
major international markets. More than ninety percent of our production is exported from
our facilities in Uppsala to approximately 100 different countries around the world.
Mercodia provides a professional scientific support system by collaborating with customers
and institutions worldwide to develop novel applications for existing products and unique
diagnostics for emerging markets.
MSD
One Merck Drive
Whitehouse Station
New Jersey 08889
USA
www.msd.com
Today’s MSD is a global healthcare leader working to help the world be well. MSD is
known as Merck in the United States and Canada. Through our prescription medicines,
vaccines, biologic therapies, and consumer care and animal health products, we work with
customers and operate in more than 140 countries to deliver innovative health solutions.
We also demonstrate our commitment to increasing access to healthcare through farreaching policies, programs and partnerships. MSD. Be well. For more information, visit
www.msd.com
XLIII
6/10/11 9:49 AM
June 26-29, 2011
Pfizer Ltd
Walton Oaks
Dorking Road, Tadworth
Surrey KT20 7NS
UK
www.pfizer.co.uk
Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and global resources to improve health and well-being. We
strive to set the standard for quality, safety and value in the discovery, development and
manufacturing of medicines for people and animals. Our diversified health care portfolio
includes human and animal biologic and small molecule medicines and vaccines, as well
as nutritional products and many best-known consumer products. Pfizer colleagues work
across developed and emerging markets to advance wellness, prevention, treatment and
cures for the diseases of our time. Consistent with our responsibility as the world’s leading
biopharmaceutical company, we also collaborate with health care providers, governments
and local communities to support access to reliable, affordable health care.
Raisio Group, Benecol Division
P.O. Box 101 (Raisionkaari 55)
FIN-21201 Raisio
Finland
www.raisio.com
www.benecol.net
Benecol® - proven to reduce cholesterol
Benecol® is the expert brand in cholesterol reduction and pioneer in cholesterol lowering
food category. The brand and the unique cholesterol lowering ingredient, Plant stanol
ester, used in Benecol products are owned by Raisio Group. The Benecol products are
manufactured and sold by the local food companies in 30 countries on five continents.
Over 60 clinical studies support the use of Benecol products as an effective, easy and
safe dietary solution to lower LDL-cholesterol. Furthermore, when Benecol products are
combined with statin treatment, the effects are accumulated.
Benecol is on a mission to lower the world’s cholesterol.
XLIV
6/10/11 9:49 AM
FINAL PROGRAMME
Randox Laboratories
55 Diamond Road
Crumlin, BT29 4QY
UK
www.randox.com
Randox is revolutionising the early detection of cardiovascular disease. The multiplexing
Cardiac Biochip Array provides rapid detection of MI and ACS, showing 20% improvement
on current tests using novel markers such as H-FABP. Using the Evidence Multistat analyser,
results are obtained within 20 minutes. An H-FABP immunoturbidimetric assay is available
for use with a wide range of clinical analysers and provides fully quantitative results in
serum within 14 minutes. Randox also offer an automated assay for evaluation of Aspirin
resistance – TxB Cardio. Measuring Thromboxane levels, it provides a direct detection of
Aspirin effect in apparently healthy individuals post ingestion.
Roche
Grenzacherstrasse 124
Basel 4070
Switzerland
www.roche.com
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with
combined strengths in pharmaceuticals and diagnostics. The Roche CardioMetabolism
Franchise is committed to developing innovative medicines to change the future for people
living with cardiovascular disease and diabetes. In 2010, Roche had over 80,000 employees
worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5
billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche
Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.
XLV
6/10/11 9:49 AM
June 26-29, 2011
Wisepress Medical Bookshop
25 High Path, Merton Abbey
London SW19 2JL
UK
www.wisepress.com
Wisepress.com, Europe’s leading conference bookseller, has a complete range of books
and journals relevant to the themes of the meeting. Books can be purchased at the stand
or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide.
In addition to attending 200 conferences per year, Wisepress has a comprehensive medical
and scientific bookshop online with great offers.
Zora Biosciences Oy
Biologinkuja 1
Espoo 02150
Finland
www.zora.fi
Zora Biosciences Oy is a biotechnology company focusing on lipidomics. Zora lipidomics
is based on mass spectrometry driven lipid biochemistry and advanced bioinformatic tools.
The Zora toolkit includes a broad selection of state-of-the art Lipidomic platforms. Today
we routinely measure over 2000 different molecular lipid species. Zora services have
been applied to pharmaceutical research and development efforts in compound selection,
toxicity studies, efficacy and safety assessment among many. Zora’s own research activities
are geared toward biomarker and drug target identification, with a particular focus on
atherosclerosis and dyslipidemia.
XLVI
6/10/11 9:49 AM
FINAL PROGRAMME
SCIENTIFIC PROGRAMME
SUNDAY, JUNE 26, 2011
XLVII
79th EAS CONGRESS
Gothenburg, Sweden, June 26-29, 2011
12:00-13:30
T. Svedberg Hall
Special Session
EAS GENERAL ASSEMBLY
EAS Members only
The EAS members’ Assembly is an opportunity for EAS members to find out more about
the Society’s activities - both ongoing and forthcoming - and to put their views and
questions to the Society’s elected officers. All EAS members are welcome - come, and take
an active part in shaping the Society’s future.
1
14:00-15:30
E. Nikkilä Hall
Pfizer Ltd. Sponsored Educational Symposium
ATORVASTATIN, AN ENDURING LEGACY
Chairpersons:
Germano Di Sciascio, Italy
Per Tornvall, Sweden
14:00
CHAIRMAN'S INTRODUCTION
Per Tornvall
Sweden
14:05
ATORVASTATIN: HISTORICAL PERSPECTIVE
David Waters
USA
14:25
ATORVASTATIN: IMPACT ON CURRENT PRACTICE
John Betteridge
UK
14:40
ATORVASTATIN: CHANGING THE FUTURE OF STATIN THERAPY
Pierre Amarenco
France
15:00
CKD: AN EMERGING RISK FACTOR FOR CVD?
Philip Kalra
UK
15:15
AUDIENCE Q & A
15:25
CLOSING REMARKS
Germano Di Sciascio
Italy
15:30
Coffee Break
2
79th EAS CONGRESS
16:00-17:30
E. Nikkilä Hall
F. Hoffmann-La Roche Ltd Sponsored Symposium
IN FOCUS: MODIFYING CETP TO REDUCE CARDIOVASCULAR RISK?
Chairpersons:
Wolfgang Koenig, Germany
Chris Packard, UK
16:00
CHAIRMAN'S INTRODUCTION
Wolfgang Koenig
Germany
16:05
HDL FUNCTION AND REVERSE CHOLESTEROL TRANSPORT IN HUMANS: CAN
THEY BE PROMOTED BY THERAPEUTIC INTERVENTION?
Marina Cuchel
USA
16:25
THE ROLE OF REDUCED CETP ACTIVITY AS A POTENTIAL THERAPEUTIC TARGET
TO DECREASE CARDIOVASCULAR EVENTS
Bryan Brewer
USA
16:45
VASCULAR FUNCTION - THERAPEUTIC TARGET OR CARDIOVASCULAR RISK
MARKER
John Deanfield
UK
17:05
DISCUSSION
17:25
SUMMARY AND CLOSE
Chris Packard
UK
3
16:00-17:30
T. Svedberg Hall
EBAC Accredited Educational Programme:
EFFECTIVE IMPLEMENTATION OF EVIDENCE-BASED CARDIOVASCULAR DISEASE
PREVENTION
Supported by an unrestricted educational grant from AstraZeneca
Chairpersons:
Andrew Tonkin, Australia
16:00
INTRODUCTION
Olov Wiklund
Sweden
16:05
CHALLENGES TO EFFECTIVE CARDIOVASCULAR RISK MANAGEMENT
Alberto Zambon
Italy
16:20
HOT TOPICS RELATING TO THE CHALLENGES FACED IN EFFECTIVE
CARDIOVASCULAR RISK MANAGEMENT
All Faculty
16:30
IMPLEMENTING EFFECTIVE CVD RISK MANAGEMENT IN CLINICAL PRACTICE
David Wood
UK
16:45
HOT TOPICS IN THE IMPLEMENTATION OF GUIDELINES IN CLINICAL PRACTICE
All Faculty
16:55
NEW OPPORTUNITIES FOR CARDIOVASCULAR DISEASE PREVENTION
Stephen Nicholls
USA
17:15
HOT TOPICS IN TARGETED INTERVENTION OF CVD RISK
All Faculty
17:25
CLOSE
Andrew Tonkin
Australia
4
79th EAS CONGRESS
18:00-20:00
OPENING CEREMONY INCLUDING THE ANITSCHKOW LECTURE
Chairpersons:
WELCOMING FROM THE CONGRESS CHAIRPERSON
Olov Wiklund
Sweden
WELCOMING FROM THE THE EAS PRESIDENT
M. John Chapman
France
WELCOMING WORDS
Conny Brännberg, Sweden, First Deputy President of the Regional Council
Elisabet Rothenberg, Sweden, First Deputy Lord Mayor of The City of Gothenburg
Ruth Frikke-Schmidt, Denmark, Scandinavian Society for Atherosclerosis Research
Musical Performance
IAS AND EAS WORKING TOGETHER
W. Virgil Brown
USA
INTRODUCTION OF THE ANITSCHKOW PRIZE WINNER
M. John Chapman
France
THE ANITSCHKOW LECTURE:
CETP INHIBITION AS A STRATEGY TO REDUCE CARDIOVASCULAR RISK
Philip Barter
Australia
Musical Performance
Followed by a Welcome Reception
5
FINAL PROGRAMME
LV
6/9/11 10:07 PM
79th EAS CONGRESS
08:30-10:30
Plenary Session:
PATHOPHYSIOLOGY AND TREATMENT OF DYSLIPDEMIAS
Chairpersons:
W. Virgil Brown, USA
08:30
NEW INSIGHTS INTO THE ETIOLOGY AND PATHOPHYSIOLOGY OF HEREDITARY
DYSLIPIDEMIAS
Helen Hobbs
USA
09:00
POST-PRANDIAL LIPID METABOLISM
Stephen Young
USA
09:30
THE GUT MICROBIOTA AS AN ENVIRONMENTAL FACTOR THAT REGULATES HOST
PHYSIOLOGY AND METABOLISM
Fredrik Bäckhed
Sweden
10:00
DIVERSITY OF HDL PARTICLES - A CHALLENGE FOR TREATMENT
M. John Chapman
France
10:30
Coffee Break and Exhibition Visit
7
6/9/11 10:07 PM
11:00-12:30
Workshop:
MECHANISMS FOR THE PROGRESSION AND REGRESSION OF ATHEROSCLEROSIS
From the Vulnerable Plaque to the
Vulnerable Patient– Challenges for
Translational Medicine
Chairpersons:
Erik A. Biessen, The Netherlands
Eva Ehrenborg, Sweden
11:00
PLAQUE ADVENTITIA: SERVICE HATCH OR BATTLEGROUND?
Erik A. Biessen
The Netherlands
11:25
MONOCYTE SUBSET INFILTRATION INTO THE VESSEL WALL: CRITICAL ROLE IN
ATHEROSCLEROSIS PROGRESSION AND REGRESSION
Stephane Potteaux
France
11:50
HUMAN BIGLYCAN EXPRESSION IN A MOUSE MODEL OF ATHEROSCLEROSIS
TRIGGERS LIPID RETENTION
Per Fogelstrand, C. Mogensen, K. Skålén, J. Borén
Sweden
12:00
SMOOTH MUSCLE CELL APOPTOSIS PROMOTES VESSEL REMODELING, VIA
ACTIVATION OF CELL MIGRATION, PROLIFERATION AND COLLAGEN SYNTHESIS
Haixiang Yu, M. Clarke, N. Figg, T.D. Littlewood, M.R. Bennett
UK
12:10
MAJOR ROLE OF PERICYTES IN THE CALCIFICATION OF ATHEROMATOUS
ARTERIES
Jimmy Davaine, R. Brion, M.F. Heymann, F. Hérisson, D. Heymann, Y. Goueffic,
G. Lambert
France
12:20
REGRESSION AND STABILIZATION OF ADVANCED MURINE ATHEROSCLEROTIC
LESIONS: A COMPARISON OF LDL LOWERING AND HDL RAISING GENE
TRANSFER STRATEGIES
Eline Van Craeyveld, S.C. Gordts, E. Nefyodova, F. Jacobs, B. De Geest
Belgium
12:30
Poster Presentations and Light Buffet
12:40
Meet the Speaker Sessions in the Poster Area
8
6/9/11 10:07 PM
79th EAS CONGRESS
11:00-12:30
E. Nikkilä Hall
Workshop:
METABOLISM OF ATHEROGENIC LIPOPROTEINS AND THEIR ROLE IN ATHEROSCLEROSIS
Chairpersons:
Marja-Riitta Taskinen, Finland
Bo Angelin, Sweden
11:00
REMNANT LIPOPROTEIN RECEPTORS AND THEIR DYSREGULATION BY DIABETES
Kevin Jon Williams
USA
11:25
MECHANISMS UNDERLYING THE ATHEROGENIC LIPID TRIAD IN INTRAABDOMINAL OBESITY AND INSULIN RESISTANCE
Marja-Riitta Taskinen
Finland
11:50
THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXENDIN-4 INHIBITS VLDL
BIOSYNTHESIS AND SECRETION IN APOE*3-LEIDEN MICE
Y. Wang, E.T. Parlevliet, J.J. Geerling, J.P. Schröder-Van der Elst, J.W.A. Smit,
L.M. Havekes, J.A. Romijn, H. Pijl, Patrick C.N. Rensen
The Netherlands
12:00
POSTPRANDIAL TRIGLYCERIDE METABOLISM IS IMPAIRED IN STATIN-TREATED
TYPE 2 DIABETIC MEN
H. Barrett, J. Pang, V. Tenneti, D. Chan, Gerald F. Watts
Australia
12:10
ORP10, A NOVEL REGULATOR OF LIPOGENESIS AND APOB100 SECRETION
Eija Nissilä, G. Liebisch, Y. Zhou, J. Perttilä, G. Schmitz, V.M. Olkkonen
Finland
12:20
ALIPOGENE TIPARVOVEC GENE THERAPY ENHANCES POST-PRANDIAL
CLEARANCE OF CHYLOMICRONS IN LIPOPROTEIN LIPASE DEFICIENT PATIENTS
A.C. Carpentier, F. Frisch, S.M. Labbé, J. Méthot, C. Gagné, S. Déry, K. Tremblay,
Janneke de Wal, J. Twisk, S. Greentree, N. van den Bulk, D. Brisson,
D. Gaudet
The Netherlands
12:30
12:40
Lipids, Lipoproteins and Lipid
Metabolism
9
6/9/11 10:07 PM
11:00-12:30
T. Svedberg Hall
Joint EAS - EACPR Workshop:
HEALTHY DIETS AND FUNCTIONAL FOOD – A ROAD TO PREVENTION
Chairpersons:
Helena Gylling, Finland
Joep Perk, Sweden
THE ROLE OF DIET COMPOSITION FOR PREVENTION OF CVD DISEASE WITH
FOCUS ON DIETARY FATS
Tine Tholstrup
Denmark
11:20
PLANT STANOLS AND STEROLS: AN EXAMPLE OF FUNCTIONAL FOODS AND
CARDIOVASCULAR DISEASE
Helena Gylling
Finland
11:40
DO WE NEED NEW CLINICAL TRIALS ON N3 PUFA IN CARDIOVASCULAR DISEASE?
Roberto Marchioli
Italy
12:00
HEALTHY DIET: WHAT DO THE NEW JOINT EUROPEAN GUIDELINES ON CVD
PREVENTION SAY?
Joep Perk
Sweden
12:20
DISCUSSION
12:30
12:40
Diagnosis, Prevention
and Treatment of
Cardiovascular Disease
11:00
10
6/9/11 10:07 PM
79th EAS CONGRESS
11:00-12:30
C. Müller Hall
Joint EAS-ESC Workshop:
THROMBOGENIC RISK FACTORS FOR ATHEROTHROMBOSIS AND ACUTE CORONARY
EVENTS
Karl Swedberg, Sweden
Lars Wallentin, Sweden
11:00
ANTIPHOSPHOLIPID ANTIBODIES, A RISK FACTOR FOR ATHEROTHROMBOSIS?
Philip G. de Groot
The Netherlands
11:20
GENETIC AND BIOMARKER RISK FACTORS IN ACUTE CORONARY SYNDROMES
Lars Wallentin
Sweden
11:40
NEW CHALLENGES IN TREATMENT OF ACUTE CORONARY SYNDROMES
Nicolas Danchin
France
12:00
ROLE OF CO-MORBIDITIES: ANAEMIA, RENAL DYSFUNCTION AND LOW GRADE
INFLAMMATION
Felicita Andreotti
Italy
12:20
DISCUSSION
12:30
12:40
Genetics, Risk Factors
and Epidemiology- from
Population to Patients
Chairpersons:
11
6/9/11 10:07 PM
12:45-14:15
E. Nikkilä Hall
NUTRITIONAL BEHAVIOUR & REDUCTION OF CARDIOVASCULAR RISK: FROM BASIC
SCIENCE TO CLINICAL PRACTICE
Supported by an unrestricted educational grant from Danone
Chairpersons:
John Deanfield, UK
12:45
INTRODUCTION: OBJECTIVES OF THE EDUCATIONAL SYMPOSIUM AND KEY
QUESTIONS
John Deanfield, UK
12:50
NEW BASIC INSIGHTS IN TASTE BUD CELLS BIOLOGY: LIPID SENSING AND
EATING BEHAVIOR
Philippe Besnard
France
13:10
WHAT TOOLS TO SUPPORT DIETARY MODIFICATION IN OUR PATIENTS?
Eric Bruckert
France
13:30
DIETARY ADVICE AS A DRIVER OF MODIFICATION IN NUTRITIONAL BEHAVIOUR:
THE RECIPE STUDY
Luis Masana
Spain
13:50
LIFETIME CARDIOVASCULAR RISK: KEY COMPONENTS
John Deanfield
UK
14:10
PANEL DISCUSSION & CONCLUSION
12
6/9/11 10:07 PM
79th EAS CONGRESS
15:00-16:30
Workshop:
CONSEQUENCES OF INFLAMMATION AND IMMUNE RESPONSE IN ATHEROSCLEROSIS
Bente Halvorsen, Norway
Andrew Newby, UK
15:00
IMMUNE REGULATION OF MACROPHAGE PHENOTYPE
Andrew Newby
UK
15:25
CHEMOKINES IN ATHEROGENIC LEUKOCYTE RECRUITMENT AND HOMEOSTATIS
Christian Weber
Germany
15:50
LACK OF ANTIGEN PRESENTATION ON MHC CLASS II AGGRAVATES
ATHEROSCLEROSIS IN APOE-/- MICE
Maria Wigren, H. Björkbacka, G.N. Fredrikson, J. Nilsson
Sweden
16:00
CD4+ NKT CELLS CONTRIBUTE TO ATHEROSCLEROSIS VIA PERFORIN- AND
GRANZYME B-DEPENDENT CYTOTOXIC MECHANISMS
K. To, Alexander Bobik, P. Tipping, B.H. Toh
Australia
16:10
THE EXPRESSION OF TLR3 IS INCREASED IN ATHEROSCLEROSIS AND MEDIATES
PROTECTION AGAINST LESION DEVELOPMENT AND WEIGHT GAIN IN APOE-/MICE
Jennifer E. Cole, T. Navin, A.J. Cross, M.E. Goddard, L. Alexopoulou, A.T. Mitra,
A.H. Davies, R.A. Flavell, M. Feldmann, C. Monaco
UK
16:20
IDENTIFICATION OF A DANGER-ASSOCIATED PEPTIDE FROM APOLIPOPROTEIN
B100 (APOBDS-1) THAT TRIGGERS INNATE PRO-ATHEROGENIC RESPONSES
Daniel F.J. Ketelhuth, F.J. Rios, H. Liu, Y. Wang, M.E. Johansson, G.N. Fredrikson,
M. Gidlund, J. Nilsson, G.K. Hansson, Z.Q. Yan
Sweden
16:30
Chairpersons:
13
6/9/11 10:07 PM
Metabolism
15:00-16:30
E. Nikkilä Hall
Workshop:
CELLULAR LIPID, METABOLISM, FROM UPTAKE TO STORAGE
Chairpersons:
Jan Borén, Sweden
Jan F.C. Glatz, The Netherlands
15:00
LIPID DROPLETS AND THEIR RELATION TO THE DEVELOPMENT OF INSULIN
RESISTANCE
Sven-Olof Olofsson
Sweden
15:25
MEMBRANE FATTY ACID TRANSPORTERS REGULATE CELLULAR LIPID
METABOLISM: IMPLICATIONS FOR METABOLIC DISEASE
Jan F.C. Glatz
The Netherlands
15:50
HOW BROWN ADIPOSE TISSUE CORRECTS HYPERLIPIDEMIA AND OBESITY:
A ROLE FOR LIPOPROTEINS
Alexander Bartelt, O.T. Bruns, H. Ittrich, A. Niemeier, M. Merkel, J. Heeren
Germany
16:00
ROLE OF HUMAN ANGIOPOIETIN-LIKE PROTEIN 3 (ANGPTL3) GLYCOSYLATION IN
THE PROTEIN SECRETION AND STABILITY
Maria Antonella Burza, C. Pirazzi, C. Maglio, A. Molinaro, S. Ginanni Corradini,
S. Romeo
UK, Italy
16:10
THE VLDL RECEPTOR PROMOTES LIPOTOXICITY AND INCREASES MORTALITY IN
MICE FOLLOWING AN ACUTE MYOCARDIAL INFARCTION
Jeanna Perman, J. Borén
Sweden
16:20
SKELETAL-MUSCLE LIPOPROTEIN EXPRESSION IS REGULATED BY TRAINING
AND TYPE 2 DIABETES IN HUMANS AND IMPROVES INSULIN SENSITIVITY IN
OBESE MICE
Emil Bartels, T. Ploug, J. Størling, T. Mandrup-Poulsen, F. Dela, L.B. Nielsen
Denmark
16:30
14
6/9/11 10:07 PM
79th EAS CONGRESS
15:00-15:40
T. Svedberg Hall
How To Session:
HOW TO USE LIPIDOMICS IN ATHEROSCLEROTIC RESEARCH
Chairperson:
Magnus Bäck, Sweden
HOW TO USE LIPIDOMICS IN ATHEROSCLEROTIC RESEARCH
Edward Dennis
USA
15:00-15:40
C. Müller Hall
How To Session:
HOW TO EVALUATE LIPOPROTEIN (a) IN THE CLINIC AND IN SCIENCE
Chairperson:
Børge Nordestgard, Denmark
HOW TO EVALUATE LIPOPROTEIN(a) IN THE CLINIC AND IN SCIENCE
Sotirios Tsimikas, USA
Børge Nordestgaard, Denmark
15
6/9/11 10:07 PM
15:45-16:30
T. Svedberg Hall
How To Session:
HOW TO MANAGE CARDIOVASCULAR RISK IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Chairperson:
Lars-Bo Nielsen, Denmark
CHRONIC KIDNEY DISEASE - A PUBLIC HEALTH PRIORITY AND HARBINGER OF
PREMATURE CARDIOVASCULAR DISEASE
Peter Stenvinkel
Sweden
16:30
15:45-16:30
C. Müller Hall
How To Session:
How To Session: HOW TO DIAGNOSE AND SCREEN FOR FAMILIAL HYPERLIPIDEMIA
Chairperson:
Mats Eriksson, Sweden
HOW TO DIAGNOSE AND SCREEN FOR FAMILIAL HYPERLIPIDEMIA
Emilio Ros
Spain
THE IMPORTANCE OF A GENETIC DIAGNOSIS OF FAMILIAL
HYOERCHOLESTEROLEMIA
Joep Defesche
The Netherlands
16:30
16
6/9/11 10:07 PM
79th EAS CONGRESS
17:00-18:30
E. Nikkilä Hall
MSD Sponsored Educational Symposium:
NEW ADVANCES IN CARDIOVASCULAR RISK REDUCTION IN HIGH-RISK PATIENTS
Chairperson:
17:00
WELCOME AND OPENING REMARKS
Finland
17:05
UNMET MEDICAL NEED IN TREATMENT OF HIGH-RISK PATIENT POPULATIONS
Ronnie Willenheimer
Sweden
17:20
EFFECTIVE TREATMENT OPTIONS WITH ADD-ODD OR COMBINATION THERAPY
Michel Farnier
France
17:45
INSIGHTS FROM SHARP STUDY RESULTS
Martin Landray
UK
18:10
PATIENT CASE STUDIES & PANEL DISCUSSION: THERAPEUTIC CHOICES IN HIGH
RISK PATIENTS
Anslem Gitt
Germany
18:25
CLOSING REMARKS
Finland
17
6/9/11 10:07 PM
17:00-18:30
T. Svedberg Hall
Genzyme Sponsored Educational Symposium:
SEVERE FAMILIAL HYPERCHOLESTEROLEMIA, A GENETIC DISEASE THAT NEEDS
AGGRESSIVE TREATMENT
Chairperson:
Erik Stroes, The Netherlands
17:00
WELCOME, MEETING OBJECTIVES AND OPENING REMARKS
Erik Stroes
The Netherlands
17:05
SCREENING AND DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA WITH
IDENTIFICATION OF PATIENTS WITH SEVERE FH
Rodrigo Alonso
Spain
17:25
LP(a) IN FAMILIAL HYPERCHOLESTEROLEMIA: IMPORTANCE OF LOOKING
BEYOND LDL-C LOWERING
Sotirios Tsimikas
USA
17:50
CURRENT AND NEW TREATMENT MODALITIES FOR PATIENTS WITH SEVERE FH
Klaus Parhofer
Germany
18:10
PANEL DISCUSSION
Faculty
18:25
TAKE-HOME MESSAGES AND CLOSING REMARKS
Erik Stroes
The Netherlands
18
6/9/11 10:07 PM
79th EAS CONGRESS
6/9/11 10:07 PM
June 26-29, 2011
LXX
6/9/11 10:07 PM
79th EAS CONGRESS
08:30-10:30
Plenary Session:
HOW TO FIND AND TREAT THE VULNERABLE PLAQUE
Chairpersons:
Petri Kovanen, Finland
Andrew Newby, UK
08:30
PATHOLOGY OF THE VULNERABLE PLAQUE: WHAT DOES IT LOOK LIKE?
Erling Falk
Denmark
09:00
THE CELLULAR BIOLOGY OF PLAQUE NECROSIS
Ira Tabas
USA
09:30
NEW IMAGING POSSIBILITIES IN ATHEROSCLEROSIS
James Rudd
UK
10:00
PHARMACOLOGICAL TREATMENT OF THE VULNERABLE PLAQUE
Peter Libby
USA
10:30
19
6/9/11 10:07 PM
Metabolism
11:00-12:30
Workshop:
MECHANISMS FOR THE PROTECTIVE ROLE OF HDL
Chairpersons:
Arnold von Eckardstein, Switzerland
Ruth Frikke-Schmidt, Denmark
11:00
INFLAMMATORY REMODELLING GENERATES DYSFUNCTIONAL HDL
Jay W. Heinecke
USA
11:25
THE ENDOTHELIUM AS A BARRIER AND TARGET OF HDL'S ANTI-ATHEROGENICTY
Arnold von Eckardstein
Switzerland
11:50
THE PLASMA CONCENTRATION OF HDL-ASSOCIATED APOM IS CONTROLLED BY
THE ACTIVITY OF THE LDL-RECEPTOR
Christina Christoffersen, M. Benn, R. Frikke-Schmidt, A. Tybjaerg-Hansen,
B. Dahlbäck, L.B. Nielsen
Denmark
12:00
ROLE OF ENDOTHELIAL LIPASE IN HDL METABOLISM AND ATHEROSCLEROSIS IN
HUMANS
Tatsuro Ishida, T. Yasuda, L. Sun, K.-I. Hirata
Japan
12:10
KRP-206, A SELECTIVE S1P(1) AGONIST INHIBITS DEVELOPMENT OF
ATHEROSCLEROSIS IN LOW-DENSITY LIPOPROTEIN RECEPTOR-DEFICIENT MICE
Sara Costa, F. Poti, V. Bergonzini, M. Galletti, H. Freise, G. Varga, M. Simoni,
J.-R. Nofer
Italy
12:20
LCAT, HDL CHOLESTEROL AND MYOCARDIAL INFARCTION - A MENDELIAN
RANDOMIZATION STUDY OF HDL CHOLESTEROL IN 54,500 INDIVIDUALS
Christiane L. Haase, A. Tybjærg-Hansen, A.A. Qayyum, J. Schou, B.G. Nordestgaard,
R. Frikke-Schmidt
Denmark
12:30
12:40
20
6/9/11 10:07 PM
79th EAS CONGRESS
11:00-12:30
E. Nikkilä Hall
Workshop:
BIOMARKERS FROM BENCH TO BEDSIDE
Gerard Pasterkamp, The Netherlands
Anders Hamsten, Sweden
11:00
CARDIOVASCULAR BIOMARKERS FOR RISK STRATIFICATION AND THERAPY
GUIDANCE
Stefan Blankenberg
Germany
11:25
INNOVATION IN BIOMARKER DISCOVERY
Gerard Pasterkamp
The Netherlands
11:50
COMPREHENSIVE METABOLIC PROFILING IMPROVES PREDICTION OF
SUBCLINICAL ATHEROSCLEROSIS IN YOUNG ADULTS
Peter Würtz, J. Raiko, C.G. Magnussen, P. Soininen, A.J. Kangas, T. Tynkkynen,
R. Thomson, R. Laatikainen, M.J. Savolainen, A. Jula, J.S. Viikari, M. Kähönen,
T. Lehtimäki, M. Juonala, M. Ala-Korpela, O.T. Raitakari
Finland
12:00
BIOLOGICAL ROLES OF THE SECRETED SOLUBLE FORM OF LR11/SORLA
Wolfgang Schneider, H. Bujo, M. Jiang, K. Ohwaki, Y. Saito
Austria
12:10
GENETIC POLYMORPHISMS OF THE MAIN TRANSCRIPTION FACTORS FOR
ADIPONECTIN GENE PROMOTER IN REGULATION OF PLASMA ADIPONECTIN
LEVEL
Lyudmyla Kedenko, C. Lamina, I. Kedenko, F. Kronenberg, B. Paulweber
Austria
12:20
SENSITIVE BIOMARKER FOR STATIN-INDUCED MYOTOXICITY
Reijo Laaksonen, K. Tarasov, D. Kauhanen, T. Sylvänne, M. Jänis, R. Hurme,
K. Ekroos, G. Mombelli, C. Sirtori, J.C. Tardif
Finland
12:30
12:40
Chairpersons:
21
6/9/11 10:07 PM
11:00-12:30
T. Svedberg Hall
Workshop:
HYPOXIA AND ANGIOGENESIS IN THE PLAQUE
Chairpersons:
Mat Daemen, The Netherlands
Lillemor Mattsson Hultén, Sweden
11:00
CELL-CELL SIGNALING IN THE REGULATION OF ANGIOGENESIS AND VASCULAR
PERMEABILITY
Christer Betsholtz
Sweden
11:30
FROM THE VULNERABLE PLAQUE TO THE VULNERABLE PATIENT-CHALLENGES
FOR TRANSATIONAL MEDICINE
Mat Daemen
The Netherlands
12:00
LACTATE AS AN ATHEROSCLEROTIC PLAQUE MARKER FOR HYPOXIA
Sandra Margaretha Bovens, G. Zomer, A. Vink, G. Pasterkamp
The Netherlands
12:10
ACIDITY INCREASES THE UPTAKE OF NATIVE LDL BY HUMAN MONOCYTEDERIVED MACROPHAGES
Katariina Öörni, R. Plihtari, P.T. Kovanen
Finland
12:20
POSITIVE CROSS-TALK BETWEEN HYPOXIA INDUCIBLE FACTOR-1Α AND LIVER X
RECEPTOR Α INDUCES FORMATION OF TRIGLYCERIDE-LOADED FOAM CELLS
Tae-Young Na, M.O. Lee
Republic of Korea
12:30
12:40
22
6/9/11 10:07 PM
79th EAS CONGRESS
11:00-12:30
C. Müller Hall
Workshop:
CEREBROVASCULAR AND CAROTID DISEASE –PREDICTION, PREVENTION AND
TREATMENT
Markku Kaste, Finland
S. Lale Tokgözoglu, Turkey
11:00
DETECTION, EVALUATION AND TREATMENT OF CAROTID STENOSES
Per Wester
Sweden
11:25
HOW TO PREVENT AND TREAT STROKE
Markku Kaste
Finland
11:50
RISK FACTORS, BIOMARKERS AND PROGNOSIS IN DIFFERENT ETIOLOGIC
SUBTYPES OF ISCHEMIC STROKE - RESULTS FROM THE SAHLGRENSKA
ACADEMY STUDY IN ISCHEMIC STROKE (SAHLSIS)
Christina Jern
Sweden
12:10
DURATION OF TYPE 2 DIABETES STRONGLY PREDICTS ALL-CAUSE MORTALITY,
CARDIOVASCULAR MORTALITY AND DEATH FROM STROKE IN SUBJECTS
UNDERGOING CORONARY ANGIOGRAPHY
Guenther Silbernagel, S. Rosinger, T.B. Grammer, B.R. Winkelmann, B.O. Boehm,
W. März
Germany
12:20
ASYMPTOMATIC CAROTID ARTERY DISEASE IN VALVULAR HEART SURGERY
Amedeo Anselmi, M. Morelli, C. Pragliola, N. Pavone, V. Tsiopoulos, F. Glieca,
M. Gaudino
Italy
12:30
12:40
23
and Treatment of
Chairpersons:
6/9/11 10:07 PM
13:50-14:30
C. Müller Hall
Special Lecture:
Supported by an unrestricted educational grant from Aegerion
Chairperson:
13:50
Sven-Olof Olofsson, Sweden
THE ROLE OF MTP IN LIPOPROTEIN ASSEMBLY AND IN THE DEVELOPMENT OF
NOVEL THERAPEUTIC APPROACHES
Marina Cuchel
USA
24
6/9/11 10:07 PM
79th EAS CONGRESS
15:00-16:30
Joint EAS-ICCR Workshop:
NEW CHALLENGES AND TARGETS OF CARDIOVASCULAR PREVENTION AND TREATMENT
Thomas Lüscher, Switzerland
Philip Barter, Australia
15:00
VASCULAR EFFECTS OF HDL: ROLE OF LIPOPROTEIN DYSFUNCTION
Thomas Lüscher
Switzerland
15:20
ANTISENSE THERAPY IN METABOLIC DYSLIPIDEMIA
Erik Stroes
The Netherlands
15:40
MOLECULAR IMAGING OF ARTERIAL INFLAMMATION
Peter Libby
USA
16:00
CARDIOMETABOLIC RISK AND SUBCLINICAL ATHEROSCLEROSIS IN YOUNG
ADULTS
Eric Larose
Canada
16:20
DISCUSSION
Philip Barter
Australia
16:30
25
and Treatment of
Chairpersons:
6/9/11 10:07 PM
15:00-16:30
E. Nikkilä Hall
Special Session:
LATE BREAKING SESSION
Chairpersons:
Alberico Catapano, Italy
Andrew Newby, UK
15:00
LIPID-LOWERING EFFECTS OF THE THYROID HORMONE ANALOGUE EPROTIROME
REQUIRES FUNCTIONAL LDL RECEPTORS: STUDIES IN A HOMOZYGOUS FH
PATIENT
Peter Benedek, B. Angelin, J. Kristensen, M. Rudling, M. Eriksson
Sweden
15:12
NONFASTING GLUCOSE AND ISCHEMIC HEART DISEASE - A MENDELIAN
RANDOMIZATION APPROACH
Marianne Benn, A. Tybjærg-Hansen, M.I. McCarthy, G.B. Jensen, P. Grande,
B.G. Nordestgaard
Denmark
15:24
TRIGLYCERIDE-RICH LIPOPROTEINS AND HIGH-DENSITY LIPOPROTEIN
CHOLESTEROL IN PATIENTS AT HIGH RISK OF CARDIOVASCULAR DISEASE:
EVIDENCE AND GUIDANCE FOR MANAGEMENT
M. John Chapman, H.N. Ginsberg, P. Amarenco, F. Andreotti, J. Borén, A. Catapano,
O.S. Descamps, E. Fisher, P. Kovanen, J.A. Kuivenhoven, P. Lesnik, L. Masana,
B.G. Nordestgaard, K. Ray, Z. Reiner, M.-R. Taskinen, L. Tokgözoglu,
A. Tybjærg-Hansen, G.F. Watts, The European Atherosclerosis Society Consensus Panel
France
15:36
PLANT STEROLS AND CARDIOVASCULAR DISEASE: A SYSTEMATIC REVIEW AND
META-ANALYSIS
Winfried März, G. Silbernagel, G. De Backer, E. Bruckert, R. Carmena,
J. Chapman, J. Deanfield, O.S. Descamps, E.R. Rietzschel, K.C. Dias, B. Genser
Germany, Austria
15:48
APOLIPOPROTEIN AV INTERNALIZED IN HUMAN ADIPOCYTE MODULATES
CELLULAR TRIGLYCERIDE ACCUMULATION
X.-Y. Zheng, Shui-Ping Zhao, B.-L. Yu, C.-L. Wu, L. Liu
China
16:00
ALIPOGENE TIPARVOVEC GENE THERAPY SIGNIFICANTLY REDUCES THE RISK OF
PANCREATITIS IN LIPOPROTEIN LIPASE DEFICIENT PATIENTS
Stephen Greentree, J. Méthot, S. Déry, K. Tremblay, J. de Wal, N. van den Bulk,
G. Ruiterkamp, A. Freidig, D. Brisson, D. Gaudet
The Netherlands
16:12
DISCUSSION
16:30
26
6/9/11 10:07 PM
79th EAS CONGRESS
15:00-16:30
T. Svedberg Hall
Workshop:
PSYCHOSOCIAL, SOCIOECONOMIC AND LIFESTYLE FACTORS AS DETERMINANTS OF
CARDIOVASCULAR DISEASE
Annika Rosengren, Sweden
Göran Bondjers, Sweden
15:00
PSYCHOSOCIAL STRESS - A CASUAL FACTOR IN THE ETIOLOGY OF CVD?
Annika Rosengren
Sweden
15:30
LOW SOCIOECONOMIC STATUS AND STRESS-RELATED CARDIOVASCULAR AND
INFLAMMATORY RESPONSES
Andrew Steptoe
UK
16:00
SOCIAL DISRUPTION STRESS ACCELERATES ATHEROSCLEROSIS IN APOE-/MICE
Maria E. Johansson, E. Bernberg, M.A. Ulleryd, G.M. Bergström
Sweden
16:10
DEPRESSION SCORES PREDICT ADHERENCE IN A DIETARY WEIGHT LOSS
INTERVENTION TRIAL.
Shawn Somerset, L. Graham, K. Markwell
Australia
16:20
CAN SKINFOLD THICKNESS PREDICT CARDIO-VASCULAR RISK FACTORS IN
YOUTHS?
Peter Schwandt, E. Liepold, G.M. Haas
Germany
16:30
Chairpersons:
27
6/9/11 10:07 PM
15:00-15:40
C. Müller Hall
Special Lecture:
Supported by an unrestricted educational grant from MSD
Chairpersons:
15:00
Jan Borén, Sweden
CETP INHIBITION: THE NEXT FRONTIER IN CARDIOVASCULAR THERAPY
Bryan Brewer
USA
15:45-16:15
C. Müller Hall
Special Session:
YOUNG INVESTOR AWARD CEREMONY
Chairpersons:
Petri Kovanen, Finland
Bart Staels, France
15:45
DNA DAMAGE LINKS MITOCHONDRIAL DYSFUNCTION TO ATHEROSCLEROSIS
AND THE METABOLIC SYNDROME
John Mercer
UK
15:55
AUGMENTED EXPRESSION AND ACTIVITY OF EXTRACELLULAR MATRIXDEGRADING ENZYMES IN REGIONS OF LOW ENDOTHELIAL SHEAR STRESS
COLOCALIZE WITH CORONARY ATHEROMATA WITH THIN FIBROUS CAPS IN PIGS
Yiannis Chatzizisis
USA
16:30
28
6/9/11 10:07 PM
79th EAS CONGRESS
17:00-18:30
E. Nikkilä Hall
NOVEL STRATEGIES FOR RAISING HDL-C: PITAVASTATIN IN CLINICAL PRACTICE
Supported by an unrestricted educational grant from Kowa Pharmaceutical Europe Co Ltd.
Chairpersons:
Yasushi Saito, Japan
17:00
CO-CHAIR'S INTRODUCTION
17:05
HDL-C: ROLE AS A RISK MODIFIER
Philip Barter
Australia
17:25
PITAVASTATIN - AN OVERVIEW
Yasushi Saito
Japan
17:35
PITAVASTATIN: NOVEL EFFECTS ON LIPID PARAMETERS
M. John Chapman
France
17:55
PITAVASTATIN: CLINICAL EFFECTS FROM THE LIVES STUDY
Tamio Teramoto
Japan
18:15
AUDIENCE Q & A
18:30
SUMMARY
Philip Barter
Australia
29
6/9/11 10:07 PM
17:00-18:30
T. Svedberg Hall
InterCHol FH Symposium:
WHAT’S NEW IN MANAGING CHILDREN WITH FH
FRESH SCREENING METHODS AND OPTIONS
In appreciation of Roger Williams and MEDPED
Chairpersons:
Joep Defesche, The Netherlands
17:00
WELCOME AND OPENING REMARKS
W. Virgil Brown
USA
17:10
NEW SCREENING METHODS AND TREATMENT OPTIONS FOR CHILDREN WITH
FAMILIAL HYPERCHOLESTEROLEMIA.
Albert Wiegman
The Netherlands
17:35
DO CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA BENEFIT FROM DIET?
Kurt Widhalm
Austria
18:00
PEDIATRIC SCREENING FOR FAMILIAL HYPERCHOLESTERLEMIA IN EUROPE.
Leiv Ose
Norway
18:25
CONCLUSIONS AND CLOSE BY CHAIRMEN
Joep Defesche, The Netherlands
17:00-17:40
C. Müller Hall
Special Lecture:
Supported by an unrestricted educational grant from Boehringer Ingelheim
Chairperson:
CARDIOVASCULAR RISK IN DIABETES: NEW THERAPEUTIC APPROACHES
Michaela Diamant
The Netherlands
30
6/9/11 10:07 PM
FINAL PROGRAMME
WEDNESDAY, JUNE 29, 2011
LXXXIII
6/9/11 10:07 PM
June 26-29, 2011
LXXXIV
6/9/11 10:07 PM
79th EAS CONGRESS
08:30-10:30
Plenary Session:
PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
Chairpersons:
Terje Pedersen, Norway
Zeljko Reiner, Croatia
08:30
THE ROLE OF INFLAMMATORY BIOMARKERS IN DAILY DECISION MAKING
Børge Nordestgaard
Denmark
09:00
IMMUNE MODULATION/VACCINATION TO TREAT AND PREVENT
ATHEROSCLEROSIS
Jan Nilsson
Sweden
09:30
WHAT IS A HEALTHY DIET, AS DEFINED BY THE CRITERIA OF EVIDENCE-BASED
MEDICINE?
Gabriele Riccardi
Italy
10:00
THE NEW EAS/ESC GUIDLINES TO TREAT DYSLIPIDEMIAS
Alberico Catapano
Italy
10:30
31
6/9/11 10:07 PM
11:00-12:30
Workshop:
IMAGING TECHNIQUES IN ATHEROSCLEROSIS, DIAGNOSTICS AND PROGRESS
MONITORING
Chairpersons:
Robin P. Choudhury, UK
Lars Johansson, Sweden
IMAGING AND TARGETED DRUG IN ATHEROSCLEROSIS
Zahi A. Fayad
USA
11:30
MOLECULAR MR IMAGING IN ATHEROSCLEROSIS
Robin P. Choudhury
UK
12:00
IMPACT OF OPTICAL COHERENCE TOMOGRAPHY (OCT), INTEGRATEDBACKSCATTER-IVUS (IB-IVUS), AND 64-SLICE MULTIDETECTOR CT (64-SLICE
MDCT) ON ACS AND STABLE LESION CHARACTERISTICS
Yukio Ozaki, M. Okumura, K. Hattori, H. Naruse, S.C. Kan, M. Ohota, H. Harigaya,
H. Kawai, M. Ishikawa, T. Hashimoto, J. Ishii
Japan
12:10
NON-INVASIVE MOLECULAR IMAGING USING CONTRAST ENHANCED
ULTRASOUND FOR DETECTION OF ARTERIAL THROMBOSIS VIA SINGLE-CHAIN
ANTIBODY-TARGETED MICROBUBBLES
Xiaowei Wang, C.E. Hagemeyer, F. Jia, E. Leitner, I. Ahrens, K. Peter
Australia
12:20
DISCUSSION
and Treatment of
11:00
32
6/9/11 10:07 PM
79th EAS CONGRESS
11:00-12:30
E. Nikkilä Hall
Workshop:
NOVEL GENES RELATED TO ATHEROGENESIS AND LIPID METABOLISM – DO THEY
INCREASE OUR UNDERSTANDING OF THE DISEASE?
Steve Humphries, UK
Anne Tybjærg-Hansen, Denmark
11:00
A MULTI-LOCUS GENETIC RISK SCORE AND RISK FOR INCIDENT CORONARY
HEART DISEASE
Sekar Kathiresan
USA
11:25
USING GENES TO DETERMINE CAUSALITY FOR ISCHEMIC HEART DISEASE
Anne Tybjærg-Hansen
Denmark
11:50
GENETIC VARIATION IN TRANSTHYRETIN, LIPID AND LIPOPROTEIN LEVELS, AND
RISK OF ISCHEMIC VASCULAR DISEASE
Louise Hornstrup, C.L. Haase, R. Frikke-Schmidt, A. Tybjærg-Hansen
Denmark
12:00
IDENTIFICATION OF TWO NEW MUTATIONS OF GPIHBP1 IN SEVERE
HYPERCHYLOMICRONEMIA
Sybil Charriere, N. Peretti, S. Bernard, M. Charcosset, A. Sassolas, A. Lachaux,
P. Moulin, C. Marçais
France
12:10
NEW GAIN OF FUNCTIONS MUTATIONS IN PCSK9 AND THEIR IMPACT IN FAMILIAL
HYPERCHOLESTEROLEMIA
Marianne AbiFadel, J.P. Rabès, M. Guérin, V. Carreau, A. Carrié, M. Varret,
M.E. Samson-Bouma, L. Tosolini, D. Erlich, P. Couvert, D. Bonnefont-Rousselot,
E. Bruckert, A. Prat, N. Seidah, C. Boileau
France , Lebanon
12:20
-203A/C POLYMORPHISM OF CHOLESTEROL 7- α HYDROXYLASE (CYP7A1) GENE
AFFECTS CYP7A1 ACTIVITY AFTER SHORT-TERM TREATMENT WITH
CHOLESTYRAMINE
Jan Kovar, M. Zimolova, M. Lenicek, L. Vitek, M. Jirsa, R. Poledne
Czech Republic
Chairpersons:
33
6/9/11 10:07 PM
Metabolism
11:00-12:30
T. Svedberg Hall
Workshop:
REACTIVE LIPID COMPOUNDS AND MODIFIED LIPOPROTEINS IN DISEASE PROCESSES
Chairpersons:
Eva Hurt-Camejo, Sweden
Norbert Leitinger, USA
11:00
OXIDIZED PHOSPHOLIPIDS AND MACROPHAGE PHENOTYPIC POLARIZATION
Norbert Leitinger
USA
11:25
LEUKOTRIENES IN CARDIOVASCULAR DISEASES
Jesper Haeggström
Sweden
11:50
ACYL CHAIN-DEPENDENT EFFECT OF LYSOPHOSPHATIDYLCHOLINES ON COX-2
EXPRESSION IN VASCULAR ENDOTHELIAL CELLS
Lada Brkic, M. Riederer, R. Malli, W. Graier, S. Frank
Austria
12:00
LIPID ALDEHYDE-MODIFIED AMINOPHOSPHOLIPIDS INDUCE ER STRESS AND
ACTIVATE THE INFLAMMATORY RESPONSE OF ENDOTHELIAL CELLS
Sean Stephen Davies, L. Guo, Z. Chen, B.E. Cox, V. Amarnath, R.F. Epand,
R.M. Epand
USA
12:10
ALOX15B IS THE MAJOR 15-LIPOXYGENASE IN HUMAN MACROPHAGES
S. Wüst, M. Crucet, M. Herová, Martin Hersberger
Switzerland
12:20
INHIBITION OF ALOX15B REDUCES INFLAMMATION IN ATHEROSCLEROSIS-PRONE
MICE
Lillemor Mattsson Hultén, A. Lundqvist, M.N. Karlsson, K. Skålén, O. Wiklund,
L. Magnusson
Sweden
34
6/9/11 10:07 PM
79th EAS CONGRESS
11:00-12:30
C. Müller Hall
Workshop:
NUCLEAR RECEPTORS AT THE CROSSROAD OF LIPID METABOLISM AND INFLAMMATION
Bart Staels, France
Marten Hofker, The Netherlands
11:00
NUCLEAR RECEPTOR CONTROL OF MACROPHAGE FUNCTIONS
Bart Staels
France
11:25
STEROL AND OXYSTEROL CONTROL OF MACROPHAGE FOAM CELL FORMATION
Christopher K. Glass
USA
11:55
FARNESOID X RECEPTOR ACTIVATION INDUCES CHOLESTERYL ESTER
TRANSFER PROTEIN EXPRESSION IN HUMANS AND TRANSGENIC MICE
T. Gautier, W. de Haan, D. Ye, M.J. Bahr, T. Claudel, T.J.C. Van Berkel, J. Grober,
L. Lagrost, F. Kuipers, M. Van Eck, P.C.N. Rensen, Uwe J.F. Tietge
The Netherlands
12:05
PPARA ACTIVATION DIFFERENTLY AFFECTS MICROPARTICLE CONTENT IN
ATHEROSCLEROTIC LESIONS AND LIVER OF A MOUSE MODEL OF
ATHEROSCLEROSIS AND NASH
Morgane Baron, A.S. Leroyer, Z. Majd, F. Lalloyer, E. Vallez, K. Bantubungi,
G. Chinetti-Gbaguidi, P. Delerive, C.M. Boulanger, B. Staels, A. Tailleux
France
12:15
C/EBPΒ CONTROLS EXERCISE-INDUCED CARDIAC GROWTH AND PROTECTS
AGAINST PATHOLOGICAL CARDIAC REMODELING
Pontus Boström, N. Mann, J. Wu, P.A. Quintero, E.R. Plovie, D.R. Panáková,
R.K. Gupta, C.K. Xiao, C.A. MacRae, A. Rosenzweig, B.M. Spiegelman
USA
12:25
DISCUSSION
Chairpersons:
35
6/9/11 10:07 PM
36
6/9/11 10:07 PM
FINAL PROGRAMME
POSTER PRESENTATIONS
AND MODERATED POSTER
SESSIONS
XCI
June 26-29, 2011
XCII
79th EAS CONGRESS
Poster Area
WORKSHOP: METABOLISM OF ATHEROGENIC LIPOPROTEINS AND THEIR ROLE IN
ATHEROSCLEROSIS
Poster No
1.01
DUAL METABOLIC DEFECTS ARE REQUIRED TO PRODUCE
HYPERTRIGLYCERIDEMIA IN OBESE SUBJECTS
Martin Adiels, M.R. Taskinen, J. Westerbacka, S. Söderlund, J. Kahri, N. Lundbom,
J. Lundbom, A. Hakkarainen, S.O. Olofsson, M. Ohro-Melander, J. Borén
Sweden
1.02
DO INTAKES OF FATTY ACIDS MODIFY THE ASSOCIATION BETWEEN GENETIC
VARIATION IN FADS-LOCUS AND LIPID CONCENTRATION?
Sophie Hellstrand, E. Sonestedt, U. Ericson, B. Gullberg, E. Wirfält, M. Svensson,
M. Orho-Melander
Sweden
1.03
EFFECT OF ONE YEAR TREATMENT WITH INSULIN AND ORAL GLUCOSELOWERING AGENTS ON LIPID LEVELS IN NON-OBESE PATIENTS WITH TYPE 2DIABETES
Søren Søgaard Lund, L. Tarnow, B. Nielsen, B. Hansen, M. Frandsen, O. Pedersen,
H.H. Parving, A. Vaag
Denmark
1.04
REGULATION OF BILE ACID AND CHOLESTEROL METABOLISM BY
ENDOGENOUS THYROID HORMONE IN HUMANS
Ylva Bonde, B. Angelin, M. Rudling
Sweden
1.05
NONFASTING BLOOD CONCENTRATION OF LIPOPROTEIN SUBFRACTIONS
AND RISK OF CORONARY HEART DISEASE IN A SWEDISH NESTED CASECONTROL STUDY
Emily Sonestedt, S. Chiu, O. Melander, M. Orho-Melander, R.M. Krauss
Sweden
1.06
MARINE N-3 FATTY ACIDS IN SERUM PHOSPHOLIPIDS AS BIOMARKERS OF
INTAKE INFLUENCE LDL HETEROGENEITY IN SUBJECTS WITH FAMILIAL
LIPOPROTEIN DISORDERS
Aleix Sala-Vila, M. Cofán, R. Mateo-Gallego, A. Cenarro, F. Civeira, E. Ros
Spain
37
Metabolism
Poster Session
Metabolism
Poster Session
Poster Area
ATHEROSCLEROSIS (contd.)
Poster No
1.07
CHANGES IN HUMAN LIPOPROTEIN COMPOSITION IN PATIENTS WITH ACUTE
CORONARY SYNDROME
Stefan Ljunggren, H. Karlsson, H. Mörtstedt, L. Hellström, J. Perk, C. Besler,
U. Landmesser, A. von Eckardstein, M. Lindahl
Sweden
1.08
THE MOLECULAR BASIS OF AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA:
ASSESSMENT IN A LARGE COHORT OF HYPERCHOLESTEROLEMIC CHILDREN
A. van der Graaf, H.J. Avis, D.M. Kusters, M.N. Vissers, B.A. Hutten, J.C. Defesche,
R. Huijgen, S.W. Fouchier, F.A. Wijburg, J.J. Kastelein, Albert Wiegman
The Netherlands
1.09
LOW LIPOPROTEIN(a) CONCENTRATION IS ASSOCIATED WITH SHORTER
SURVIVAL: A POPULATION-BASED COHORT STUDY (THE JMS COHORT STUDY)
Motoji Sawabe, N. Tanaka, M.N. Mieno, S. Ishikawa, K. Kayaba, K. Nakahara,
S. Matsushita, The JMS Cohort Study Group
Japan
1.10
THE FUNCTION OF APOA5 IN THE METABOLISM OF TRIGLYCERIDE-RICH
LIPOPROTEINS (TRL) PARTIALLY DEPENDS ON LRP1
Karoline Brügelmann, A. Bartelt, J. Heeren, M. Merkel
Germany
1.11
HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN NORWAY, SWEDEN,
DENMARK AND FINLAND- SUBSTANTIAL VARIATION IN FREQUENCY OF THE
DIAGNOSIS
A Græsdal, M.P. Bogsrud, Y. Stålstrøm, K. Retterstøl, G. Langslet, L. Ose
Norway
1.12
A VARIANT NEAR THE MELANOCORTIN-4 RECEPTOR (MC4R) GENE REGULATE
POSTPRANDIAL LIPID METABOLISM IN A HEALTHY CAUCASIAN POPULATION
Pablo Perez-Martinez, J. Delgado-Lista, A. Garcia-Rios, N. Delgado-Casado,
C. Marin, P. Gomez-Luna, F. Perez-Jimenez, J. Lopez-Miranda
Spain
1.13
MOLECULAR DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA: THE UTILITY
OF A COUNTRY SPECIFIC PROTOCOL
Maria D'Agostino, M. Romano, M.D. Di Taranto, G. Marotta, M. Gentile,
A. Iannuzzi, P. Rubba, G. Fortunato
Italy
38
79th EAS CONGRESS
Poster Area
Poster No
1.14
INSULIN RESISTANCE IS ASSOCIATED WITH THE METABOLIC SYNDROME BUT
NOT WITH PERIPHERAL ARTERIAL DISEASE
Alexander Vonbank, C.H. Saely, P. Rein, C. Boehnel, S. Greber, H. Drexel
Austria, Liechtenstein
1.15
APOLIPOPROTEIN PROFILES IN ATHEROSCLEROTIC DISEASE
Marilena Formato, A.J. Lepedda, E. Zinellu, A. Cigliano, F. Piredda, P.P. Bacciu,
A. Guarino, R. Spirito
Italy
1.16
SERUM INTESTINAL APOB-48 IS INCREASED IN PATIENTS WITH SEVERE
HYPERTRIGLYCERIDEMIA
A. Abed, P. Giral, R. Bittar, D. Bonnefont-Rousselot, Jean-Marc Lacorte
France
1.17
EFFICACY OF EZETIMIBE/STATINS AND STATIN MONOTHERAPY AND FACTORS
ASSOCIATED WITH TREATMENT RESPONSE: POOLED ANALYSIS OF >21,000
SUBJECTS FROM 27 TRIALS
Peter P Toth, D. Morrone, W. Weintraub, M.E. Hanson, R.S. Lowe, J. Lin, A. Shah,
A.M. Tershakovec
USA
1.18
METABOLIC BENEFITS OF ECCENTRIC ENDURANCE EXERCISE IN OVERWEIGHT
AND OBESE INDIVIDUALS
P. Rein, C.H. Saely, A. Vonbank, S. Aczel, C. Boehnel, V. Kiene, Veronika Drexel,
T. Bochdansky, H. Drexel
1.19
EFFECTS OF EPA ON THE RISK OF CORONARY ARTERY DISEASE
IN HYPERCHOLESTEROLEMIC PATIENTS IN RELATED WITH NONATTAINMENT
THE LIPID MANAGEMENT GOALS FOR LDL-C OR NON HDL-C: SUB-ANALYSIS OF
THE JELIS
Jun Sasaki, M. Yokoyama, M. Matsuzaki, Y. Saito, H. Origasa, Y. Ishikawa, S. Oikawa,
H. Itakura, H. Hishida, T. Kita, A. Kitabatake, N. Nakaya, T. Sakata, K. Shimada,
K. Shirato, Y. Matsuzawa
Japan
1.20
INFLUENCE OF APOE GENOTYPE IN THE PHENOTYPE OF CLINICAL DIAGNOSED
PORTUGUESE FH PATIENTS
Ana Margarida Medeiros, T. Santos, A.C. Alves, M. Bourbon, on behalf of the
Investigators of the Portuguese FH Study
Portugal
39
Metabolism
Poster Session
Metabolism
Poster Session
Poster Area
Poster No
1.21
COMPARISON OF THE EFFECTS OF SIMVASTATIN VERSUS ROSUVASTATIN
VERSUS SIMVASTATIN/EZETIMIBE ON PARAMETERS OF CARBOHYDRATE
METABOLISM
E. Moutzouri, E. Liberopoulos, M. Kostapanos, H. Milionis, Moses Elisaf
Greece
1.22
CHANGES IN LDL-C LEVELS AND GOAL ATTAINMENT ASSOCIATED WITH ADDING
EZETIMIBE ONTO SIMVASTATIN, ATORVASTATIN AND ROSUVASTATIN
COMPARED WITH TITRATING STATINS
J.M. Foody, Peter P Toth, S. Sajjan, D.R. Ramey, D.R. Neff, A.M. Tershakovec,
H. Hu, J.E. Tomassini, K. Tunceli
USA
1.23
TEMPORAL RESPONSES OF CHOLESTYRAMINE TREATMENT ON FGF19 LEVELS,
BILE ACID AND CHOLESTEROL SYNTHESIS, SERUM TRIGLYCERIDES AND BILE
ACID LEVELS
Beatrice Sjöberg, S. Straniero, B. Angelin, M. Rudling
Sweden
1.24
COMBINATION EZETIMIBE/SIMVASTATIN + EXTENDED-RELEASE NIACIN THERAPY
IMPROVES ATTAINMENT OF RECOMMENDED LDL-C, NON-HDL-C AND APOB
LEVELS IN HYPERLIPIDEMIC PATIENTS
Sergio Fazio, J.R. Guyton, J. Lin, J.E. Tomassini, A. Shah, A.M. Tershakovec
USA
1.25
SERUM LEVELS OF VASPIN AND CARDIOVASCULAR RISK FACTORS IN MORBID
OBESE PATIENTS
Atefeh Golpaie, Z. Karbaschian, N. Tajik, M.J. Hosseinzadeh-Attar
Iran
1.26
PRO-ATHEROGENIC POSTPRANDIAL PROFILE: MEAL INDUCED CHANGES OF
LIPOPROTEIN SUB-FRACTIONS AND INFLAMMATION MARKERS IN OBESE BOYS
Alberto Zambon, L. Pinelli, M.G. Surano, M. Carlon, S. Cordioli, S. Gasperotti,
D. Vianello, C. Maffeis
Italy
1.27
RISK FACTORS FOR NON-ALCOHOLIC FATTY LIVER DISEASE IN RUSSIAN
FEDERATION IN NATIONAL-WIDE DIREG-L-01903 STUDY
Oxana M Drapkina, V.T. Ivashkin
Russia
1.28
THE LIVER SIEVE IN CHOLESTEROL METABOLISM INFLUENCES BOTH LIFESTYLE
AND FAMILIAL ATHEROSCLEROSIS
Robin Fraser, B.R. Dobbs, V.C. Cogger, D.G. Le Couteur
New Zealand
40
79th EAS CONGRESS
Poster Area
Poster No
1.29
TOTAL CHOLESTEROL TO APOLIPOPROTEIN B100 RATIO IN ADVANCED STABLE
ANGINA PATIENTS TREATED WITH STATINS
Pawel Burchardt, B. Zuchowski, A. Palasz, J. Zurawski, H. Wysocki
Poland
1.30
STUDY ON EFFECT OF COMBINING ORLISTATE - EZETIMIDE ON LIPIDEMIC
PROFILE ON OBESE PATIENTS
Stefanos Patiakas, C. Charalampous
Greece
1.31
EXTENDED RELEASE NIACIN/LAROPIPRANT LOWERS ATHEROGENIC LIPIDS
ACROSS PATIENT SUBGROUPS
C.M. Ballantyne, H.E. Bays, A.K. Shah, C. Sisk, Q. Dong, Darbie Maccubbin
USA
1.32
LIPID PARAMETERS IN ACUTE CORONARY SYNDROMES VERSUS STABLE
CORONARY ARTERY DISEASE
Alexander Vonbank, C.H. Saely, P. Rein, C. Boehnel, V. Jankovic, J. Breuss,
H. Drexel
1.33
OXIDATIVE STRESS AND ANTIOXIDANT PARAMETERS IN PATIENTS WITH
HYPERLIPIDEMIA
Odkhuu Enkhtaivan, M. Malchinkhuu, L. Tserenkhuu
Mongolia
1.34
ROLE OF BLOOD CHOLESTEROL TRANSPORT SYSTEM DISTURBANCES IN
ATHEROSCLEROSIS IN RHEUMATOID ARTHRITIS (RA)
Tatiana Popkova, D. Novikova, A. Novikov, E. Alexandrova, E. Nasonov
Russia
1.35
ASSOCIATIONS OF APOE POLYMORPHISMS WITH BASELINE LIPIDS AND
RESPONSE TO ROSUVASTATIN VARY IN CHINESE PATIENTS WITH AND WITHOUT
FAMILIAL HYPERCHOLESTEROLAEMIA
Miao Hu, V.W.L. Mak, E.W.M. Poon, B. Tomlinson
Hong Kong S.A.R.
1.36
MECHANISM OF HYPERCHOLESTEROLEMIA IN PHHC RAT
Miluše Zimolová, M. Schmiedtová, M. Heczková, R. Poledne, M. Jirsa,
J. Kovář
Czech Republic
1.37
COMPARATIVE EFFECT OF APHERESIS VS ATORVASTATIN/APHERESIS ON
MARKERS OF INFLAMMATION IN PATIENTS WITH FAMILIAL
Mariarita Puntoni, F. Sbrana, F. Bigazzi, F. Minichilli, T. Sampietro
Italy
41
Metabolism
Poster Session
Metabolism
Poster Session
Poster Area
Poster No
1.38
POLIDISTRECTUAL VASCULAR INVOLVEMENT IN FAMILIAL
HYPERCHILOMICRONEMIA
Francesco Sbrana, M. Puntoni, F. Bigazzi, M. Margelli, C. Petersen, R. Bonini,
T. Sampietro
Italy
1.39
AVERAGE LIPID PARAMETERS IN THREE CENTERS OF CENTRAL AND EASTERN
EUROPE: HAPIEE PROJECT
Ksenia Makarenkova, S. Malyutina, G. Simonova, M. Bobak, Y. Nikitin, HAPIEE Group
Russia
1.40
SMOKING INTENSITY MAY HINDER THE BENEFICIAL EFFECT OF STATIN THERAPY
ON CIRCULTING OXIDIZED LOW-DENSITY LIPOPROTEIN LEVELS AND CAROTID
AHTEROMATOUS STENOSIS
Sofoklis Kougialis, E. Skopelitis, D. Levisianou, A. Zervou, T. Gialernios, N. Kosmas,
E. Mouka, A. Galanopoulou, H. Mpilinis, A. Polydorou
Greece
1.41
OBESITY AND METABOLIC SYNDROME
Pavol Hlubik, H. Stritecka, J. Hlubik
Czech Republic
1.42
HOW IS LIPID PROFILE ALTERED AFTER CARDIAC SURGERY
Renato Alves, D. Aguiar, B. Andrade, K. Nakiri
Brazil
1.43
STUDY ON CHANGE OF VALUES OF CHOLESTEROL AND TRIGLYCERIDES IN
HYPERLIPIDEMIC PATIENTS IN RELATION TO THE SEASON OF THE YEAR
S.S. Patiakas, Charalampos C. Charalampous
Greece
1.44
ATHEROGENIC INDEX OF PLASMA [=(LOG10TRIGLYCERIDES/HDL-CHOLESTEROL)]
AND CRP DURING CHRONIC HEMODIALYSIS TREATMENT
Vladimir Soska, D. Sobotova
Czech Republic
1.45
LIPIDS AND INFLAMMATORY MARKERS IN THE ACUTE PHASE RESPONSE OF
MYOCARDIAL INFARCTION
Luis Bronze, J. Azevedo, M.J. Relvas, M.L. Andrade, I. Arroja, M. Mendes, M. Seabra,
G. Morais, A. Aleixo
Portugal
42
79th EAS CONGRESS
Poster Area
Poster No
1.46
DISORDERS OF LIPIDS METABOLISM IN PATIENTS WITH RHEUMATOID ARTHRITIS
Iryna Klymas
Ukraine
1.47
ACUTE EXERCISE INCREASES REMNANT LIPOPROTEIN CHOLESTEROL IN TYPE 1
DIABETES (T1DM)
Marta Gonzalez, L. Brugnara, S. Murillo, M. Guardiola, A. Novials, J. Ribalta
Spain
1.48
EFFECT OF STANDARD COMBINATION OF VALSARTAN WITH EITHER AMLODIPINE
OR HYDROCHLOROTHIAZIDE ON LDL SUBFRACTION PROFILE IN PATIENTS WITH
HYPERTENSION
Leonidas G. Christogiannis, M.S. Kostapanos, H.J. Milionis, Z. Mitrogianni,
E. Moutzouri, A.D. Tselepis, M.S. Elisaf
Greece
WORKSHOP: CELLULAR LIPID METABOLISM, FROM UPTAKE TO STORAGE
1.49
ARAP2-INDUCED CHANGES IN SPHINGOLIPID BIOSYNTHESIS PROMOTE LIPID
DROPLET FORMATION BY INCREASING GLUT1 LEVELS IN THE PLASMA
MEMBRANE
Lu Li, R. Mobini, E. Lu, M. Rutberg, M. Ståhlman, L. Håversen, B. Liu, T. Larsson,
R. Perkins, L. Andersson, K. Koistinen, K. Ekroos, J. Borén, S.O. Olofsson
Sweden
1.50
A NOVEL THREE-PROTEIN COMPLEX REGULATES IN VITRO VTV-GOLGI
FUSION
Shadab A Siddiqi, E. Nafi-Valencia, S. Siddiqi, A. Rahim
USA
1.51
MURINE BONE MARROW-DERIVED MACROPHAGES DIFFERENTIATED WITH
GM-CSF BECOME FOAM CELLS BY PI 3-KINASE GAMMA-DEPENDENT FLUIDPHASE PINOCYTOSIS OF NATIVE LDL
J.J. Anzinger, J. Chang, Q. Xu, T. Bohnacker, M.P. Wymann, Howard S. Kruth
USA
1.52
LIPID DROPLETS: STRUCTURE, PROTEIN ORGANIZATION AND BIOGENESIS
Horst Robenek, N.J. Severs, G. Weissen-Plenz, A. Ruebel, I. Buers
Germany
43
Metabolism
Poster Session
Metabolism
Poster Session
Poster Area
WORKSHOP: CELLULAR LIPID METABOLISM, FROM UPTAKE TO STORAGE (contd.)
Poster No
1.53
TRIACYLGLYCEROL-RICH LIPOPROTEINS INFLUENCE ON THE INACTIVATION
OF LIPOPROTEIN LIPASE BY ANGPTL 3 AND ANGPTL 4
Stefan Nilsson, M. Larsson, E. Worrsjö, A. Lookene1, V. Suokonina, E. Makoveichuk,
J. Heeren, G. Olivecrona
Sweden
1.54
THE GAIN OF FUNCTION D374Y-PCSK9 MUTANT CAN BE FUNCTIONALLY
INHIBITED IN VITRO BY AN EGF-A PEPTIDE
Angelo B. Cefalu', D. Noto, E. Pinotti, V. Valenti, P. Tarugi, M.R. Averna
Italy
1.55
PCSK9 IN FAMILIAL HYPERCHOLESTEROLEMIA (FH)
Gilles Lambert, K.A. Rye, J. Burnett, P. Barter, D. Marais
France, Australia
1.56
RIP2 LINKS IMMUNE SIGNALING AND SUBENDOTHELIAL LIPID
ACCUMULATION BY REGULATING TLR4-DEPENDENT LIPID UPTAKE IN
MACROPHAGES
Malin Levin, P. Jirholt, M. Johansson, A. Wramstedt, A. Lundberg, M. Ståhlman,
P. Fogelstrand, M. Brisslert, Z.Q. Yan, G. Hansson, H. Björkbacka, S.-O. Olofsson,
J. Borén
Sweden
1.57
APOLIPOPROTEINS A1 AND B AND THE RISK OF CARDIOVASCULAR
RECURRENCES IN ISCHEMIC STROKE PATIENTS
Simone Vidale, A. Sampietro, L. Tancredi, M. Arnaboldi
Italy
1.58
LDL SIZE DETERMINANTS DURING ANTIRETROVIRAL THERAPY INCLUDING
PROTEASE INHIBITORS IN HIV-1 INFECTED PATIENTS
Randa Bittar
France
44
79th EAS CONGRESS
Poster Area
Poster No
1.59
CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH OR
WITHOUT METABOLIC SYNDROME
Jesus Millan, C. Garcia Calzado, C. Recarte
Spain
1.60
CONSTITUTIVE INHIBITION OF PLASMA CHOLESTERYL ESTER TRANSFER
PROTEIN (CETP) BY APOLIPOPROTEIN C1 IN NORMOLIPIDEMIC, BUT NOT IN
HYPERLIPIDEMIC PATIENTS WITH CORONARY ARTERY DISEASE.
CONSEQUENCES ON PLASMA CHOLESTEROL DISTRIBU
X. Pillois, T. Gautier, J.-P. Pais de Barros, A. Jeannin, J. Bonnet, Laurent Lagrost
France
1.61
CHOLESTEROL LOWERING DRUGS INHIBIT THE ABSORPTION OF
CARDIOPROTECTIVE OMEGA-3 FATTY ACIDS
David Blackwood, A. Al-Busaidi, R. La Vallee, D. Jassal, G. Pierce
Canada
1.62
GROUP V SECRETORY PHOSPHOLIPASE A2 PROTECTS AGAINST CARDIAC
FIBROSIS - A POSSIBLE TARGET FOR HEART FAILURE TREATMENT
Boris Boyanovsky
USA
1.63
LACK OF INVARIANT NATURAL KILLER T CELLS DOES NOT AFFECT ADIPOSE
TISSUE INFLAMMATION AND METABOLIC DYSREGULATION IN DIET-INDUCED
OBESE MICE
Daniela Strodthoff, H.E. Agardh, A.M. Lundberg, G. Paulsson-Berne, G.K. Hansson,
N. Gerdes
Sweden
1.64
LIPID DROPLETS IN HUMAN MACROPHAGES RECRUIT CYTOSOLIC
PHOSPHOLIPASE A2 AND PROMOTE SECRETION OF INFLAMMATORY MEDIATORS
P. Boström, Y. Wickström, Lillemor Mattsson Hultén, R. Perkins, M. Ståhlman,
O. Wiklund, S.O. Olofsson, J. Borén
Sweden
1.65
REDUCED SYNTAXIN-5 IN SKELETAL MUSCLE OF PATIENTS WITH TYPE 2
DIABETES. A LINK BETWEEN LIPID STORAGE AND INSULIN RESISTANCE
Linda Andersson, S. Myhre, P. Bostrom, M. Ståhlman, B. Vind, L. Håversen, J. Borén,
K. Hojlund, S.O. Olofsson
Sweden
45
Metabolism
Poster Session
Metabolism
Poster Session
Poster Area
Poster No
1.66
SALVIANOLIC ACID B CAN INHIBIT MACROPHAGE UPTAKE OF MODIFIED-LDL BY
DIRECTLY BINDING TO TYPE B SCAVENGER RECEPTOR CD36
Li Wang, Y. Bao, Y. Xu, Y. Yang, L. Wang, S. Si, S. Cho, B. Hong
China
1.67
INHIBITION OF ENDOPLASMIC RETICULUM STRESS RECOVERS ABCA-1
EXPRESSION AND APO A-I-MEDIATED CHOLESTEROL EFFLUX IN MACROPHAGES
SUBMITTED TO GLYCOXIDATION
Gabriela Castilho, L.S. Okuda, E.R. Nakandakare, C.X.C. Santos, F.R.M. Laurindo,
M. Passarelli
Brazil
1.68
TG INTERACTING FACTOR ACTS AS A TRANSCRIPTIONAL REPRESSOR OF ACAT2
IN HUMAN
Camilla Pramfalk, M. Eriksson, P. Parini
Sweden
1.69
DIETARY SUGAR INCREASES LIVER CHOLESTEROL PARTLY THROUGH REDUCED
BILIARY SECRETION OF CHOLESTEROL AND BY REDUCED SYNTHESIS OF BILE
ACIDS
Johanna Lundberg, L. Persson, C. Gälman, B. Angelin, M. Rudling
Sweden
1.70
INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INCREASES
LIPID ACCUMULATION IN MACROPHAGES
Tuva Boerresdatter Dahl, T. Ranheim, S. Holm, P. Aukrust, B. Halvorsen
Norway
1.71
ANTI-ARRHYTHMIC EFFECTS OF VERY LOW DENSITY LIPOPROTEINS
Yangzhen Shao, A. Mijatovic, S. Gizurarson, T. Råmunddal, J. Borén, E. Omerovic
Sweden
1.72
FATTY ACID BINDING PROTEIN 4 INDUCES ENDOTHELIAL DYSFUNCTION
THROUGHT INSULIN-SIGNALING PATHWAY IN HUMAN UMBILICAL VEIN
ENDOTHELIAL CELLS
Gemma Aragonès, J. Girona, I. Lázaro, A. Cabré, L. Masana
Spain
46
79th EAS CONGRESS
Poster Area
Poster No
1.73
RELATIONSHIPS BETWEEN HSCRP REDUTION AND LDL-C, NON-HDL-C, APOB
AND HDL-C IN HYPERLIPIDEMIC PATIENTS TREATED WITH
EZETIMIBE/SIMVASTATIN + EXTENDED-RELEASE NIACIN
W Virgil Brown, S. Fazio, J.R. Guyton, Q. Dong, J.E. Tomassini, A. Shah,
A.M. Tershakovec
USA
1.74
COMPLETE SEQUENCING OF APOB GENE OF PATIENTS WITH CLINICAL
DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLAEMIA
Ana Catarina ALves, M. Bourbon
Portugal
1.75
VARIABILITY OF DIURNAL TRIGLYCERIDE LEVELS IN MEN AND WOMEN
Boudewijn Klop, A.J.H.H.M. van Oostrom, J.P.H. van Wijk, A. Alipour, E. Birnie,
J.W.F. Elte, J.S. Cohn, M. Castro Cabezas
The Netherlands
1.76
POST-PRANDIAL LIPIDEMIA IS REDUCED BY TREATMENT OF OBSTRUCTIVE
SLEEP APNOEA: A RANDOMISED, PLACEBO CONTROLLED TRIAL OF
CONTINUOUS POSITIVE AIRWAY PRESSURE
David Richmond Sullivan, N. Lai, C. Phillips, R. Grunstein, B. Yee, P. Liu
Australia
1.77
INFLUENCE OF THE GLUCOSE TOLERANCE TEST ON PRO-ATHEROGENIC
MODIFICATION OF LDL AND ITS RELATION TO PARAOXONASE ACTIVITY
Handrean Soran, V. Charlton-Menys, N. Younis, M. France, M. Bannerjee,
K. Cruickshank, P. Durrington
UK
1.78
SERUM LEVELS OF LIPIDS, OXIDATIVE STRESS AND HEPATIC HISTOLOGY IN
OBESE PATIENTS UNDERGOING BARIATRIC SURGERY
Osamah Amin Hussein, I. Shams, K. Abu Jabal, I. Dashkovsky, S. Szvalb,
I. Waksman
Israel
47
Metabolism
Poster Session
Metabolism
Poster Session
Poster Area
Poster No
1.79
MILDER PHENOTYPE OF RELATIVES OF INDEX PATIENTS CAN MISDIAGNOSE
FAMILIAL HYPERCHOLESTEROLEMIA
Ana Margarida Medeiros, A.C. Alves, M. Bourbon, on behalf of the Investigators of the
Portuguese FH Study
Portugal
1.80
SEASONAL VARIATIONS IN TRANS-SIALIDASE ACTIVITY IN HUMAN BLOOD
A.N. Orekhov, A.S. Feoktistov, E.A. Orekhova, V.A. Smutova, I.A. Sobenin,
Alexey V. Pshezhetsky
Canada
1.81
CHOLESTEROL METABOLISM IN PATIENTS WITH DIABETES MELLITUS TYPE 1
AND IMPACT OF WEIGHT REDUCTION
Jana Lesná, V. Bláha, A. Tichá, R. Hyńpler, F. Musil, L. Sobotka, A. Ńmahelová
Czech Republic
1.82
EZITIMIBE ALONE AND IN COMBINATION LOWERS CONCENTRATIONS OF SMALL,
DENSE LOW DENSITY LIPOPROTEINS IN TYPE 2 DIABETES MELLITUS
Karl Winkler, S. Jacob, T. Schewe, G. Putz, M.M. Hoffmann, T. Konrad
Germany
1.83
LIPOPROTEIN(A) AND FAMILY HISTORY OF CARDIOVASCULAR DISEASE IN
CHILDREN
Ornella Guardamagna, F. Abello, P. Assandro, G. Anfossi, M. Pirro
Italy
1.84
EZETIMIBE/SIMVASTATIN 10/40MG VERSUS ATORVASTATIN 40MG IN HIGH
CARDIOVASCULAR RISK PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: A
RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY
Fernando Civeira, A.G. Dan, P.L.K. Hing, M.E. Hanson, R. Massaad, C. Milardo,
J. Triscari
Spain
1.85
EZETIMIBE MONO-THERAPY AMELIORATES VASCULAR FUNCTION IN PATIENTS
WITH HYPERCHOLESTEROLEMIA THROUGH DECREASING OXIDATIVE STRESS
Hirotsugu Kurobe, K.I. Aihara, Y. Hirata, T. Motoki, M. Sugano, T. Kanbara,
T. Nakayama, T. Kitaichi, M. Akaike, M. Sata, T. Matsumoto, T. Kitagawa
Japan
1.86
IMPROVED PLASMA LIPID PROFILE AND REDUCTION IN HEPATIC STEATOSIS
WITH RIMONABANT THERAPY IN MORBIDLY OBESE PATIENTS
Anthony S Wierzbicki, S. Pendleton, Z. MacMahon, A. Dar, M.A. Crook, A.J. Botha
UK
48
79th EAS CONGRESS
Poster Area
Poster No
1.87
UPDATE OF THE BIOCHEMICAL AND MOLECULAR RESULTS OF PORTUGUESE
PATIENTS WITH FAMILIAL COMBINED HYPERLIPIDAEMIA
T. Santos, Q. Rato, I.M. Gaspar, M.T. Rico, J.M. Silva, Mafalda Bourbon
Portugal
1.88
THE EFFECTS OF COMBINING ROSUVASTATIN WITH SARTANS OF DIFFERENT
PPARΓ ACTIVATING CAPACITY ON LOW-DENSITY LIPOPROTEIN SUBFRACTIONS
AND LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2
C.V. Rizos, E.N. Liberopoulos, C.C. Tellis, M. Florentin, Moses S. Elisaf, A.D. Tselepis
Greece
1.89
THE PRESENCE OF REMNANT LIPOPROTEINS IN THE FASTING PLASMA WITH TG
LEVELS LESS THAN 150 MG/DL
Katsuyuki Nakajima, T. Nakano, Y. Tokita, T. Nagamine, S. Yatsuzuka,
Y. Shimomura, A. Tanaka
Japan
1.90
HYPERLIPIDEMIA AND OXIDATIVE STRESS ARE THE MAIN DETERMINANTS OF
INTIMA-MEDIA THICKNESS IN CHILDREN WITH CHRONIC KIDNEY DISEASE
Slavica Spasic, J. Kotur-Stevuljevic, A. Peco-Antic, M. Kostic, D. Vasic, A. Stefanovic,
A. Vujovic, Z. Jelic-Ivanovic, V. Spasojevic-Kalimanovska, D. Kornic
Serbia
1.91
IN SILICO MODELLING OF HUMAN LIPOPROTEIN METABOLISM
Martin Jansen, K. Winkler, G. Pütz, P. Pfaffelhuber
Germany
1.92
ATORVASTATIN INCREASES CHOLESTEROL LEVELS IN APOE/LDLR-DEFICIENT
MICE
Martina Slanarova, E. Brcakova, L. Vecerova, Z. Strasky, J. Rathouska, R. Hyspler,
A. Ticha, P. Nachtigal
Czech Republic
1.93
DETERMINATION OF SDLDL PARTICLES IN PATIENTS WITH FAMILIAL
HYERCHOLESTEROLAEMIA AND FAMILIAL COMBINED HYPERLIPIDAEMIA
A. Gomes, T. Santos, Mafalda Bourbon
Portugal
1.94
ACUTE STIMULATION OF ENDOGENOUS ESTROGEN IN WOMEN ALTERS
CHOLESTEROL METABOLISM AND REDUCES PCSK9 AND LDL CHOLESTEROL
LEVELS
Lena Persson, P. Henriksson, E. Westerlund, O. Hovatta, B. Angelin, M. Rudling
Sweden
49
Metabolism
Poster Session
Metabolism
Poster Session
Poster Area
Poster No
1.95
TARGET LIPID LEVELS AND RESERVES IN HYPOLIPIDEMIC THERAPY IN THE
PATIENTS AT VERY HIGH RISK OF CARDIOVASCULAR EVENTS
Jozef Petrus, F. Málek, J. Dvořák, V. Skalníková, P. Neužil
Czech Republic
1.96
OXIDIZED-LDL AND APO B48 IN DIABETIC KIDNEY DISEASE
Nicola Fanton, T. Moreno, M.J. Alférez, M. Jiménez, I. Coca, D. Vianello, A. Zambon,
P. ValdivielsoItaly
Italy
1.97
REDUCED ATHEROSCLEROTIC PLAQUE FORMATION IN APOE-/- MICE
LACKING PERILIPIN
Prakash Krishnamurti Doddapattar, E. Aflaki, B. Radovic, N. Rathke,
R.B. Gruenberger, D. Kratky
Austria
1.98
DYNASORE, A DYNAMIN GTPASE INHIBITOR, BLOCKS LATE
ENDOSOMAL/LYSOSOMAL CHOLESTEROL TRAFFICKING IN HUMAN
MACROPHAGES
Emmanuelle Girard, J.-L. Paul, P. Beaune, C. Lamaze, B. Védie
France
1.99
CHOLESTEROL LOADING OF HUMAN MACROPHAGES REDUCES GROWTH
FACTOR-INDUCED HETEROGENEITY OF GENE EXPRESSION INVOLVED IN FOAM
CELL FORMATION
Jani Lappalainen, N. Yeung, M. Jauhiainen, P.T. Kovanen, M. Lee-Rueckert
Finland
1.100
LOW DENSITY LIPOPROTEIN ENHANCES C-REACTIVE PROTEIN-MEDIATED
FCγ RECEPTOR SIGNAL TRANSDUCTION IN MACROPHAGES BUT NOT IN
MONOCYTES
Kefei Li, M. Radermacher, M. Kächele, C. Röcker, A. Pott, D. Manolov, W. Ito,
U. Nienhaus, J. Torzewski, O. Zimmermann, J. Wiehe, M. Bienek-Ziolkowski,
H. Ruland, K. Vogt
Germany, China
50
79th EAS CONGRESS
Poster Area
Poster No
1.101
IMPACT OF OMEGA 3 AND OMEGA 6 FATTY ACIDS MEMBRANE
INCORPORATION ON CHOLESTEROL EFFLUX FROM CULTURED RAT
CARDIOMYOCYTES
Natalie Fournier, A. Reboulleau, V. Robert, B. Vedie, J.L. Paul , A. Grynberg
France
1.102
NEW LMF1 VARIANTS IDENTIFIED IN HYPERTRIGLYCERIDEMIC PATIENTS
Isabel De Castro-Orós, E. Ros, F. Civeira, M. Pocoví
Spain
1.103
REGULATION OF LIVER AND ADIPOSE TISSUE LIPOGENESIS IN HUMAN
OBESITY
Joerg Heeren, M. Vossen, T. Scherer, L. Eissing, U. Knippschield, K. Toedter,
C. Buettner, A. Wolf, L. Scheja
Germany
1.104
SERUM LEVELS OF ANGIOPOIETIN-LIKE PROTEIN 4 (ANGPTL4) ARE INVERSELY
CORRELATED WITH OBESITY IN HEALTHY YOUNG ADULT TWINS
Marius Robert Robciuc, J. Naukkarinen, H. Tyynismaa, T. Raivio, A. Ortega-Alonso,
A. Suomalainen, J. Kaprio, A. Rissanen, M. Jauhiainen, C. Ehnholm,
K. Pietiläinen
Finland
1.105
THE REDUCTION IN HDL RECEPTOR LEVELS IN MACROPHAGES IS RELATED TO
ROS GENERATION INDUCED BY ADVANCED GLYCATED ALBUMIN
Raphael Souza Pintio, B.A. Paim, G. Castilho, E.R. Nakandakare, A.E. Vercesi,
M. Passarelli
Brazil
1.106
AGE-ALBUMIN INDUCES INTRACELLULAR LIPID ACCUMULATION BY MODIFYING
THE EXPRESSION OF GENES INVOLVED IN MACROPHAGE REVERSE
CHOLESTEROL TRANSPORT AND CHOLESTEROL HOMEOSTASIS
A. Machado-Lima, R.T. Iborra, R.S. Pinto, C.H. Sartori, E.R. Oliveira, J.T. Stefano,
E.R. Nakandakare, D. Giannella-Neto, M.L. Corrêa-Giannella, Marisa Passarelli
Brazil
1.107
INCREASED EXPRESSION OF LDLR AND ACCUMULATION OF CHOLESTEROL
ESTERS IN RISK AND INFARCT AREA OF PIG HEARTS AFTER MYOCARDIAL
INFARCTION
L. Karlsson, Christina Olsson, M. Ståhlman, T. Larsson, J. Perman, L. Grip, J. Borén,
S.O. Olofsson
Sweden
51
Metabolism
Poster Session
Metabolism
Poster Session
Poster Area
Poster No
1.108
EFFECTS OF THE COMBINATION OF SIMVASTATIN AND EZETIMIBE IN
CHYLOMICRON KINETICS IN PATIENTS WITH STABLE CORONARY ARTERY
DISEASE
Otavio Celeste Mangili, R.D. dos Santos, R.C. Maranhão, A.C.M. Gagliardi,
L.C. Mangili
Brazil
1.109
PHOSPHOLIPIDOSIS IN STRESSED BY PRESENCE OF TNFA AND FATTY ACIDS
(MIMICKING METABOLIC SYNDROMECONDITION) ENDOTHELIAL CELLS
Beata Kiec-Wilk, U. Czech, A. Knapp, M. Awsiuk, J. Goralska, A. Sliwa, A. Gruca,
H. Robenek, G. Schmitz, A. Dembinska-Kiec
Poland
1.110
PANCREATITIS DUE TO MASSIVE HYPERTRIGLYCERIDAEMIA IN ALSTRÖM`S
SYNDROM - A CASE REPORT
Niels Gauer, E. Giannakidou-Jordan, E. Steinhagen-Thiessen, U. Kassner
Germany
1.111
ADIPOSE TISSUE GENE EXPRESSION OF FACTORS RELATED TO LIPID
PROCESSING IN OBESITY
M. Clemente-Postigo, F.J. Tinahones, Fernando Cardona
Spain
1.112
OLD MYTHS AND NEW INSIGHTS: INTERACTION OF LDL-SUBCLASSES WITH
HUMAN FIBROBLASTS
Gerhard Putz, K. Winkler
Germany
1.113
ELEVATED APOLIPOPROTEIN C-III CONTENT IN RECONSTITUTED LOW-DENSITY
LIPOPROTEIN EXACERBATED CELLULAR ATHEROSCLEROSIS AND
NONENZYMATIC PROTEIN GLYCATION.
Seong-Min Kim, K.H. Cho
Republic of Korea
1.114
ADIPOPHILIN ACCUMULATED CELLULAR LIPID THROUGH ERK1/2-PPARΓ
PATHWAY IN RAW264.7 CELLS
Zhonghua Yuan, Q. Liu, Z. Liu, C. Tang, Z. Wang, G. Yi, Y. Yang
China
1.115
WHAT CAN TEACH US CORRELATIONS BETWEEN MRNAS CONTENTS IN
MACROPHAGES FROM MEN AND WOMEN?
A. Smirnov, T.A. Shchelkunova, I.A. Morozov, P.M. Rubtsov, I.A. Sobenin,
Alexander N. Orekhov, I.V. Andrianova, E.G. Rudymov
Russia
52
79th EAS CONGRESS
Poster Area
Poster No
1.116
ESTIMATION OF THE CONTRIBUTION OF MACROPHAGE MRNAS TO THE
OBSERVED CHANGES IN MRNAS LEVELS IN THE VESSEL INTIMA AT
ATHEROGENESIS
A. Smirnov, T.A. Shchelkunova, I.A. Morozov, P.M. Rubtsov, I.A. Sobenin,
Alexander N. Orekhov, I.V. Andrianova
Russia
1.117
ENHANCED BIOSYNTHESIS OF GANGLIOSIDE GM3 IN ATHEROSCLEROSIS
Nelya N Samovilova, E.V. Gracheva, N.K. Golovanova, O. Kaliya, N.V. Prokazova
Russia
1.118
POSSIBLE ROLE OF SPHINGOLIPIDS IN BETA-CAROTENE -INDUCED ENDOTHELIA
PROANGIOGENIC ACTIVITY
Anna Polus, B. Kiec-Wilk, M. Mikołajczyk, J. Hartwich, R. Goralczyk,
A. Dembinska-Kiec
Poland
WORKSHOP: MECHANISMS FOR THE PROTECTIVE ROLE OF HDL
1.119
NOVEL ABCA1 MUTATIONS IN L PATIENTS WITH SEVERE HDL DEFICIENCY WITH
OR WITHOUT CLASSIC MANIFESTATIONS OF TANGIER DISEASE
Paolo Zanoni, T. Fasano, P.B. Deegan, A. Park, M.D. Feher, F. Gurakan, E. Favari,
F. Bernini, S. Calandra
Italy
1.120
SPHINGOSINE KINASE INHIBITION INDUCES BOTH PRO- AND ANTI-ATHEROGENIC
EFFECTS IN LOW-DENSITY LIPOPROTEIN RECEPTOR-DEFICIENT MICE
Sara Costa, F. Poti, M. Bot, V. Bergonzini, M. Galletti, L. Maynes, G. Varga, M. Simoni,
J.R. Nofer
Italy
1.121
MITOCHONDRIAL INHIBITORY FACTOR 1 (IF1) IS PRESENT IN HUMAN SERUM
AND ITS LEVEL IS POSITIVELY ASSOCIATED TO HDL-C
A. Genoux, V. Pons, M. Laffargue, G. Combes, J.B. Ruidavets, J. Ferrières, B. Perret,
Laurent O Martinez
France
1.122
HDL FUNCTION IS IMPAIRED IN PATIENTS WITH ACUTE MYOCARDIAL
INFARCTION INDEPENDENT OF PLASMA HDL CHOLESTEROL LEVELS
Wijtske Annema, H.M. Willemsen, R.A. Tio, U.J.F. Tietge
The Netherlands
53
Metabolism
Poster Session
Metabolism
Poster Session
Poster Area
WORKSHOP: MECHANISMS FOR THE PROTECTIVE ROLE OF HDL (contd.)
Poster No
1.123
NIACIN, ATORVASTATIN AND FENOFIBRATE DECREASE PLASMA CETP BY
REDUCTION OF THE HEPATIC MACROPHAGE CONTENT IN APOE*3-LEIDEN.CETP
MICE
Y. Wang, Z. Li, M. Hoekstra, V. Bieghs, R. Shiri-Sverdlov, T.J.C. Van Berkel,
J.W.A. Smit, H.M.G. Princen, J.A. Romijn, L.M. Havekes, Patrick C.N. Rensen
The Netherlands
1.124
PROTEOMIC ALTERATIONS OF HDL FROM HEMODIALYSIS PATIENTS ARE
ASSOCIATED WITH IMPAIRED CHOLESTEROL EFFLUX CAPACITY
Michael Holzer, R. Birner-Gruenberger, V. Binder, D. El-Gamal, G. Marsche
Austria
1.125
PROTECTION OF HDL AGAINST SPHINGOMYELINASE-MODIFIED LDL
AGGREGATION AT ACIDIC PH
Su Duy Nguyen, K. Öörni, P.T. Kovanen
Finland
1.126
THE INHIBITION OF HEPATIC ACYL COENZYME A:CHOLESTEROL
ACYLTRANSFERASE (ACAT) 2 POSITIVELY AFFECTS HDL METABOLISM AND
FUNCTIONALITY IN MICE
Matteo Pedrelli, P. Davoodpour, C. Degirolamo, M. Gomaraschi, L. Larsson,
L.L. Rudel, L. Calabresi, J.Å. Gustafsson, K. Steffensen, M. Eriksson,
P. Parini
Sweden
1.127
ANTI-INFLAMMATORY EFFECTS OF A NOVEL INDUCER OF APOLIPOPROTEIN
A-I SYNTHESIS: INSIGHTS FROM THE ASSERT STUDY
Stephen J Nicholls, A. Gordon, J. Johansson, C.M. Ballantyne, J.J. Kastelein,
N.C. Wong, M. Borgman, K. Wolski, S.E. Nissen
USA
1.128
PROTEIN CARBAMYLATION RENDERS HIGH-DENSITY LIPOPROTEIN
DYSFUNCTIONAL
Gunther Marsche, M. Gauster, M. Holzer
Austria
1.129
DIABETIC DYSLIPIDEMIA IS RESPONSIBLE FOR QUALITATIVE AND QUANTITATIVE
CHANGES IN HDL LIPID COMPOSITION
Marcus Ståhlman, A. Kontush, B. Fagerberg, K. Ekroos, J. Chapman,
J. Borén
Sweden
54
79th EAS CONGRESS
Poster Area
Poster No
1.130
APOLIPOPROTEIN A-I STIMULATES BOTH APOLIPOPROTEIN E AND
CHOLESTERYL ESTER TRANSFER PROTEIN SECRETION IN LIPID LOADED
MACROPHAGES
Loredan Stefan Niculescu, C.S. Stancu, M. Robciuc, A.V. Sima
Romania
1.131
MAST CELL ACTIVATION IN VIVO IMPAIRS THE MACROPHAGE REVERSE
CHOLESTEROL TRANSPORT PATHWAY IN THE MOUSE
Reija Silvennoinen, M. Lee-Rueckert, N. Rotllan, I. Judstrom, F. Blanco-Vaca,
M. Jauhiainen, J. Metso, J.C. Escola-Gil, P.T. Kovanen
Finland
1.132
CELLULAR CHOLESTEROL EFFLUX CAPACITY AND ANTIOXIDATIVE ACTIVITY OF
HDL SUBPOPULATIONS SHARE MAJOR COMPOSITIONAL AND STRUCTURAL
DETERMINANTS: ARE COMMON MECHANISMS INVOLVED?
Laurent Camont, M. Lhomme, S. Chantepie, F. Rached, R. Frigola, W. Le Goff,
M.J. Chapman, A. Kontush
France
1.133
AGE-ASSOCIATED DECREASE IN HDL AND PON-1 ANTI-INFLAMMATORY ACTIVITY
AND EFFECT OF OLIVE OIL SUPPLEMENTATION
Soumaya Loued, O. Helal, T. Saiid, A.J. Rouleau, H. Berrougui, A. Khalil
Canada
1.134
COMPARISON OF THEORETICAL AND EXPERIMENTAL RELATIONSHIPS BETWEEN
HDL SIZE AND THE RATIO OF HDL CHOLESTEROL (HDL-C) TO APOLIPOPROTEIN
A-I (APOA-I)
Norman A. Mazer, S. Mora
Switzerland
1.135
HISTONE DEACETYLASE (HDAC) INHIBITORS UPREGULATE
CLUSTERIN/APOLIPOPROTEIN J EXPRESSION IN VASCULAR SMOOTH MUSCLE
CELLS (VSMCS)
Frank M. Yatsu, K. Ranganna, O.P. Mathew
USA
1.136
CHOLESTEROL EFFLUX POTENTIAL OF SERA FROM PATIENTS BEFORE AND
AFTER LDL-APHERESIS
Elda Favari, M.P. Adorni, F. Sbrana, M. Puntoni, F. Bigazzi, F. Zimetti, F. Bernini,
T. Sampietro
Italy
1.137
INCREASING CIRCULATING CONCENTRATION OF ALL HDL PARTICLE
SUBCLASSES IN HYPER-RESPONDERS TO APOLIPOPROTEIN A-I INDUCTION:
INSIGHTS FROM THE ASSERT STUDY
Stephen J. Nicholls, A. Gordon, J. Johansson, C.M. Ballantyne, J.J. Kastelein,
N.C. Wong, M. Borgman, K. Wolski, S.E. Nissen
USA
55
Metabolism
Poster Session
Metabolism
Poster Session
Poster Area
Poster No
1.138
LYCOPENE REDUCES INFLAMMATION AND IMPROVES HDL FUNCTIONALITY IN
OVERWEIGHT INDIVIDUALS
J. McEneny, Lauren Wade, A. Mcginty, I. Young, F. Thies
UK
1.139
EFFECT OF DALCETRAPIB ON NON-CHOLESTEROL MARKERS OF CHOLESTEROL
HOMEOSTASIS IN HEALTHY SUBJECTS
Eric J Niesor, E. Chaput, A. Staempfli, M. Derks, D. Kallend
Switzerland
1.140
CERAMIDE AS A POTENTIAL LIPIDOME BIOMARKER OF HDL FUNCTIONALITY:
RELEVANCE TO POTENT ANTI-APOPTOTIC ACTIVITY IN SMALL, DENSE HDL3
Anatol Kontush, M. Stahlman, M. Lhomme, J. de Souza, J. Boren,
M.J. Chapman
France
1.141
ARE HDL PARTICLES DYSFUNCTIONAL IN ACUTE CORONARY SYNDROME
PATIENTS WITH STEMI AND LOW HDL-CHOLESTEROL LEVELS: IMPACT OF
STATIN?
Fabiana Hanna Rached, C.V. Serrano Jr, L. Camont, A.L. Pinto, M. Barros, W. Goff,
J. Chapman, A. Kontush
France, Brazil
1.142
ATORVASTATIN AND HORMONE REPLACEMENT THERAPY AFFECT EXPRESSION
OF GENES REGULATING THE REVERSE CHOLESTEROL TRANSPORT IN
MONONUCLEAR CELLS FROM POSTMENOPAUSAL WOMEN
Alvaro Cerda, F.D. Genvigir, C.B. Rohde, M. Issa, S.A. Cavalli, M.C. Bertolami,
M.H. Hirata, R.D. Hirata
Brazil
1.143
TANGIER DISEASE: A PLASMA PROTEOME APPROACH
Mariarita Puntoni, C. Boccardi, F. Sbrana, S. Rocchiccioli, F. Bigazzi, L. Citti,
T. Sampietro
Italy
1.144
EFFECT OF EZETIMIBE ON COMPONENTS OF HDL SUBCLASS IN PATIENTS WITH
END-STAGE RENAL DISEASE
Yasuki Ito, T. Hirano, K. Nohtomi, N. Nakanishi, T. Watanabe, T. Hyodo, T. Taira
Japan
1.145
GENE PROFILING ON THE EFFECTS OF HDL ON ACTIVATED HUMAN
MONOCYTES
Xiao Lei Moore, Y. Fu, I. Haviv, D. Sviridov, J. Chin-Dusting
Australia
56
79th EAS CONGRESS
Poster Area
Poster No
1.146
A NOVEL APOA-I MIMETICS, FAMP CONSTRUCTS PRE-BETA HDL IN VITRO
AND IN VIVO
Yoshinari Uehara, K. Oniki, H. Tanigawa, S. Abe, S. Ando, E. Yahiro, S.-I. Miura,
K. Saku
Japan
1.147
CORONARY ANGIOPLASTY CHANGES THE HDL PROTEOME OF PATIENTS
WITH CORONARY DISEASE
Elena Burillo, I. Jorge, E. Nuñez, R. Mateo-Gallego, P. Martin-Fuentes, A. Cenarro,
J. Vazquez, F. Civeira
Spain
1.148
ADDITIVE EFFECTS OF NIACIN ON TOP OF SIMVASTATIN TREATMENT IN
REDUCING ATHEROSCLEROSIS IN APOE*3LEIDEN.CETP MICE
Mieke Louwe, S. Kühnast, J. Smit, L. Havekes, P. Rensen, J. van der Hoorn,
H. Princen, W. Jukema
The Netherlands
1.149
DETERMINATION OF PARAOXONASE-3 CONCENTRATION IN HUMAN SERUM:
METHOD EVALUATION, REFERENCE VALUES AND INFLUENCE OF GENOTYPES IN
A POPULATION-BASED STUDY
Jordi Camps, G. Aragonès, A. García, M. Barreda, J. Marsillach, R. Beltrán-Debón,
A. Rull, B. Mackness, M. Mackness, J. Joven
Spain
1.150
REGULAR EXERCISE INCREASED PLASMA PRE-BETA 1-HDL
CONCENTRATION IN ADULT WOMEN WITH METABOLIC SYNDROME
M. Rosety-Rodriguez, F.J. Ordoñez, I. Rosety, A. Diaz-Ordoñez, M.A. Rosety,
A. Camacho, N. Garcia, J. Rosety, Gabriel Fornieles-Gonzalez
Spain
1.151
HDL2 LEVELS REDUCE THE ASSOCIATION OF LDL WITH ARTERIAL
PROTEOGLYCANS : A NOVEL ANTI-ATHEROSCLEROTIC ROLE OF HDL
SUBCLASSES
Germán Camejo, B. Rosengren, M. Umaerus, E. Hurt-Camejo
Sweden
57
Metabolism
Poster Session
Metabolism
Poster Session
Poster Area
Poster No
1.152
HDL MODULATES INSULIN SENSITIVITY AND SECRETION DURING ACUTE
PHASE OF MYOCARDIAL INFARCTION
Luiz Sérgio Fernandes De Carvalho, R.M.R. Cintra, A.L.R. Araújo, F.A. Moura, J.C.Q.E.
Silva, O.R. Coelho, A.C. Sposito
Brazil
1.153
OLIVE OIL CONSUMPTION EFFECT ON CHOLESTEROL EFFLUX AND
INFLAMMATION MARKERS
Olfa Helal, H. Berrougui, A. Khalil
Canada
1.154
EFFECT OF CHRONIC RENAL FAILURE ON SERUM AND HDL CHOLESTEROL
EFFLUX CAPACITY AND MACROPHAGE ABCA1/ABCG1 EXPRESSION
Sabine Schreier, M. Hollaus, E. Pemberger, S. Fruhwürth, C. Röhrl, F. Liebscher,
B. Englinger, J. Becker, A. Schmidt, H. Scharnagl, C. Aufricht, H. Stangl,
W. Strobl
Austria
1.155
SKIN AUTOFLUORESCENCE IS INVERSELY RELATED TO HDL ANTI-OXIDATIVE
CAPACITY IN TYPE 2 DIABETES MELLITUS
Douwe J. Mulder, J.F. De Boer, R. Graaff, R. De Vries, W. Annema, J.D. Lefrandt,
A.J. Smit, U.J.F. Tietge, R.P.F. Dullaart
The Netherlands
1.156
A HIGH-FAT CHOLESTEROL-CONTAINING DIET PROMOTES REVERSE
CHOLESTEROL TRANSPORT FROM MACROPHAGES TO FECES IN VIVO THAT
DEPENDS ON ABCG5/G8
Joan Carles Escolà-Gil, G. Llaverias, J. Julve, D. Santos, J. Méndez-González,
F. Blanco-Vaca
Spain
1.157
THE ANTIATHEROGENIC PROPERTIES OF HDL AFTER BARIATRIC SURGERY
Osamah Amin Hussein, I. Shams, K. Abu Jabal, I. Waksman, I. Dashkovsky,
S. Szvalb, N. Volkova, B. Fuhrman, M. Aviram
Israel
1.158
GLYCOXIDATION IMPAIRS THE HDL-MEDIATED OXYSTEROLS EFFLUX AND
INDUCES STEROL ACCUMULATION IN MACROPHAGES
Rodrigo Tallada Iborra, A. Machado-Lima, G. Castilho, V.S. Nunes,
E.R. Nakandakare, D.S. Abdalla, M. Passarelli
Brazil
58
79th EAS CONGRESS
Poster Area
Poster No
1.159
KEY ROLE OF LOW HDL CHOLESTEROL FOR THE ASSOCIATION OF METABOLIC
SYNDROME WITH INFLAMMATION IN PATIENTS WITH PERIPHERAL ARTERIAL
DISEASE
Philipp Rein, J. Ortmann, C.H. Saely, C. Boehnel, S. Beer, A. Vonbank,
I. Baumgartner, H. Drexel
1.160
HDL LOSES ITS ANTI-INFLAMMATORY PROPERTY AND EVEN INDUCES MORE
INFLAMMATION IN S100B OR LPS-STIMULATED MACROPHAGES PREVIOUSLY
EXPOSED TO AGE-ALBUMIN
Ligia Shimabukuro Okuda, G. Castilho, D.D.F.M. Rocco, E.R. Nakandakare,
S. Catanozi, M. Passarelli
Brazil
1.161
V156K-APOA-I IN LIPID-BOUND STATE IS MORE RESISTANT TO MODIFICATION OF
FRUCTOSYLATION IN STRUCTURAL AND FUNCTIONAL PROPERTIES
Jeong-Hye Yoon, K.H. Cho
Republic of Korea
1.162
HDL - ASSOCIATED PARAOXONASE 1 (PON1) HYDROLYZING ACTIVITY AGAINST
MACROPHAGE OXIDIZED LIPIDS PROTECTS AGAINST MACROPHAGE FOAM CELL
FORMATION AND ATHEROGENESIS
Michael Aviram
Israel
1.163
SERUM PARAOXONASE ESTERASE AND LACTONASE ACTIVITIES CORRELATE
WITH INTERMEDIATE SIZE HDL PARTICLES
Alejandro Gugliucci, T. Menini, K. Kotani, R. Hermo, R. Caccavello
USA
1.164
ROLE OF HOMOCYSTEINE THIOLACTONASE ACTIVITY AND ADMA LEVELS IN
HEMODIALYZED AND RENAL TRANSPLANTED PATIENTS
György Paragh, F. Sztanek, M. Harangi, L. Lőcsey, J.T. Padra, L. Asztalos, I. Seres
Hungary
1.165
INTERRELATIONSHIP BETWEEN LIPID METABOLISM AND MACULAR PIGMENT
OPTICAL DENSITY
Sanne van der Made, E. Kelly, T. Berendschot, J. Plat, R.P. Mensink
The Netherlands
1.166
IMPACT OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION ON NUCLEAR
MAGNETIC RESONANCE DERIVED LIPOPROTEIN PARTICLE PARAMETERS
Nina Rashedi, D. Brennan, J.J. Kastelein, S.E. Nissen, S. Nicholls
USA
59
Metabolism
Poster Session
Metabolism
Poster Session
Poster Area
Poster No
1.167
SEX HORMONES MODULATE REVERSE CHOLESTEROL TRANSPORT IN HUMAN
MACROPHAGES
A.N. Smirnov, T.A. Shchelkunova, I.A. Morozov, P.M. Rubtsov, I.A. Sobenin,
I.V. Adrianova, E.G. Rudymov, N.M. Mukhamedova, D.M. Martirosyan,
Alexander N. Orekhov
Russia
1.168
THE NASCENT HDL-LIKE PARTICLES CONTAINING APO A-I OR APO A-II ARE
INDEPENDENTLY GENERATED DURING PHOSPHOLIPIDS MEDIATED HDL
REMODELING
Anna Wolska, M. Czyżewska, K. Wołoszyn, A. Szutowicz, M. Wróblewska
Poland
WORKSHOP: REACTIVE LIPID COMPOUNDS AND MODIFIED LIPOPROTEINS IN DISEASE
PROCESSES
1.169
A RAPID EVALUATION MODEL FOR INFLAMMATORY DEATH USING
ZEBRAFISH LARVAE BY OXIDIZED LOW-DENSITY LIPOPROTEIN AND
DYSFUNCTIONAL HIGH-DENSITY LIPOPROTEINS
J. Park, K.H. Park, Kyung-Hyun Chos
Republic of Korea
1.170
APOLIPOPROTEIN M BINDS OXIDIZED PHOSPHOLIPIDS AND INCREASES THE
ANTIOXIDANT EFFECT OF HDL
Sara Elsoe Nielsen, J. Ahnström, C. Christoffersen, A.N. Hoofnagle, P. Plomgaard,
J.W. Heinecke, H. Björkbacka, B. Dahlbäck, L.B. Nielsen
Denmark
1.171
ANTI-ATHEROGENIC EFFECTS OF PERSIMMON (DIOSPYROS KAKI) PEEL IN
LDLR-/--DEFICIENT MICE: PLAQUE REDUCTION, INHIBITION OF OXLDL/Β2GPI
AUTOANTIGEN AND THROMBOXANE PLATELET ACTIVATION
Eiji Matsuura, N. Quan, K. Kobayashi, Y. Matsunami, M. Ide, M. Makarova, L. Shen,
S. Ohno, Y. Zheng, H. Kobayashi, L.R. Lopez
Japan
1.172
VITAMIN K ROLE IN ARTERIAL STIFFNESS DURING METABOLIC SYNDROME IN
RAT: DIRECT OR INDIRECT EFFECT VIA LIPID METABOLISM
Léa Emonnot, N. Côté, P. Mathieu, É. Levy, P. Moreau
Canada
60
79th EAS CONGRESS
Poster Area
PROCESSES (contd.)
Poster No
1.173
OXIDIZED LDL TRIGGER ENDOPLASMIC RETICULUM STRESS AND
AUTOPHAGY : PREVENTION BY HDL
Cécile Vindis, C. Muller, R. Salvayre, A. Nègre-Salvayre
France
1.174
PKC Γ IS INVOLVED IN OXIDIZED LDLS -INDUCED APOPTOSIS OF VASCULAR
SMOOTH MUSCLE CELLS
Cécile Ingueneau, P. Larroque, M.E. Reyland, R. Salvayre, A. Nègre-Salvayre,
C. Vindis
France, USA
1.175
PHOSPHATIDYLCHOLINE HYDROPEROXIDE-INDUCED RAC ACTIVATION: ITS
INVOLVEMENT IN THP-1 CELL ADHESION TO ICAM-1 VIA ACTIN POLYMERIZATION
Akira Asai, K. Nakagawa, F. Okajima, Y. Nakajima, M. Nagao, T. Miyazawa, S. Oikawa
Japan
1.176
APOE*3LEIDEN.CETP TRANSGENIC MICE AS MODEL FOR THE METABOLIC
SYNDROME
A.M. van den Hoek, J.W.A. van der Hoorn, M.C.E. Maas, C.M. van den Hoogen,
A. van Nieuwkoop, E.O. Offerman, E.J. Pieterman, L.M. Havekes, H.M.G. Princen
The Netherlands
1.177
DOES APO A-II CYCLE BETWEEN MATURE Α-HDL AND NASCENT PRE-Β HDL A-II
PARTICLES?
Anna Wolska, M. Czyżewska, K. Wołoszyn, A. Szutowicz, M. Wróblewska
Poland
1.178
HDL FROM ELDERLY AND RECONSTITUTED HDL CONTAINING GLYCATED
APOLIPOPROTEINS A-I SHARE PRO-ATHEROSCLEROTIC AND PRO-SENESCENT
PROPERTIES WITH INCREASED CHOLESTEROL INFLUX
K.H. Park, Kyung-Hyun Cho
Republic of Korea
1.179
PARAOXONASE AND HOMOCYSTEINE THIOLACTONASE ACTIVITIES AND
ASYMMETRIC DIMETHYL-ARGININE (ADMA) LEVEL IN HEMODIALYZED PATIENTS
Ildikó Seres, F. Sztanek, L. Lőcsey, M. Harangi, G. Paragh
Hungary
61
Metabolism
Poster Session
Metabolism
Poster Session
Poster Area
Poster No
1.180
TRANSFER OF LIPIDS TO HDL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
WITH AND WITHOUT CORONARY ARTERY DISEASE
Marilia C.O. Sprandel, W.A. Hueb, A. Casella-Filho, C.A. Segre, F.R. Freitas,
R.C. Maranhão
Brazil
1.181
ITINERARY OF HIGH DENSITY LIPOPROTEINS AND APOLIPOPROTEIN A-I
TRANSPORT THROUGH THE ENDOTHELIUM
Damir Perisa, L. Rohrer, A. von Eckardstein
Switzerland
1.182
MODIFIED APOLIPOPROTEIN (APO) A-I BY ARTIFICIAL SWEETENER CAUSES
SEVERE PREMATURE CELLULAR SENESCENCE AND ATHEROSCLEROSIS
Juyi Seo, K.H. Cho
Republic of Korea
1.183
LOW HDL IN SOUTH ASIAN IMMIGRANTS: COULD DYSFUNCTIONAL HDL BE THE
MISSING LINK?
S. Dodani, Lei Dong, S. Reddy
USA
1.184
REVERSE CHOLESTEROL TRANSPORT KEY PROTEINS AND ATHEROSCLEROSIS
Ekaterina Demina, V. Miroshnikova, A. Denisenko, A. Schvarzman
Russia
1.185
SERUM PARAOXONASE PHENOTYPE DISTRIBUTION IN EXUDATIVE AGE RELATED
MACULAR DEGENERATION AND ITS RELATIONSHIP TO HOMOCYSTEINE AND
OXIDIZED LOW DENSITY LIPOPROTEIN
Amir Ghorbanihaghjo, A. Javadzadeh, E. Bahreini, N. Rashtchizadeh, H. Argani,
S. Alizadeh
Iran
1.186
UNFOLDING OF EXCHANGEABLE APOLIPOPROTEINS
Alexander Dergunov
Russia
1.187
CHANGES IN FUNCTION AND STRUCTURE OF HIGH-DENSITY LIPOPROTEIN IN
OBESE PATIENTS COMPARED WITH HEALTHY CONTROLS
Salam Hama, H. Soran, Y. Liu, V. Charlton-Menys, R. Zadeh, M. France, R. Yadav,
M. Jeziorska, B. Ammori, P. Durrington
UK
62
79th EAS CONGRESS
Poster Area
Poster No
1.188
ASSESSMENT OF 2 METHODS FOR ISOLATION OF HIGH-DENSITY LIPOPROTEIN
(HDL)
Salam Hama, H. Soran, V. Charlton-Menys, Y. Liu, R. Yadav, M. France, B. Ammori,
P. Durrington
UK
1.189
HDL CHOLESTEROL/ APOLIPOPROTEIN AI RATIO INVERSELY LINKED WITH ACUTE
CORONARY SYNDROME, INDEPENDENT TO HDL CHOLESTEROL
Sung Yoon Lim, H.-S. Seo, E.J. Kim, J.O. Na, C.U. Choi, H.E. Lim, S.W. Rha, C.G. Parl,
D.J. Oh
Republic of Korea
1.190
RELATIONSHIP BETWEEN ALBUMINURIA AND SERUM LIPIDS IN TYPE 1 DIABETES
MELLITUS
T. Bulum, Ingrid Prkačin, L. Duvnjak
Croatia
1.191
IMPAIRED HIGH-DENSITY LIPOPROTEIN ANTIOXIDANT CAPACITY IN TYPE II
DIABETES
Raveenan Mingpakanee, N. Charoensa, Y. Phrawisat, W. Dahlan
Thailand
1.192
CARDIOVASCULAR PARAMETERS IN HIV POSITIVE PATIENTS WITH CHRONIC
PERIODONTITIS
R.V. Orellana, Andrea Monteiro, M.A. Gidlund, A. Mantesso, Eduardo Ramos Samches,
Henrique Fonseca
Brazil
1.193
SPECIFIC AGONIST OF THE CONSTITUTIVE ANDROSTANE RECEPTOR IMPROVES
REVERSE CHOLESTEROL TRANSPORT AND CHOLESTEROL HOMEOSTASIS IN
HYPERLIPIDEMIC MICE
D. Masson, A.L. Sberna, T. Gautier, J. Grober, A. Athias, M. Assem, L. Lagrost
France
PROCESSES
1.194
SUBCLINICAL HYPOTHYROIDISM IS RELATED TO A SPECIFIC LIPID PROFILE
INDEPENDENTLY OF TSH LEVELS
Antonio Hernández-Mijares, A. Jover, C. Bañuls, M. Rocha, E. Solá, L. Bellod
Spain
1.195
AMLODIPINE RESTORES ENDOTHELIAL FUNCTION ALTERED BY IRREVERSIBLY
GLYCATED LOW DENSITY LIPOPROTEINS
Laura Toma, C.S. Stancu, G.M. Sanda, A.V. Sima
Romania
63
Metabolism
Poster Session
Metabolism
Poster Session
Poster Area
PROCESSES (contd.)
Poster No
1.196
ANALYSIS OF EICOSANOIDS IN HUMAN LDL BEFORE AND AFTER CU-INDUCED
OXIDATION
Juliane Dorow, L. Kortz, S. Becker, J. Thiery, S. Hauschildt, U. Ceglarek
Germany
1.197
A GENETIC VARIANT WITHIN CAVEOLIN-3 PROTECTS AGAINST STATIN-INDUCED
MYOPATHY
Eleni Giannakidou-Jordan, C. Gelsinger, U. Kassner, H. Knoblauch, S. Spuler,
A. Busjahn, E. Steinhagen-Thiessen
Germany
1.198
DIFFERENTIAL EFFECT OF ASPIRIN ON OXIDATIVE STRESS, THROMBOXANE,
NITRIC OXIDE METABOLITES AND P-SELECTIN IN TYPE 2 DIABETES MELLITUS
Luis R Lopez, I. Muncy, E. Matsuura, J. Batuca, A. Oregon-Miranda, I. Garcia De La Torre,
P.R. Ames
USA
1.199
LDL FROM PATIENTS WITH METABOLIC SYNDROME OR TYPE 2 DIABETES SHOW
INCREASED LIPID PEROXIDATION AND ACTIVATE PLATELETS
Catherine Calzada, R. Colas, M. Guichardant, A. Sassolas, C. Cugnet-Anceau, M. Moret,
P. Moulin, M. Lagarde
France
1.200
DO MTTP MUTATIONS OVERCOME HETEROZYGOUS FAMILIAL
HYPERCHOLESTEROLEMIA? SEGREGATION ANALYSIS IN A FAMILY WITH BOTH
LDLR AND MTTP MUTATIONS
Mathilde Di Filippo, N. Peretti, P. Moulin, C. Jacobs, S. Chebel, A. Lachaux,
A. Sassolas
France
1.201
PLAQUE OXYSTEROLS INDUCE IMBALANCED UP-REGULATION OF MMP-9 IN
MACROPHAGIC CELLS THROUGH REDOX-SENSITIVE SIGNALING PATHWAYS
Simona Gargiulo, P. Gamba, B. Sottero, G. Poli, G. Leonarduzzi
Italy
1.202
SAFETY PROFILE OF STATINS ALONE OR COMBINED WITH EZETIMIBE: A POOLED
ANALYSIS OF OVER 21,000 PATIENTS
Peter P Toth, W. Weintraub, D. Morrone, M.E. Hanson, R.S. Lowe, J. Lin, A. Shah,
A.M. Tershakovec
USA
64
79th EAS CONGRESS
Poster Area
PROCESSES (contd.)
Poster No
1.203
PITAVASTATIN HAS PLEIOTROPIC ANTI-OXIDATIVE AND ANTI-INFLAMMATORY
BENEFITS IN PATIENTS WITH DYSLIPIDAEMIA: RESULTS FROM A PHASE III STUDY
PROGRAMME
Neil Hounslow
UK
1.204
CORRELATION BETWEEN LP(A) AND PARAOXONASE IN PSORIASIS
Gianna Ferretti, T. Bacchetti, A. Campanati, O. Simonetti, A. Offidani
Italy
1.205
EFFECT OF EZETIMIBE ON MARKERS OF OXIDATIVE STRESS IN PATIENTS WITH
Michael S Kostapanos, A.T. Spyrou, C.C. Tellis, I.F. Gazi, A.D. Tselepis,
E.N. Liberopoulos, M.S. Elisaf
Greece
1.206
ASSOCIATION OF HYPERTENSION WITH SMALL, DENSE LOW-DENSITYLIPOPROTEIN IN PATIENTS WITHOUT METABOLIC SYNDROME
Yun Kyung Kim, H.S. Seo, J.O. Na, C.U. Choi, H.E. Lim, E.J. Kim, S.W. Rha, C.G. Park,
D.J. Oh
Republic of Korea
1.207
LIPID PROFILE IN PATIENTS WITH INFLAMMATORY POLYARTHRITIS PRIOR TO
THERAPY
Awal Zaki Alhusain, S.M. Verstappen, H. Mirjafari, D. Symmons, V. Charlton-Menys,
P. Durrington, D. Bunn, I.N. Bruce
UK
1.208
PROTEIN DISULFIDE ISOMERASE INHIBITION BY 4-HYDROXYNONENAL-ADDUCTS
CONTRIBUTES TO OXIDIZED LOW DENSITY LIPOPROTEIN-INDUCED APOPTOSIS
C. Muller, J. Bandemer, C. Vindis, R. Salvayre, Anne Negre-Salvayre
France
1.209
INDUCTION OF CYTOSKELETON REORGANISATION BY OX-LDL MEDIATES ID1DEPENDENT ANGIOGENESIS
Juhui Qiu, G. Wang, J. Hu, Y. Zheng, Q. Peng, X. Luo, C. Tang
China
1.210
THE CORRELATION BETWEEN APOLIPOPROTEINS B/A1 RATIO AND ARTERIAL
STIFFNESS IN THE PATIENTS WITH HYPERTENSION
Lucia Agoston-Coldea, S. Lupu, T. Mocan
Romania
1.211
LDL-APHERESIS FOR PREVENTION OF RECURRENT HYPERTRIGLYCERIDEMIAINDUCED ACUTE PANCREATITIS, A CASE REPORT
A. Saad, Patrick Moriarty
USA
65
Metabolism
Poster Session
Metabolism
Poster Session
Poster Area
PROCESSES (contd.)
Poster No
1.212
INCREASED LEVELS OF LOW-DENSITY LIPOPROTEIN S-HOMOCYSTEINYLATION IN
CHRONIC KIDNEY DISEASE (CKD)
Angelo Zinellu, G. Loriga, A.E. Satta, L. Deiana, C. Carru
Italy
1.213
CHANGES OF PLASMA ADIPONECTIN LEVEL AND LIPID PROFILE IN SEVERELY
OBESE PATIENTS BEFORE AND AFTER BARIATRIC SURGERY
Mohammad Javad Hosseinzadeh-Attar, A. Golpaie, M. Hosseini, H. Darakhshanian,
M. Talebpour
Iran
1.214
INVESTIGATION OF THE PATHOGENESIS OF ATHEROSCLEROSIS: ASSOCIATION
BETWEEN OXIDIZED LOW DENSITY LIPOPROTEINS AND ATHEROSCLEROSIS RISK
FACTORS
Zita Aušrelė Kučinskienė, L. Bagdonaite
Lithuania
1.215
IRREVERSIBLY GLYCATED LDL INCREASE INTRACELLULAR FREE CALCIUM
CONCENTRATION IN HUMAN VASCULAR SMOOTH MUSCLE CELLS
Gabriela Maria Sanda, C.S. Stancu, A.V. Sima
Romania
1.216
CLONING AND EXPRESSION OF A FLUOBODY RECOGNIZING MINIMALLY
MODIFIED LOW-DENSITY LIPOPROTEIN
Tanize Espírito Santo Faulin, V.R. Hering, M.J. Politi, D.S.P. Abdalla
Brazil
1.217
THE EFFECT OF PITAVASTATIN AND PRAVASTATIN ON THE SERUM
PHOSPHATIDYLCHOLINE HYDROPEROXIDE (PCOOH) CONCENTRATION
Shinichi Oikawa, F. Okajima, A. Asai, Y. Ishigaki, Y. Oka, S. Kono, J. Sasaki, H. Sugihara,
K. Nakagawa, T. Miyazawa
Japan
1.218
THE ROLE OF CARDORIUM PLUS ON SERUM LIPIDS, INFLAMMATION AND
OXIDATIVE STRESS IN HYPERLIPIDEMIC BROILER CHICKS
Murty S S G P M V R Devarakonda, Rajesh Enjamoori
India
1.219
MULTIPLEX MASSARRAY SPECTROMETRY ASSAY FOR DETECTING 36 FH
MUTATIONS/POLYMORPHISMS IN GREEK AND CYPRIOT PATIENTS
Evy Bashiardes, S. Xenophontos, G. Miltiadous, M. Elisaf, M. Cariolou
Cyprus
66
79th EAS CONGRESS
Poster Area
PROCESSES (contd.)
Poster No
1.220
OXIDIZED PHOSPHOLIPIDS (OXPLS) INDUCE PRODUCTION OF STEM CELL
FACTOR (SCF) AND ACTIVATION OF ITS RECEPTOR C-KIT IN ENDOTHELIAL CELLS
Taras Afonyushkin, O.V. Oskolkova, V.N. Bochkov
Austria
1.221
METABOLIC SYNDROME IN SOUTH ASIAN IMMIGRANTS: MORE THAN LOW HDL
REQUIRING AGGRESSIVE MANAGEMENT
Sunita Dodani, M. Butler, J. Vacek, K. Gupta
USA
1.222
LONG CHAIN N-3 POLYUNSATURATED FATTY ACIDS (LCN3PUFA),
EICOSAPENTAENOIC ACID (EPA) AND DOCOSAHEXAENOIC ACID (DHA),
MODULATE HUMAN THP-1 MACROPHAGE CHOLESTEROL LEVELS
Sheila McCartan, A. McGinty, B. Green, C. Mercer, J. McEneny, L.A. Powell
UK
1.223
APOLIPOPROTEIN B OF LOW-DENSITY LIPOPROTEIN REDUCES NITRIC OXIDEMEDIATED ENDOTHELIUM-DEPENDENT RELAXATION IN RAT MESENTERIC
ARTERIES
Cang-Bao Xu, W. Zhang, Y. Zhang, L. Edvinsson
Sweden
1.224
HEALTH EFFECTS OF OXIDIZED COD LIVER OIL IN HEALTHY SUBJECTS:
A RANDOMIZED CONTROLLED TRIAL
Inger Ottestad, G. Vogt, M. Myhrstad, K. Retterstøl, A. Nilsson, J.E. Haugen,
G. Ravn-Haren, K.W. Brønner, L.F. Andersen, K. Holven, S. Ulven
Norway
1.225
PLASMA MALONDIALDEHYDE MEASUREMENT BY FIELD-AMPLIFIED SAMPLE
STACKING (FASI) CAPILLARY ELECTROPHORESIS UV DETECTION
A. Zinellu, B. Scanu, E. Pisanu, M. Sanna, V. De Murtas, M.A. Pinna, D. Cambedda,
L. Deiana, Ciriaco Carru
Italy
67
Metabolism
Poster Session
Metabolism
Poster Session
Poster Area
PROCESSES (contd.)
Poster No
1.226
OX-LDL INHIBITS THE MIGRATION OF VASCULAR SMOOTH MUSCLE CELLS VIA
UP-REGULATION OF P53 EXPRESSION
Jianjun Hu, G. Wang, J. Qiu, Y. Zheng, Y. Teng, H. Chen, C. Tang, T. Yin
China
1.227
THE EFFECT OF OXIDATIVE STRESS UPON MEMBRANE AND CYTOPLASMIC
LIPIDS PEROXIDATION IN ERYTHROCYTES FROM PATIENTS WITH
CARDIOVASCULAR AND CEREBROVASCULAR PATHOLOGIES
Cristian Romeo S. Revnic, C. Ginghina, F.G. Revnic, G. Prada, S. Prada, C. Pena,
S. Botea
Romania
1.228
YOUNGER PATIENTS WHO UNDERWENT MYOCARDIAL INFARCTION, HAD
INCREASED LEVELS OF OXIDATION-SUSCEPTIBLE LIPIDS
Pawel Burchardt, B. Zuchowski, H. Wysocki
Poland
1.229
EFFECT OF N-3 FATTY ACIDS AND STATINS ON OXIDATIVE STRESS IN STATINTREATED HYPERCHOLESTORELEMIC AND NORMOCHOLESTEROLEMIC WOMEN
M. Carrapeiro, M. Rogero, M. Bertolami, P. Botelho, N. Castro, Inar Castro
Brazil
1.230
THE EFFECT (OF IDENTICAL TO THE TYPE AND DOSE) OF STATINS TREATMENT IN
PATIENTS WITH CAD DEPENDS ON SMOKING
Pawel Burchardt, B. Zuchowski, A. Palasz, H. Wysocki
Poland
1.231
EZETIMIBE IMPROVES NAFLD AGGRAVATION INDUCED BY DIETARY
CHOLESTEROL OXIDATION PRODUCTS IN NON-HUMAN PRIMATES
Michiyo Deushi, K. Nakano, K. Osada, T. Kaizuka, K. Egashira, M. Yoshida
Japan
68
79th EAS CONGRESS
Poster Session
Poster Area
WORKSHOP: MECHANISMS FOR THE PROGRESSION AND REGRESSION OF
ATHEROSCLEROSIS
2.01
OXYSTEROL-BINDING PROTEIN-RELATED PROTEIN (ORP8) - A NEW PROATHEROGENIC FACTOR?
Olivier Beaslas, E. van Kampen, T. Vihervaara, G. Liebisch, R.B. Hildebrand, G. Schmitz,
M. Van Eck, V.M. Olkkonen
Finland
2.02
TARGETED GENE DELETION IN THE TGF-BETA SIGNALING PATHWAY
AFFECTS ATHEROSCLEROSIS AND TH17 CELL DIFFERENTIATION IN
HYPERCHOLESTEROLEMIC MICE
Anton Gisterå, A.K. Robertson, J. Andersson, D.F.J. Ketelhuth, A.M. Lundberg, M.O. Li,
R.A. Flavell, G.K. Hansson
Sweden
2.03
NANO- AND MICRO-STRUCTURE OF CALCIFICATION IN HUMAN AORTIC
VALVE, AORTA AND CORONARY WALL
Sergio Bertazzo, K.L. Cloyd, E. Gentleman, I. El-Hamamsy, A.H. Chester, M.H. Yacoub,
M.M. Stevens
UK
2.04
OSTEOPONTIN IS IMPORTANT FOR DEVELOPMENT OF UREMIC
ATHEROSCLEROSIS
Tanja Xenia Pedersen, N. Junker, M. Madsen, S. Bro, A. Hultgaardh-Nilsson, L.B. Nielsen
Denmark
2.05
SERINE PROTEASE INHIBITOR A3 INFLUENCES AORTIC ANEURYSM
FORMATION BUT NOT ATHEROSCLEROSIS
Dick Wågsäter, D. Johansson, X. Zhou, P. Eriksson
Sweden
2.06
GLYCATED HEMOGLOBIN FOR THE DIAGNOSIS OF TYPE 2 DIABETES IN
PERSONS UNDERGOING CORONARY ANGIOGRAPHY: THE LURIC STUDY
Guenther Silbernagel, M.E. Kleber, T.B. Grammer, B.R. Winkelmann, B.O. Boehm,
W. März
Germany
69
Poster No
Poster Session
Poster Area
Poster No
2.07
SPONTANEOUS PLAQUE DISRUPTIONS, DISSECTION, EROSION AND
INTRAPLAQUE HEMORRHAGE IN MURINE VEIN GRAFTS CAN BE ATTENUATED BY
TIMP-1 OVEREXPRESSION
Margreet R. de Vries, H.W.M. Niessen, C.W. Löwik, J.W. Jukema, P.H.A. Quax
The Netherlands
2.08
THE INFLUENCE OF INTRACORONARY INJECTION OF MONONUCLEAR BONE
MARROW CELLS ON PROTHROMBOTIC MARKERS IN PATIENTS WITH ACUTE
Svein Solheim, I. Seljeflot, K. Lunde, S. Aakhus, V. Bratseth, K. Forfang,
H. Arnesen
Norway
2.09
SOLUBLE FORM OF THE ENDOTHELIAL ADHESION MOLECULE CD146 BINDS
PREFERENTIALLY PROINFLAMMATORY-PROATHEROSCLEROTIC CD16+
MONOCYTE SUBSET
Chiara Barisione, G. Ghigliotti, P. Fabbi, P. Altieri, C. Brunelli, P. Spallarossa, A. Barsotti,
S. Garibaldi
Italy
2.10
ISOPRENOID PATHWAY INHIBITORS BLOCK INNATE PATHWAYS OF IMPORTANCE
FOR EARLY ATHEROGENESIS
Harald Loppnow, M. Buerke, A. Schlitt, U. Müller-Werdan, K. Werdan
Germany
2.11
INFLAMMATORY MARKERS AND DISEASE SEVERITY IN PATIENTS WITH CHRONIC
HEART FAILURE. LIMITED EFFECTS OF EXERCISE TRAINING
Rune Byrkjeland, B.B. Nilsson, A.S. Westheim, H. Arnesen, I. Seljeflot
Norway
2.12
SPECIFIC LP(A) APHERESIS FOR CAROTID ATHEROSCLEROSIS STABILIZATION IN
CHD PATIENTS WITH ELEVATED LP(A) LEVELS
Maya Safarova, M. Ezhov, O. Afanasieva, T. Balakhonova, I. Adamova, G. Konavalov,
S. Pokrovsky
Russia
70
79th EAS CONGRESS
Poster Session
Poster Area
2.13
CATECHOL-O-METHYLTRANSFERASE (COMT) IS DISPENSABLE FOR VASCULAR
PROTECTION BY ESTRADIOL IN MICE
Anna S. K. Wilhelmson, J. Bourghardt, P. Fogelstrand, J.A. Gogos, Å. Tivesten
Sweden
2.14
LONG-TERM TREATMENT WITH LOW-DOSE METOPROLOL CR/XL IS ASSOCIATED
WITH INCREASED PLAQUE ECHOGENICITY: THE BETA-BLOCKER CHOLESTEROLLOWERING ASYMPTOMATIC PLAQUE STUDY (BCAPS)
Gerd Östling, I. Gonçalves, J. Wikstrand, G. Berglund, J. Nilsson, B. Hedblad
Sweden
2.15
INFLAMMATION, LEUKOCYTE ACTIVATION, AND SURROGATE ATHEROSCLEROSIS
MARKERS IN RHEUMATOID ARTHRITIS PATIENTS ARE RELATED TO
MITOCHONDRIAL DEPOLARISATION AND OXIDATIVE STRESS
Chary Lopez-Pedrera, C. Perez-Sanchez, P. Ruiz-Limón, M.A. Aguirre, R.M. Carretero,
N. Barbarroja, A. Rodriguez-Ariza, E. Collantes-Estevez, J.M. Villalba, F. Velasco,
M. Khamashta, M.J. Cuadrado
Spain
2.16
IN VITRO DIFFERENTIATION OF BONE MARROW-DERIVED PORCINE
MESENCHYMAL STEM CELLS INTO ENDOTHELIAL CELLS: POTENTIAL ROLE OF
CANONICAL WNT SIGNALING PATHWAY
Devendra K Agrawal, D. Pankajakshan, V. Kansal
USA
2.17
EFFECTS OF LOW-DOSE TNF-Α-ADMINISTRATION ON OXIDATIVE/NITROSATIVE
STRESS, THE AKT/ENOS/NO PATHWAY AND VIABILITY IN CARDIAC ENDOTHELIAL
CELLS
Hans Strijdom, A. Genis, M. Mudau, C. Westcott, A. Lochner
South Africa
2.18
AN ASSOCIATION OF MUTATIONS OF MITOCHONDRIAL DNA WITH AORTIC
ATHEROSCLEROTIC LESIONS
Igor Sobenin M.A. Sazonova, A.Y. Postnov, A.N. Orekhov
Russia
2.19
THE JAK2 INHIBITOR-TYRPHOSTIN AG490 DOWN-REGULATES NAPDH OXIDASE
ACTIVITY AND EXPRESSION IN THE AORTA OF HYPERCHOLESTEROLEMIC APOEDEFICIENT MICE
Monica Raicu, I.M. Fenyo, I.C. Florea, A. Manea
Romania
71
Poster No
Poster Session
Poster Area
Poster No
2.20
RESISTIN UP- REGULATES FRACTALKINE AND CX3CR1 EXPRESSION IN
VASCULAR SMOOTH MUSCLE CELLS BY MAPK - NF-KB PATHWAY
Ana-Maria Gan, I. Manduteanu, V. Simion, D. Stan, M.M. Pirvulescu, M. Calin, E. Butoi,
M. Simionescu
Romania
2.21
RELATION OF EPICARDIAL ADIPOSE TISSUE TO CORONARY ATHEROSCLEROSIS
IS REGION-SPECIFIC AND INDEPENDENT OF CONVENTIONAL RISK FACTORS AND
INTRA-ABDOMINAL ADIPOSITY
Tzung-Dau Wang, W.J. Lee, W.J. Chen, M.F. Chen
Taiwan R.O.C.
2.22
PREDICTION OF LDL TRANSPORT AND PLAQUE FORMATION IN THE CAROTID
ARTERY
Nenad Filipovic, N. Meunier, M. Rosic, I. Tanaskovic, D. Fotiadis
Serbia
2.23
A ROLE FOR OXIDATIVE STRESS IN CIGARETTE SMOKE-INDUCED ELEVATION OF
OSTEOPONTIN IN CULTURED ENDOTHELIAL CELLS
Emma Louise Bishop, I.M. Fearon
UK
2.24
PLEIOTROPIC EFFECTS OF NIACIN THERAPY IN ADDITION TO ATORVASTATIN IN
CORONARY HEART DISEASE PATIENTS WITH ELEVATED LIPOPROTEIN(A) LEVELS
Maya Safarova, E. Trukhacheva, M. Ezhov, O. Afanasieva, M. Tripoten, S. Pokrovsky
Russia
2.25
ATHEROPROTECTIVE EFFECTS OF ADIPONECTIN OVER-EXPRESSION IN A
MODEL OF ANGII-ACCELERATED ATHEROSCLEROSIS
C.M.W. van Stijn, J. Kim, D. Becerra, Rajendra K. Tangirala
USA
2.26
CORONARY ARTERY CALCIFICATION AND DIABETES MELLITUS: SEXSPECIFIC IMPACT ON INCIDENCE OF CARDIOVASCULAR DISEASE - RESULTS OF
THE HEINZ NIXDORF RECALL-STUDY
Susanne Moebus, S. Möhlenkamp, N. Dragano, U. Slomiany, S. Pechlivanis, R. Erbel,
K. Mann, K.H. Jöckel, Heinz Nixdorf Recall Study Group
Germany
2.27
A POSSIBLE LINK BETWEEN ATHEROSCLEROTIC PLAQUE INFLAMMATION
AND VISCERAL FAT INFLAMMATION
Sung Eun Kim, E.J. Kim, J.S. Yeo, H.S. Seog
Republic of Korea
72
79th EAS CONGRESS
Poster Session
Poster Area
2.28
UROKINASE PLASMINOGEN ACTIVATOR (UPA) AND ATHEROSCLEROSIS
Bianca Fuhrman, J. Khateeb, Y. Lati, M. Aviram
Israel
2.29
ACCELERATED ATHEROSCLEROSIS IN FEMALE MICE LACKING THE
ANDROGEN RECEPTOR
Johan Bourghardt, A. Wilhelmson, C. Alexanderson, K. De Gendt, G. Verhoeven,
A. Holmäng, A. Krettek, S.O. Olofsson, C. Ohlsson, Å. Tivesten
Sweden
2.30
ATHEROSCLEROSIS REGRESSION IN A MOUSE MODEL WITH HUMAN-LIKE
J. Björkegren, S. Hägg, S. Maleki, M. Shang, T. Michoel, Josefin Skogsberg
Sweden
2.31
TRANSCRIPTOMIC ANALYSIS OF MACROPHAGE POLARIZATION: ROLE OF
PPARY IN ALTERNATIVE ACTIVATION
Eleonora Derlindati, D. Ardigò, I. Zavaroni
Italy
2.32
ENHANCED EXPRESSION OF SIRT1 IN ATHEROSCLEROTIC PLAQUES IS INVOLVED
IN THE PATHOGENESIS OF ACUTE CORONARY SYNDROMES
Kinta Hatakeyama, Y. Sato, T. Tsuruda, Y. Sekita, K. Nishihira, Y. Shibata, Y. Asada
Japan
2.33
EXPOSURE OF HUMAN MACROPHAGES TO TOBACCO SMOKE INDUCES MMP14
EXPRESSION AND GENERATION OF PROTEOLYTICALLY ACTIVE MICROVESICLES
C. Li, Y. Liu, D. Yu, K.J. Williams, Ming-Lin Liu
USA
2.34
OVEREXPRESSION OF ABCA1 IN HUMAN PLAQUES EXPOSED TO
HYPERCHOLESTEROLEMIA: ROLE OF MICRORNA MODULATION
Claudia Mandolini, D. Santovito, F. Buttitta, V. De Nardis, A. Marchetti, L. Felicioni,
M. Bucci, S. Ucchino, A. Mezzetti, F. Cipollone
Italy
2.35
CHOLESTEROL CONTENT OF ERYTHROCYTE MEMBRANES IS ASSOCIATED WITH
LIPID CORE SIZE IN ANIMAL MODEL OF ATHEROSCLEROSIS
Dimitrios Tziakas, A. Kapelouzou, G. Chalikias, D. Stakos, S. Apostolakis, A. Agapaki,
A. Kostakis, H. Boudoulas, S. Konstantinides
Greece
2.36
THERAPEUTIC REGRESSION OF ATHEROSCLEROSIS
Ahsan Ali, E. Grinevich, A. Mansharipova
Kazakhstan
73
Poster No
Poster Session
Poster Area
Poster No
2.37
IMPACT OF LOWER LIMB REVASCULARIZATION ON AORTIC AUGMENTATION
INDEX AND SUBENDOCARDIAL VIABILITY RATIO IN PATIENTS WITH PERIPHERAL
ARTERIAL DISEASE
Vincenzo Jacomella, A. Shenoy, K. Mosimann, M. Kohler, C. Thalhammer,
B. Amann-Vesti, M. Husmann
Switzerland
2.38
PHARMACOLOGICAL INHIBITION OF JAK/STAT SIGNALING PREVENTS HIGHGLUCOSE-INDUCED UP-REGULATION OF ENDOTHELIN-1 EXPRESSION IN HUMAN
ENDOTHELIAL CELLS
Simona Manea, A. Manea, C. Heltianu
Romania
2.39
METOPROLOL REDUCES PRO-INFLAMMATORY CYTOKINES AND
ATHEROSCLEROSIS IN APOE-/- MICE
Maria E Johansson, E. Bernberg, M.A. Ulleryd, G. Bergström
Sweden
2.40
THE LEGACY OF METABOLIC MEMORY AND THE ACTIVATION OF PROINFLAMMATORY GENES ARE ASSOCIATED WITH EPIGENETIC PERSISTENCE
Assam El-Osta
Australia
2.41
EARLY CHANGES IN VASCULAR SMOOTH MUSCLE CELLS GENE EXPRESSION
PROFILE IN RESPONSE TO VASCULAR INJURY
Anton Fedorov, A. Razuvaev, A. Kostareva, U. Hedin, J. Raud, J. Roy
Russia, USA
2.42
KYNURENINE PATHWAY - A NEW LINK BETWEEN ENDOTHELIAL DYSFUNCTION
AND CAROTID ATHEROSCLEROSIS IN CHRONIC KIDNEY DISEASE PATIENTS
Krystyna Pawlak, M. Mysliwiec, D. Pawlak
Poland
2.43
EXTRACORONARY ATHEROSCLEROSIS: RELATIONSHIP WITH VASCULAR
ALTERATIONS AND LIPOPROTEIN (A)
Rocio Toro, P. Gomez, M. Virseda, I. Tinoco, C. Rodriguez Leal, A. Mangas
Spain
2.44
SUPPRESSOR OF CYTOKINE SIGNALING-3 AND INTIMAL HYPERPLASIA IN
PORCINE CORONARY ARTERIES FOLLOWING CORONARY INTERVENTION
Devendra K Agrawal, G.K. Gupta, M.G. DelCore, G.I. Hatzoudis
USA
2.45
EFFECTS OF CIGARETTE SMOKE AND ITS INTERACTION WITH LDL IN A 3DIMENSIONAL COCULTURE MODEL OF PLAQUE DEVELOPMENT
Yvonne Steffen, D. Weiss, S. Lebrun, K. Stolle, M. Lietz, J. Schueller, T. Wallerath
Germany
74
79th EAS CONGRESS
Poster Session
Poster Area
2.46
THE APOE-/- MOUSE AS A CIGARETTE SMOKE-RESPONSIVE ATHEROSCLEROSIS
MODEL SHOWING REVERSIBILITY UPON SMOKING CESSATION
Katrin Stolle, M. Lietz, Y. Steffen, H. Weiler, M. Möhring, A. Berges, S. Lebrun
Germany
2.47
DOUBLE NEGATIVE T CELLS IN ANGIOTENSIN II DEPENDENT HYPERTENSION
Tomasz Mikołajczyk, R. Nosalski, A. Sagan, D. Skiba, D. Ludew, P. Matusik, R. Korbut,
T. Guzik
Poland
2.48
PERIPHERAL ARTERIAL DISEASE IN METABOLIC SYNDROME (METS):
PREDOMINANT LOCALIZATION OF ATHEROSCLEROSIS, HORMONE ABNORMALITY
AND CARDIOVASCULAR COMORBIDITY
Vladimir Andreev, V. Zelinsky
Russia
2.49
DARBEPOETIN ENHANCES ENDOTHELIUM-DEPENDENT VASOMOTOR
FUNCTION IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE ONLY
AFTER PRECEDING ISCHAEMIA-REPERFUSION
Lindsey Tilling, J. Hunt, A. Donald, B. Clapp, P. Chowienczyk
UK
2.50
RELATION OF MATRIX METALLOPROTEINASES (MMPS)-POSITIVE
MACROPHAGES TO CORONARY PLAQUE FRAGILITY AND CORONARY ARTERIAL
OUTWARD REMODELING
T. Ito, S. Yamada, N. Hirayama-Kuniyoshi, Masashi Shiomi
Japan
2.51
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2-INHIBITION
PREVENTS ENDOTHELIAL SUSCEPTIBILITY TO TNF-Α UNDER CHRONIC NONUNIFORM SHEAR STRESS
Katharina Urschel, W.G. Daniel, C.D. Garlichs, I. Cicha
Germany
2.52
THE GUT MICROBIOTA MODULATES ATHEROSCLEROSIS PROGRESSION IN
MALE APOE-/- MICE
Frida Fåk, C. Reinhardt, F.P. Martin, F. Bäckhed
Sweden
2.53
ALCOHOL INHIBITS NOTCH SIGNALING IN VASCULAR SMOOTH MUSCLE
CELLS AT THE LEVEL OF γ-SECRETASE
D. Morrow, J. Cullen, P. Cahill, Eileen Redmond
USA
75
Poster No
Poster Session
Poster Area
Poster No
2.54
CB2 RECEPTOR SIGNALING DOES NOT MODULATE ATHEROGENESIS IN MICE
Florian Willecke, K. Zeschky, D. Wolf, M. Moser, I. Hilgendorf, C. Bode, A. Zirlik
Germany
2.55
MICRORNA 143-145 DEFICIENCY IS ASSOCIATED WITH IMPAIRED VASCULAR
FUNCTION
Giuseppe Danilo Norata, C. Pinna, F. Zappella, L. Elia, G. Condorelli, A. Catapano
Italy
2.56
CARDIOVASCULAR RISK IN YOUNG WOMEN WITH PREMATURE OVARIAN FAILURE
AND SURGICAL MENOPAUSE
Natalia Sharashkina, O. Tkacheva, N. Latysheva, I. Novikova, L. Butoreva
Russia
2.57
CROSS-TALK OF HOMOCYST(E)INE AND THIOREDOXIN IN CORONARY ARTERY
DISEASE
Liangwei Zhong, Y. Wu, L. Yang
China
2.58
ROLE OF PERI-RENAL FAT(PRF) IN ASSOCIATION WITH RISK FACTORS FOR
ATHEROSCLEROSIS: A NEW METHODOLOGY.
Leonardo Borges Roever, E.S. Resende, N.P. Silva, A.D. Debs, L.H. Resende,
Atherosclerosis
Brazil
2.59
Β2-GLYCOPROTEIN I ENHANCES ENDOTHELIAL NITRIC OXIDE SYNTHASE
EXPRESSION AND NITRIC OXIDE GENERATION IN HUMAN AORTIC ENDOTHELIAL
CELLS
An-Na Chiang, W.C. Chiu, W.H.H. Sheu, S.Y. Lin
Taiwan R.O.C.
2.60
CORRELATION BETWEEN SERUM PARAOXONASE AND HOMOCYSTEINE
THIOLACTONASE ACTIVITY , ADIPOKINES AND ASYMMETRIC DIMETHYLARGININE
LEVELS IN RENAL TRANSPLANT PATIENTS
Lajos Locsey, I. Seres, F. Sztanek, L. Szabo, L. Asztalos, G. Paragh
Hungary
2.61
3-HYDROXYKYNURENINE - A NEW FACTOR ASSOCIATED WITH CAROTID
ATHEROSCLEROSIS, OXIDATIVE STRESS AND INFLAMMATION IN URAEMIA
Dariusz Pawlak, M. Mysliwiec, K. Pawlak
Poland
2.62
LEPTIN TRIGGERS DISTURBED CA2+ TRANSPORT IN MONOCYTES OF
OVERWEIGHT PATIENTS
János Tamás Padra, I. Seres, G. Fóris, Z. Balogh, G. Kónya, Z. Karányi, G. Paragh
Hungary
76
79th EAS CONGRESS
Poster Session
Poster Area
CHLOROGENIC ACID REDUCE PLASMA LIPIDS AND INFLAMMATORY-RELATED
GENE EXPRESSION IN HYPERLIPIDEMIC RABBITS
Ya-Mei Yu, W.C. Chang
Taiwan R.O.C.
2.64
IMPACT OF CIGARETTE SMOKE ON THE TRANSMIGRATION OF MONOCYTES
THROUGH AN ENDOTHELIAL CELL LAYER
Inka Gallitz, R. Janssens, K. Stolle, Y. Steffen, S. Wagner, S. Lebrun, M. Lietz
Germany
2.65
INVOLVEMENT OF PROTEIN TYROSINE PHOSPHATASE HYPERHOMOCYSTEINEMIA
AND HYPERCHOLESTEROLEMIA INDUCED VASCULAR ENDOTHELIAL
DYSFUNCTION
Saurabh Sharma, M. Singh, P.L. Sharma
India
2.66
VASOPROTECTIVE ACTIVITY OF SUPRAMOLECULAR SUPEROXIDE DISMUTASE CHONDROITIN SULFATE - CATALASE CONJUGATE
Alexander V. Maksimenko, A.V. Vavaev, E.G. Tischenko
Russia
2.67
CELL PROLIFERATION IN DIFFERENT ATHEROSCLEROTIC LESIONS OF HUMAN
ARTERIES
Alexander N. Orekhov, E.R. Andreeva, I.V. Adrianova, Y.V. Bobryshev
Russia, Australia
2.68
DISTRIBUTION OF HLA-DR-EXPRESSING CELLS IN THE INTIMA OF HUMAN AORTA:
POSSIBLE ROLE IN SURVEILLANCE AND MAINTENANCE OF VASCULAR
HOMEOSTASIS
Yuri V. Bobryshev, M.M. Moisenovich, O.L. Pustovalova, I.I. Agapov,
A.N. Orekhov
Russia, Australia
2.69
RELATIONSHIP BETWEEN INSULIN SENSITIVITY AND LIPID PROFILE IN
EUTHYROID TYPE 1 DIABETIC PATIENTS
T. Bulum, L. Duvnjak, Ingrid Prkačin
Croatia
2.70
ASSOCIATION BETWEEN EXTRACELLULAR MATRIX PROTEINS AND MATRIX
METALLOPROTEINASE ACTIVITY IN PATIENTS WITH ATHEROSCLEROTIC AND
NON-ATHEROSCLEROTIC THORACIC AORTIC ANEURYSMS
Olga Irtyuga, I. Voronkina, L. Smagina, V. Uspensky, N. Tsoy, E. Shlyakhto, O. Moiseeva
Russia
77
Poster No
2.63
Poster Session
Poster Area
Poster No
2.71
PURE TOCOTRIENOL ISOMERS REDUCE PROTEIN AND GENE EXPRESSION OF
LPS-INDUCED INFLAMMATION AND ENDOTHELIAL ACTIVATION IN ENDOTHELIAL
CELLS
S. Muid, G.R.A. Froemming, Hapizah Nawawi
Malaysia
2.72
RELATIONSHIP BETWEEN ENDOTHELIAL AND RENAL FUNCTION IN PATIENTS
WITH CHRONIC HEART FAILURE AND PRESERVED EJECTION FRACTION
Olga Mytrokhina, O. Kuryata, A. Miroshnichenko
Ukraine
WORKSHOP: CONSEQUENCES OF INFLAMMATION AND IMMUNE RESPONSE IN
ATHEROSCLEROSIS
2.73
RECOMBINANT ANTI-PHOSPHORYLCHOLINE IGG ANTIBODIES PREVENT
POST-INTERVENTIONAL ACCELERATED ATHEROSCLEROTIC VASCULAR
REMODELING
Mark M Ewing, S.A. Karabina, M. Nordzell, J.C. Karper, R. Atout, M.R. de Vries,
D. Sexton, H. Lettesjö, I. Dahlbom, O. Camber, J. Frostegard, E. Ninio, J.W. Jukema,
K. Pettersson, P.H. Quax
The Netherlands, France
2.74
THE NOVEL SPLEEN TYROSIN KINASE INHIBITOR FOSTAMATINIB DISODIUM
ATTENUATES INFLAMMATION AND ATHEROGENESIS IN LOW DENSITY
LIPOPROTEIN RECEPTOR DEFICIENT MICE
I. Hilgendorf, I. Remer, S. Eisele, K. Zeschky, C. Colberg, N. Hoppe, C. Bode, A. Zirlik,
Florian Willecke
Germany
2.75
COMPLEMENT FACTOR C5A MODULATES VEIN GRAFT REMODELING AND
ACCELERATED ATHEROSCLEROSIS VIA INTERFERENCE IN MAST CELL
ACTIVATION
Margreet R. de Vries, A. Wezel, A. Schepers, J. Kuiper, I. Bot, P.H.A. Quax
The Netherlands
2.76
INTERLEUKIN 15 PLAYS AN IMPORTANT ROLE IN ATHEROGENESIS IN
APOLIPOPROTEIN E KNOCKOUT MICE
Omid Dadoo, A. Ashkar, C. Richards, B. Trigatti
Canada
78
79th EAS CONGRESS
Poster Session
Poster Area
2.77
NUMERICAL AND FUNCTIONAL DEFECTS OF CIRCULATING DENDRITIC CELLS
IN PATIENTS WITH CORONARY ARTERY DISEASE
Ilse Van Brussel, E.A. Van Vré, G.R. De Meyer, C.J. Vrints, J.M. Bosmans, H. Bult
Belgium
2.78
LOSS OF PHOSPHOINOSITIDE 3-KINASE GAMMA ACTIVITY LEADS TO
DECREASED NEOINTIMA FORMATION AFTER VASCULAR INJURY IN MICE
Natalia Smirnova, N. Malet, S. Gayral, A.-P. Gadeau, M. Wymann, L. Martinez,
M. Laffargue
France
2.79
LTB4 PATHWAY ACTIVATION: ONE OF THE MECHANISMS UNDERLYING EARLY
ATHEROSCLEROSIS IN OBSTRUCTIVE SLEEP APNEA SYNDROME
F. Stanke-Labesque, J.L. Pépin, T. de Jouvencel, C. Arnaud, J.P. Baguet, R. Tamisier,
J.F. Jourdil, P. Lévy, Magnus Bäck
France, Sweden
2.80
SELECTIVE DEPLETION OF T REGULATORY CELLS IMPACTS EXPERIMENTAL
ATHEROSCLEROSIS PROGRESSION AND VLDL METABOLISM
R. Klingenberg, N. Gerdes, Robert M. Badeau, D. Ketelhuth, M. Rudling, D. Strodthoff,
S.K. Nilsson, K. Öörni, M. Jauhiainen, C. Lohmann, T. Lüscher, K. Lahl, T. Sparwasser,
G.K. Hansson
Sweden
2.81
EVALUATION OF ENDOTHELIAL PROGENITOR CELLS AND MICROPARTICLES
AFTER HIPOLIPEMIANT TREATMENT IN PATIENTS WIHT SUBCLINICAL
ATHEROSCLEROSIS
Carolina Nunes França, C.E.S. Ferreira, M.C.O. Izar, F.A. Helfenstein Fonseca
Brazil
2.82
CORONARY-HEART DISEASE (CHD), PERIPHERAL-VASCULAR DISEASE (PVD) OR
BOTH (C&PD): PROGNOSTIC IMPLICATIONS FOR RECURRENT EVENTS. THE
AIRVAG COHORT EXTENDED FOLLOW-UP
M.L. Peralta, C. Aranda, A.I. Huelmos, I. Gonzalez Anglada, E. Puras, B. Herreros,
C. Sanchez, V. Castilla, L. Lopez Bescos, Carlos Guijarro, The AIRVAG Investigators
Spain
79
Poster No
Poster Session
Poster Area
Poster No
2.83
VISFATIN AND HSCRP IN RELATION TO ABDOMINAL OBESITY IN MORBID OBESE
SUBJECTS
Zohreh Karbaschian, A. Golpaie, M.J. Hosseinzadeh-Attar, M. Hosseiny, M. Talebpor,
N. Karbaschian
Iran
2.84
THE ROLE OF EXTRACELLULAR HYALURONAN IN DEVELOPMENT OF
ATHEROSCLEROSIS AND ENGINEERED BEE HYALURONIDASE AS A POTENTIAL
TOOL FOR THE TREATMENT
Brigitte Greiderer-Kleinlercher, A. Iliás, S. Reitinger, G. Lepperdinger
Austria
2.85
RELATIONSHIPS BETWEEN BLOOD PRESSURE AND LIPID MARKERS OF
ATHEROSCLEROSIS
Elena Vitalyevna Pello, S.K. Malyutina, G.I. Simonova, Y.P. Nikitin
Russia
2.86
OSTEOCALCIN AND METABOLIC SYNDROME
Paloma Diez Romero, M.A.A. Rodriguez, C.D. Romero, I.C. Estevanez, C.L. Paredes,
F.D. Serrano, M.T. Valdeperez, J.S.F. Rubio, J.M. Nuñez-Cortes
Spain
2.87
EFFECTS OF QUINAPRIL AND TELMISARTAN ON MATRIX METALLOPROTEINASE-2
AND ITS TISSUE INHIBITOR IN PATIENTS WITH CAD UNDERWENT PTCA
Vladimir Naumov, A. Partigulova, Y. Kosenkov, E. Orlova, V. Kuharchuk, V. Masenko
Russia
2.88
ATHEROGENIC LIPID PROFILE AND DEVELOPMENT OF MULTIVESSEL CORONARY
ARTERY DISEASE IN WOMEN
Ryuhei Saito, Y. Kawai, M. Watanabe, A. Motoyama, R. Ishida, M. Kitayama,
K. Kajinami
Japan
2.89
RELATIONSHIP BETWEEN THE NUMBER OF STENOSED CORONARY ARTERIES
AND RENAL FUNCTION IN PATIENTS WITH ISCHEMIC HEART DISEASE
Nataliia Bardachenko, O. Kuryata, L. Bardachenko
Ukraine
2.90
HUMAN PLASMA PHOSPHOLIPID TRANSFER PROTEIN (PLTP) EXPRESSION IN
TRANSGENIC RABBITS IS PROATHEROGENIC
David Masson, V. Deckert, T. Gautier, A. Klein, C. Desrumaux, C. Viglietta,
J.P. Pais de Barros, N. Le Guern, J. Grober, J. Labbé, F. Ménétrier, P.J. Ripoll,
M. Leroux-Coyau, G. Jolivet, L.M. Houdebine, L. Lagrost
France
80
79th EAS CONGRESS
Poster Session
Poster Area
2.91
INFLUENCE OF INDUCIBLE NITRIC OXIDE SYNTHASE IN THE DEVELOPMENT OF
ANEURYSMS IN THE ABDOMINAL AORTA OF RATS: NEW EXPERIMENTAL MODEL
Paula Prudente, K. Mata, E. Floriano, J. Junior, S. Ramos
Brazil
2.92
IMPORTANT CYTOKINES AND CHEMOATTRACTANTS FOR VULNERABLE
ATHEROSCLEROTIC PLAQUE AND ACUTE CORONARY SYNDROME. RESULTS OF
ARTERIAL WALL AND BLOOD STUDIES
Yulia I. Ragino, A.M. Chernjavski, Y.V. Polonskaja, A.M. Volkov, E.V. Kashtanova
Russia
2.93
ANNEXIN A5 PREVENTS REACTIVE STENOSIS IN A DOSE-DEPENDENT FASHION:
POTENTIAL FOR CLINICAL APPLICATION
Mark M. Ewing, K. Pettersson, J.C. Karper, M.R. de Vries, M.L. Sampietro, J.W. Jukema,
P.H. Quax
The Netherlands
2.94
SILENCING OF SOCS-3 GENE DUE TO HYPERMETHYLATION INDUCED BY BOTH
TNF-Α AND IGF-1 IN HUMAN CORONARY ARTERY SMOOTH MUSCLE CELLS
Kajari Dhar, D. Pankajakshan, D.K. Agrawal
USA
2.95
CHLAMYDIA PNEUMONIAE INFECTION IMPAIRS ENDOTHELIAL FUNCTION IN THE
ABSENCE OF A HOST IMMUNE RESPONSE
Justin Deniset, E. Dibrov, G. Pierce
Canada
2.96
ATORVASTATIN SUPPRESS OXIDIZED LOW DENSITY LIPOPROTEIN-INDUCED
DENDRITIC CELL-LIKE DIFFERENTIATION OF RAW264.7 CELLS BY INACTIVATION
OF THE P38 MAPK PATHWAY
L. Hu, Linghong Shen, S. Jin, D. Li, H. Xiao, P. Nie, J. Yi, B. He
China
2.97
NEW THIAZOLIDINE-2,4-DIONES IMPROVE LIPID PROFILE AND DOW-REGULATE
PRO-INFLAMMATORY GENE EXPRESSION IN LDL RECEPTOR-DEFICIENT MICE
F.A. César, M. Rudnicki, C.A.I. Saito, S.L. Galdino, M.C.A. Lima, I.R. Pitta,
Dulcineia Saes Parra Abdalla
Brazil
2.98
REDUCED NUMBER OF DENDRITIC CELLS IN ATHEROSCLEROTIC PLAQUES OF
UREMIC PATIENTS
Daniel Neureiter, V. Campean, D. Wachter, A. Yilmaz, K. Amann
Austria
2.99
5,6-SECOSTEROL AFFECTS MACROPHAGE DIVERSITY AND INDUCES PROINFLAMMATORY MACROPHAGE ACTIVATION
Brigitta Buttari, E. Profumo, R. Monticolo, L. Iuliano, R. Businaro, R. Riganò
Italy
81
Poster No
Poster Session
Poster Area
Poster No
2.100
CHARACTERIZATION OF T CELLS INFILTRATING PERIVASCULAR CORONARY
ADIPOSE TISSUE IN ATHEROSCLEROSIS.
Dominik Ludew, K. Urbanski, B. Kapelak, T. Mikolajczyk, R. Nosalski, R. Korbut,
T.J. Guzik
Poland
2.101
CD137 ON CD4+T LYMPHOCYTES IN PATIENTS WITH ACUTE CORONARY
SYNDROME MIGHT BE A MARKER FOR VASCULAR SMOOTH MUSCLE CELL
DEATH
J.E. Park, J.Y. Lee, J.Y. Kim, B.S. Kwon, Bok Soo Lee
Republic of Korea
2.102
MYCOPHENOLIC ACID HAS ANTI-INFLAMMATORY CAPACITY BY INHIBITION OF
MONOCYTE CHEMOATTRACTANT PROTEIN-1 PRODUCTION IN VASCULAR
SMOOTH MUSCLE CELLS
Mirjam Schuchardt, M. Tölle, J. Prüfer, S. Huber, W. Zidek, M. van der Giet
Germany
2.103
TRIGLYCERIDE METABOLISM AND INTERLEUKIN-6 LEVELS ARE ALTERED IN
CARRIERS OF THE MINOR ALLELE OF AN INTERLEUKIN-1B GENE VARIATION (1473G/C)
Javier Delgado-Lista, P. Perez-Martinez, A. Garcia-Rios, J. Solivera,
E.M. Yubero-Serrano, F. Fuentes, L.D. Parnell, J. Shen, P. Gomez, Y. Jimenez-Gomez,
M.J. Gomez-Luna, C. Marin, S.E. Belisle, F. Rodriguez-Cantalejo, S.N. Meydani,
J.M. Ordovas, F. Perez-Jimenez, J. Lopez-Miranda
Spain
2.104
MANNOSE BINDING LECTIN AS CARDIOVASCULAR RISK FACTOR: A COHORT
STUDY
Boudewijn Klop, A. Alipour, A. Westzaan, E. Birnie, G.J.M. van de Geijn, T. Njo,
J.W. Janssen, N. van der Meulen, J.W.F. Elte, A.P. Rietveld, M. Castro Cabezas
The Netherlands
2.105
ASSOCIATION OF PERIODONTAL DISEASE WITH ISCHEMIC STROKE: A CASECONTROL STUDY
Masatsune Ogura, H. Iwabuchi, M. Ishihara, H. Sato, Y. Sato, R. Tsukinoki-Murakami,
K. Matsushita
Japan
2.106
ROLE OF ROSUVASTATIN AND CLOPIDOGREL ALONE AND COMBINED IN
ENDOTHELIAL PROGENITOR CELLS AND ENDOTHELIAL MICROPARTICLES
Carolina Nunes França, L.F.M. Pinheiro, M.C.O. Izar, F.A. Helfenstein Fonseca
Brazil
2.107
THE ROLES OF CHOLESTEROL AND INFLAMMATION IN THE FORMATION AND
PROGRESSION OF ATHEROSCLEROSIS
Hong Seog Seog, E.J. Kim, H.J. Baek, J.O. Na, C.U. Choi, H.E. Lim, S.W. Rha, C.G. Parl,
D.J. Oh, B.W. Yeom
Republic of Korea
82
79th EAS CONGRESS
Poster Session
Poster Area
2.108
CIRCULATING SOLUBLE INTERCELLULAR ADHESION MOLECULE-1 AND
TRANSFORMING GROWTH FACTOR-BETA-1 IN PATIENTS WITH RECURRENT
ISCHEMIA AFTER CORONARY ARTERY BYPASS GRAFTING SURGERY
Karina V. Korzhenevskaya, N.A. Gavrisheva, A.V. Panov, T.P. Ses, G.A. Alekseeva,
M.Z. Alugishvili, I.T. Abesadze, N.L. Lohovinina
Russia
2.109
INVOLVEMENT OF TOLL LIKE RECEPTOR-4 IN INFLAMMATORY RESPONSES OF
ENDOTHELIAL CELLS
R. Menghini, M. Tesauro, V. Rovella, A. Marino, R. Lauro, M. Federici, Carmine Cardillo
Italy
2.110
ATHEROGENIC IN VIVO LDL OXIDATION, THROMBOXANE-MEDIATED PLATELET
ACTIVATION AND SIMULTANEOUS OCCURRENCE OF NATURAL IMMUNITY IN
ATHEROSCLEROSIS-PRONE (LDLR-/- AND APOE-/-) MICE
Eiji Matsuura, L. Shen, Y. Matsunami, N. Quan, K. Kobayashi, Y. Shoenfeld, K. Oguma,
L.R. Lopez
Japan
2.111
AN APPROACH BASED ON LIPID NANOPARTICULES TO DETERMINE THE ROLE OF
MONOCYTES/MACROPHAGES IN THE DEVELOPMENT OF AORTIC VALVE
Manuela Calin, I. Manduteanu, E. Butoi, D. Stan, E. Dragan, A.M. Gan, M. Simionescu
Romania
2.112
ADVANCED ABDOMINAL AORTIC ANEURYSMS DISPLAY A SPECIFIC
INFLAMMATORY-PROATHEROSCLEROTIC PROFILE WITH RENAL DYSFUNCTION,
RAISED D-DIMER, EXPANDED CD14++CD16+-MONOCYTES HAVING HIGH CD143
Chiara Barisione, G. Ghigliotti, D. Palombo, D. Palmieri, G. Spinella, B. Pane, P. Fabbi,
P. Altieri, P. Spallarossa, C. Brunelli, S. Garibaldi
Italy
2.113
THE ROLE OF NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) IN ANTIINFLAMMATORY AND ANTI-ATHEROSCLEROTIC ACTION OF NICOTINIC ACID IN
MOUSE MODEL OF ACCELERATED ATHEROSCLEROSIS
Łukasz Mateuszuk, M. Sternak, M. Gajda, M. Szafarz, J. Szymura-Oleksiak,
M. Franczyk-Żarów, R. Kostogrys, S. Chłopicki
Poland
2.114
EVALUATION OF A DIABETIC RABBIT MODEL FOR IN-STENT RESTENOSIS
P. W. Radke, A. Joost, A. Kaiser, M. Basler, M. Mandapathil, C. Weber, S. Yla-Herttuala,
W. Ito
Germany
2.115
RELATIONSHIPS BETWEEN MARKERS OF APOPTOSIS AND ANTIBODIES TO
OXIDIZED LOW-DENSITY LIPOPROTEINS IN PROGRESSING ATHEROSCLEROSIS
Victor Gurevich, L. Vasina, N. Petrischev, A. Lugovaya
Russia
83
Poster No
Poster Session
Poster Area
Poster No
2.116
THE DELETERIOUS INFLUENCE OF TENOFOVIR-BASED THERAPIES ON THE
PROGRESSION OF ATHEROSCLEROSIS IN HIV-INFECTED PATIENTS
Gerard Aragones, P. Pardo, R. Beltrán-Debón, A. Rull, L. Fernández-Sender, J. Joven,
C. Alonso-Villaverde
Spain
2.117
DUFFY BLOOD ALLOANTIGEN SYSTEM INFLUENCES INFLAMMATORY CHEMOKINE
CONCENTRATION IN SERUM BUT NOT PLASMA: GEOGRAPHIC DIFFERENTIATION
AS AN ADDITIONAL CONFOUNDING FACTOR
María Barreda, G. Aragones, A. Rull, R. Beltrán-Debón, J. Camps, J. Joven
Spain
2.118
PLASMA CHEMERIN IS ASSOCIATED WITH MARKERS OF INFLAMMATION AND
CORONARY ARTERY DISEASE IN PATIENTS NOT ON ASPIRIN
M. Herová, M. Schmid, Martin Hersberger
Switzerland
2.119
CHANGES OF ENDOGLIN LEVELS IN SERUM AND MICE AORTA WITH RESPECT TO
CHOLESTEROL AND ATORVASTATIN
Lenka Večeřová, Z. Strasky, J. Rathouska, M. Slanarova, E. Brcakova, P. Nachtigal
Czech Republic
2.120
THE EFFECT OF PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY UPON
MMP2,MMP9,TIMP1 AND NOX1 RELEASE IN PATIENTS WITH STABLE ANGINA
C. Revnic, C. Ginghina, A. Mereuta, D. Gradinaru, Floarea Revnic
Romania
2.121
A SHORT-TERM HIGH COMPLEX-CARBOHYDRATE DIET REDUCES THE BASELINE
INFLAMMATORY PROFILE
Itzhak Shapira, O. Rogowski, S. Berliner, O. Raz
Israel
2.122
EFFECTS OF INTENSIVE LIPID-LOWERING ON PLATELET ACTIVATION & MARKERS
OF SYSTEMIC INFLAMMATION IN PATIENTS AT ELEVATED CARDIOVASCULAR
RISK
Eleanor Catherine Wicks, P. Maciocia, S. Bournazos, R. Hilling-Smith, I. Dransfield,
N. Uren
UK
2.123
ERK SIGNALING IS INVOLVED IN INFLAMMATION AND VASCULAR REMODELING
PROCESS IN PREMATURE CORONARY ARTERY DISEASE
Veena Dhawan, N. Mahajan, O.M. Bhat, A. Bahl, I. Sharma
India
2.124
OXIDATIVE STRESS MEDIATES APL-INDUCED THROMBOSIS AND
ATHEROSCLEROSIS DEVELOPMENT IN ANTIPHOSPHOLIPID SYNDROME
P. Ruiz-Limón, C. Perez-Sanchez, M.A. Aguirre, N. Barbarroja, R.M. Carretero,
A. Rodriguez-Ariza, E. Collantes-Estevez, J.M. Villalba, F. Velasco, M. Khamashta,
M.J. Cuadrado, Chary Lopez-Pedrera
Spain
84
79th EAS CONGRESS
Poster Session
Poster Area
2.125
MONOCYTE CHEMOATTRACTANT PROTEIN-1 AND PARAOXONASE-1 IN
PERIPHERAL ARTERIAL DISEASE: A MODEL OF INTERACTION BETWEEN
DEFENSE AGAINST OXIDATIVE STRESS AND INFLAMMATION
Anna Rull, R. García, L. Fernández-Sender, R. Beltrán-Debón, G. Aragonès, J.M. Alegret,
C. Alonso-Villaverde, M. Mackness, J. Camps, V. Martin-Paredero, J. Joven
Spain
2.126
TAQIB AND I405V CETP POLYMORPHISMS DO NOT MODIFY PLASMA
INFLAMMATORY MARKERS: A STUDY IN A BRAZILIAN POPULATION SAMPLE
Eliane Soler Parra, F.L. D'Alexandri, N.B. Panzoldo, D.B. Kaplan, E.C. de Faria
Brazil
2.127
SOLUBLE CELLULAR ADHESION MOLECULES, MYELOPEROXIDASE, AND
NEOPTERIN IN METABOLIC SYNDROME PATIENTS WITH STABLE AND UNSTABLE
ANGINA PECTORIS
Peteris Tretjakovs, A. Jurka, I. Bormane, I. Mikelsone, D. Reihmane, G. Krievina,
K. Elksne, J. Verbovenko, G. Bahs, D. Fuchs
Latvia
2.128
ENDOGLIN-RELATED PATHWAYS ARE NOT RELATED TO DISTINCT
PREDISPOSITION TO ATHEROSCLEROSIS IN C57BL/6J AND C3H/HEJ MICE
Jana Rathouska, Z. Strasky, L. Vecerova, E. Brcakova, M. Slanarova, P. Nachtigal
Czech Republic
2.129
CORRELATIONS BETWEEN CLINICAL, IMMUNOLOGICAL AND METABOLIC
CONTRIBUTORS AND ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS
Enrico Ammirati, R. Contri, E. Bozzolo, S. Tramontana, K. Garlaschelli, A. Palini,
D. Cianflone, A.L. Catapano, M.G. Sabbadini, G.D. Norata
Italy
2.130
EZETIMIBE INHIBITS PMA-INDUCED MONOCYTIC DIFFERENTIATION INTO
MACROPHAGE-LIKE PHENOTYPE THROUGH THE MICRORNA PATHWAY
Paloma Muñoz-Pacheco, A. Ortega-Hernández, A. Fernández-Cruz,
D. Gómez-Garre
Spain
2.131
ATHEROSCLEROSIS RISK FACTORS, INFLAMMATION AND DENTAL STATE IN
PATIENTS WITH CARDIO-CEREBROVASCULAR DISEASE AND EXCESSIVE
OBESITY (BMI OVER 40) FROM ROMANIA
Ioan Axente Gutiu, L.I. Gutiu, F.S. Radulescu
Romania
2.132
ASSESSMENT OF INSULIN RESISTANCE, DYSLIPIDEMIA, OXIDATIVE STRESS AND
INFLAMMATORY RESPONSE IN MALE PATIENTS WITH ANGIOGRAPHICALLY
PROVEN CORONARY ARTERY DISEASE
Binita Goswami, D. Tayal, S. Tyagi, V. Mallika
India
85
Poster No
Poster Session
Poster Area
Poster No
2.133
ASSOCIATION BETWEEN INFLAMMATION AND ATHEROSCLEROSIS IN METABOLIC
SYNDROME PATIENTS: THE SAME IN ALL ARTERIAL BEDS?
Philipp Rein, C.H. Saely, S. Beer, A. Vonbank, C. Boehnel, V. Drexel, V. Kiene,
H. Drexel
Austria, Liechtenstein, USA
2.134
STATE CELLULAR LEVEL OF IMMUNE RESPONSE IN PATIENTS WITH CHD,
DEPENDING ON THE AVAILABILITY OF SIMPLE OR COMPLEX CORONARY
STENOSIS
Oleksandr Lomakovskyi
Ukraine
2.135
CARDIOVASCULAR RISK FACTORS AND INFLAMMATORY MARKERS IN SYSTEMIC
LUPUS ERYTHEMATOSUS: GENDER DIFFERENCES
Tatiana A Panafidina, T.V. Popkova, N.G. Klukvina, D.S. Novikova, E.N. Alexandrova,
Z.S. Alekberova, E.L. Nasonov
Russia
2.136
ASSOCIATION OF TNF-ALPHA AND ANTICARDIOLIPIN ANTIBODIES IN TYPE II
DIABETES MELLITUS
Mirjana Becarevic, J. Seferovic, S. Ignjatovic, N. Majkic-Singh
Serbia
2.137
DECREASED TITERS OF ANTI-OXLDL ANTIBODIES AFTER ACUTE CORONARY
SYNDROME IN PATIENTS WITH METABOLIC SYNDROME ARE ASSOCIATED WITH
SEVERITY OF ATHEROSCLEROSIS
Henrique A Fonseca, C.M. Monteiro, L.F. Pinheiro, F.A. Fonseca, S.A. Brandao,
S.C. Fischer, A.O. Santos, M.A. Gidlund, A.M. Monteiro, A.M. Figueiredo Neto,
M. Izar
Brazil
2.138
PERIODONTAL TREATMENT INDUCES REDUCTION RISK MARKERS FOR
ATHEROSCLEROSIS
Andrea Moreira Monteiro, M. Jardini, S. Alves, A. Figueiredo Neto, M. Gidlund
Brazil
2.139
HLA-G AND NPC1L1 GENE POLYMORPHISMS IN CAD PATIENTS WITH DIFFERENT
LEVELS OF LDL
Chiara Boiocchi, E. Maggioli, S. Bozzini, M. Cuccia, C. Falcone
Italy
2.140
CRYPTOCOCCUS NEOFORMANS CAUSES LIPID PEROXIDATION; THEREFORE IT IS
A POTENTIAL INDUCER OF ATHEROGENESIS
Connie Jarrstrand Hall, U. Dizcfalusy, K. Sandstedt, L.R. Bouhafs
Sweden
86
79th EAS CONGRESS
Poster Session
Poster Area
Poster No
2.141
LEVELS OF ADHESION MOLECULES (S-ICAM-1 AND S-VCAM-1) IN DIFFERENT
DEGREE OF ISCHEMIC CHRONIC HEART FAILURE: CORRELATION WITH HS-CRP
Slavica Radovanovic, D. Popovic-Lisulov, N. Ninkovic, A. Djokovic, S. Hinic, M. Krotin,
T. Simic, A. Savic-Radojevic
Serbia
2.142
HIGH ENDOTHELIAL SHEAR STRESS INDUCES RUPTURE-PRONE PLAQUES
FORMATION DUE TO ANGIOGENESIS
Guixue Wang, J. Qiu, J. Hu, H. Liu, L. Ye, Y. Zheng, Y. Teng, D. Zhang
China
2.143
18
FDG-PET IMAGING AND GENE EXPRESSION OF MARKERS OF
NEOANGIOGENESIS, MICRO VESSEL DENSITY AND VULNERABILITY IN
ATHEROSCLEROTIC HUMAN CAROTID PLAQUES
Sune Folke Pedersen, M. Græbe, A.M.F. Hag, L. Højgaard, H. Sillesen, A. Kjær
Denmark
2.144
THE INFLUENCE OF MYOCARDIAL REVASCULARIZATION ON ANGIOGENIC
GROWTH FACTORS IN CORONARY ARTERY DISEASE PATIENTS
Igor V. Sergienko, E.V. Merculov, A.E. Semenova, V.P. Masenko
Russia
2.145
MACROPHAGE SUBSETS VARY IN THEIR ASSOCIATION WITH PLAQUE
STABILITY
Heather Jean Medbury, J. Ngo, V. James, K. Hitos, A.K. Guiffre, J.P. Fletcher
Australia
2.146
IMPORTANCE OF VIMENTIN IN FOAM-CELL FORMATION AND
ATHEROGENESIS
Jeanna Perman, J. Borén
Sweden
2.147
LEUKOTIENE-INDUCED CALCIFICATION AND OSTEOGENIC DIFFERENTIATION
OF HUMAN AORTIC VALVE INTERSTITIAL CELLS
Edit Nagy, D.C. Andersson, G.K. Hansson, M. Bäck
Sweden
87
WORKSHOP: HYPOXIA AND ANGIOGENESIS IN THE PLAQUE (contd.)
Poster Session
Poster Area
Poster No
2.148
INTERLEUKIN-6 REGULATES LXRΑ-RESPONSIVE EXPRESSION OF ABCA1 AND
ABCG1 VIA A JAK/STAT SIGNALING PATHWAY-DEPENDENT WAY
Chao-Ke Tang, J. Xiao, K. Yin
China
2.149
EFFECTS OF TACROLIMUS-ELUTING STENTS IN A DIABETIC RABBIT MODEL
OF IN-STENT RESTENOSIS
P. W. Radke, A. Joost, A. Kaiser, M. Mandapathil, M. Basler, S. Yla-Herttuala, C. Weber,
W. Ito
Germany, Finland
2.150
IMPACT OF ANTI-TNFALPHA THERAPY ON SUBCLINICAL ATHEROSCLEROSIS
IN PATIENTS WITH PSORIATIC ARTHRITIS
Massimo Puato, M. Zanardo, R. Ramonda, E. Faggin, M. Zanon, G. Balbi, A. Lo Nigro,
M. Rattazzi, A. Doria, P. Pauletto
Italy
2.151
THE AKITA-LDLR-/- MOUSE AS A MODEL OF DIABETIC ATHEROSCLEROSIS
Daniel Engelbertsen, F. To, P. Dunér, O. Kotova, I. Söderberg, R. Alm, M. Gomez,
J. Nilsson, E. Bengtsson
Sweden
2.152
EFFECTOR MEMORY T LYMPHOCYTES ARE ASSOCIATED WITH
CARDIOVASCULAR DISEASE IN HUMANS AND AORTIC ATHEROSCLEROSIS IN
APOE AND LDL-R KNOCK-OUT ANIMALS.
Giuseppe Norata, E. Ammirati E, M. Banfi, V. Vacchio, S. Tramontana, K. Garlaschelli,
F. Pelegatta, L. Grigore, D. Cianflone, A. Maseri, A. Catapano, A. Palini
Italy
2.153
IS HYPOXIA THE COMMON TRIGGER FOR INFLAMMATION AND APOPTOSIS IN
HUMAN CAROTID ATHEROSCLEROTIC PLAQUES?
Alessandra Bitto, G. De Caridi, F. Spinelli, F. Squadrito
Italy
2.154
POLYPHENOLS FROM RED PROPOLIS SUPPRESSES ANGIOGENESIS BY INDUCING
VON HIPPEL-LINDAU-DEPENDENT HIF-1 ALPHA DEGRADATION
J.B. Daleprene, M. Rudnicki, T.P. Ong, M. Ikegaki, H. Menrad, T. Geis, T. Schmid,
N. Dehne, B. Bruene, Dulcineia Saes Parra Abdalla
Brazil
88
79th EAS CONGRESS
Poster Session
Poster Area
2.155
INTRA-PLAQUE VESSEL DENSITY, INFLAMMATORY CELLS AND EXISTENCE OF
THROMBIN-CLEAVED FORM OF OSTEOPONTIN ARE THE RISK FACTORS FOR
SYMPTOMATIC STROKE
Mie Kurata, T. Okura, Y. Kumon, H. Watanabe, M. Tagawa, J. Higaki, M. Nose
Japan
2.156
THE ROLE OF PRENATAL CHRONIC HYPOXIA ON MYOCARDIAL ISCHEMIA /
REPERFUSION INJURY IN ADULT RABBITS OFFSPRING
Ziyang Huang, Z. Wang, J. Yang
China
2.157
THE IMPORTANCE OF DE NOVO LIPOGENESIS OF LIPID LOADING IN HUMAN
MACROPHAGES
L. Mattsson Hultén, B. Liu, M. Levin, E. Lu, L. Håversen, C. Ullström, S.O. Olofsson, Lu Li
Sweden
2.158
HYPOXIC CELLS ARE ABUNDANT IN MURINE ATHEROSCLEROTIC LESIONS
Nanna Junker, E.D. Bartels, T.X. Pedersen, C. Christoffersen, L.B. Nielsen
Denmark
2.159
HIGH MAST CELL NUMBERS IN HUMAN CAROTID ATHEROSCLEROTIC PLAQUES
HAVE PREDICTIVE VALUE FOR FUTURE CARDIOVASCULAR EVENTS
Sanne Willems, A. Vink, I. Hoefer, P. Quax, G. Pasterkamp
The Netherlands
WORKSHOP: NUCLEAR RECEPTORS AT THE CROSSROAD OF LIPID METABOLISM AND
INFLAMMATION
2.160
THE TRANSCRIPTION FACTOR HNF-4Α: A KEY ACTOR OF THE INTESTINAL
UPTAKE OF FATTY ACIDS IN MOUSE
V. Frochot, M. Alqub, A.-L. Cattin, V. Carrière, A. Houiller, L. Barbot, S. Saint-Just,
A. Ribeiro-Pillet, P. Cardot, J. Chambaz, M. Rousset, Jean-Marc Lacorte
France
2.161
ROLES OF LXRΑ AND LXRΒ IN THE REGULATION OF INTESINAL
CHOLESTEROL ABSORPTION: DISTINCTIVE EFFECTS ON BILE ACID METABOLISM
IN MICE
X. Hu, K. Steffensen, Z.Y. Jiang, P. Parini, J.Å. Gustafsson, M. Gåfvels, Gösta Eggertsen
Sweden
89
Poster No
Poster Session
Poster Area
Poster No
2.162
FAR INFRA-RED THERAPY PROMOTES ISCHEMIA-INDUCED ANGIOGENESIS IN
DIABETIC MICE AND RESTORES HIGH GLUCOSE-SUPPRESSED ENDOTHELIAL
PROGENITOR CELL FUNCTIONS
Shing-Jong Lin, P.H. Huang, J.W. Chen
Taiwan R.O.C
WORKSHOP: NUCLEAR RECEPTORS AT THE CROSSROAD OF LIPID METABOLISM AND
INFLAMMATION (contd.)
2.163
PPARA GENE LEVEL DIFFERENTLY AFFECTS LIPID METABOLISM AND
INFLAMMATION IN APOLIPOPROTEIN E2 KNOCK-IN MICE
Fanny Lalloyer, K. Wouters, E. Vallez, J. Vanhoutte, M. Baron, R. Shiri-Sverdlov,
M. Hofker, B. Staels, A. Tailleux
France
2.164
ATHEROSCLEROTIC LESION REMODELLING IN REV-ERBΑ-DEFICIENT MICE
Eric Bauge, C. Comte, C. Duhem, J. Vanhoutte, B. Staels, H. Duez
France
2.165
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS REGULATE NADPH
OXIDASE EXPRESSION AND FUNCTION IN HUMAN AORTIC SMOOTH MUSCLE
CELLS
Adrian Manea, S.A. Manea, I.M. Fenyo, M. Raicu
Romania
90
79th EAS CONGRESS
Poster Session
Poster Area
WORKSHOP: THROMBOGENIC RISK FACTORS FOR ATHEROTHROMBOSIS AND ACUTE
CORONARY EVENTS
3.01
NADPH OXIDASE-RELATED OXIDATIVE STRESS ENHANCES PLATELET
THROMBOXANE PRODUCTION IN ASPIRIN-TREATED PATIENTS UNDERGOING
ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
Pasquale Pignatelli, S. Basili, G. Tanzilli, S. Di Santo, R. Carnevale, D. Pastori,
M. Schillizzi, C. Calabrese, E. Mangeri, P. Ferroni, F. Violi
Italy
3.02
TIMING AND DOSE OF STATIN THERAPY DEFINE ITS IMPACT ON INFLAMMATORY
AND ENDOTHELIAL RESPONSES DURING MYOCARDIAL INFARCTION
Luiza Pego, S.N. Santos, E.C. Faria, D.S.P. Abdalla, A.A. Sousa Soares, A.V.T. Japiassú,
J.C. Quinaglia e Silva, J.A.F. Ramires, O.R. Coelho, A.C. Sposito, on behalf of the Brasilia
Heart Study Group
Brazil
3.03
PITAVASTATIN PROVIDES CONSISTENT LONG-TERM HDL-CHOLESTEROL
IMPROVEMENTS IN A RANGE OF PATIENTS WITH DYSLIPIDAEMIA: RESULTS
FROM A PHASE III STUDY PROGRAMME
Neil Hounslow
UK
3.04
INCIDENCE OF CORONARY EVENTS AND CASE-FATALITY RATES IN RELATION TO
CONCENTRATIONS OF BLOOD LEUKOCYTES
Samuel Adamsson Eryd, J.G. Smith, O. Melander, B. Hedblad, G. Engström
Sweden
3.05
THE CLASS II PHOSPHOINOSITIDE 3-KINASE ISOFORM Β REGULATES PLATELET
FUNCTION AND ARTERIAL THROMBOSIS IN MICE
Gianpaolo Tibolla, S.S. Barbieri, S. Gianellini, L. Arnaboldi, A. Corsini, E. Tremoli,
M. Falasca, G.D. Norata, A.L. Catapano
Italy
3.06
THE IMPACT OF LOW DENSITY LIPOPROTEIN RECEPTOR(LDLR) GENE MUTATION
ON CAROTID INTIMA MEDIA THICKNESS, IN PATIENTS WITH FAMILIAL
Vasiliki Metaxa, C. Pitsavos, I. Skoumas, A. Miliou, E. Oikonomou, K. Aznaouridis,
K. Masoura, C. Stefanadis
Greece
3.07
THE INFLUENCE OF TF AND TFPI POLYMORPHISMS ON THROMBIN GENERATION
IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE
Trine Baur Opstad, A.Å. Pettersen, V. Bratseth, H. Arnesen, I. Seljeflot, Center for Clinical
Heart Research
Norway
3.08
THE EFFECT OF STATIN TYPE ON THE ACTIVITY OF ANTIPLATELET THERAPY :
POST-HOC ANALYSIS OF CILON-T TRIAL
Jung Won Suh, M.J. Cha, S.P. Lee, H.S. Kim, CILON-T Investigators
Republic of Korea
91
Poster No
Poster Session
Poster Area
CORONARY EVENTS (contd.)
Poster No
3.09
HOMOCYSTEINE LOWERING AND GLUTATHIONE INCREASING EFFECTS OF NACETYLCYSTEINE IN ACUTE CORONARY SYNDROME
I. Squellerio, G. Marenzi, F. Veglia, G. Falcucci, L. Boccotti, S. Eligini, E. Tremoli,
Viviana Cavalca
Italy
3.10
THE SEX-RELATED DIFFERENCES IN ASSOCIATIONS BETWEEN ACTIVITY OF
FIBRINOLYSIS AND SOME CARDIOVASCULAR DISEASES IN MOSCOW RESIDENTS
AGED 55+
Victoria A Metelskaya, L.A. Ratnikova, S.A. Shalnova, M.A. Shkolnikova, A.D. Deev
Russia
3.11
INFLUENCE OF DAILY ALCOHOL CONSUMPTION ON SERUM ADIPONECTIN
LEVELS IN MEN
Shinji Makita, A. Abiko, M. Nagai, M. Nakamura
Japan
3.12
ERECTILE DYSFUNCTION AS A SUBROGATE MARKER OF CORONARY ARTERY
DISEASE
Antonio Hernández-Mijares, A. Jover, E. Solá, C. Bañuls, K. García-Malpartida,
M. Rocha, V.M. Víctor
Spain
3.13
CHANGING ROLE OF THE “CARDIOVASCULAR RISK FACTOR PROFILE” IN ACUTE
Rahul Potluri
UK
3.14
VARYING PROPORTIONS OF PERIPHERAL VASCULAR DISEASE INTERVENTIONS
COMPARED WITH CORONARY VASCULAR DISEASE IN ENGLAND.IMPLICATIONS
FOR THE AETIOPATHOLOGY OF ATHEROSCLEROSIS?
Naseer Ahmad, C. Chan
UK
3.15
ASSOCIATION OF THROMBOMODULIN GENE VARIANTS IN INDIAN PATIENTS WITH
CORONARY ARTERY DISEASE (CAD)
Tester Ashavaid, S. Shah, C. Ponde, R. Rajani, R. Mankeshwar
India
3.16
IDENTIFICATION OF HAEMATOLOGICAL MARKERS ASSOCIATED WITH POOR
OUTCOME IN PATIENTS WITH ACUTE CORONARY SYNDROME
Oona Merono, C. Garcia, M. Cladellas, L. Recasens, V. Bazan, N. Ribas, G. Rivas,
A. Sainz, E. Valles, J. Bruguera
Spain
92
79th EAS CONGRESS
Poster Session
Poster Area
3.17
REVERSIBLE MYOCARDIAL DYSFUNCTION AND LEFT VENTRICULAR DILATATION
IN ACUTE MYOCARDIAL INFARCTION
Anis Alavy Lutfullaevich, S. Kenjaev Rashidovich, M. Kenjaev Latipovich
Uzbekistan
3.18
THE DECREASE OF MEAN PLATELET VOLUME AFTER EXTRACORPOREAL LDLCHOLESTEROL ELIMINATION IN PATIENTS WITH SEVERE FAMILIAL
M. Blaha, M. Lanska, Vladimir Blaha, I. Fatorova
Czech Republic
3.19
PREVALENCE AND PROGNOSTIC FACTORS OF ANAEMIA IN PATIENTS WITH
ACUTE MYOCARDIAL INFARCTION
Ioannis Kanonidis, G. Rompolas, K. Martiadou, C. Kagiadaki, G. Dadoush, G. Sakantamis
Greece
3.20
DYSLIPIDAEMIA AND ITS COMPONENTS: PREVALENCE IN HEALTH CARE
PROFESSIONALS AND IN THE REST OF THE WORKING POPULATION
Pedro Valdivielso-Felices, E. Calvo-Bonacho, C. Catalina-Romero,
M.Á. Sánchez-Chaparro, J.C. Sainz-Gutierrez, I. Romero-Mateos, L. Palacio-Olmos,
M. Gálvez-Godoy, J.A. Gelpi-Méndez, L.M. Ruilope-Urioste
Spain
3.21
PARAMETERS OF PLATELETS ACTIVATION AND METABOLISM OF
CARDIOMYOCYTES IN ACUTE MYOCARDIAL INFARCTION.
Alicja Polek, W. Sobiczewski, J. Matowicka-Karna
Poland
3.22
ENDOTHELIAL DERIVATIVES AS THE POSSIBLE PREDICTORS OF THE
CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS PATIENTS (RA) WITH
Robert Rupinski, E. Walewska, A. Filipowicz-Sosnowska, P. Gluszko
Poland
3.23
BACK TO THE FUTURE IN TREATMENT OF REFRACTORY NO-REFLOW AFTER
PRIMARY PERCUTANEOUS CORONARY INTERVENTION: INTRACORONARY
EPINEPHRINE
Tolga Aksu, A. Colak, M. Durukan, U. Guray, H. Kısacık
Turkey
3.24
EFFECT OF QUERCETIN ON THE DYNAMICS OF THE LEVEL OF NT-PROBNP IN
PATIENTS WITH ACUTE CORONARY SYNDROME
Anis Alavy Lutfullaevich, S. Varisxanova, S. Kenjaev
Uzbekistan
93
Poster No
Poster Session
Poster Area
WORKSHOP: BIOMARKERS - FROM BENCH TO BEDSIDE
Poster No
3.25
HIGH SERUM TESTOSTERONE IS ASSOCIATED WITH REDUCED RISK OF
CARDIOVASCULAR EVENTS IN ELDERLY MEN
C. Ohlsson, E. Barrett-Connor, S. Bhasin, E. Orwoll, F. Labrie, M.K. Karlsson,
Ö. Ljunggren, L. Vandenput, D. Mellström, Åsa Tivesten
Sweden
3.26
C-REACTIVE PROTEIN (CRP) AND LIPID LEVELS TO PREDICT THE RISK OF
CORONARY HEART DISEASE IN STATIN-TREATED STABLE CORONARY PATIENTS
Benoit J Arsenault, S.M. Boekholdt, P. Deedwania, D.A. DeMicco, W.H. Bao,
G.M. Preston, D.D. Waters, J.C. LaRosa, P. Barter, J.J.P. Kastelein, the Treating to New
Targets (TNT) Investigators
The Netherlands
3.27
PREVALENCE OF ELEVATED C-REACTIVE PROTEIN LEVELS IN A PRIMARY
CVD PREVENTION POPULATION IN EUROPE: THE EURIKA STUDY
Julian Halcox, J.R. Banegas, J. Dallongeville, G.D. Backer, E. Guallar,
E.L. Massó-González, J. Perk, F. Rodriguez Artalejo, P.G. Steg, F. Tubach, C. Borghi
UK
3.28
DEVELOPMENT OF A NOVEL HOMOGENEOUS ASSAY FOR REMNANT LIKE
PARTICLE CHOLESTEROL
Yasuki Ito, Y. Hirao
Japan
3.29
RELATION OF CENTRAL AND BRACHIAL BLOOD PRESSURE TO LEFT
VENTRICULAR HYPERTROPHY. THE CZECH POST-MONICA STUDY
Peter Wohlfahrt, D. Wichterle, J. Seidlerová, J. Filipovský, J. Bruthans, V. Adámková,
R. Cífková
Czech Republic
3.30
APOLIPOPROTEIN M (APOM) - A NOVEL BIOMARKER FOR ACUTE KIDNEY
INJURY
Eva Martha Madsen Svarrer, H.Ø. Andersen, M. Helvind, M.C.J. Slagman, G. Navis,
R.P.F. Dullaart, B. Dahlbäck, L.B. Nielsen
Denmark
3.31
TARGETED PHOSPHOLIPID METABOLITE PROFILING IN THE CLINICAL
LABORATORY USING MALDI-QIT-TOF-MS/MS
Gerald Stübiger, E. Aldover-Macasaet, W. Bicker, K. Pock, V. Bochkov, K. Widhalm,
O. Belgacem
Austria
94
79th EAS CONGRESS
Poster Session
Poster Area
WORKSHOP: BIOMARKERS - FROM BENCH TO BEDSIDE (contd.)
Poster No
3.32
EFFICACY BIOMARKER FOR PCSK9 INHIBITORS
Reijo Laaksonen, K. Koistinen, R. Huuhilo, K. Tarasov, R. Hurme, K. Ekroos, A. Prat,
N. Seidah, M. Jänis
Finland
3.33
THE IMPACT OF PERCUTANEOUS CORONARY INTERVENTION(PCI) WITH STENT
IMPLANTATION UPON MMP9 AND INFLAMATORY MARKERS IN PATIENTS WITH
ACUTE CORONARY SYNDROMES
Floarea Revnic, C.R. Revnic, C. Ginghina, A. Mereuta, D. Gradinaru, G. Prada, S. Prada,
C. Pena, C. Borsa, C. Ionescu
Romania
3.34
ACUTE CORONARY SYNDROME AND LOW-HDL CHOLESTEROL. RELATIONSHIP
WITH LIPOPROTEIN (A)
R. Toro, P. Gomez, C. Rodriguez, I. Tinoco, D. Biedma, M. Virseda, Alipio Mangas
Spain
3.35
IP-10 AND ACUTE MYOCARDIAL INFARCTION
Ali Esmaeili Nadimi
Iran
3.36
COLLAGEN MATRIX OF ATHEROSCLEROTIC PLAQUE AND LIPID SPECTRUM IN
PATIENTS WITH MYOCARDIAL INFARCTION TREATED WITH ROZUVASTATIN
DEPENDING ON REVASCULARIZATION METHOD
Natalya A Koziolova, E. Malgina
Russia
3.37
GLYCAEMIC CONTROL AND SECONDARY PREVENTION TREATMENT IN
POSTINFARCTION PATIENTS REDUCE THE INTENSITY OF CARDIOVASCULAR RISK
FACTORS CORRELATION
Eleonora Vataman, S. Filimon, D. Lisii, O. Priscu, A. Grivenco
Moldova
3.38
CLINICAL AND ECONOMIC IMPACT OF ANTITHROMBOTIC MANAGEMENT
PATTERNS IN ACUTE CORONARY SYNDROMES: RATIONALE AND DESIGN OF THE
EPICOR STUDY
H. Bueno, F. Van de Werf, N. Danchin, M. Tafalla, C. Bernaud, L. Annemans
Belgium
95
Poster Session
Poster Area
Poster No
3.39
MOLECULAR INSIGHTS INTO CARDIOMYOCYTE APOPTOSIS: TREATMENT WITH
PIOGLITAZONE IN LOW-DOSE STREPTOZOTOCIN AND HIGH FAT DIET FED
OBESITY IN MURINE MODEL
Uma Bhandari, V. Kumar, C.D. Tripathi, G. Khanna, C. Hemantkumar, K.K. Pillai
India
3.40
DEVELOPMENT OF A NOVEL HOMOGENEOUS ASSAY FOR SMALL HDL
Maiko Higuchi, T. Hirano, Y. Ito
Japan
3.41
ROLE OF MITOCHONDRIAL DNA DAMAGE IN ATHEROSCLEROSIS
John Mercer, L. Hurst, M. Bennett
UK
3.42
CIRCULATING CD4+CD25+FOXP3+ REGULATORY T CELLS DO NOT PREDICT RISK
FOR ACUTE CARDIOVASCULAR EVENTS
Maria Wigren, H. Björkbacka, B. Hedblad, G.N. Fredrikson, J. Nilsson
Sweden
3.43
INFLAMMATION-SENSITIVE PROTEINS AND RISK OF ATRIAL FIBRILLATION: A
POPULATION-BASED COHORT STUDY
Samuel Adamsson Eryd, J.G. Smith, O. Melander, G. Engström, B. Hedblad
Sweden
3.44
DECREASED PLASMA LEVELS OF SRAGE ARE ASSOCIATED TO CORONARY
FIBRO-LIPIDIC WALL VOLUME IN PATIENTS WITH PROVEN OR SUSPECTED CAD
Giuseppina Basta, S. Del Turco, T. Navarra, A. Mazzarisi, F. Cocci, M. Coceani,
M. Bianchi, M. Schlueter, P. Marraccini
Italy
3.45
ASSOCIATION OF BLOOD ACTIVE MATRIX METALLOPROTEINASE-3 WITH
CAROTID PLAQUE SCORE IN MALE FROM A COMMUNITY POPULATION IN TAIWAN
Li-Ming Lien, Y.C. Hsieh, C.H. Bai, W.H. Chen, H.C. Chiu, F.I. Hsieh, K.G. Shyu,
H.Y. Chiou
Taiwan R.O.C.
3.46
ASSOCIATION OF COPY NUMBER VARIATIONS AND SINGLE NUCLEOTIDE
POLYMORPHISMS IN METALLOTHIONEIN GENES WITH PATHOGENESIS OF
DIABETES AND CORONARY ARTERY DISEASE
Rahila Kozarova, A. Postadzhiyan, B. Finkov, M. Apostolova
Bulgaria
3.47
SMALL ARTERIES DILATION AND ENDOTHELIAL MARKERS IN CARDIOVASCULAR
RISK PATIENTS
Gemma Aragonès, R. Ferré, J. Girona, N. Plana, J. Merino, M. Heras, L. Masana
Spain
96
79th EAS CONGRESS
Poster Session
Poster Area
3.48
THE RELATIONSHIP BETWEEN HDL-CHOLESTEROL AND HDL FUNCTION
Lauren Wade, M. Widdowson, A. Mcgown, J. Gibney, F. Thies, A. Mcginty, I. Young,
J. McEneny
UK
3.49
THE IMPACT OF PLASMA ADIPOCYTE FATTY ACID-BINDING PROTEIN ON RENAL
INSUFFICIENCY AND CORONARY LESION SEVERITY IN DIABETIC PATIENTS
Toru Miyoshi, M. Doi, K. Takeda, S. Usui, K. Nakamura, S. Kusachi, K. Kusano, H. Ito
Japan
3.50
EVALUATION OF SERA BIOMARKERS FOR CORONARY ARTERY DISEASE AND
DIABETES
Nadya Ivanova, A. Postadzhiyan, B. Finkov, M. Apostolova
Bulgaria
3.51
ASSOCIATION OF ANGIOTENSIN II TYPE 1 RECEPTOR +1166 A/C GENE
POLYMORPHISM WITH HUMAN CAROTID PLAQUE VULNERABILITY
Ana Kolakovic, M. Zivkovic, D. Radak, I. Koncar, T. Djuric, L. Davidovic, D. Alavantic,
A. Stankovic
Serbia
3.52
INCREASED PREGNANCY ASSOCIATED PROTEIN A (PAPP-A) PREDICTED EARLY
SURVIVAL IN CHRONIC HEMODIALYSIS (HD) PATIENTS
Vladimir Blaha, E. Mistrik, S. Dusilova-Sulkova, M. Kalousova, C. Andrys, M. Blaha,
L. Sobotka
Czech Republic
3.53
A COMPARISON OF SERUM ANDROGENS IN PRE-ECLAMPTIC AND NORMOTESIVE
PREGNANT WOMEN DURING THE THIRD TRIMESTER OF PREGNANCY
Maryam Kashanian, F. Sharifzadeh, F. Fatemi
Iran
3.54
SIGNIFICANT LABORATORY BIOCHEMICAL BIOMARKERS FOR CORONARY
ATHEROSCLEROSIS AND ITS COMPLICATION
Yulia I. Ragino, A.M. Chernjavski, Y.V. Polonskaja, N.V. Eremenko, M.V. Ivanova,
E.V. Kashtanova
Russia
3.55
COMPARISON OF THE VARIOUS LIPID RATIOS AND INDICES FOR RISK
ASSESSMENT IN PATIENTS OF MYOCARDIAL INFARCTION
Binita Goswami, M. Rajappa, B. Singh, S. Kumar, V. Mallika
India
3.56
PITAVASTATIN REDUCES ELEVATED SOLUBLE LECTIN-LIKE OXIDIZED LDL
RECEPTOR-1 LEVELS IN SUBJECTS WITH HYPERCHOLESTEROLEMIA: SUBANALYSIS OF KISHIMEN MULTICENTER PROSPECTIVE STUDY
Noriaki Kume, Y. Fujioka, A. Taniguchi, S. Kagimoto, Y. Nakamura, T. Yamamoto,
S. Fujimoto, Y. Hamamoto, K.I. Hirata, H. Koshiyama, KISHIMEN Investigators
Japan
97
Poster No
Poster Session
Poster Area
Poster No
3.57
VITAMIN D DEFICIENCY AND ANAEMIA IN OVERWEIGHT/OBESE SUBJECTS
Christina Katsagoni, A. Evangelopoulos, A. Giotopoulou, M. Bonou, N. Vallianou,
V. Bountziouka, P. Avgerinos, E. Vogiatzakis, J. Barbetseas, D.B. Panagiotakos
Greece
3.58
NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN URINE CONCENTRATIONS
MAY SERVE AS AN EARLY PROGNOSTIC MARKER FOR ACUTE KIDNEY INJURY IN
MYOCARDIAL INFARCTION PATIENTS
Dimitrios Tziakas, G. Chalikias, C. Tsigalou, S. Apostolakis, D. Stakos, A. Thomaidi,
K. Mitrousi, P. Kikas, P. Kriki, T. Gioka, S. Panagoutsos, V. Vargemezis,
S. Konstantinides
Greece
3.59
BASIC EVALUATION AND CLINICAL APPLICATION OF BLOOD LIPIDS
MEASUREMENT USING A POINT OF CARE TESTING AMONG JAPANESE
Norio Tada, K. Ito, Y. Tomono, H. Yoshida, S. Hoshina
Japan
3.60
RELATIONSHIP BETWEEN LYMPHOCYTE CASPASE-3 ACTIVITY AND
ATHEROSCLEROTIC PLAQUE VULNERABILITY
Tatjana Ristic, V. Cosic, P. Vlahovic, M. Deljanin Ilic, V. Djordjevic
Serbia
3.61
SERUM THIOREDOXIN ACTIVITY IS NEGATIVELY ASSOCIATED WITH TOTAL
HOMOCYSTEINE LEVELS IN PATIENTS WITH CORONARY ARTERY DISEASE
Wu Yunfei, L. Yang, Z. Liangwei
China
3.62
THE EFFECT OF ROSUVASTATIN TREATMENT ON D-DIMER LEVELS IN OBESE
PATIENTS WITH PRIMARY DYSLIPIDEMIA
Dimitris I. Agapakis, C. Savopoulos, K. Tziomalos, E.V. Massa, N. Katsiki, E. Satsoglou,
A.I. Hatzitolios
Greece
3.63
THE LINK BETWEEN CARDIAC AUTONOMIC FUNCTION AND MARKERS OF
OXIDATIVE STRESS IN CORONAY ARTERY DISEASE (CAD)
Slavica Radovanovic, L. Stojanovic, M. Zdravkovic, M. Krotin, B. Milovanovic
Serbia
3.64
ISCHEMIA MODIFIED ALBUMIN (ΙΜΑ) IN POSTMENOPAUSAL WOMEN WITH OR
WITHOUT CORONARY ARTERY DISEASE (CAD) IN RELATION TO BMI AND OGTT
K. Kazanis, M. Dalamaga, E. Kassi, G. Merantzi, I. Vagionas, G. Jullien,
Amalia Dionyssiou –Asteriou
Greece
3.65
DISORDERS OF PURINE METABOLISM ENZYMES IN ATHEROSCLEROSIS
Slavica Kundalic, B. Kundalic, T. Ristic, D. Stankovic-Ferlez
Serbia
98
79th EAS CONGRESS
Poster Session
Poster Area
3.66
PREDICTIVE VALUE OF INFLAMMATORY MARKERS ON CARDIOVASCULAR
EVENTS IN PATIENTS WITH CHRONIC HEART FAILURE
Slavica Radovanovic, L. Stojanovic, M. Krotin, A. Djokovic, A. Savic-Radojevic,
S. V Dragan, T. Simic
Serbia
3.67
A COMPARISON BETWEEN INSULIN RESISTANCE SCORES PARAMETERS IN
IDENTIFYING METABOLIC SYNDROME (MS) PATIENTS
Angela Cozma, A.V. Sitar-Taut, D. Pop, D.T. Zdrenghea
Romania
3.68
ASSOCIATION OF SCLEROSTIN SERUM LEVELS WITH THE SEVERITY OF AORTIC
VALVE CALCIFICATION
Ralf Koos, A.H. Mahnken, N. Marx, V. Brandenburg
Germany
3.69
PLASMA VISFATIN CONCENTRATION IS A MARKER OF AN ATHEROGENIC
METABOLIC PROFILE
Theodosios Filippatos, V. Tsimihodimos, C.S. Derdemezis, I.F. Gazi, V. Saougos,
A.D. Tselepis, M.S. Elisaf
Greece
3.70
CHARACTERISTICS AND PREDICTIVE BIOMARKERS OF IN-STENT RESTENOSIS
WITHIN DRUG-ELUTING STENTS
Sang-Hyun Kim, H.L. Lee, J.B. Seo, W.Y. Chung, J.H. Zo, H.S. Ahn, M.A. Kim
Republic of Korea
3.71
GRAFT STENOSIS IS ASSOCIATED WITH LIPOPROTEIN(A) C REACTIVE PROTEIN
AND PLASMINOGEN ACTIVATOR INHIBITOR-1 IN PATIENTS UNDERGOING
CORONARY ARTERY BYPASS SURGERY
Syed Shahid Habib, A.G.M. Abdel Gader, M.I. Kurdi, Z.A. Aseri
Saudi Arabia
3.72
HIGH HEART RATE AS A RISK FACTOR FOR INCREASED ATHEROSCLEROSIS IN
CORONARY ARTERY DISEASE(CAD)PATIENTS, STRONGLY RELATED TO NEW
CARDIOVASCULAR EVENTS
S. Radovanovic, Aleksandra Djokovic, D. Simic, I. Zivanovic, S. Jelic, M. Krotin
Serbia
3.73
ENDOTHELIAL PROGENITOR CELL MOBILIZATION IS ENHANCED IN HIGH
PREFORMANCE ATHLETES
Maria Cristina Izar, C.R. Bittencourt, C.N. Franca, H.R. Fonseca, H.T. Bianco,
V.L. Schwerz, F.A. Fonseca
Brazil
99
Poster No
Poster Session
Poster Area
Poster No
3.74
CIRCULATING MICRORNAS: POTENTIAL BIOMARKERS IN
ARTHEROSCLEROSIS
Dwi Setyowati Karolina, A. Armugam, K. Jeyaseelan
Singapore
3.75
FACIAL WRINKLES, GREY HAIR AND BALDNESS PREDICT RISK OF ISCHEMIC
HEART DISEASE AND ISCHEMIC CEREBROVASCULAR DISEASE INDEPENDENT OF
CHRONOLOGICAL AGE
Mette Christoffersen, R. Frikke-Schmidt, P. Schnohr, G.B. Jensen, B.G. Nordestgaard,
A. Tybjærg-Hansen
Denmark
3.76
FABP4 PREDICTS ATHEROGENIC DYSLIPIDEMIA DEVELOPMENT. THE
PREDIMED STUDY
A. Cabré, N. Babio, I. Lazaro, M. Bulló, A. Garcia-Arellano, Lluís Masana,
J. Salas-Salvadó
Spain
3.77
THE APPLICATION OF RESEQUENCING MICROARRAY IN THE SCREENING OF
FAMILIAL HYPERCHOLESTEROLEMIA
Min-Ji Charng, K.R. Chiou
Taiwan R.O.C.
3.78
ASSOCIATION OF ANTIBODY AGAINST HEAT SHOCK PROTEIN-27 AND PROOXIDANT-ANTIOXIDANT BALANCE WITH THE SEVERITY OF CORONARY ARTERY
DISEASE AND METABOLIC SYNDROME
Majid Ghayour-Mobarhan, H. Pourghadamyari, M. Moohebati, S.M.R. Parizadeh,
S. Tavallaie, A. Sahebkar, A. Rahsepar, R. Paydar, G. Ferns
Iran
3.79
ARTIFICIAL NEURAL NETWORK SYSTEM PREDICTS 6-YEAR INCIDENCE OF
METABOLIC SYNDROME USING SERUM MARKERS FOR ATHEROSCLEROSIS
Hiroshi Hirose, T. Takayama, S. Hozawa, I. Saito
Japan
3.80
BIOMARKERS OF INFLAMMATION AND OXIDATIVE STRESS INDEPENTLY PREDICT
THE PROGRESSION OF SUBCLINICAL ATHEROSCLEROSIS
Douwe J. Mulder, J.D. Lefrandt, E. Tremoli, D. Baldassarre, A.J. Smit,
on behalf of the IMPROVE Study Group
The Netherlands
100
79th EAS CONGRESS
Poster Session
Poster Area
3.81
PLASMA 1-DEOXYSPHINGOID BASES AS BIOMARKERS IN METABOLIC SYNDROME
Alaa Othman, M.F. Rütti, A. von Eckardstein, T. Hornemann
Switzerland
3.82
LIPOPROTEIN(A) IS AN INDEPENDENT RISK FACTOR FOR RECURRENT
CORONARY EVENTS IN CHD PATIENTS
Marat Ezhov, M. Safarova, O. Afanasieva, A. Lyakishev, S. Pokrovsky
Russia
3.83
ANEMIA AND IRON DEPLETION INDEPENDENTLY ASSOCIATED WITH
ANGIOGRAPHIC CORONARY ARTERY DISEASE. (THE LUDWIGSHAFEN RISK AND
CARDIOVASCULAR HEALTH STUDY)
Tanja Grammer, G. Silbernagel, S. Pilz, M. Kleber, A. Tomaschitz, B. Boehm,
B. Winkelmann, W. Maerz
Germany
3.84
PERIPHERAL ARTERIAL DIASESE AND TYPE 2 DIABETES MELLITUS: ROLE OF
INFLAMMATORY AND HEMATOLOGICAL PARAMETERS
J. Mancera, J. Rioja, M.A. Sánchez-Chaparro, T. Moreno, M.R. Sánchez-Pérez,
M.J. Ariza-Corbo, P. González-Santos, Pedro Valdivielso
Spain
3.85
HIGH LIPOPROTEIN (A) IN CHILDREN OF PATIENTS WITH PREMATURE CORONARY
HEART DISEASE. RELATION TO OWN AND PARENTAL RISK FACTORS
Michael Konnov, L. Dobordzhginidze, A. Deev, N. Gratsiansky
Russia
3.86
ETHNIC DIFFERENCES IN CIRCULATING MARKERS OF ANGIOGENESIS AND THEIR
ASSOCIATION WITH CARDIOVASCULAR RISK FACTORS AND PERIPHERAL
ARTERIAL DISEASE
Philip Christopher Bennett, S.H. Silverman, P.S. Gill, A.D. Blann, G.Y. Lip
UK
3.87
BIOMARKERS ASSOCIATED WITH LONG TERM CARDIOVASCULAR EVENTS IN
PATIENTS WITH TYPE 2 DIABETES MELLITUS
Henrique Tria Bianco, M.C. Izar, T. Helfenstein, H.R. Fonseca, S.C. Fischer,
C.E. Ferreira, S.P. Barbosa, R.M. Povoa, F.A. Fonseca, Gold Investigators
Brazil
3.88
LOW ANKLE-BRACHIAL INDEX IS ASSOCIATED WITH CHRONIC KIDNEY DISEASE
Peter Wohlfahrt, J. Bruthans, V. Adámková, R. Cífková, The Czech post-MONICA
Czech Republic
3.89
SMALL DENSE LDL-CHOLESTEROL IS SUPERIOR TO LDL-CHOLESTEROL FOR
DETERMINING SEVERE CORONARY ATHEROSCLEROSIS
Y Meguro, Y. Ito, S. Koba, Y. Yokota, T. Hirano, Y. Ban, F. Tsunoda, T. Sato, M. Shoji,
H. Suzuki, E. Geshi, Y. Kobayashi, T. Katagiri
Japan
101
Poster No
Poster Session
Poster Area
Poster No
3.90
FENOFIBRATE REDUCES C-REACTIVE PROTEIN IN NON-OBESE
HYPERTRIGLYCERIDEMIC PATIENTS WITH HIGH RISKS
Chee Jeong Kim, M.A. Kim
Republic of Korea
3.91
CORRELATION OF THE LEPTIN:ADIPONECTIN RATIO WITH INSULIN RESISTANCERELATED FACTORS IN JAPANESE MEN
Yukio Ikeda, N. Hisakawa, T. Ohguro, Y. Kumon
Japan
3.92
PLASMA AMINOTHIOL PROFILE IN APPARENTLY HEALTHY SUBJECTS FROM THE
AZORES ARCHIPELAGO, PORTUGAL
Maria Leonor Pavão, A. Lima, R. Ferin, J. Baptista
Portugal
3.93
DIFFERENTIAL INDICATORS ASSOCIATED WITH SUBCLINICAL CORONARY
ATHEROSCLEROSIS IN SUBJECTS WITH OR WITHOUT METABOLIC SYNDROME
T.Y. Chiu, C.I. Chern, S.Y. Chen, C.C. Soon, Jaw-Wen Chen
Taiwan R.O.C.
3.94
EFFECT OF CYCLOOXYGENASE-1 POLYMORPHISMS ON URINARY 11DEHYDROTHROMBOXANE B2 LEVELS IN PATIENTS UNDERGOING STENT
IMPLANTATION PRETREATED WITH ASPIRIN
Gustavs Latkovskis, N. Licis, B. Krivmane, E. Liepins, M. Dambrova, I. Urtane, A. Knipse,
M. Zabunova, M. Berzina, A. Erglis
Latvia
3.95
RAPID AND EFFICIENT IMMUNOCHROMATOGRAPHIC FATTY ACID BINDING
PROTEIN ASSAY FOR EARLY DIAGNOSIS OF MYOCARDIAL INFARCTION
Mikhail Voevoda, V. Shulman, L. Polikarpov, O. Shtegman, K. Nikolaev
Russia
3.96
THE IMPORTANCE OF INFLAMMATORY MARKERS FOR EARLY DIAGNOSTIC IN
ADOLESCENTS WITH METABOLIC DISEASES
Vasile Negrean, M. Adam, T. Alexescu, S. Tarmure, F. Tomesc, D. Sturzu, A. Nemes
Romania
WORKSHOP: PSYCHOSOCIAL, SOCIOECONOMIC AND LIFE STYLE FACTORS AS
DETERMINANTS OF CARDIOVASCULAR DISEASE
3.97
INFLAMMATION AND CARDIOVASCULAR FITNESS IS GENDER AND BODY MASS
INDEX DEPENDENT
Itzhak Shapira, O. Rogowski, S. Berliner
Israel
102
79th EAS CONGRESS
Poster Session
Poster Area
DETERMINANTS OF CARDIOVASCULAR DISEASE (contd.)
3.98
A 12-WEEK CIRCUIT RESISTANCE PROGRAM IMPROVED ANTIOXIDANT ENZYME
ACTIVITY IN YOUNG ADULTS WITH DOWN SYNDROME
Francisco Javier Ordonez, I. Rosety, A. Camacho-Molina, M.A. Rosety, M. Rosety,
G. Fornieles, N. Garcia, M. Rosety-Rodriguez, A.J. Diaz-Ordonez
Spain
3.99
INCREASING INTENSITIES OF LEISURE-TIME PHYSICAL ACTIVITY ARE
ASSOCIATED WITH LOWER LEVELS OF C-REACTIVE PROTEIN IN HEALTHY 58YEAR OLD MEN
Caroline Schmidt, G. Bergström
Sweden
3.100
WALKING THERAPY FOR PATIENTS WITH DIABETES MELLITUS AND PERIPHERAL
ARTERIAL DISEASE WHO ARE LIMITED BY LEG PAIN AND/OR FATIGUE
Tracie Collins
USA
3.101
OBJECTIVELY MEASURED DAILY PHYSICAL ACTIVITY RELATED TO BODY FAT IN
YOUNG CHILDREN
Magnus Dencker, O. Thorsson, M.K. Karlsson, C. Lindén, L.B. Andersen
Sweden
3.102
THE EFFECT OF AEROBIC EXERCISE TRAINING ON ENDOTHELIN-1
CONCENTRATION IN OLD WOMEN
Vahdat Boghrabadi, S. Nejatpour, A. Baghi
Iran
3.103
DEMANDS AND HEART RATE VARIABILITY IN DANISH WHITE-COLLAR WORKERS
Nanna Eller, M. Blønd, M. Nielsen, J. Kristiansen, B. Netterstrøm
Denmark
3.104
COST EFFICACY IN HOSPITALIZED PATIENTS WITH DIABETES IS RELATIVE TO
TREATMENT DECISION MAKING AND CLINICAL OUTCOME
Christina Voulgari, S. Paximadas, N. Tentolouris
Greece
3.105
LOW BONE MINERAL DENSITY IS NOT ASSOCIATED WITH CORONARY
ATHEROSCLEROSIS IN PATIENTS WITH TYPE 2 DIABETES
Stefan Beer, C.H. Saely, G. Hoefle, A. Vonbank, P. Rein, A. Muendlein, H. Drexel
3.106
IMPACT OF ACCULTURATION ON CORONARY ARTERY DISEASE IN THE SOUTH
ASIAN IMMIGRANTS- UNIQUE POPULATION WITH INCREASED RISK
Sunita Dodani, L. Dong
USA
103
Poster No
Poster Session
Poster Area
Poster No
3.107
LIVING ALONE AND PERMANENT DISABILITY ARE ASSOCIATED WITH POOR
PROGNOSIS AFTER ELECTIVE PCI
O. Shakhmatova, Andrew Komarov, E. Panchenko
Russia
3.108
TOTAL BODY FAT AND ABDOMINAL FAT RELATED TO COMPOSITE RISK FACTOR
SCORE FOR CVD IN YOUNGER CHILDREN
Magnus Dencker, O. Thorsson, M.K. Karlsson, C. Lindén, P. Wollmer, L.B. Andersen
Sweden
3.109
BODY MASS INDEX AND WAIST CIRCUMFERENCE AS PREDICTORS OF THE
INCIDENCE OF TYPE 2 DIABETES AMONG ANGIOGRAPHIED CORONARY PATIENTS
Christoph H. Saely, P. Rein, A. Vonbank, S. Beer, C. Boehnel, S. Greber, H. Drexel
3.110
SYMPATHETIC OUTFLOW TO BONE MARROW MEGAKARYOCYTES STIMULATES
NEOINTIMA FORMATION VIA PLATELET-DERIVED NEUROPEPTIDE Y
Ken Abe, S. Saadat, J. Fennessy, S. Dandamudi, J. Kitlinska, J. Tilan, C. Lu,
M.K. Hellerstein, Z. Zukowska
USA
3.111
SHORT ENDURANCE TRAINING PROGRAM IMPROVED ENDOTHELIAL
DYSFUNCTION IN DIABETIC FATTY RATS
Ignacio Rosety, F. Ordonez, M. Rosety-Rodriguez, A. Camacho-Molina, A. Diaz-Ordonez,
G. Fornieles, N. Garcia, M. Rosety, M.A. Rosety
Spain
3.112
ASSOCIATION BETWEEN PHYSICAL EXERCISE AND SUBCLINICAL CORONARY
ATHEROSCLEROSIS - RESULTS OF THE HEINZ NIXDORF RECALL STUDY
Silke Andrich, N. Dragano, S. Möhlenkamp, U. Slomiany, U. Roggenbuck, J. Siegrist,
K.H. Jöckel, R. Erbel, S. Moebus
Germany
3.113
INFLUENCE OF TRAUMA LIFE-THREATENING ON LIPID METABOLISM
Natalia Klyueva, A. Denisenko, T. Avaliani, O. Fedotova, A. Pshenichnaya, S. Tsikunov
Russia
3.114
INFLUENCE OF DEPRESSION ON THE RISK OF CARDIOVASCULAR DISEASES AT
MEN AGED 25-64 DURING 14 YEARS IN RUSSIA
Valery Gafarov, E. Gromova, A. Gafarova, I. Gagulin
Russia
3.115
ROLE OF FAMILY MILIEU IN TOBACCO ADDICTION
A. Aggarwal, Shridhar Dwivedi, N. Singh
India
3.116
PROINFLAMMATION STATUS IN DEPRESSION AND ISCHEMIC HEART DISEASE
Rudolf Poledne, A. Pilipcincova, M. Bobak, H. Pikhart, P. Stavek, J. Pitha
Czech Republic
104
79th EAS CONGRESS
Poster Session
Poster Area
3.117
THE PARAOXONASE POLYMORPHISMS (PON1 LEU55MET AND GLN192ARG; PON2
SER311CYS) ARE NOT RELATED TO ACUTE MYOCARDIAL INFARCTION IN THE
TUNISIAN POPULATION
Sounira Mehri, M. Hammami
Tunisia
3.118
SOME POPULATIONAL PECULIARITIES OF ATHEROSCLEROSIS IN SIBERIA
Yuri Nikitin, G. Simonova, S. Malyutina
Russia
3.119
CVD SCREENING IN A FAITH BASED SETTING IMPROVES ACCESS
Devaki Nair, A. Jain, J.W. Persaud, D. Harvey, L. Robertson, D.P. Mikhailidis
UK
3.120
SLEEP QUALITY: RISK FOR DEVELOPING TYPE 2 DIABETES?
D.B. Araujo, A. Bertolami, Y. Nakamura, H.P. Zatz, A.A. Faludi, Marcelo Bertolami
Brazil
3.121
TYPE 2 DIABETES AND THE PROGRESSION OF VISUALIZED
ATHEROSCLEROSIS TO CLINICAL CARDIOVASCULAR EVENTS
C.H. Saely, P. Rein, A. Vonbank, K. Huber, Heinz Drexel
3.122
YOUTH WHOSE PARENTS SMOKED HAVE REDUCED FLOW-MEDIATED
DILATATION AS YOUNG ADULTS
M. Juonala, Costan G. Magnussen, A. Venn, J.S.A. Viikari, T. Dwyer, O.T. Raitakari
Australia
3.123
ECCENTRIC ENDURANCE EXERCISE ECONOMICALLY IMPROVES GLUCOSE
TOLERANCE
Markus Zeppetzauer, C.H. Saely, P. Rein, A. Vonbank, H. Drexel
Austria
3.124
EFFECT OF BODY MASS INDEX ON ISCHAEMIC HEART DISEASE RISK:
OBSERVATIONAL AND CAUSAL ESTIMATES ON 76000 INDIVIDUALS
Børge G Nordestgard, T.M. Palmer, M. Benn, J. Zacho, A. Tybjærg-Hansen,
G. Davey Smith, N.J. Timpson
Denmark
105
Poster No
Poster Session
Poster Area
Poster No
3.125
EFFECT OF AN ADHERENCE PROGRAMME ON CARDIOVASCULAR EVENTS IN
HIGH-RISK PATIENTS WITH HYPERCHOLESTEROLEMIA
Jacqueline Müller-Nordhorn, H. Englert, K. Wegscheider, H. Völler, F. Sonntag,
W. Meyer-Sabellek, E. Windler, H.A. Katus, S.N. Willich
Germany
3.126
EFFECTS OF TREADMILL TRAINING ON WALKING DISTANCE AND
ENDOTHELIAL FUNCTION IN PATIENTS WITH INTERMITTENT CLAUDICATION
Rafał Adam Januszek, P. Mika, A. Konik, R. Nowobilski, R. Niżankowski,
A. Szczeklik
Poland
3.127
WAIST CIRCUNFERENCE AND VASCULAR ALTERATIONS IN YOUNG MEN
R. Toro, D. Biedma, P. Gomez, I. Tinoco, C. Rodriguez, M. Virseda, Alipio Mangas
Spain
3.128
THE RELATIONSHIP BETWEEN JOB STRESS AND DYSLIPIDEMIA
Pedro Valdivielso, C. Catalina-Romero, A. González-Quintela, M.Á. Sánchez-Chaparro,
J.C. Sainz-Gutiérrez, C. Sanz-Martín, F. Gutiérrez-González, E. Calvo, L.M. Ruilope
Spain
3.129
RED CELL DISTRIBUTION WIDTH AND INCIDENCE OF HEART FAILURE:
A POPULATION-BASED COHORT STUDY
Yan Borné, J.G. Smith, O. Melander, B. Hedblad, G. Engström
Sweden
3.130
PREVALENCE OF DIABETES AND OF IMPAIRED GLUCOSE TOLERANCE IN
PATIENTS WITH ATHEROSCLEROSIS: THE IMPORTANCE OF THE INVOLVED
ARTERIAL BEDS
Christoph H Saely, P. Rein, S. Beer , A. Vonbank, C. Boehnel, V. Jankovic, V. Drexel,
V. Kiene, H. Drexel
106
79th EAS CONGRESS
Poster Session
Poster Area
3.131
HIGH PREVALENCE OF IMPAIRED GLUCOSE METABOLISM IN OVERWEIGHT
PATIENTS WITH PERIPHERAL ARTERIAL DISEASE
P. Rein, J. Ortmann, C.H. Saely, S. Beer, A. Vonbank, Christian Boehnel, H. Drexel,
I. Baumgartner
3.132
PERSONAL ANXIETY AND RISK DEVELOPMENT OF CARDIOVASCULAR DISEASES
AT POPULATION MEN 25-64 YEAR OLD DURING 24 YEARS (WHO “MONICA”)
V. Gafarov, Elena Gromova, A. Gafarova, I. Gagulin
Russia
3.133
IMPACT OF CIGARETTE SMOKING ON SERUM LIPIDS IN TYPE 1 DIABETES
MELLITUS
T. Bulum, L. Duvnjak, Ingrid Prkačin
Croatia
3.134
PREVALENCE OF SEVERE PVD IN A HIGH-RISK URBAN POPULATION RECEIVING
SELF-EXPANDING NITINOL (SUPERA) STENTS
Jayanth Koneru, A. Samuel, A. Hamdan, F. Shamoon, M. Bikkina
USA
3.135
METABOLIC ALTERATIONS RELATED TO THE INCREASED RISK FOR DIABETES IN
A GROUP OF MEXICAN OBESE NON-DIABETIC WOMEN
Jorge L Ble-Castillo, E. Lopez-Juarez, A.M. Nolasco-Coleman, R. Cordova-Uscanga,
I.E. Juarez-Rojop, C. Cervantes-Toache, J.C. Diaz-Zagoya, M.A. Juarez-Oropeza
Mexico
3.136
INTERPLAY BETWEEN NITRIC OXIDE AND SUPEROXIDE ANION RADICAL DURING
PROGRESSIVE EXERCISE IN ELITE SOCCER PLAYERS
M. Zlatkovic, V. Jakovljevic, O. Stanojlovic, Dragan Djuric
Serbia
3.137
LIFESTYLE BEHAVIOR AND CARDIOVASCULAR RISK IN
HYPERCHOLESTEROLEMIA: IMPACT OF CONSUMPTION OF PHYTOSTEROLSUPPLEMENTED YOGURT
Lluís Masana, O. Descamps, E. Bosi, F.A. Allaert, M.J. Chapman, E. Bruckert
Spain
3.138
OBJECTIVELY MEASURED PHYSICAL ACTIVITY RELATED TO COMPOSITE RISK
FACTOR SCORE FOR CVD IN CHILDREN
Magnus Dencker, O. Thorsson, M.K. Karlsson, C. Lindén, P. Wollmer,
L.B. Andersen
Sweden
107
Poster No
Poster Session
Poster Area
WORKSHOP: NOVEL GENES RELATED TO ATHEROGENESIS – DO THEY ADD TO RISK
PREDICTION OR TREATMENT?
Poster No
3.139
INTERACTIONS OF T-786C POLYMORPHISM OF ENOS GENE WITH ATORVASTATIN
ON PARAMETERS OF LIPID METABOLISM IN BRAZILIAN ADULTS
Vanessa Helena de Souz Zago, J.E. Tanus-Santos, M.R.G. Danelon, R.M.M. da Silva,
E.C. de Faria
Brazil
3.140
ATHEROGENIC SUBFRACTIONAL BLOOD LIPOPROTEINS PROFILE AND ITS
GENETIC MARKERS IN WEST SIBERIA
Elena Shakhtshneider, Y. Ragino, Y. Polonskaya, E. Kashtanova, I. Kulikov, M. Voevoda
Russia
3.141
MIR-21, MIR-210, MIR-34A, MIR-146A AND MIR-146B-5P ARE UP-REGULATED IN
HUMAN ATHEROSCLEROTIC PLAQUES
Emma Kristiina Raitoharju, L.P. Lyytikäinen, M. Levula, N. Oksala, A. Mennander,
R. Laaksonen, T. Lehtimäki
Finland
3.142
THE M62I GENE POLYMORPHISM IN P-SELECTIN GLYCOPROTEIN LIGAND (PSGL-1)
WITH CAROTID ATHEROSCLEROSIS: A PRELIMINAR STUDY
Ana Kolakovic, I. Koncar, O. Stančic, L. Davidovic, D. Alavantic, A. Stankovic, M. Zivkovic
Serbia
3.143
LPLCHIP®, A NOVEL MOLECULAR DIAGNOSTICS TOOL FOR THE IDENTIFICATION
OF MUTATIONS IN THE LPL GENE
R. Rodrigues, M. Artieda, J. Räty, T. Ritsema, Diego Tejedor, A. Martínez
Spain
3.144
CC GENOTYPE OF THE ANGIOTENSIN II TYPE I RECEPTOR GENE PREDICTS
ACUTE MYOCARDIAL INFARCTION IN A TUNISIAN COHORT
Sounira Mehri, S. Mahjoub, A. Zaroui, R. Mechmeche, B. Baudin, M. Hammami
Tunisia
3.145
ASSOCIATION OF POLYMORPHIC MARKERS C3386A OF HMGCR GENE AND
G(-198)A OF FDFT1 GENE WITH CORONARY ARTERY DISEASE
Alexey Nikolaevich Brovkin, K.A. Blagodatskikh, D.A. Zateyshchikov, L.O. Minushkina,
A.G. Nikitin, V.V. Nosikov
Russia
3.146
GENETIC EVIDENCE THAT LIPOPROTEIN(A) CAUSES ATHEROSCLEROSIS
RATHER THAN THROMBOSIS
P.R. Kamstrup, A. Tybjærg-Hansen, Børge G. Nordestgaard
Denmark
108
79th EAS CONGRESS
Poster Session
Poster Area
PREDICTION OR TREATMENT? (contd.)
3.147
IN VITRO FUNCTIONAL CHARACTERIZATION OF NOVEL AMINO ACID
SUBSTITUTIONS IN PCSK9 FOUND IN HYPOCHOLESTEROLEMIC SUBJECTS
Elisa Pinotti, E. Di Leo, C. Valenti, B. Cefalù, D. Noto, D. Norata, A. Catapano, M. Averna,
P. Tarugi
Italy
3.148
FAMILIAL HYPERCHOLESTEROLEMIA IN MEXICO. AN APPROXIMATION TO
THE MUTATIONAL DIVERSITY.
Gerardo Vaca, A. Vàzquez, T. Magaña, L. Ramìrez, I. Dàvalos, B. Marìn, E. Martìnez,
G. Carrillo
Mexico
3.149
MUTATION SPECTRUM IN THE LDL RECEPTOR GENE IN PATIENTS FROM THE
SOUTH-EASTERN PART OF POLAND
Malgorzata Walus-Miarka, B. Idzior-Walus, M. Sanak, B. Katra, M. Malecki, J. Starzyk,
M. Wojcik, S. Dziedzina
Poland
3.150
NOVEL RARE VARIANTS OF APOA5 GENE IN PATIENTS WITH SEVERE
HYPERTRIGLYCERIDEMIA.
Livia Pisciotta, R. Fresa, V. Guido, A. Bellocchio, S. Calandra, S. Bertolini
Italy
3.151
NOVEL MUTATIONS IN SAR1B AND MTP GENES IN CHYLOMICRON RETENTION
DISEASE AND ABETALIPOPROTEINEMIA
Tatiana Fancello, M. Najah, A.L. Magnolo, A. Jelassi, E. Di Leo, N. Slimene, P. Tarugi
Italy
3.152
CORRELATION OF GENETIC VARIATIONS OF GENES INVOLVED IN LOW HIGH
DENSITY LIPOPROTEINS CHOLESTEROL SYNTHESIS IN INDIANS
Tester Ashavaid, A. Sawant, R. Mankeshwar
India
109
Poster No
Poster Session
Poster Area
Poster No
3.153
COMBINING EXOME SEQUENCING WITH EXCLUSION LINKAGE ANALYSIS AS A
TOOL TO UNRAVEL THE MOLECULAR BASIS OF A COMMON GENETIC DISEASE
Mohammad Mahdi Motazacker, R. Huijgen, J. Peter, J.C. Defesche, J.J.P. Kastelein,
G.K. Hovingh, S. Kathiresan, N. Zelcer, S.W. Fouchier
The Netherlands, USA
3.154
REGULATION AND FUNCTIONAL ANALYSIS OF MRAS
Jennifer Freyer, E. Alcolak, J.F.P. Berbeè, M. Behrensen, Z. Aherrahrou,
P. Linsel-Nitschke, J.J. Zwaginga, H. Schunkert, J. Erdmann
Germany
3.155
A MULTIGENIC MODEL TO PREDICT RISK OF ISCHEMIC STROKE IN SUBJECTS
WITH TYPE 2 DIABETES
Roberto Pola, C.H. Kimber, I. Giarretta, A. Doney, A.M. Morris, E. Gaetani, C.N. Palmer
Italy, USA
3.156
ABC TRANSPORTER GENES AND RISK OF TYPE 2 DIABETES
Jesper Schou, A. Tybjærg-Hansen, B.G. Nordestgaard, R. Frikke-Schmidt
Denmark
3.157
APOLIPOPROTEIN E GENE MUTATIONS IN SUBJECTS WITH MIXED
HYPERLIPOPROTEINEMIA AND A CLINICAL DIAGNOSIS OF FAMILIAL COMBINED
HYPERLIPIDEMIA
M. Solanas-Barca, I. de Castro-Orós, A.M. Bea, M. Cofán, N. Plana, E. Ros, L. Masana,
M. Pocoví, F. Civeira, Ana Cenarro
Spain
3.158
HYPOALPHA-HYPOBETALIPOPROTEINEMIA (FAMILIAL COMBINED
HYPOLIPIDEMIA) CAUSED BY LOSS OF FUNCTION MUTATIONS OF ANGPTL3 GENE
Livia Pisciotta, E. Di Leo, P. Tarugi, R. Fresa, I. Zavaroni, D. Ardigò, S. Bertolini,
S. Calandra
Italy
3.159
ASSOCIATION OF DIABETES-MELLITUS-RELATED GENETIC VARIANTS WITH
CORONARY ARTERY CALCIFICATION
Sonali Pechlivanis, A. Scherag, T.W. Mühleisen, S. Möhlenkamp, R. Erbel, K.H. Jöckel,
M.M. Nöthen, S. Moebus, Heinz Nixdorf Recall Study Group
Germany
3.160
ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE (ALCAM) AND PROGNOSIS
IN ACUTE ISCHEMIC STROKE
Linda Merete Smedbakken, J.K. Jensen, J. Hallén, D. Atar, J.L. Januzzi, B. Halvorsen,
P. Aukrust, T. Ueland
Norway
110
79th EAS CONGRESS
Poster Session
Poster Area
3.161
DEVELOPMENT OF GENDER PRESPECIFIED PREDICTION MODEL BASED ON
BAYESIAN BELIEVE NETWORKS METHOD FOR RISK ESTIMATION AFTER ACUTE
CORONARY SYNDROME
Marina A Evdokimova, I.V. Uporov, I.N. Kurochkin, A.V. Sulimov, D.N. Vtyurina,
V.V. Nosikov, D.A. Zateyshchikov
Russia
3.162
OVEREXPRESSION OF Β2-GLYCOPROTEIN I THAT INHIBITS CELL MIGRATION IN
HUMAN AORTIC ENDOTHELIAL CELLS
Wen-Chin Chiu, W.H.H. Sheu, S.Y. Lin, A.N. Chiang
Taiwan R.O.C.
3.163
THE PREVALENCE OF POLYMORPHISMS PROTROMBOGENIC FACTORS IN
PATIENTS WITH CORONARY HEART DISEASE
Galina Alexandrovna Chumakova, A.A. Kozarenko, N. Veselovskaya
Russia
3.164
FATTY ACID BINDING PROTEIN 4 AS A BIOMARKER OF CAROTID
ATHEROSCLEROSIS AND OUTCOME IN PATIENTS WITH ACUTE ISCHEMIC STROKE
Sverre Holm, T. Ueland, T.B. Dahl, A.E. Michelsen, M. Skjelland, D. Russell,
K. Krogh-Sørensen, O.P. Clausen, D. Atar, J.L. Januzzi, P. Aukrust, J.K. Jensen,
B. Halvorsen
Norway
3.165
GENOME ANALYSIS IS MORE EFFFECTIVE THAN SINGLE-GENE ANALYSIS IN
IDENTIFYING SUBJECTS AT HIGH RISK FOR ATHEROTHROMBOSIS
Alberto Izzotti
Italy
3.166
RISK IMPACT OF 12 PRIOR GWAS CANDIDATE GENES/LOCI FOR CORONARY
ARTERY DISEASES IN THE GENETIC ISOLATED NEWFOUNDLAND AND LABRADOR
POPULATION
Ya-Gang Xie, J. Cui, E. Randell, J. Renouf, S. Li, A. Pope, S. Sun, W. Gulliver, B. Sussex,
F.Y. Han
Canada
3.167
DAXX AS A NOVEL TARGET IN THE PREVENTION OF ATHEROSCLEROSIS
Duanfang Liao, Q. Tuo, G. Xu, B. Su, Q. He, B. Zhu
China
3.168
KV1.5 MODULATES OXLDL-INDUCED ENDOTHELIAL INJURY VIA MITOCHONDRIAL
ROS
Guan-Lei Wang, Y.Y. Guan, W.L. Chen
China
111
Poster No
Poster Session
Poster Area
Poster No
3.169
GENETIC VARIANTS ASSOCIATED WITH PRIMARY HYPERTRIGLYCERIDEMIA
María Solanas-Barca, E. Jarauta, P. Martín-Fuentes, M. Cofán, E. Ros, L. Masana,
N. Plana, A. Cenarro, F. Civeira
Spain
3.170
A POLYMORPHISM IN THE HEART SPECIFIC FATTY ACID TRANSPORT PROTEIN 6
IS ASSOCIATED WITH THE METABOLIC SYNDROME AND CARDIOVASCULAR
DISEASE
Annegret Auinger, U. Helwig, D. Rubin, M. de Vrese, M. Lüdde, T. Rausche, N. Elmoktari,
N. Frey, J. Schrezenmeir
Germany
3.171
GENETIC PREDISPOSITION AND ADHERENCE TO THE MEDITERRANEAN DIET IN
George Vassileios Dedoussis, E.V. Theodoraki, T. Nikopensius, J. Suhorutńenko,
M. Yannakoulia, M. Dimitriou, V. Peppes, G. Kolovou, N. Zakopoulos, A. Metspalu
Greece
3.172
CHILHOOD-ONSET CHYLOMICRONEMIA WITH REDUCED PLASMA LPL ACTIVITY
AND MASS: IDENTIFICATION OF A NOVEL GPIHBP1 MUTATION
Joelle Magne, I. Coca-Prieto, O. Kroupa, P. Gonzalez-Santos, G. Olivecrona,
E. Ehrenborg, P. Valdivielso
Sweden
3.173
DO THE DIFFERENT NUMBER OF CA REPEATS IN P1 PROMOTER OF IGF1 GENE
MAY INFLUENCED PLASMA IGF1 LEVELS?
Pawel Burchardt, A. Gozdzicka-Jozefiak, W. Nowak, T. Siminiak
Poland
3.174
THE TRP719ARG VARIANT OF KIF6 AND CARDIOVASCULAR OUTCOMES IN
STATIN-TREATED, CORONARY STABLE PATIENTS OF THE TNT AND IDEAL
PROSPECTIVE STUDIES
Benoit J Arsenault, S.M. Boekholdt, G.K. Hovingh, C.L. Hyde, D.A. DeMicco,
A. Chatterjee, P. Barter, P. Deedwania, D.D. Waters, J.C. LaRosa, T.R. Pedersen,
J.J.P. Kastelein, the Treating to New Targets (TNT) and the Incremental Decrease in End
Points Through Aggressive Lipid-Lowering (IDEAL) Investigators
The Netherlands
3.175
HIGH-DOSE ATORVASTATIN REDUCES APOLIPOPROTEIN E CONCENTRATION
SIGNIFICANTLY AND THIS IS INFLUENCED BY THE APOLIPOPROTEIN E GENOTYPE
Yifen Liu, H. Soran, V. Charlton-Menys, D. Bhatnagar, M. Rutter, S. Kwok, M. France,
P. Durrington
UK
112
79th EAS CONGRESS
Poster Session
Poster Area
3.176
APOA5 -1131 T>C POLYMORPHISM IS A DETERMINANT OF TRIGLYCERIDE LEVELS
IN THE SOUTH ASIAN POPULATION
Elizabeth A Hughes, J.V. Patel, P. Gill, J. Chackathayil, G.Y. Lip
UK
3.177
SELECTED GENES POLYMORPHISMS AND ATHEROSCLEROTIC CHANGES
DEVELOPMENT IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Katarzyna Fischer, A. Walecka, L. Ostanek, M. Ostanek, M. Sawicki, A. Bińczak-Kuleta,
A. Ciechanowicz, M. Brzosko
Poland
3.178
EVALUATION OF THE ASSOCIATION BETWEEN COMMON VARIANTS AT THE GCK,
GCKR, MTNR1B, AND G6PC2 LOCI WITH ANGIOGRAPHICALLY CHARACTERIZED
CORONARY ATHEROSCLEROSIS
Axel Muendlein, C.H. Saely, N. Stark, K. Geiger, S. Geller-Rhomberg, P. Rein,
A. Vonbank, H. Drexel
3.179
ANTIRETROVIRAL TREATMENT-INDUCED DYSLIPIDEMIA IN HIV-INFECTED
PATIENTS IS INFLUENCED BY THE APOC3-RELATED RS10892151 POLYMORPHISM
Raúl Beltrán-Debón, G. Aragones, C. Alonso-Villaverde, A. Rull, E. Rodríguez, P. Pardo,
J. Camps, J. Joven
Spain
3.180
PHARMACOGENETICS OF STATIN TREATMENT EFFICACY: ANALYSIS OF GENETIC
VARIATION AT EIGHT CANDIDATE GENE LOCI
Michal Vrablik, J. Hubacek, V. Adamkova, M. Prusikova, L. Zlatohlavek, V. Lanska,
R. Ceska
Czech Republic
3.181
DIFFERENTIAL PERIPHERAL-BLOOD GENE EXPRESSION IN PATIENTS WITH
ACUTE MYOCARDIAL INFARCTION AND STABLE CORONARY DISEASE
Sagi Nahum, Y. Drier, N. Avidan, E. Domani, E. Sprecher, D. Aronson
Israel
3.182
HIGH FREQUENCY OF NPY POLYMORPHISM IN IRAN AND ITS ASSOCIATION WITH
Ali Masoudi Kazemabad, M. Ghayour Mobarhan, K. Jamialahmadi, M. Moohebati,
M. Mojarrad, R. Dehghan manshadi, M.M. Forghanifard
Iran
3.183
AHSG GENE POLYMORPHISM AFFECTS PLASMA LEVELS OF NON-HIGH-DENSITY
LIPOPROTEIN CHOLESTEROL IN CAUCASIANS
Pavel Suchanek, J.A. Hubacek, I. Kralova Lesna, V. Adamkova
Czech Republic
113
Poster No
Poster Session
Poster Area
Poster No
3.184
GENDER DEPENDENT ASSOCIATION BETWEEN KIF6 POLYMORPHISM AND RISK
OF UNFAVORABLE OUTCOME IN PATIENTS SURVIVED ACUTE CORONARY
SYNDROME
O.S. Koroleva, M.A. Evdokimova, A.A. Pushkov, K.A. Blagodatskich, V.V. Nosikov,
Dmitry A. Zateyshchikov
Russia
3.185
RENIN-ANGIOTENSIN SYSTEM AND ACUTE MYOCARDIAL INFARCTION IN
TUNISIAN POPULATION
S. Mehri, Mohamed Hammami
Tunisia
3.186
THE MTRR GG GENOTYPE IS ASSOCIATED WITH RESTENOSIS AFTER ELECTIVE
PCI
Olga Shakhmatova, A. Komarov, E. Panchenko
Russia
3.187
ASSOCIATION BETWEEN THE PRO198LEU POLYMORPHISM IN THE GLUTATHIONE
PEROXIDASE 1 (GPX1) GENE AND MYOCARDIAL INFARCTION IN A TUNISIAN
POPULATION
Riadh Jemaa, A. Kallel, Y. Sediri, H. Khorchfi, M. Feki, S. Abdessalem, M.S. Mourali,
R. Mechmeche, N. Kaabachi
Tunisia
3.188
EFFECT OF APOLIPOPROTEIN E GENOTYPES ON THE EFFICACY OF EZETIMIBE
MONOTHERAPY IN PATIENTS WITH STATIN INTOLERANCE
Mariann Harangi, I. Seres, G. Béke, I. Balogh, J. Harangi, T. Köbling, G. Paragh
Hungary
3.189
POLYMORPHIC MARKERS OF THBD AND PROC GENES AND GENETIC
PREDISPOSITION TO UNFAVOURABLE OUTCOMES IN PATIENTS AFTER ACUTE
CORONARY SYNDROME
Alexander Alekseevich Pushkov, K.A. Blagodatskikh, A.G. Nikitin, M.A. Evdokimova,
D.A. Zateyshchikov, V.V. Nosikov
Russia
3.190
NPC1L1 GENE POLYMORPHISMS AFFECTING CHOLESTEROL ABSORPTION
Tomomi Maeda, M. Numakura, Y. Mashimo, N. Yoshimura, J. Kusano, T. Ishikawa,
K. Murata, M. Fujita, A. Honda, M. Kinoshita, Y. Matsuzaki, T. Teramoto
Japan
3.191
OVERWEIGHT DETERMINES THE INFLUENCE OF THE ADIPONECTIN G276T
POLYMORPHISM ON LIPID LEVELS IN HEALTHY ADOLESCENTS
Pía Riestra, A. García-Anguita, M.A. Lasunción, A. Mangas, C. Garces
Spain
114
79th EAS CONGRESS
Poster Session
Poster Area
3.192
TIMP-4 SINGLE NUCLEOTIDE POLYMORPHISM AND CARDIAC FUNCTION IN HEART
FAILURE PATIENTS
Alberto Alves, Y. Rivlin, U. Rosenschein, F. Ribeiro, J.A. Duarte, M. Sagiv, J. Oliveira,
E. Goldhammer
Portugal
3.193
CORRELATION BETWEEN ANGIOTENSIN II TYPE 1 RECEPTOR POLYMORPHISMS
AND CORONARY ARTERY CALCIFICATION IN CORONARY ARTERY DISEASE
Amir Hooshang Mohammadpour, J. Behravan, S. Nazemi, M. Foroughi,
N. Milani Moghaddam, H. Hashemizadeh
Iran
3.194
VARIATION IN PROMOTER REGIONS OF GENES FOR CC CHEMOKINES CCL19 AND
CCL21 IN CZECH MYOCARDIAL INFARCTION PATIENTS
Jana Petrkova, A. Stahelova, M. Taborsky, F. Mrazek, M. Petrek
Czech Republic
3.195
MONOCYTE CHEMOATTRACTANT PROTEIN-1 -2518A>G GENE POLYMORHISM AND
THE RISK OF ISCHAEMIC STROKE IN CAUCASIAN SUBJECTS
Anna Tavridou, E. Giannakopoulou, G. Ragia, S. Marousi, J. Ellul, V.G. Manolopoulos
Greece
3.196
A5237G POLYMORPHISM OF CRP GENE IS ASSOCIATED WITH UNFAVOURABLE
OUTCOMES IN PATIENTS WITH AFTER CORONARY SYNDROME
Konstantin Aleksandrovich Blagodatskikh, A.A. Pushkov, A.G. Nikitin,
M.A. Evdokimova, V.S. Osmolovskaya, D.A. Zateyshchikov, V.V. Nosikov
Russia
3.197
PLASMA PHOSPHOLIPID TRANSFER PROTEIN (PLTP) IS A PROCOAGULANT
FACTOR IN VIVO
Catherine Desrumaux, V. Deckert, S. Lemaire-Ewing, C. Mossiat, A. Athias,
D. Vandroux, L. Dumont, S. Monier, J.P. Pais de Barros, A. Klein, E. De Maistre,
D. Blache, A. Beley, C. Marie, P. Garnier, L. Lagrost
France
115
Poster No
Poster Session
Poster Area
Poster No
3.198
MICRORNAS 340* AND 624* ARE UPREGULATED IN PLATELETS IN PATIENTS
WITH CORONARY ARTERY DISEASE
Brigitte Marlene Sondermeijer, A. Bakker, A. Halliani, S. Maiwald, S. Sivapalaratnam,
T.A. Mulders, M.W.J. de Ronde, A.J. Tijsen, J.A. Marquart, P.D. Moerland, M.D. Trip,
J.C.M. Meijers, E.E. Creemers, S.J. Pinto-Sietsma
The Netherlands
3.199
GENETIC VARIATIONS, MRNA EXPRESSION AND CIRCULATING LEVELS OF
MATRIX METALLOPROTEINASE-9 IN PATIENTS WITH CORONARY ARTERY
DISEASE
Trine Baur Opstad, A.Å. Pettersen, S. Åkra, T. Weiss, H. Arnesen, I. Seljeflot,
Center for Clinical Heart Research
Norway
LOW HDL-CHOLESTEROL OF WOMEN AT RISK PREDICTED PRE-DIABETES
Ruth Maria Korth
Germany
3.200
116
79th EAS CONGRESS
Poster Session
Poster Area
WORKSHOP: HEALTHY DIETS AND FUNCTIONAL FOOD – A ROAD TO PREVENTION
4.01
THE EFFECTS OF FETAL UNDERNUTRITION ON THE GENE EXPRESSION OF
WHITE ADIPOSE TISSUE IN RAT
Meiju Saukko, E. Malo, M. Santaniemi, M. Hietaniemi, O. Ukkola, Y.A. Kesäniemi
Finland
4.02
THE EFFECT OF FETAL UNDERNUTRITION ON GLUCOSE METABOLISM IN RAT
OFFSPRING
Elina Malo, M. Saukko, M. Santaniemi, M. Hietaniemi, O. Ukkola, Y.A. Kesäniemi
Finland
4.03
ADDING SKIMMED MILK TO A HIGH-FAT MEAL AFFECTS POSTPRANDIAL
MARKERS FOR INFLAMMATION AND ENDOTHELIAL ACTIVATION IN OVERWEIGHT
MEN
Christiaan J. Masson, L.E. van Meijl, R.P. Mensink
The Netherlands
4.04
PLANT STEROLS DO EXERT A MODEST SERUM TRIGLYCERIDE LOWERING
EFFECT: A META-ANALYSIS OF INDIVIDUAL SUBJECT DATA
Isabelle Demonty, L. Meijer, H.C.M. van der Knaap, R.T. Ras, P.L. Zock, J.M. Geleijnse,
E.A. Trautwein
The Netherlands
4.05
THE ROLE OF SOLUBLE FIBER INTAKE IN PATIENTS UNDER HIGHLY
EFFECTIVE LPID-LOWERING THERAPY
S.C. Ramos, F.A. Fonseca, S.H. Kasmas, F.T. Moreira, T. Helfenstein, N.C. Borges,
R.A. Moreno, V.M. Rezende, F.C. Silva, Maria Cristina Izar
Brazil
4.06
SERUM AMYLOID A DECREASES FOLLOWING FRUIT AND VEGETABLE
INTERVENTION
Nida Nadeem, J. Woodside, I. Young, J. McEneny
UK
4.07
POSTPRANDIAL SERUM SITOSTANOL AND NON-CHOLESTEROL STEROLS
AFTER AN ACUTE DOSE OF PLANT STANOL ESTER ON ITS CHRONIC
CONSUMPTION
Piia Simonen, H. Miettinen, H. Gylling, M. Hallikainen, M. Nissinen, T.A. Miettinen
Finland
117
and Treatment of
Poster No
Poster Session
Poster Area
(contd.)
and Treatment of
Poster No
4.08
BENEFICIAL EFFECTS OF ALTERNATE DIETARY REGIMEN ON LIVER
INFLAMMATION, ATHEROSCLEROSIS AND RENAL ACTIVATION
Peter Y. Wielinga, G.K. Yakala, P. Heeringa, R. Kleemann, T. Kooistra
The Netherlands
4.09
IS THE OMEGA-3 FATTY ACIDS SUPPLEMENTATION JUSTIFIED TO MODIFY MAJOR
CARDIOVASCULAR OUTCOMES? A META-ANALYSIS
E.C. Rizos, E.E. Ntzani, E. Bika, M. Kostapanos, Moses C. Elisaf
Greece
4.10
VITAMIN B6, B12 AND FOLIC ACID SUPPLEMENTATION AND LONG-TERM
PROGNOSIS AFTER ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
Olga Shakhmatova, A. Komarov, E. Panchenko
Russia
4.11
ALCOHOL AND STIMULANTS DIETARY PATTERN IN RELATION TO HAPTOGLOBIN
LEVELS, AMONG APPARENTLY HEALTHY INDIVIDUALS
Vassiliki Bountziouka, A. Evangelopoulos, A. Giotopoulou, M. Bonou, N. Vallianou,
P. Avgerinos, E. Vogiatzakis, J. Barbetseas, D. Panagiotakos
Greece
4.12
INFLUENCE OF DIETARY PATTERNS ON VASCULAR HEALTH AND ITS RISK
FACTORS
Julie Ann Lanigan, S. Low, M. Kokoreli, K. Northstone, J. Deanfield, A. Lucas, A. Singhal
UK
4.13
DEALCOHOLISED RED AND WHITE WINES ATTENUATE ATHEROSCLEROSIS IN
APOE-DEFICIENT MICE BY UP-REGULATING HEME OXYGENASE-1
Maria Teresa Mitjavila, B. Bonacasa, M.C. Zaragozá, R.C. Siow, G.E. Mann,
N. Martinez
Spain
4.14
REDUCED ATHEROSCLEROTIC LESION DEVELOPMENT IN APOLIPOPROTEIN EDEFICIENT MICE FED A WESTERN-TYPE DIET ENRICHED WITH OIL FROM
CALANUS FINMARCHICUS
Karl-Erik Eilertsen, H. Mæhre, I.J. Jensen, B. Østerud, E.O. Elvevoll
Norway
4.15
EFFECTS OF LEAN RED MEAT OR LEAN WHITE MEAT INTAKE ON THE LIPID
PROFILE IN WOMEN: A RANDOMIZED CROSSOVER STUDY
Rocio Mateo-Gallego, S. Perez-Calahorra, A.M. Bea, E. Burillo, J. Horno, E. Ros,
F. Civeira
Spain
118
79th EAS CONGRESS
Poster Session
Poster Area
(contd.)
4.16
EFFECT OF OLEIC ACID IN COMBINATION WITH VARIED LEVELS OF FISH OIL ON
THE LIPID PROFILE OF HEALTHY MEN
Omar Obeid, D. El-Bistami, M. Mattar, S. Halis
Lebanon
4.17
ADHERENCE TO THE MEDITERRANEAN DIET IS ASSOCIATED WITH REDUCED
URIC ACID METABOLISM AMONG SUBJECTS WITH METABOLIC SYNDROME
Christina Katsagoni, A. Evangelopoulos, A. Giotopoulou, M. Bonou, N. Vallianou,
V. Bountziouka, P. Avgerinos, E. Vogiatzakis, J. Barbetseas, D.B. Panagiotakos
Greece
4.18
EFFECT OF MODERATE INTAKE OF DIFFERENT ALCOHOLIC DRINKS OVER THE
PLASMATIC CONCENTRATION OF PRO-INFLAMMATORY MARKERS INDUCED BY A
FAT-ENRICHED DIET
Ana Torres, V. Cachofeiro, E. Bello, J. Millán, C. Recarte, V. Lahera,
L.A. Alvarez-Sala
Spain
4.19
DIETARY CARBOHYDRATE, FATS, AND CORONARY ATHEROSCLEROSIS IN
ASYMPTOMATIC POSTMENOPAUSAL WOMEN
Min-Kyung Kim, H.E. Park, S.Y. Choi
Republic of Korea
4.20
POTENTIAL BENEFITS OF CHILLI PEPPER IN A MEAL AND A CAPSULE
Madeleine Ball, K. Ahuja, N. Green, M. Adams, I. Robertson
Australia
4.21
LYCOPENE SUPPRESSES CYCLIC STRAIN-INDUCED ENDOTHELIN-1 EXPRESSION
VIA THE INDUCTION OF ACTIVATING TRANSCRIPTION FACTOR 3 IN HUMAN
UMBILICAL VEIN ENDOTHELIAL CELLS
Tzu-Hurng Cheng, H.H. Chao, J.J. Chen, J.C. Liu
Taiwan R.O.C.
4.22
OLEUROPEIN REDUCES ENDOTHELIAL PROGENITOR CELLS SENESCENCE AND
PROTECTS AGAINST OXIDATIVE STRESS INDUCED BY ANGIOTENSIN II
Andrzej Parzonko, M. Naruszewicz
Poland
4.23
A COMPARATIVE STUDY OF THE EFFECTS OF OLEUROPEIN AND OLEACEIN ON
HUMAN NEUTROPHIL OXIDATIVE BURSTS AND MONOCYTES NITRIC OXIDE
PRODUCTION
Monika Czerwińska, A.K. Kiss, M. Naruszewicz
Poland
4.24
DIETARY INTAKE OF PLANT STEROL ESTER ENRICHED MARGARINE INCREASES
THE SERUM CONCENTRATION OF 7Β-HYDROXYSITOSTEROL IN HUMANS
Constanze Husche, O. Weingärtner, U. Laufs, D. Lutjohann
Germany
119
and Treatment of
Poster No
Poster Session
Poster Area
(contd.)
and Treatment of
Poster No
4.25
TOCOTRIENOL-TOCOPHEROL MIXED FRACTION SUPPLEMENTATION PREVENTS
INFLAMMATION IN ESTABLISHED ATHEROSCLEROSIS
N. Aishah, Effat Omar, A. Thuhairah, H. Nawawi
Malaysia
4.26
POTASSIUM CHANNELS ARE INVOLVED IN THE VASODILATATION OF HUMAN
UMBILICAL VEIN BY RESVERATROL
Dragana Protic, S. Spremovic-Radjenovic, N. Radunovic, V. Kanjuh, H. Heinle,
L. Gojkovic-Bukarica
Serbia
4.27
REDUCED SERUM CHOLESTEROL CONCENTRATION IN CRTITICALLY ILL
PATIENTS PREDICTS REQUIREMENT FOR PARENTERAL NUTRITION
William Gordon Simpson, W.J. Mutch, R. Peake, B.L. Croal, K.A. Deans, M. Rehan,
D. Noble
UK
4.28
ANTIATHEROGENICITY OF HYDROPHILIC EXTRACTS FROM H. INCRASSATA
SEAWEED IN VITRO AND IN VIVO
Ariadna Costa-Mugica, D. Mondejar, A.E. Batista, A. Samokhin, D. Bromme, Y. Soto,
V. Britto, A.M. Vázquez, C. Zaldivar, A. Vidal
Cuba
4.29
ISOENERGETIC REPLACEMENT OF DIETARY SATURATED WITH
MONOUNSATURATED FAT VIA MACADAMIA NUTS CAN AFFECT CORONARY RISK
IN OVERWEIGHT SUBJECTS
Shawn Somerset, L. Graham, K. Markwell, D. Colquhoun
Australia
4.30
PREVALENCE OF THE COMPONENTS OF THE METABOLIC SYNDROME AND
LIFESTYLE IN GERMAN YOUTH PARTICIPATING IN THE PEP FAMILY HEART STUDY
Gerda Maria Haas, E. Liepold, P. Schwandt
Germany
4.31
“BENEFICIAL EFFECT OF BANANA RESISTANT STARCH TO REDUCE GLYCEMIA
AND LIPIDS IN TWO ANIMAL MODELS WITH DISMETABOLIC DISORDERS”
Jorge L Ble-Castillo, M.A. Aparicio-Trápala, V. Olvera-Hernandez,
A. Rodriguez-Hernandez, I.E. Juarez-Rojop, H. Aguilar-Mariscal, M.P. Vázquez-Sanchez,
J.C. Diaz-Zagoya
Mexico
4.32
THE SHORT-TERM EFFECT OF MEDITERRANEAN-TYPE DIET ON SERUM
INFLAMMATORY MARKERS IN SUBJECTS WITH ABDOMINAL OBESITY
Loukianos S Rallidis, A. Kolomvotsou, J. Lekakis, P. Farajian, G. Vamvakou, G. Liakos,
S. Efstathiou, M. Anastasiou-Nana, A. Zampelas
Greece
120
79th EAS CONGRESS
Poster Session
Poster Area
(contd.)
4.33
BOTH PUFA-ENRICHED AND PUFA-DEPRIVED DIETS COUNTERACT AGE-RELATED
HYPERCHOLESTEROLEMIA IN RATS
Sara Straniero, G. Cavallini, A. Donati, M. Rudling, E. Bergamini
Sweden
4.34
EFFECTS OF CONSUMPTION OF HYPERCHOLESTEROLEMIC DIETS CONTAINING
GLUCOMANNAN AND SPIRULIN-ENRICHED SQUID-SURIMI ON PLASMA LIPID
CONCENTRATIONS IN ZUCKER FA-FA RATS
Miguel Vázquez-Velasco, L. González-Torres, R. Olivero, S. Bastida, F.J. Sánchez-Muniz,
M.I. Sánchez-Reus, M.J. González-Muñoz, J. Benedí
Spain
4.35
INSULIN RESISTANCE/SENSIBILITY BIOMARKERS CHANGES IN ZUCKER FA/FA
RATS FED DIABETOGENIC DIET ENRICHED IN SQUID SURIMI CONTAINING
GLUCOMANNAN AND A MICROALGA
Miguel Vázquez-Velasco, L. González-Torres, A. Schultz, S. Bastida, F.J. Sánchez-Muniz,
M.I. Sánchez-Reus, M.J. González-Muñoz, J. Benedí
Spain
4.36
THE EFFECT OF WINE POLYPHENOL RESVERATROL IN THE RAT RENAL ARTERY
Ljiljana Gojkovic-Bukarica, J. Markovic-Lipkovski, S. Cirovic, R. Novakovic, V. Kanjuh,
H. Heinle
Serbia
4.37
INHIBITORY EFFECT OF SALVIA MILTIORRHIZA ON OXIDATIVE STRESS AND
APOPTOSIS IN ANIMAL MODEL OF ATHEROSCLEROSIS
Weng-Cheng Chang, Y.M. Yu
Taiwan R.O.C.
4.38
HIGH FULL FAT DAIRY PRODUCTS INTAKE IS ASSOCIATED WITH INCREASED
BLOOD GLUCOSE LEVELS, AMONG HYPERTENSIVE PEOPLE
Natalia Vallianou, V. Bountziouka, A. Evangelopoulos, M. Bonou, C. Katsagoni,
J. Barbetseas, P. Avgerinos, E. Vogiatzakis, D. Panagiotakos
Greece
4.39
CONSUMPTION OF STARCHY FOODS AND LEGUMES IS ASSOCIATED WITH
INCREASED SERUM ALBUMIN LEVELS, AMONG HEALTHY ADULTS
Amalia Giotopoulou, V. Bountziouka, A. Evangelopoulos, N. Vallianou, M. Bonou,
J. Barbetseas, E. Vogiatzakis, P. Avgerinos, D. Panagiotakos
Greece
4.40
A SIMPLE METHOD OF COMPARING DIETARY APPROACHES THAT REDUCE
SATURATES, IMPROVE FAT QUALITY AND INDICATES LIKELY EFFECT ON BLOOD
CHOLESTEROL
Janice Irene Harland
UK
121
and Treatment of
Poster No
Poster Session
Poster Area
(contd.)
and Treatment of
Poster No
4.41
COMPLIANCE TO TREATMENTS AND LIFESTYLE MEASURES CORONARY HEART
DISEASE PATIENTS IN THE BANJA LUKA REPUBLIC OF SRPSKA/BOSNIA AND
HERZEGOVINA 2004-2005
Dusko Vulic, S. Loncar, L. Sormaz, B. Vulic, J. Marinkovic, M. Ostojic
Bosnia-Herzegovina
4.42
ETHANOLIC EXTRACT OF SEEDS OF LINUM USSITATTIMUM (FLAX LIGNAN
CONCENTRATE) PREVENTS DOXORUBICIN-INDUCED CARDIOTOXICITY IN RATS
Anand Zanwar, M.V. Hegde, S.L. Bodhankar
India
4.43
GENE-DIET INTERACTION EFFECTS ON OXIDATIVE STRESS LEVELS IN
INDIVIDUALS WITH STATIN-CONTROLLED DYSLIPIDAEMIA
P.B. Botelho, C.O. Fioratti, M.M. Rogero, L.P. Barroso, M.C. Bertolami, Inar Alves Castro
Brazil
4.44
COMPARATIVE STUDY OF THE ATHEROSCLEROTIC PARAMETERS IN MONGOLIAN
AND JAPANESE PATIENTS WITH HYPERTENSION AND DIABETES MELLITUS
Uurtuya Shuumarjav, K. Kotani
Mongolia
4.45
INVESTIGATING THE IMPACT OF DIETARY AND PHYSICAL ACTIVITY TARGET
ACHIEVEMENT ON WEIGHT AND WAIST CIRCUMFERENCE IN CORONARY HEART
DISEASE PATIENTS
Rooshi Nathwani
UK
4.46
PENTA-O-GALLOYL-Β-D-GLUCOSE INHIBITS NEUTRAL ENDOPEPTIDASE (NEP)
ACTIVITY AND ROS PRODUCTION IN NEUTROPHILS ISOLATATES FROM HEALTHY
SUBJECTS AND FROM PATIENTS WITH AMI
Anna Kiss, A. Kapłon -Cieślicka, K. Filipiak, G. Opolski, M. Naruszewicz
Poland
4.47
EFFECT OF THERAPEUTIC LIFESTYLE CHANGE ON HIGH DENSITY LIPOPROTEIN
CHOLESTEROL IN PATIENTS WITH METABOLIC SYNDROME
Sang Hyun Kim, H.L. Lee, J.B. Seo, W.Y. Chung, J.H. Zo, M.A. Kim
Republic of Korea
4.48
INTERMITTENT FASTING: PHYSIOLOGICAL DATA REGARDING A NEW APPROACH
FOR THE NUTRITIONAL PREVENTION OF ATHEROSCLEROSIS
Edielle Santanna Melo, F. Reis de Azevedo, L.H. Monteiro, B. Caramelli
Brazil
4.49
THE INFLUENCE OF DIET ON LEVEL OF ENDOGENOUS MELATONIN, VASCULAR
INFLAMMATION AND LIPID PROFILE IN HYPERTENSIVE PATIENTS
Corina Grigore, O. Grigore, L. Dawkins, D. Isacoff, I. Bruckner
Romania
122
79th EAS CONGRESS
Poster Session
Poster Area
(contd.)
Poster No
4.50
DETERMINATION OF HOMOCYSTEINE VALUES ON OBESE PATIENTS ASSOCIATED
WITH NUTRITION
S. Patiakas, Charalampos Charalampous
Greece
4.51
OMEGA-3 FATTY ACID ENRICHED EGGS ARE HEART FRIENDLY
M.V. Hegde, Anand Arvind Zanwar, S.A. Khan, U.V. Wagh
India
4.52
THE ROLE OF CERTAIN NATURAL POLYPHENOLS IN EXPERIMENTAL ARTERIAL
HYPERTENSION
Manuela Ciocoiu, A. Miron, C. Badescu, D. Tutunaru, M. Badescu
Romania
4.53
THE BENEFICIAL EFFECTS OF NATURAL POLYPHENOLS ON THE DISLIPIDEMY
AND EYE COMPLICATIONS IN THE EXPERIMENTAL DIABETES MELLITUS
Magda Badescu, C. Badescu, D. Tutunaru, O. Badulescu, M. Ciocoiu
Romania
4.54
MODES OF ACTION OF SOY CONSTITUENTS IN LDL MANAGEMENT
Jan H. van Ee
The Netherlands
4.55
CORRELATION OF ANTHROPOMETRIC INDICES LIKE ABDOMINAL
CIRCUMFERENCE AND BODY MASS INDEX IN PATIENTS WITH NON-ALCOHOLIC
FATTY LIVER DISEASE(NAFLD)
Ileana Pantea, O. Andreescu, L. Nedelcu, C. Scarneciu, M. Vâlcu, I. Brezean
Romania
4.56
EXTENSIVE MANAGEMENT APPROACH IN THE TREATMENT OF OBESITY - FIRST
RESULTS
Ursula Kassner, A. Binder, A. Ahnis, M. Haupt, B. Klapp, E. Steinhagen-Thiessen,
E. Giannakidou-Jordan
Germany
4.57
CAROTID PLAQUE MEASUREMENT IS SUPERIOR TO IMT
J. David Spence
Canada
4.58
C-REACTIVE PROTEIN IS NOT ASSOCIATED WITH CAROTID TOTAL PLAQUE AREA
OR STENOSIS
J. David Spence
Canada
123
and Treatment of
WORKSHOP: CEREBROVASCULAR DISEASE - PREVENTION AND TREATMENT
Poster Session
Poster Area
WORKSHOP: CEREBROVASCULAR DISEASE - PREVENTION AND TREATMENT (contd.)
and Treatment of
Poster No
4.59
CLOPIDOGREL VERSUS ASPIRIN TREATMENT ON ADMISSION IMPROVES 5-YEAR
SURVIVAL AFTER A FIRST-EVER ACUTE ISCHEMIC STROKE
Michael S Kostapanos, H.J. Milionis, G. Gerotziafas, A. Vemmou, P. Zis, K. Spengos,
M.S. Elisaf, K.N. Vemmos
Greece
4.60
MAJOR ADVERSE CARDIAC EVENTS AND MORTALITY IN PERIPARTUM LUPUS
PATIENTS: A POPULATION-BASED STUDY
Pao-Hsien Chu, C.H. Tang
Taiwan R.O.C.
4.61
FORMONONETIN, A CLA1 UPREGULATOR, REDUCES ATHEROSCLEROTIC LESION
FORMATION IN APOE-/- MICE
Y. Xu, Q. Liu, P. Zhao, N. Li, F. Lai, Y. Xu, X. He, W. Jiang, B. Hong, Shuyi Si
China
4.62
TOTAL SERUM B12 AND HOMOCYSTEINE LEVELS ARE ASSOCIATED WITH
INCREASED RISK OF COGNITIVE DYSFUNCTION: A 4 YEARS PROSPECTIVE STUDY
Christina Voulgari, S. Paximadas, P. Dilaveris, C. Stefanadis, N. Katsilambros,
N. Tentolouris
Greece
4.63
YKL-40 IN CAROTID ATHEROSCLEROSIS
Annika Elisabet Michelsen, C.N. Rathcke, M. Skjelland, S. Holm, T. Ranheim,
K. Krohg-Sørensen, M. Klingvall, F. Brosstad, E. Øie, H. Vestergaard, P. Aukrust,
B. Halvorsen
Norway
4.64
STRUCTURE AND CYTOKINE PATTERN OF CAROTID PLAQUES IN ELDERLY
PATIENTS
Helena Grufman, A. Edsfeldt, A. Persson, M. Nitulescu, M. Nilsson, J. Nilsson,
I. Goncalves
Sweden
4.65
COMPARISON OF THE NEW UNIFIED CRITERIA FOR METABOLIC SYNDROME WITH
CONVENTIONAL IDF CRITERIA: RISK FOR DEVELOPING CARDIOVASCULAR
DISEASE
Jiro Suwa
Japan
4.66
CEREBRAL MICROBLEEDS IS ASSOCIATED WITH ARTERIAL CALCIFICATION
Kwang-Yeol Park, P.W. Chung
Republic of Korea
124
79th EAS CONGRESS
Poster Session
Poster Area
Poster No
4.67
RELATIONSHIP BETWEEN PLASMA ADMA LEVELS AND CAROTID NARROWING
DEGREE IN CAROTID ENDARTERECTOMY (CEA) PATIENTS
A. Zinellu, M.A. Casu, F. Piredda, P. Porcu, L. Deiana, Ciriaco Carru
Italy
4.68
COMPREHENSIVE METABOLIC PROFILING IN RISK STRATIFICATION OF HUMAN
CAROTID ATHEROSCLEROSIS
Joseph Shalhoub, P.A. Vorkas, C. Monaco, E.J. Want, M.R. Lewis, A.H. Davies,
E. Holmes, J.K. Nicholson
UK
4.69
EFFECT OF PHYSICAL ACTIVITY ON IMT OF CAROTID ARTERY IN SMOKERS
Hiroyuki Katano, M. Ohno, K. Yamada
Japan
4.70
CAROTID RESTENOSIS AFTER ENDARTERECTOMY: THE ROLE OF
APOLIPOPROTEINS
Simone Vidale, S. Bellocchi, P. Casiraghi, D. Trevisan, M. Arnaboldi, R. Caronno,
A. Taborelli
Italy
4.71
ENDOTHELIALIZATION AND IN-STENT RESTENOSIS OF GLYCOPROTEIN IIIA
MONOCLONAL ANTIBODY ELUTING STENT
Tieying Yin, G. Wang, D. Du, Z. Li, L. Luo, D. Zhang, Y. Wang, C. Ruan
China
4.72
EVALUATION OF CHOLESTEROL LOWERING TREATMENT OF PATIENTS WITH
FAMILIAL HYPERCHOLESTEROLEMIA.
Vasiliki Metaxa, I. Skoumas, C. Pitsavos, E. Oikonomou, E. Tsetsekou, C. Chrysochoou,
K. Masoura, C. Stefanadis
Greece
4.73
PLANT STEROL AND STANOL ESTERS INDUCE DIFFERENTIAL EFFECTS ON
OXIDATIVE STRESS, INFLAMMATION, LEUCOCYTES, VASCULAR FUNCTION AND
TISSUE CONCENTRATIONS IN MICE
Oliver Weingärtner, C. Ulrich, D. Lütjohann, K. Ismail, S.H. Schirmer, T. Vanmierlo,
M. Böhm, U. Laufs
Germany
125
and Treatment of
(contd.)
Poster Session
Poster Area
(contd.)
and Treatment of
Poster No
4.74
HIGH SODIUM INTAKE INCREASES INFLAMMATORY ACTIVITY, CARDIAC
PRESSURE OVERLOAD AND TOTAL MORTALITY AFTER MYOCARDIAL
INFARCTION
Guilherme Fernandes de Carvalho, A.P.R. Costa, U.C.P. Silva, J.M. Andrade,
E.C. de Faria, D.S.P. Abdalla, O.L.R. de Almeida, S.N. Santos, J.C. Quinaglia e Silva,
O.R. Coelho, A.C. Sposito, Brasília Heart Study Group
Brazil
4.75
THE INFLUENCE OF DOCOSAHEXAENOIC ACID SUPPLEMENTATION ON
VASCULAR FUNCTION: A DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMISED
TRIAL
Atul Singhal, J.A. Lanigan, S. Low, A. Lucas, J. Deanfield
UK
4.76
NON-FAT DAIRY PRODUCTS ARE ASSOCIATED WITH LOWER TRIGLYCERIDE
CONCENTRATIONS IN A SPANISH HYPERTRIGLYCERIDAEMIC COHORT
Jordi Merino, R. Mateo-Gallego, N. Plana, A.M. Bea, J. Ascaso, C. Lahoz,
J.L. Aranda, on behalf of the Hypertriglyceridemia Registry of the Spanish Arteriosclerosis
Society
Spain
4.77
EFFECTS OF PLANT STEROL- OR STANOL-ENRICHED MARGARINE ON SERUM
OXYPHYTOSTEROL CONCENTRATIONS IN HEALTHY SUBJECTS
Sabine Baumgartner, R.P. Mensink, C. Husche, D. Lütjohann, J. Plat
The Netherlands
4.78
SIMULTANEOUS INTAKE OF OAT BRAN AND ATORVASTATIN REDUCES THEIR
EFFICACY TO LOWER TOTAL CHOLESTEROL AND ATHEROSCLEROSIS IN LDLRECEPTOR-DEFICIENT MICE
Simone Eussen, C. Rompelberg, K. Andersson, O. Klungel, P. Hellstrand, R. Öste,
J. Garssen
The Netherlands
4.79
ADHERENCE TO THE MEDITERRANEAN DIET IS ASSOCIATED WITH
DECREASED HAPTOGLOBIN LEVELS, AMONG APPARENTLY HEALTHY
INDIVIDUALS
Vassiliki Bountziouka, A. Evangelopoulos, C. Katsagoni, M. Bonou, N. Vallianou,
P. Avgerinos, E. Vogiatzakis, D. Panagiotakos
Greece
126
79th EAS CONGRESS
Poster Session
Poster Area
(contd.)
Poster No
4.80
LIPID RESPONSE TO PHYTOSTEROLS IN A HYPERCHOLESTEROLEMIC
POPULATION IS NOT AFFECTED BY APOLIPOPROTEIN E POLYMORPHISM OR
DIAMETER OF LOW-DENSITY LIPOPROTEIN
Victor M Victor, C. Bañuls, L. Bellod, A. Jover, M. Rocha, A. Hernandez-Mijares
Spain
4.81
CAROTID ARTERY PLAQUE: THE ROLE OF IL-8 AND PTX-3 IN ASYMPTOMATIC AND
SYMPTOMATIC PATIENTS.
Stefania Ferraro, L. Schembri, M. Tozzi, G. Piffaretti, F. Marino, P. Castelli
Italy
4.82
THE ASSOCIATION OF CXCL16 A181V GENE POLYMORPHISM WITH CAROTID
ATHEROSCLEROSIS IN PATIENTS SUBJECTED TO ENDATERECTOMY
Maja Zivkovic, M. Popovic, L. Stojkovic, D. Radak, I. Koncar, L. Davidovic, A. Kolakovic,
A. Stankovic, D. Alavantic
Serbia
4.83
RELATIONSHIP BETWEEN ABDOMINAL OBESITY AND OTHER CARDIOVASCULAR
RISK FACTORS IN PATIENTS WITH SYMPTOMATIC CAROTID ATHEROSCLEROSIS
Milos Maksimovic, H. Vlajinac, D. Radak, J. Marinkovic, J. Maksimovic, J. Jorga
Serbia
4.84
DAILY CONSUMPTION OF VITAMIN D-FORTIFIED YOGURT DRINK BOTH IMPROVED
GLYCEMIC CONTROL AND DECREASED SERUM CARDIAC MYEOLOPEROXIDASE
IN TYPE 2 DIABETICS
Tirang R Neyestani, B. Nikooyeh, H. Alavi-Majd, A. Gharavi, A. Kalayi, N. Shariatzadeh,
S. Heravifard, N. Tayebinejad, S. Salekzamani, M. Zahedirad
Iran
4.85
EVALUATION OF THE SELF-DESIGNED ULTRASONIC ATOMIZATION SPRAYING
EQUIPMENT FOR INTRAVASCULAR STENTS
Y. Chen, G. Wang, Y. Hou, Chiming Wei, T. Yin, L. Luo, H. Chen, C. Tang
China
4.86
EFFECT OF QUERCETIN ON VIABLE MYOCARDIUM IN PATIENTS WITH ST
ELEVATION ACUTE MYOCARDIAL INFARCTION
A. Alavy Lutfullaevich, Sirojiddin Kenjaev Rashidovich, M. Kenjaev Latipovich
Uzbekistan
127
and Treatment of
Poster Session
Poster Area
and Treatment of
Poster No
4.87
THE EFFECT OF NICOTINIC ACID/LAROPIPRANT ON LIPIDS, FASTING PLASMA
GLUCOSE, GLYCOSYLATED HEMOGLOBIN AND URIC ACID IN PATIENTS WITH
MIXED DYSLIPIDEMIA
A. Kei, E. Liberopoulos, E. Moutzouri, C. Rizos, Moses Elisaf
Greece
4.88
PREVALENCE OF ABDOMINAL AORTIC ANEURYSM BY MAGNETIC RESONANCE
IMAGES (MRI) IN MEN OVER 50 YEARS WITH LOW BACK PAIN
Moslem Shakeri Bavil
Iran
4.89
TREATMENT OF DYSLIPIDEMIA IN PATIENTS WITH METABOLIC SYNDROME USING
SIMVASTATIN AND URSODEOXYCHOLIC ACID
Oxana M Drapkina, V.T. Ivashkin
Russia
4.90
THE FEATURES OF CEREBRAL HEMODYNAMICS IN PATIENTS WITH CORONARY
HEART DISEASE END DIABETES MELLITUS TYPE 2
Olga Sheludchenko
Ukraine
4.91
NORPURPURINE, ALKALOID ISOLATED FROM THE LEAVES OF ANNONA
INCONFORMIS, HAS ANTI-AGGREGATING EFFECTS ON HUMAN PLATELETS
G. Sanchez, G. Acha, O. Estrada, A. Cardozo, M.C. Ruiz, A.Z. Fernandez,
Claudia Pilar Alvarado-Castillo
Venezuela
4.92
STRONG ASSOCIATION OF PERIODONTAL DISEASE WITH STROKE
Leopoldo Penteado Nucci da Silva1,2, I.G. Pedron, J.L. Simone, C. Gun
Brazil
4.93
GENDER DIFFERENCES IN THE DEVELOPMENT OF SUBCLINICAL
ATHEROSCLEROSIS IN PATIENTS WITH EARLY SIGNS OF CEREBROVASCULAR
INSUFFICIENCY
Veronika Alexandrovna Myasoedova, I.A. Sobenin, D.M. Merculova, T.V. Kirichenko,
U.A. Merculov, A.N. Orekhov
Russia
4.94
PREVALENCE OF METABOLIC SYNDROME IN PATIENTS WITH OSTEOPOROSIS
Dimitris Agapakis, E. Alexiou, I. Floudaras, S. Maraslis, C. Chatziathanasiadou,
M. Damianidou, S. Sereti, E. Satsoglou
Greece
128
79th EAS CONGRESS
Poster Session
Poster Area
4.95
EFFECT OF CASPASE INHIBITOR AC-DEVD-CHO ON APOPTOSIS OF VASCULAR
SMOOTH MUSCLE CELLS INDUCED BY ARTESUNATE
J. Zhang, H. Chen, G. Wang, T. Yin, Y. Teng, Chaojun Tang
China
4.96
INHIBITORY EFFECTS OF SAPPAN LIGNUM EXTRACT ON VASCULAR RESTENOSIS
IN THE RAT CAROTID ARTERY BALLOON INJURY MODEL
G. Wang, G. Long, B. Ling, C. Wei, H. Chen, L. Wu, T. Yin, Chaojun Tang
China
4.97
THE IMPACT OF LOW DENSITY LIPOPROTEIN RECEPTOR(LDLR) GENE MUTATION
ON INCIDENCE OF PREMATURE CARDIOVASCULAR DISEASE, IN FAMILIAL
HYPERCHOLESTEROLEMIC PATIENTS
Vasiliki Metaxa, C. Pitsavos, I. Skoumas, A. Miliou, E. Oikonomou, K. Masoura,
C. Stefanadis
Greece
4.98
ASSOCIATION OF MACROPHAGE COLONY-STIMULATING FACTOR RECEPTOR
POLYMORPHISM WITH STROKE IN CAUCASIAN POPULATION OF SIBERIA
M. Voevoda, Vladimir Maksimov, S. Shishkin, E. Shakhtshneider, A. Romaschenko
Russia
4.99
EMBOLIC OCCLUSION OF THE MIDDLE AND INTERNAL CAROTIDE ARTERY.
EMERGENT TREATMENT WITH RT-PA THROMBOLYTIC AGENT
Apostolos Limuris, N. Fistas
Greece
4.100
DETERMINANTS OF THE CEREBROVASCULARE REACTIVITY BY ELDERLY
PATIENTS WITH CORONARY HEART DISEASES
Gulnora Rozikhodjaeva
Uzbekistan
4.101
INTIMA-MEDIA THICKNESS OF COMMON AND INTERNAL CAROTID ARTERIES IN
PATIENTS WITH HEPATOSPLENIC SCHISTOSOMIASIS MANSONI
Carlos Teixeira Brandt, A.V. Guimarães, Schistosomiasis Mansoni
Brazil
4.102
AN ASSESSMENT OF POTENTIAL ANORECTIC, LIPOLYTIC AND WEIGHT REDUCING
PROPERTIES OF KOLANUT (C.NITIDA) IN ADULT WISTER RATS
Sunny Banjoko, O. Ogunleye, O. Babalola, A. Ayoka
Nigeria
4.103
STATE OF SYSTEM METABOLISM IN PATIENTS AFTER MYOCARDIAL INFARCTION
IN CONCOMITANT ARTERIAL HYPERTENSION
Valentyn A. Shumakov, I. Malynovska, T. Talaeva, L. Tereshkevysh,, I. Gotenko,
O. Yanus
Ukraine
129
and Treatment of
Poster No
Poster Session
Poster Area
Poster No
4.104
THE ROLE OF OMACOR TREATMENT IN MORPHOLOGICAL CHANGES OF VENOUS
GRAFTS IN PATIENTS AFTER SURGICAL MYOCARDIAL REVASCULARISATION
A.V. Panov, L.B. Mitrofanova, M.Z. Alugishvili, Elena A. Usova
Russia
4.105
INCREASING BIOLOGICAL EFFECTIVENESS OF ANTISENSE OLIGONUCLEOTIDES
TARGETING APOB BY INTRODUCTION OF MISMATCHES
Mikhail Voevoda, A. Dudarev, M. Ivanova, Y. Ragino
Russia
4.106
ENDOTHELIAL FUNCTION, ANTICOAGULATIVE SYSTEM AND FIBRINOLYSIS
FEATURES IN PATIENTS WITH ISCHEMIC STROKE, CAUSED BY
ATHEROSCLEROSIS AND ARTERIAL HYPERTENSION
Alla Anatolevna Shabalina, M.V. Kostyreva, M.Y. Maksimova, V.G. Ionova
Russia
4.107
ARTERIAL HYPERTENSION AND ATHEROSCLEROSIS IN THE AGED WOMEN
Nina K. Gorshunova, E.V. Tereshina, D.N. Ukraintzeva
Russia
4.108
12- AND 15-LIPOXYGENASES IN HUMAN CAROTID ATHEROSCLEROTIC LESIONS:
ASSOCIATIONS WITH CEREBROVASCULAR SYMPTOMS
Karl Gertow, E. Nobili, L. Folkersen, J.W. Newman, T.L. Pedersen, J. Ekstrand,
J. Swedenborg, H. Kühn, C.E. Wheelock, G.K. Hansson, U. Hedin, J.Z. Haeggström,
A. Gabrielsen
Sweden
4.109
EPIGENETIC CHANGES IN HUMAN ADVANCED CAROTID ARTERY LESIONS
Jaroslav Pelisek, M. Culmes, R. Napieralski, H.H. Eckstein
Germany
WORKSHOP: NEW CHALLENGES AND TARGETS OF CARDIOVASCULAR PREVENTION AND
TREATMENT
and Treatment of
4.110
ETOPOSIDE ASSOCIATED WITH CHOLESTEROL-RICH NANOEMULSIONS
REDUCE ATHEROSCLEROTIC LESIONS IN RABBITS
Raul C. Maranhão, E.R. Tavares, F.R. Freitas, J. Diament
Brazil
130
79th EAS CONGRESS
Poster Session
Poster Area
TREATMENT (contd.)
4.111
BARIATRIC SURGERY AND PREVENTION OF MYOCARDIAL INFARCTION IN
OBESE INDIVIDUALS WITH TYPE 2 DIABETES IN THE SWEDISH OBESITY
SUBJECTS STUDY
Cristina Maglio, C. Pirazzi, M.A. Burza, M. Peltonen, L. Sjöström, L.M. Carlsson,
S. Romeo
Sweden
4.112
THE RELATIONSHIP BETWEEN STATIN THERAPY AND PROGRESSION OF
RENAL DAMAGE AMONG 10305 HYPERTENSIVE PATIENTS RANDOMISED IN THE
ASCOT-LIPID-LOWERING ARM (LLA)
Ajay Gupta, C.L. Chang, D. Collier, B. Dahlof, N.R. Poulter, P.S. Sever, on behalf of the
ASCOT Investigators
UK
4.113
PEPTIDE-BASED IMMUNIZATION AGAINST PCSK9 REDUCES TOTAL
CHOLESTEROL IN MICE
Gergana Galabova, G. Winsauer, B. Wanko, F. Mattner, W. Schmidt, S. Brunner
Austria
4.114
MIPOMERSEN, AN APOB SYNTHESIS INHIBITOR, EVALUATION OF POTENTIAL
TO REDUCE NECESSITY FOR LIPID-APHERESIS IN PATIENTS WITH
HETEROZYGOUS FH AND CAD
Klaus G. Parhofer, A. Vogt
Germany
4.115
A RANDOMIZED TRIAL OF ATORVASTATIN PLUS ETIDRONATE COMBINATION
THERAPY FOR ATHEROSCLEROTIC AORTIC PLAQUES
Tetsuya Kawahara, M. Nishikawa, T. Furusawa, T. Inazu, G. Suzuki
Japan
4.116
5-AMINOLEVULINIC ACID-DERIVED PROTOPORPHYRIN IX MEDIATED
FLUORESCENCE DIAGNOSIS AND PHOTODYNAMIC THERAPY OF MACROPHAGES
WITHIN THE ATHEROSCLEROTIC PLAQUE
Ye Tian, C. Peng, X. Sun, J. Cheng, L. Yang, J. Wu, Z. Zhang, W. Cao
China
131
and Treatment of
Poster No
Poster Session
Poster Area
TREATMENT (contd.)
and Treatment of
Poster No
4.117
EFFECT OF MIPOMERSEN ON LP(A) IN PATIENTS WITH HETEROZYGOUS
FAMILIAL HYPERCHOLESTEROLEMIA; RESULTS FROM TWO PHASE 3 STUDIES
Elisabeth Steinhagen-Thiessen, J.L. Witztum, S. Tsimikas, J.M. Donovan, W. Cromwell
Germany
4.118
OCCURRENCE OF CORONARY HEART DISEASE IN A COHORT OF HETEROZYGOUS
FAMILIAL HYPERCHOLESTEROLEMIC PATIENTS IN NORWAY
Gisle Langslet, T. Dadd, A. Jarman, K. Retterstøl, L. Ose
Norway
4.119
NITRIC OXIDE-DONATING STATINS EXERT BENEFICIAL EFFECTS ON ACUTE
VASCULAR INFLAMMATION IN NORMOCHOLESTEROLEMIC RABBITS
R. Baetta, A. Granata, L. Arnaboldi, N. Ferri, S. Bellosta, A. Bonomo, D. Miglietta,
P. Pfister, Alberto Corsini
Italy
4.120
LONG TERM COURSE IN PATIENTS WITH HOMOZYGOUS FAMILIAL
HYPERCHOLESTEROLEMIA UNDERGOING LIPID-APHERESIS
Anja Vogt, C. Keller, N. Weiss
Germany
4.121
EFFECTS OF VARIOUS LIPID-LOWERING DRUGS ON DIABETIC NEPHROPATHY IN
DB/DB MICE
Hidenori Arai, Y. Tamura, T. Murayama, M. Minami, M. Yokode
Japan
4.122
CARDIOVASCULAR EVENT RATE IN STABLE CORONARY PATIENTS WITH
CHRONIC KIDNEY DISEASE (CKD) INCREASED BY BEING OBESE IS REDUCED BY
ATORVASTATIN
Prakash Deedwania, J. Shepherd, D. Wilson, the Treating to New Targets (TNT)
Investigators
USA
4.123
ANTIATHEROSCLEROTIC POTENTIAL OF PHENOLIC COMPOUNDS: AN
EXPERIMENTAL STUDY IN RABBITS
Bassim Irheim Mohammad, N.R. Hadi, M. Sahlawi
Iraq
4.124
METABOLIC SYNDROME IS ASSOCIATED WITH ELEVATED GLOMERULAR
FILTRATION RATE AND INCREASED RENAL RESISTANCE INDEX
Gustavo Giunta, A. Fava, G. Trentadue, P. Mendez, A. Hnatiuk, L. Chiaramonte,
A. Pereyra, P. D'Angelo, L. Cuniberti, H. Baglivo, R. Sanchez
Argentina
132
79th EAS CONGRESS
Poster Session
Poster Area
TREATMENT (contd.)
4.125
CURRENT STATIN TREATMENT OF PATIENTS WITH FAMILIAL
HYPERCHOLESTEROLAEMIA (FH): RESULTS FROM THE ROYAL COLLEGE OF
PHYSICIANS UK NATIONAL AUDIT
Mary Seed, M. Roughton, D. Nair, K. Pederson, T. Wang, A.H.W. Neil, S.E. Humphries
UK
4.126
LOW CHOLESTEROL IN MIDLIFE PREVENTS MORTALITY AND PREDICTS
SUCCESSFUL OLD AGE
Laura Hyttinen, T.E. Strandberg, A.Y. Strandberg, V.V. Salomaa, K.H. Pitkälä, R.S. Tilvis,
T.A. Miettinen
Finland
4.127
ASYMPTOMATIC SUBJECTS WITH A POSITIVE FAMILY HISTORY FOR PREMATURE
CORONARY ARTERY DISEASE BENEFIT FROM PREVENTIVE TREATMENT: A POSTHOC ANALYSIS
T. Mulders, S. Sivapalaratnam, E. Stroes, A. Guerci, S. Pinto-Sietsma
The Netherlands
4.128
DYSLIPIDEMIA REVEALED IN NEONATES - SIGNIFICANT ASPECTS OF GENETIC
PREDISPOSES OF ATHEROSCLEROSIS
Nodar N. Kipshidze, K.A. Nadaraia, A.T. Jabauri, T.A. Gegenava
Georgia
4.129
DOES SARPOGRELATE TREATMENT REDUCE NEO-INTIMAL HYPERPLASIA IN
PATIENTS UNDERWENT PERCUTANEOUS CORONARY INTERVENTION WITH
DRUG-ELUTING STENTS?
Jae-Hun Jung, P.K. Min, T.S. Kang, J.H. Seong, J.Y. Kim, B.K. Kim
Republic of Korea
4.130
ENHANCING BAROREFLEX ACTIVITY AS A NOVEL TARGET FOR TREATING
ATHEROSCLEROSIS DEPENDS ON CHOLINERGIC ANTI-INFLAMMATORY PATHWAY
Guo-Jun Cai
China
4.131
A PACLITAXEL DERIVATIVE (PACLITAXEL OLEATE) ASSOCIATED WITH A
CHOLESTEROL-RICH NANOEMULSION DECREASES THE TRANSPLANT HEART
VASCULAR DISEASE IN RABBIT GRAFT MODEL
Raul Maranhão, D.D. Lourenço-Filho, C.A. Méndez-Contreras, E.R. Tavares, F.R. Freitas,
N.A. Stolf
Brazil
133
and Treatment of
Poster No
Poster Session
Poster Area
TREATMENT (contd.)
and Treatment of
Poster No
4.132
EFFECTIVITY OF COLESEVELAM IN STATIN INTOLERANT PATIENTS ± EZETIMIBE
Stefanie Maierhofer, A. deCampo, T. Stojakovic, H. Jahnel, H. Toplak
Austria
4.133
THE PROGNOSTIC SIGNIFICANCE OF THE FREQUENCY AND THE MORPHOLOGY
OF PREMATURE VENTRICULAR CONTRACTIONS DURING AMBULATORY HOLTER
MONITORING
Georges Ephrem, M. Levine, P. Friedmann, P. Schweitzer
USA
4.134
ACCURACY AND PRECISION OF POINT-OF-CARE TESTING FOR SERUM
CHOLESTEROL, TRIGLYCERIDES AND HDL CHOLESTEROL
J.V. Patel, G. Thorpe, L. Springer, Elizabeth A. Hughes
UK
4.135
MORE AGGRESSIVE LDL-C AND NON-HDL-C TARGETS MUST BE ACHIEVED IN
PATIENTS RECEIVING LIPID-LOWERING THERAPY TO NORMALIZE APOBCONTAINING LIPOPROTEINS
John Betteridge, J.R. Guyton, M. Farnier, L.A. Leiter, J. Lin, A. Shah,
A.O. Johnson-Levonas, P. Brudi
UK
4.136
FAVOURABLE IMPACT ON LIPID LEVELS OF INCREASING STATIN DOSE IN HIGHRISK PATIENTS WITH VERY HIGH BASELINE LDL-C: RESULTS FROM VOYAGER
P. Lundman, M.K. Palmer, B.W. Karlson, P.J. Barter, S.J. Nicholls
Sweden
4.137
EFFECT OF ROSUVASTATIN AND ATORVASTATIN DOSE ON LDL-C < 70MG/DL
GOAL ATTAINMENT IN PATIENTS WITH DIABETES MELLITUS: RESULTS FROM
VOYAGER
B. W. Karlson, P.J. Barter, M.K. Palmer, P. Lundman, S.J. Nicholls
Sweden
4.138
INCREASED CARDIOVASCULAR EVENT RATE IN STABLE CORONARY PATIENTS
WITH METABOLIC SYNDROME COMPLICATED BY CHRONIC KIDNEY DISEASE IS
REDUCED BY ATORVASTATIN
Prakash Deedwania, J. Shepherd, D. Wilson, the Treating to New Targets (TNT)
Investigators
USA
4.139
PREDICTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH ANKYLOSING
SPONDYLITIS AND PSORIATIC ARTHRITIS
Anne Grete Semb, T.K. Kvien, R. Fayyad, D. DeMicco, T.R. Pedersen, J.C. LaRosa,
J. Betteridge, I. Holme
Norway
134
79th EAS CONGRESS
Poster Session
Poster Area
TREATMENT (contd.)
4.140
INFLUENCE OF OBESITY AND THE ONSET OF THE DISEASE ON EARLY
ATHEROSCLEROSIS CHANGES IN CHILDREN WITH JUVENILE CHRONIC ARTHRITIS
(JCA)
Barbara Głowińska-Olszewska, E. Dobreńko, A. Hryniewicz, M. Wojciuk,
B. Żelazowska-Rutkowska, W. Łuczyński, D. Piotrowska-Jastrzębska, A. Bossowski
Poland
4.141
PREVALENCE OF LOW HDL AND HIGH TRIGLYCERIDES IN PRIMARY PREVENTION
OF CARDIOVASCULAR DISEASE IN EUROPE: THE EURIKA STUDY
Julian Halcox, on behalf of the EURIKA Steering Committee
UK
4.142
EFFECT OF INTENSIVE LIPID LOWERING ON CARDIOVASCULAR OUTCOME IN
PATIENTS WITH AND WITHOUT INFLAMMATORY JOINT DISEASE
Anne Grete Semb, T.K. Kvien, R. Fayyad, D. DeMicco, J.C. LaRosa, T.R. Pedersen,
J. Betteridge, I. Holme
Norway
4.143
EFFECT OF DOXYCYCLINE ON ATHEROSCLEROSIS PROGRESSION IN
HYPERCHOLESTEROLEMIC RABBITS
Najah Raiesh Hadi, B.I. Mohammad, H.A. Chassap
Iraq
4.144
DIABETES: THE MAIN PREDICTOR OF EXTENSIVE CORONARY CALCIFICATION IN
STABLE ANGINA?
Rachel Nicoll, A. Magedanz, Y. Zhao, U. Wiklund, A. Schmermund, M. Henein
Sweden
4.145
PHENOTYPIC DIFFERENCES OF PATIENTS WITH MOLECULARLY DEFINED APOB
AND LDLR DEFECTIVE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Anja Vogt, C. Keller, C. Heigl, N. Weiss
Germany
4.146
GENDER DIFFERENCES IN PREVALENCE AND CONTROL OF CARDIOVASCULAR
DISEASE RISK FACTORS AMONG PATIENTS WITH TYPE 2 DIABETES: THE MIND.IT
STUDY
Laura Franzini, D. Ardigò, F. Cavalot, R. Miccoli, A. Rivellese, M. Trovati, I. Zavaroni,
O. Vaccaro, MIND.IT Study Group
Italy
4.147
COMPARISON OF DRUG-ELUTING STENT VERSUS BARE METAL STENT IN RENAL
TRANSPLANT PATIENTS
Jae-Hun Jung, P.K. Min, Y.G. Ko, D. Choi, Y. Jang, K.J. Lee, K.H. Park, M.K. Kim
Republic of Korea
135
and Treatment of
Poster No
Poster Session
Poster Area
TREATMENT (contd.)
and Treatment of
Poster No
4.148
LONGITUDINAL ANALYSIS OF THE EFFECT OF HEART RATE SYNCHRONIZED
LOCAL SOUND WAVE THERAPY FOR CIRCULATORY SYSTEM
Ferenc Ihász, Z. Szabo, A. Széll, J. Rikk, Group of Sonoterapy
Hungary
4.149
ASSOCIATION BETWEEN ARTERIAL STIFFNESS AND ESTIMATED GLOMERULAR
FILTRATION RATE IN CHRONIC KIDNEY DISEASE PATIENTS
Enkhtuvshin Enkhtamir, T. Ariunaa, E. Odkhuu, M. Munkhzol
Mongolia
4.150
TREATMENT OF PATIENTS WITH HEART FAILURE WITH PRESERVED SYSTOLIC
FUNCTION: INFLUENCE OF BETA-BLOCKER ON ENDOTHELIAL FUNCTION,
ALBUMINURIA AND FIBRONECTINE
Olena Soya, O. Kuryata, A. Miroshnichenko
Ukraine
4.151
CORRELATION BETWEEN LDL-LOWERING BY STATINS AND HEMORHEOLOGICAL
PROFILES: A SUBSTUDY OF THE PATROL TRIAL
Keijiro Saku, B. Zhang, Y. Uehara, K. Noda
Japan
4.152
THE EFFECT OF NICOTINIC ACID/LAROPIPRANT ADMINISTRATION ON THE
LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) ACTIVITY IN PATIENTS
WITH MIXED DYSLIPIDEMIA
A. Kei, E. Liberopoulos, K. Tellis, C. Rizos, A. Tselepis, Moses Elisaf
Greece
4.153
REGIONAL CORRECTION IN WAIST CIRCUMFERENCE EVALUATION NEEDED IN
LATVIA
Inga Stukena, A. Kalvelis, G. Bahs, I. Skuja, A. Lejnieks
Latvia
4.154
BONE MARROW-DERIVED MESENCHYMAL STEM CELL TRANSPLANTATION FOR
THE TREATMENT OF CRITICAL LIMB ISCHEMIA
Evgeny Shlyakhto, V. Vavilov, A. Zaritskey, D. Polyntsev, P. Kruglyakov, A. Krylov,
I. Senchik, A. Krutikov
Russia
4.155
CARDIOVASCULAR RISK PROFILE IN NONOBESE AND OBESE HYPERTENSIVE
ADOLESCENTS. STUDY BASED ON BIOMARKERS AND ULTRASONOGRAPHIC
ASSESSMENT OF EARLY ATHEROSCLEROSIS
Barbara Głowińska-Olszewska, W. Łuczyński, J. Tołwińska, A. Bossowski
Poland
136
79th EAS CONGRESS
Poster Session
Poster Area
TREATMENT (contd.)
4.156
SAFETY AND EFFICACY OF NCX 6560, A NITRIC OXIDE (NO)-DONATING
ATORVASTATIN, IN A FIRST-INTO-MAN RANDOMISED, DOUBLE-BLIND, PLACEBOAND ACTIVE-CONTROLLED STUDY
Pascal Pfister, J. Djian, T. Ferreira, R. Maucci, J. Croizier, P. Tocchetti, L. Gheyle,
S. Mesens
France
4.157
ADDITIONAL EFFECTIVENESS OF EZETIMIBE CO ADMINISTERED WITH
ATORVASTATIN IN HIGH RISK PATIENTS WITH CORONARY HEART DISEASE AND
Kakha A. Nadaraia, N.N. Kipshidze, T.A. Gegenava
Georgia
4.158
EPICARDIAL FAT AND A RISK OF CORONARY ATHEROSCLEROSIS
Galina Chumakova, N. Veselovskaya, A. Kozarenko, O. Gritsenko
Russia
4.159
CANNABINOID RECEPTOR 1 DOES NOT CORRELATE WITH PERIADVENTITIAL FAT
ADIPONECTIN AND VISFATIN EXPRESSION IN AORTIC AND CORONARY
Sofia G Spiroglou, C.G. Kostopoulos, P.P. Keryttopoulos, J.N. Varakis, H.H. Papadaki
Greece
4.160
VALUE OF THE HYPERURICAEMIA IN PATIENTS WITH CHRONIC HEART FAILURE
Vera Larina, B. Bart
Russia
4.161
THE EFFECT OF ROSUVASTATIN ON NEOANGIOGENESIS, NITROSATIVE STRESS
AND INFLAMMATION IN PATIENTS WITH MULTIFOCAL ARTERIAL DISEASE
Y.V. Shchukin, E.I. Seleznev, Elena Alexandrovna Medvedeva
Russia
4.162
CARDIOVASCULAR RISK FACTORS MANAGEMENT IN PRIMARY PREVENTION OF
CARDIOVASCULAR DISEASE IN THE RUSSIAN FEDERATION (THE EURIKA STUDY)
Sergey Boytsov
Russia
4.163
TOBACCO CESSATION CLINIC AND WHO'S MPOWER POLICIES
A. Aggarwal, S. Dwivedi, Piyush Jain
India
4.164
IMPACT OF ASPIRIN RESISTANCE ON ONE YEAR´S PROGNOSIS IN CHRONIC
STABLE ANGINA IN SEMNAN - IRAN
Rahimeh Eskandarian, M. Darabian
Iran
137
and Treatment of
Poster No
Poster Session
Poster Area
TREATMENT (contd.)
Poster No
4.165
PHARMACOLOGICAL CORRECTION OF THE SYSTEMIC INFLAMMATORY
RESPONSE SYNDROME IN PATIENTS WITH ATHEROSCLEROSIS
Ketevan Tamazi Kapanadze, M. Rogava, T. Bochorishvili, E. Berberashvili, G. Sukoyan,
K. Bokuridze
Georgia
4.166
REAL WORLD 12 MONTH EVALUATION OF VARENICLINE THERAPY
J. Shand, Andrew Howe, N. Cinnamond, S. Hussey, I.B. Menown
UK
4.167
PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA IN LDL APHERESIS HAVE
FREQUENT SIDE EFFECTS ALTHOUGH PATIENT SATISFACTION IS HIGH
Anders Hovland, T. Enebakk, R. Hardersen, T.E. Mollnes, K.T. Lappegård
Norway
and Treatment of
WORKSHOP: IMAGING TECHNIQUES IN ATHEROSCLEROSIS, DIAGNOSTICS AND
PROGRESS MONITORING
4.168
WESTERN TYPE DIET INDUCES ENDOTHELIAL DYSFUNCTION IN WILD-TYPE
MICE: AN 18F-FDG PET STUDY OF THE MOUSE AORTA
Anne Mette Fisker Hag, S.F. Pedersen, A. Kjaer
Denmark
4.169
PERICARDIAL FAT INFLAMMATION IN PATIENTS WITH ACUTE CORONARY
SYNDROME ASSESSED BY 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION
TOMOGRAPHY
Sungeun Kim, E.J. Kim, J.S. Yeo, H.S. Seog
Republic of Korea
4.170
CHANGES OF CAROTID INTIMA-MEDIA THICKNESS (IMT) AFTER ADDING
EZETIMIBE TO STATIN THERAPY. PROSPECTIVE EVALUATION IN A CLINICAL
SETTING
Emilio Ros, R. Gilabert, A. Sala-Vila, I. Núñez, M. Doménech, M. Cofán
Spain
138
79th EAS CONGRESS
Poster Session
Poster Area
PROGRESS MONITORING (contd.)
4.171
ANGIOTENSIN CONVERTING ENZYME INHIBITORS EFFECT ON ENDOTHELIAL
DYSFUCNTION: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS
Yousef Shahin, J. Khan, N. Samuel, I. Chetter
UK
4.172
GENDER SPECIFIC IMPACT OF INFLAMMATION AND OBESITY ON
SUBCLINICAL ATHEROSCLEROSIS IN THE GENERAL POPULATION
Suzanne Holewijn, M.D. Heijer, D. Swinkels, A. Stalenhoef, J.D. Graaf
The Netherlands
4.173
LOW CAROTID CALCIUM SCORE IS ASSOCIATED WITH HIGHER LEVELS OF
GLYCOSAMINOGLYCANS, TNF-ALPHA AND PTH IN HUMAN CAROTID PLAQUES
Andreas Edsfeldt, N. Dias, B. Elmståhl, M.F. Müller, K. Berg, M. Nitulescu, A. Persson,
O. Ekberg, I. Gonçalves
Sweden
4.174
MICROALBUMINURIA, ANKLE-BRACHIAL INDEX (ABI) AND SYSTOLIC
HYPERTENSION ARE THE STRONGEST PREDICTORS OF RECURRENT
ATHEROSCLEROTIC EVENTS. THE AIRVAG COHORT EXTENDED FOLLOW-UP
C. Aranda, M.L. Peralta, I. Gonzalez Anglada, A.I. Huelmos, C. Sanchez, E. Puras,
M.L. Casas, L. Lopez Bescos, Carlos Guijarro, The AIRVAG Investigators
Spain
4.175
THE ASSOCIATION OF TOBACCO SMOKE WITH SUBCLINICAL
ATHEROSCLEROSIS AND ATHEROSCLEROSIS PROGRESSION IS STRONGER IN
WOMEN THAN IN MEN
Elena Tremoli, F. Veglia, M. Amato, A. Ravani, D. Sansaro, C. Tedesco, A. Discacciati,
B. Frigerio, S. Castelnuovo, D. Baldassarre, on behalf of the IMPROVE Study Group
Italy
4.176
NOVEL APPROACHES TO PREVENTION OF CHRONIC KIDNEY DISEASE IN
PATIENTS WITH METABOLIC SYNDROME
Tea Gamezardashvili, N. Kipshidze
Georgia
139
and Treatment of
Poster No
Poster Session
Poster Area
and Treatment of
Poster No
4.177
ASSOCIATION BETWEEN HOMEOSTASIS MODEL ASSESSMENT AND
CORONARY ARTERY CALCIUM SCORE
Hossein Fakhrzadeh, F. Sharifi, Z. Badamchizadeh, M. Ghaderpanahi, M. Mirarefin,
A. Mostashfi
Iran
4.178
SUBCLINIC ATHEROSCLEROSIS IN A WELL MOLECULAR DEFINED FAMILIAL
HYPERCHOLESTEROLAEMIA POPULATION DETERMINED BY AORTIC MAGNETIC
RESONANCE IMAGING
Nelva Mata, R. Alonso, P. Caballero, P. Rosado, I. Rodriguez-San Pedro,
L.J. Jiménez-Borreguero, P. Mata
Spain
4.179
NEUROIMAGING ALTERATIONS IN TYPE 2 DIABETES MELLITUS:
CORRELATIONS WITH BIOCHEMICAL AND ANTHROPOMETRIC PARAMETERS
Natalia García-Casares, M.L. Berthier, J. Rioja, J.A. Garcia-Arnés, A. Gutiérrez,
A. Nabrozidis, P. González-Santos
Spain
4.180
SIMVASTATIN IMPROVES ENDOTHELIAL FUNCTION IN PATIENTS WITH
CARDIOVASCULAR DISEASE BUT NOT IN PATIENTS WITH PERIPHERAL ARTERY
DISEASE
H. Froehlich, F. Hafner, J. Binder, K. Amrein, H. Scharnagl, M. Brodmann,
Tatjana Stojakovic
Austria
4.181
THORACIC AORTIC ATHEROSCLEROSIS IN PATIENTS WITH AORTIC
REGURGITATION
Sara Shimoni, L. Zilberman, S. Goland, O. Edry, J. George
Israel
4.182
THE FASTEST PROGRESSION OF CAROTID INTIMA MEDIA THICKNESS IS
ASSOCIATED WITH INCREASED VASCULAR EVENTS IN THE IMPROVE STUDY
Damiano Baldassarre, F. Veglia, E. Tremoli, on behalf of the IMPROVE Studiy Group
Italy
140
79th EAS CONGRESS
Poster Session
Poster Area
4.183
IS FAT IN CARDIOMYOCYTES A COMPONENT OF THE METABOLIC SYNDROME?
Marit A. Granér, R. Sirén, J. Lundbom, A. Hakkarainen, M.O. Pentikäinen, K. Nyman,
N. Lundbom, M.S. Nieminen, M.R. Taskinen
Finland
4.184
C-REACTIVE PROTEIN AS PREDICTOR OF CAROTID INTIMA-MEDIA THICKNESS IN
HEALTHY ADOLESCENTS
Egle Silva, G. Bermudez, J. Villasmil, L. Chacin, M. Bracho, C. Esis, S. Briceno
Venezuela
4.185
ARTERIAL STIFFNESS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IS
CORRELATED WITH IMT AND IS DEPENDENT OF TRIGLYCERIDES
Sandra Parra, R. Ferré, G. Vives, J. Ribalta, F. Marimon, M. González, A. Castro
Spain
4.186
INTIMA-MEDIA THICKNESS CORRELATES WITH FEATURES OF METABOLIC
SYNDROME IN YOUNG PERSONS WITH CLINICAL DIAGNOSIS OF FAMILIAL
Barbara Idzior-Walus, M. Walus-Miarka, D. Czarnecka, M. Sanak, B. Katra,
E. Wozniakiewicz, P. Miarka
Poland
4.187
IMAGING OF NITRIC OXIDE DIRECTLY IN CELLS AND ARTERIES WITH A COPPER
(II) FLUORESCENT PROBE AND TWO-PHOTON MICROSCOPY
Mitrajit Ghosh, N.M.S.V.D. Akker, C. Weber, D.G.M. Molin, M.A.M.J.V. Zandvoort
The Netherlands, Germany
4.188
INCREASING SPATIAL RESOLUTION ALTERS MEASUREMENT VARIABILITY OF
CAROTID PLAQUES
Diederik F van Wijk, R. Duivenvoorden, D.F. Enklaar, R.J. van der Geest, E. de Groot,
E.S. Stroes, A.J. Nederveen
The Netherlands
4.189
DEGRADATION OF SPIO INDUCED FERRITIN BY LYSOSOMAL CATHEPSINS,
RELATED IMMUNE RESPONSE AND INTERACTION WITH ATHEROMA RELEVANT
CELLS
Amit Laskar, M. Ghosh, S.I. Khattak, W. Li, X. Yuan
Sweden
4.190
FASTEST IMT PROGRESSION: A NOVEL MARKER TO ANALYZE THE EVOLUTION
OF CAROTID INTIMA-MEDIA THICKNESS.
Fabrizio Veglia, D. Baldassarre, M. Amato, A. Ravani, D. Sansaro, C.C. Tedesco,
A. Discacciati, B. Frigerio, E. Tremoli, IMPROVE Study Group
Italy
141
and Treatment of
Poster No
Poster Session
Poster Area
and Treatment of
Poster No
4.191
DUAL ENERGY COMPUTED TOMOGRAPHY IMAGING OF ATHEROSCLEROSIS IN A
DIET-INDUCED ATHEROMA RABBIT MODEL
Eric Lacoste, N. Amalric
France
4.192
ASSESSMENT OF AORTIC ELASTIC PROPERTIES IN PATIENTS WITH SARCOIDOSIS
Idris Ardic, M.G. Kaya, M. Yarlioglues, H. Buyukoglan, O. Dogdu, M. Akpek, A. Kanbay,
C. Bol, I. Ozdogru
Turkey
4.193
AMBULATORY BLOOD PRESSURE MONITORING AS PREDICTOR OF SUBCLINICAL
ATHEROSCLEROSIS IN ADOLESCENTS
Egle Silva, J. Villasmil, L. Chacin, G. Bermudez, A. Gonzalez, M. Bracho, C. Esis,
S. Briceno
Venezuela
4.194
IMPAIRED AORTIC ELASTIC PROPERTIES IN NORMOTENSIVE PATIENTS WITH
PSORIASIS
Idris Ardic, M.G. Kaya, M. Yarlioglues, Z. Karadag, A. Dogan, H. Yildiz, O. Dogdu,
C. Zencir, E. Aktas, A. Ergin
Turkey
4.195
COMPARATIVE EVALUATIONS OF HEART RATE VARIABILITY, QT INTERVAL,
TRADITIONAL CARDIOVASCULAR RISK FACTORS AND DISEASE SEVERITY IN
PATIENTS WITH RHEUMATOID ARTHRITIS
Diana Novikova, T. Popkova, E. Udachkina, A. Volkov, A. Novikov, E. Alexandrova,
E. Nasonov
Russia
4.196
WIDE EXTENT OF CORONARY CALCIFICATIONS MAY BE COMMON IN CAD HIGHRISK PATIENTS DESPITE NORMAL CORONARY ANGIOGRAPHY
Piotr Pysz, J. Dąbek, J. Głogowska-Ligus, M. Sosnowski, Z. Gąsior
Poland
4.197
ASSESSMENT OF THE INTIMA-MEDIA THICKNESS OF THE FEMORAL ARTERY IN
PATIENTS WITH TYPE 2 DIABETES MELLITUS
Nelufar Djalilovna Akhmedova, F.A. Rozikhodjaeva, Z. Ikramova
Uzbekistan
4.198
IRON STATUS OF CIRCULATING MONOCYTES IS ASSOCIATED WITH IMPAIRED
CAROTID ELASTICITY AND ENDOTHELIAL DYSFUNCTION IN HEALTHY MEN OF
PRIMARY PREVENTION
Pavel J. Kraml, P. Syrovatka, K. Hulikova, J. Potockova, M. Andel
Czech Republic
142
79th EAS CONGRESS
Poster Session
Poster Area
4.199
FLOW CYTOMETRY-BASED FUNCTIONAL VALIDATION OF LDLR MUTATIONS FOR
AN ACCURATE DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA
A. Etxebarria, L. Palacios, M. Stef, Diego Tejedor, A. Oleaga, L. Irigoyen, B. Torres,
H. Ostolaza, C. Martin
Spain
4.200
ATRIAL REMODELING AND ARTERIAL STIFFNESS IN THE PATIENTS WITH
HYPERTENSION
Lucia Agoston-Coldea, T. Mocan, S. Lupu
Romania
4.201
COMPARISON OF EFFECTS OF EZETIMIBE ON CAROTID ARTERIAL ELASTIC
MODULUS AND C-REACTIVE PROTEIN WITH FLUVASTATIN IN PATIENTS WITH
Toshio Yamagishi, M. Kato, K. Omata, H. Hasegawa, H. Kanai
Japan
4.202
RELATION BETWEEN SUBCLINICAL ATHEROSCLEROSIS AND COMPONENTS OF
THE METABOLIC SYNDROME IN HYPERTENSIVE PATIENTS
Corina Serban, S. Dragan, I. Mozos, L. Susan, R. Christodorescu, L. Noveanu,
A. Pacurari, A. Caraba, R. Mateescu, I. Romosan
Romania
4.203
AN ASSOCIATION OF INTIMA-MEDIA THICKENING OF COMMON CAROTID
ARTERIES WITH SUBCLINICAL SIGNS OF INSUFFICIENCY OF CEREBRAL BLOOD
FLOW
T.V. Kirichenko, Veronica A. Myasoedova, D.M. Mironova, I.A. Sobenin
Russia
4.204
RISK FACTORS OF CORONARY ARTERY CALCIFICATION IN PATIENTS WITH
UNCOMPLICATED ARTERIAL HYPERTENSION SHOWING HIGH COMPLIANCE WITH
TREATMENT
Irina Shatunova, N.A. Koziolova, I. Lazarev
Russia
4.205
AORTIC STIFFNESS IS A DETERMINANT OF CAROTID INTIMA MEDIA THICKNESS IN
PATIENTS AT INTERMEDIATE CARDIOVASCULAR RISK
Raimon Ferré, J. Merino, N. Plana, M. Heras, C. Buixadera, L. Masana
Spain
143
and Treatment of
Poster No
Poster Session
Poster Area
and Treatment of
Poster No
4.206
CAROTID ARTERY DOPPLER IN PREOPERATIVE ASSESSMENT FOR CORONARY
REVASCULARIZATION ASSOCIATION OF RISK FACTORS FOR ATHEROSCLEROTIC
LESIONS AND CAROTID ARTERY STENOSIS
Marzieh Motevalli
Iran
4.207
ARTERIAL STIFFNESS IN FAMILIES WITH PREMATURE CORONARY ARTERY
DISEASE
T Mulders, B. vd Bogaard, A. Bakker, M. Trip, E. Stroes, B. vd Born, S. Pinto-Sietsma
The Netherlands
4.208
DOES PRESENCE OF ANTIPHOSPHOLIPID SYNDROME IN PATIENTS WITH
SYSTEMIC LUPUS ERYTHEMATOSUS ACCELERATE CAROTID ARTERIES INTIMA
MEDIA THICKNESS CHANGES?
Aleksandra Djokovic, L. Stojanovich, V. Bisenic, S. Radovanovic, N. Ninkovic, M. Krotin
Serbia
4.209
DIAGNOSTIC EVIDENCE OF ACCELERATED ATHEROSCLEROSIS IN PATIENTS
WITH ANTIPHOSPHOLIPID SYNDROME - THE ROLE OF 64 MULTI SLICED
COMPUTED TOMOGRAPHY
Aleksandra Djokovic, J. Saponjski, L. Stojanovich, D. Mrda, M. Krotin
Serbia
4.210
QUANTITATIVE EVALUATION OF EPICARDIAL ADIPOSE TISSUE AFTER ACUTE
MYOCARDIAL INFARCTION AND DURING EARLY POSTINFARCTION REMODELLING
Margareta Scharin Täng, L. Grip, E. Omerovic
Sweden
4.211
LOW-DOSE PRAVASTATIN PLUS EZETIMIBE VERUS STANDARD-DOSE
PRAVASTATIN: THE EFFECT ON THE CAROTID ATHEROSCLEROSIS OF PATIENTS
WITH HYPERCHOLESTEROLEMIA
Yasunori Sawayama
Japan
4.212
ELECTROCARDIOGRAM ABNORMALITIES AND CORONARY CALCIFICATION IN
POSTMENOPAUSAL WOMEN
Siamak Sabour, D.E. Grobbee, A. Rutten, M. Prokop, M.L. Bartelink, Y.T. van der Schouw,
M.L. Bots
Iran, The Netherlands
4.213
COLOR DOPPLER SONOGRAPHIC FINDINGS OF CAROTID ARTERIES IN
RHEUMATOID ARTHRITIS PATIENTS TAKING MEDICAL TREATMENT
Abolhassan Shakeri Bavil, A. Khabbazi, M. Babaei Bazzaz, M. Nemati, H. Nosratinia
Iran
144
79th EAS CONGRESS
Poster Session
Poster Area
4.214
SERUM LEVEL OF HOMOSYSTEINE IS ASSOCIATED WITH MAXIMUM CAROTID
INTIMA MEDIA THICKNESS IN TYPE II DIABETES AND NON DIABETES SUBJECTS
Hossein Fakhrzadeh, F. Sharifi, A. Mostashfi, Z. Badamchizade, M. Ghaderpanahi,
M. Mirarefin
Iran
4.215
THE EFFECT OF AGGRESSIVE CARDIOVASCULAR TREATMENT ON THE
PROGRESSION OF CAROTID INTIMA-MEDIA THICKNESS: EXPERIENCE OF AN
ATHEROSCLEROSIS PREVENTION CENTER
Patrick M Moriarty, C.A. Gibson, J.M. Backes, D. Eldringhoff, S. Powell, J.F. Ruisinger
USA
4.216
ACCURACY OF ANKLE-BRACHIAL INDEX MEASURED BY UPPER ARM
AUTOMATED BLOOD PRESSURE DEVICES IN PATIENTS WITH DIABETES
MELLITUS
Javier Ena, T. Lozano, G. Verdu, C.R. Argente, V.L. Gonzalez
Spain
4.217
PREVALENCE AND PREDICTORS OF RENAL ARTERY STENOSIS IN HYPERTENSIVE
PATIENTS UNDERGOING CORONARY ANGIOGRAPHY
Samad Ghaffari
Iran
4.218
EVALUATION OF SOME MARKERS OF SUBCLINICAL ATHEROSCLEROSIS IN
EGYPTIAN YOUNG ADULT MALES WITH ABDOMINAL OBESITY
Manal Mohamed Mahmoud, A.S. Abdu, G.M. Magour
Egypt
4.219
ORIGINAL METHOD OF EVALUATION OF ENDOTELIAL DYSFUNCTION BRACHIAL
ARTERY
Gulnora Rozikhodjaeva, A.M. Ashurmetov
Uzbekistan
4.220
IS IT POSSIBLE TO ESTABLISH THE PATHOGENICITY OF MUTATIONS IN THE LDLR
GENE WITHOUT FUNCTIONAL STUDIES?
L. Palacios, Diego Tejedor, M. Stef
Spain
4.221
CLINICAL AND ANGIOGRAPHIC CHARACTERISTICS OF CORONARY
ATHEROSCLEROSIS IN INDIGENOUS POPULATIONS (NORTH - EASTERN PART OF
SIBERIA)
Natalya Makharova, M. Voevoda, L. Pavlov, V. Tarasova, L. Myarina, S. Petrova,
M. Tomskij
Russia
145
and Treatment of
Poster No
Poster Session
Poster Area
and Treatment of
Poster No
4.222
ALTERATIONS IN CUTANEOUS VASOMOTOR RESPONSES AND INFLAMMATORY
STATE AFFECTED BY CHRONIC CIGARETTE SMOKING AND AGING
Indra Mikelsone, I. Bormane, Z. Simsone, P. Tretjakovs
Latvia
4.223
DEVELOPMENT OF GENDER PRESPECIFIED PREDICTIVE MODEL BASED ON
BAYESIAN BELIEVE NETWORKS METHOD FOR UNFAVOURABLE OUTCOMES
AFTER ACUTE CORONARY SYNDROME
I. V. Uporov, I.N. Kurochkin, M.A. Evdokimova, V.V. Nosikov, D.A. Zateyshchikov
Russia
4.224
CARDIOVASCULAR RISK FACTORS AND SPECIFIC CORONARY ARTERY
CALCIFICATION IN POSTMENOPAUSAL WOMEN
Siamak Sabour, M.L. Bartelink, A. Rutten, D.E. Grobbee, M. Prokop, Y.T. van der Schouw,
M.L. Bots
Iran, The Netherlands
4.225
ROLE OF INTIMA-MEDIA COMPLEX AND ANKLE-BRACHIAL INDEX IN THE EARLY
DETECTION OF ATHEROSCLEROSIS IN HIV PATIENTS
Carlos Teixeira Brandt, E.T. Godoi
Brazil
4.226
NONINVASIVE ASSESSMENT OF LEFT INTERNAL MAMMARY ARTERY GRAFT
PATENCY USING TRANSTHORACIC COLOR DOPPLER ECHOCARDIOGRAPHY
BEFORE AND AFTER DIPYRIDAMOLE INFUSION
Daryoosh Javidi, N. Saffarian
Iran
146
79th EAS CONGRESS
Poster Session
Poster Area
LATE-BREAKING POSTERS
Poster No
5.01
ENDOTHELIAL LIPASE (EL) ALTERS CELLULAR LIPID COMPOSITION
Monika Riederer, H. Köfeler, M. Lechleitner, M. Tritscher, S. Frank
Austria
5.02
PATIENTS WITH ACUTE CORONARY SYNDROME SHOW OLIGOCLONAL T-CELL
EXPANSION AND LESIONAL RECRUITMENT OF DIFFERENT T LYMPHOCYTE
SUBTYPES
Susanne Wangler, T.J. Dengler, J. Haas, B. Wildemann, D. Böckler, H.A. Katus,
C. Erbel
Germany
5.03
MICRORNA 302A IS A POTENTIAL MODULATOR OF CHOLESTEROL EFFLUX IN
MACROPHAGES
S. Meiler, E. Toulmin, K. Seng, E. Collier, William A. Boisvert
USA
5.04
DECREASED CIRCULATING FIBROCYTE NUMBER CONTRIBUTES TO
ATHEROSCLEROTIC PLAQUE INSTABILITY
Lu Fang
Australia
5.05
IN VIVO MRS ANALYSIS OF NON-ALCOHOLIC FATTY LIVER DISEASE IN A
TRANSLATIONAL MODEL FOR THE METABOLIC SYNDROME
José WA van der Hoorn, R.A. van de Molengraaf, R. Nachabe, J. Pikkemaat, M. Vlaming,
C.F. Sio, R. Lamerichs, J. Degroot, O.C. Steinbach
The Netherlands
5.06
PHYTOSTEROL SUPPLEMENTATION DOES NOT AFFECT PLASMA ANTIOXIDANT
CAPACITY IN PATIENTS WITH METABOLIC SYNDROME
Theodora-Eirini Sialvera, A.E. Koutelidakis, D.J. Richter, G. Yfanti, M. Kapsokefalou,
G. Pounis, G. Goumas, E. Diamantopoulos, A. Zampelas
Greece
5.07
EXPLORING THE CONTRIBUTION OF PLASMA CETP TO THE MODULATION OF HDL
CHOLESTEROL DURING NIACIN ADMINISTRATION IN DIABETIC PATIENTS WITH
DYSLIPIDEMIA
Themistoklis Tzotzas, S. Karras, T. Gautier, V. Deckert, K. Tziomalos, T. Kaltsas,
L. Lagrost
Greece
147
June 26-29, 2011
CCIV
FINAL PROGRAMME
INDEX
CCV
Ahuja, K.
Aihara, K.I.
Aishah, N.
Akaike, M.
Akhmedova, N.
Akker, N.M.S.
Akpek, M.
Åkra, S.
Aksu, T.
Aktas, E.
Ala-Korpela, M.
Alavantic, D.
Alavi-Majd, H.
Alavy, Lutfullaevich, A.
Al-Busaidi, A.
Alcolak, E.
Aldover-Macasaet, E.
Alegret, J.M.
Aleixo, A.
Alekberova, Z.
Alekseeva, G.
Alexanderson, C.
Alexandrova, E.
Alexescu, T.
Alexiou, E.
Alexopoulou, L.
Alférez, M.J.
Alhusain, A.
Ali, A.
Alipour, A.
Alizadeh, S.
Allaert, F.A.
Alm, R.
Alonso, R.
Alonso-Villaverde, C.
Alqub, M.
Altieri, P.
Alugishvili, M.
Alvarado-Castillo, C.
Alvarez-Sala, L.A.
Alves, A.
Alves, R.
Alves, S.
A
Aakhus, S.
70
Abdalla, D.
58, 66, 81, 88, 91, 126
Abdel Gader, A.G.
99
Abdessalem, S.
114
Abdu, A.
145
Abe, K.
104
Abe, S.
57
Abed, A.
39
Abello, F.
48
Abesadze, I.
83
AbiFAdel, M.
33
Abiko, A.
92
Abu Jabal, K.
47, 58
Acha, G.
128
Aczel, S.
39
Adam, M.
102
Adámková, V.
94, 101, 113
Adamova, I.
70
Adams, M.
119
Adiels, M.
37
Adorni, M.P.
55
Adrianova, I.
60, 77
Afanasieva, O.
70, 72, 101
Aflaki, E.
50
Afonyushkin, T.
67
Agapaki, A.
73
Agapakis, D.
98, 128
Agapov, I.
77
Agardh, H.
45
Aggarwal, A.
104, 137
Agoston-Coldea, L.
65, 143
Agrawal, D.
71, 74, 81
Aguiar, D.
42
Aguilar-Mariscal, H.
120
Aguirre, M.A.
71, 84
Aherrahrou, Z.
110
Ahmad, N.
92
Ahn, H.S.
99
Ahnis, A.
123
Ahnström, J.
60
Ahrens, I.
32
149
119
48
120
48
142
141
142
116
93
142
21
97, 108, 127
127
93, 127
45
110
94
85
42
86
83
73
41, 86, 142
102
128
13
50
65
73
47, 82
62
107
88
18, 140
84, 85, 113
89
70, 83
83, 130
128
119
39, 47, 48, 115
42
86
Amalric, N.
142
Amann, K.
81
Amann-Vesti, B.
74
Amarenco, P.
2, 26
Amarnath, V.
34
Amato, M.
139, 141
Ames, P.
64
Ammirati, E, E.
88
Ammirati, E.
85
Ammori, B.
62, 63
Amrein, K.
140
Anastasiou-Nana, M.
120
Andel, M.
142
Andersen, H.
94
Andersen, L.
103, 104, 107
Andersen, L.F.
67
Andersson, D.
87
Andersson, J.
69
Andersson, K.
126
Andersson, L.
43, 45
Ando, S.
57
Andrade, B.
42
Andrade, J.
126
Andrade, M.
42
Andreescu, O.
123
Andreev, V.
75
Andreeva, E.
77
Andreotti, F.
11, 26
Andrianova, I.
52, 53
Andrich, S.
104
Andrys, C.
97
Anfossi, G.
48
Angelin, B.
9, 26, 37, 40, 46, 49
Annema, W.
53, 58
Annemans, L.
95
Anselmi, A.
23
Anzinger, J.
43
Aparicio-Trápala, M.
120
Apostolakis, S.
73, 98
Apostolova, M.
96, 97
Aragonès, G.
46, 57, 84, 85, 96, 113
Arai, H.
132
Aranda, C.
79, 139
Aranda, J.L.
126
Araújo, A.L.
58
Araujo, D.
105
Ardic, I.
142
Ardigò, D.
73, 110, 135
Argani, H.
62
Argente, C.R.
145
Ariunaa, T.
136
Ariza-Corbo, M.J.
101
Armugam, A.
100
Arnaboldi, L.
91, 132
Arnaboldi, M.
44, 125
Arnaud, C.
79
Arnesen, H.
70, 91, 116
Aronson, D.
113
Arroja, I.
42
Arsenault, B.
94, 112
Artieda, M.
108
Asada, Y.
73
Asai, A.
61, 66
Ascaso, J.
126
Aseri, Z.
99
Ashavaid, T.
92, 109
Ashkar, A.
78
Assandro, P.
48
Assem, M.
63
Asztalos, L.
59, 76
Atar, D.
110, 111
Athias, A.
63, 115
Atout, R.
78
Aufricht, C.
58
Auinger, A.
112
Aukrust, P.
46, 110, 111, 124
Avaliani, T.
104
Averna, M.
44, 109
Avgerinos, P.
98, 118, 119, 121, 126
Avidan, N.
113
Aviram, M.
58, 59, 73
Avis, H.
38
Awsiuk, M.
52
Ayoka, A.
129
Azevedo, J.
42
Aznaouridis, K.
91
150
Bao, W.
94
Bao, Y.
46
Baptista, J.
102
Barbarroja, N.
71, 84
Barbetseas, J.
98, 118, 119, 121
Barbieri, S.
91
Barbosa, S.
101
Barbot, L.
89
Bardachenko, L.
80
Bardachenko, N.
80
Barisione, C.
70, 83
Baron, M.
35, 90
Barreda, M.
57, 84
Barrett, H.
9
Barrett-Connor, E.
94
Barros, M.
56
Barroso, L.
122
Barsotti, A.
70
Bart, B.
137
Bartelink, M.
144, 146
Bartels, E.
14, 89
Bartelt, A.
14, 38
Barter, P.
5, 25, 29, 44, 94, 112, 134
Bashiardes, E.
66
Basili, S.
91
Basler, M.
83, 88
Basta, G.
96
Bastida, S.
121
Batista, A.E.
120
Batuca, J.
64
Baudin, B.
108
Bauge, E.
90
Baumgartner, I.
59, 107
Baumgartner, S.
126
Bays, H.
41
Bazan, V.
92
Bea, A.
110
Bea, A.M.
118, 126
Beaslas, O.
69
Beaune, P.
50
Becarevic, M.
86
Becerra, D.
72
Becker, J.
58
Becker, S.
64
Beer, S.
59, 86, 103, 104, 106, 107
B
Babaei Bazzaz, M.
Babalola, O.
Babio, N.
Bacchetti, T.
Bacciu, P.
Bäck, M.
Backer, G.D.
Backes, J.
Bäckhed, F.
Badamchizade, Z.
Badamchizadeh, Z.
Badeau, R.
Badescu, C.
Badescu, M.
Badulescu, O.
Baek, H.J.
Baetta, R.
Bagdonaite, L.
Baghi, A.
Baglivo, H.
Baguet, J.P.
Bahl, A.
Bahr, M.
Bahreini, E.
Bahs, G.
Bai, C.H.
Bakker, A.
Balakhonova, T.
Balbi, G.
Baldassarre, D.
Ball, M.
Ballantyne, C.
Balogh, I.
Balogh, Z.
Ban, Y.
Bandemer, J.
Banegas, J.
Banfi, M.
Banjoko, S.
Bannerjee, M.
Bantubungi, K.
Bañuls, C.
144
129
100
65
39
15, 79, 87
94
145
7, 75
145
140
79
123
123
123
82
132
66
103
132
79
84
35
62
85, 136
96
116, 144
70
88
100, 139, 140, 141
119
41, 54, 55
114
76
101
65
94
88
129
47
35
63, 92, 127
151
Behravan, J.
Behrensen, M.
Béke, G.
Beley, A.
Belgacem, O.
Belisle, S.
Bello, E.
Bellocchi, S.
Bellocchio, A.
Bellod, L.
Bellosta, S.
Beltrán-Debón, R.
Benedek, P.
Benedí, J.
Bengtsson, E.
Benn, M.
Bennett, M.
Bennett, P.
Berbeè, J.
Berberashvili, E.
Berendschot, T.
Berg, K.
Bergamini, E.
Berges, A.
Berglund, G.
Bergonzini, V.
Bergström, G.
Berliner, S.
Bermudez, G.
Bernard, S.
Bernaud, C.
Bernberg, E.
Bernini, F.
Berrougui, H.
Bertazzo, S.
Berthier, M.L.
Bertolami, A.
Bertolami, M.
Bertolini, S.
Berzina, M.
Besler, C.
Besnard, P.
Betsholtz, C.
Betteridge, J.
Bhandari, U.
Bhasin, S.
Bhat, O.
Bhatnagar, D.
Bianchi, M.
Bianco, H.
Bicker, W.
Biedma, D.
Bieghs, V.
Bienek-Ziolkowski, M.
Biessen, E.A.
Bigazzi, F.
Bika, E.
Bikkina, M.
Bińczak-Kuleta, A.
Binder, A.
Binder, J.
Binder, V.
Birner-Gruenberger, R.
Birnie, E.
Bisenic, V.
Bishop, E.
Bittar, R.
Bittencourt, C.
Bitto, A.
Björkbacka, H.
Björkegren, J.
Blache, D.
Blackwood, D.
Blagodatskikh, K.
Blaha, M.
Bláha, V.
Blanco-Vaca, F.
Blankenberg, S.
Blann, A.
Ble-Castillo, J.
Blønd, M.
Bobak, M.
Bobik, A.
Bobryshev, Y.
Boccardi, C.
Boccotti, L.
Bochdansky, T.
Bochkov, V.
Bochorishvili, T.
Böckler, D.
115
110
114
115
94
82
119
125
109
63, 127
132
57, 84, 85, 113
26
121
88
20, 26, 105
8, 96
101
110
138
59
139
121
75
71
20, 53
27, 74, 103
84, 102
141, 142
33
95
27, 74
53, 55
55, 58
69
140
105
56, 68, 105, 122
109, 110
102
38
12
22
2, 30, 134, 135
96
152
94
84
112
96
99, 101
94
95, 106
54
50
8
41, 42, 55, 56
118
107
113
123
140
54
54
47, 82
144
72
39, 44
99
88
13, 44, 60, 96
73
115
45
108, 114, 115
93, 97
48, 93, 97
55, 58
21
101
107, 120
103
42, 104
13
77
56
92
39
67, 94
138
147
Bode, C.
76, 78
Bodhankar, S.
122
Boehm, B.
101
Boehm, B.O.
23, 69
Boehnel, C. 39, 41, 59, 86, 104, 106, 107
Boekholdt, S.
94, 112
Boghrabadi, V.
103
Bogsrud, M.
38
Böhm, M.
125
Bohnacker, T.
43
Boileau, C.
33
Boiocchi, C.
86
Boisvert, W.
147
Bokuridze, K.
138
Bol, C.
142
Bonacasa, B.
118
Bonde, Y.
37
Bondjers, G.
27
Bonini, R.
42
Bonnefont-Rousselot, D.
33, 39
Bonnet, J.
45
Bonomo, A.
132
Bonou, M.
98, 118, 119, 121, 126
Borén, J. 8, 14, 26, 28, 37, 43, 44, 45, 46
51, 54, 56, 87
Borges, N.
117
Borghi, C.
94
Borgman, M.
54, 55
Bormane, I.
85, 146
Borné, Y.
106
Borsa, C.
95
Bosi, E.
107
Bosmans, J.
79
Bossowski, A.
135, 136
Boström, P.
35, 45
Bot, I.
78
Bot, M.
53
Botea, S.
68
Botelho, P.
68, 122
Botha, A.
48
Bots, M.
144, 146
Boudoulas, H.
73
Bouhafs, L.
86
Boulanger, C.
35
Bountziouka, V.
98, 118, 119, 121, 126
Bourbon, M.
Bourghardt, J.
Bournazos, S.
Bovens, S.
Boyanovsky, B.
Boytsov, S.
Bozzini, S.
Bozzolo, E.
Bracho, M.
Brandao, S.
Brandenburg, V.
Brandt, C.
Brännberg, C.
Bratseth, V.
Brcakova, E.
Brennan, D.
Breuss, J.
Brewer, B.
Brezean, I.
Briceno, S.
Brion, R.
Brisslert, M.
Brisson, D.
Britto, V.
Brkic, L.
Bro, S.
Brodmann, M.
Bromme, D.
Brønner, K.W.
Bronze, L.
Brosstad, F.
Brovkin, A.
Brown, W.V.
Bruce, I.
Bruckert, E.
Bruckner, I.
Brudi, P.
Bruene, B.
Brügelmann, K.
Brugnara, L.
Bruguera, J.
Brunelli, C.
Brunner, S.
Bruns, O.
Bruthans, J.
153
39, 47, 48, 49
71, 73
84
22
45
137
86
85
141, 142
86
99
129, 146
5
70, 91
49, 84, 85
59
41
3, 28
123
141, 142
8
44
9, 26
120
34
69
140
120
67
42
124
108
5, 7, 30, 47
65
12, 26, 33, 107
122
134
88
38
43
92
70, 83
131
14
94, 101
Brzosko, M.
Bucci, M.
Bueno, H.
Buerke, M.
Buers, I.
Buettner, C.
Buixadera, C.
Bujo, H.
Bulló, M.
Bult, H.
Bulum, T.
Bunn, D.
Burchardt, P.
Burillo, E.
Burnett, J.
Burza, M.A.
Businaro, R.
Busjahn, A.
Butler, M.
Butoi, E.
Butoreva, L.
Buttari, B.
Buttitta, F.
Buyukoglan, H.
Byrkjeland, R.
Camejo, G.
57
Camont, L.
55, 56
Campanati, A.
65
Campean, V.
81
Camps, J.
57, 84, 85, 113
Cao, W.
131
Caraba, A.
143
Caramelli, B.
122
Cardillo, C.
83
Cardona, F.
52
Cardot, P.
89
Cardozo, A.
128
Cariolou, M.
66
Carlon, M.
40
Carlsson, L.
131
Carmena, R.
26
Carnevale, R.
91
Caronno, R.
125
Carpentier, A.
9
Carrapeiro, M.
68
Carreau, V.
33
Carretero, R.M.
71, 84
Carrié, A.
33
Carrière, V.
89
Carrillo, G.
109
Carru, C.
66, 67, 125
Carvalho, L.S.
58
Casas, M.L.
139
Casella-Filho, A.
62
Casiraghi, P.
125
Castelli, P.
127
Castelnuovo, S.
139
Castilho, G.
46, 51, 58, 59
Castilla, V.
79
Castro, A.
141
Castro, Cabezas, M.
47, 82
Castro, I.
68, 122
Castro, N.
68
Casu, M.
125
Catalina-Romero, C.
93, 106
Catanozi, S.
59
Catapano, A. 26, 31, 76, 85, 88, 91, 109
Cattin, A.L.
89
Cavalca, V.
92
Cavalli, S.
56
113
73
95
70
43
51
143
21
100
79
63, 77, 107
65
41, 68, 112
57, 118
44
14, 131
81
64
67
72, 83
76
81
73
142
70
C
Caballero, P.
Cabré, A.
Caccavello, R.
Cachofeiro, V.
Cahill, P.
Cai, G.J.
Calabrese, C.
Calabresi, L.
Calandra, S.
Calin, M.
Calvo, E.
Calvo-Bonacho, E.
Calzada, C.
Camacho, A.
Camacho-Molina, A.
Cambedda, D.
Camber, O.
140
46, 100
59
119
75
133
91
54
53, 109, 110
72, 83
106
93
64
57
103, 104
67
78
154
Cavallini, G.
121
Cavalot, F.
135
Cefalu', A.
44
Cefalù, B.
109
Ceglarek, U.
64
Cenarro, A.
37, 57, 110, 112
Cerda, A.
56
Cervantes-Toache, C.
107
César, F.
81
Ceska, R.
113
Cha, M.J.
91
Chacin, L.
141, 142
Chackathayil, J.
113
Chalikias, G.
73, 98
Chambaz, J.
89
Chan, C.
92
Chan, D.
9
Chang, C.
131
Chang, J.
43
Chang, W.C.
77, 121
Chantepie, S.
55
Chao, H.H.
119
Chapman, M.J. 5, 7, 12, 26, 29, 54, 55, 56
107
Chaput, E.
56
Charalampous, C.
41, 42, 123
Charcosset, M.
33
Charlton-Menys, V.
47, 62, 63, 65, 112
Charng, M.J.
100
Charoensa, N.
63
Charriere, S.
33
Chassap, H.
135
Chatterjee, A.
112
Chatziathanasiadou, C.
128
Chatzizisis, Y.
28
Chebel, S.
64
Chen, H.
68, 127, 129
Chen, J.J.
119
Chen, J.W.
90, 102
Chen, M.F.
72
Chen, S.Y.
102
Chen, W.H.
96
Chen, W.J.
72
Chen, W.L.
111
Chen, Y.
127
Chen, Z.
Cheng, J.
Cheng, T.H.
Chern, C.I.
Chernjavski, A.
Chester, A.
Chetter, I.
Chiang, A.N.
Chiaramonte, L.
Chin-Dusting, J.
Chinetti-Gbaguidi, G.
Chiou, H.Y.
Chiou, K.R.
Chiu, H.C.
Chiu, S.
Chiu, T.Y.
Chiu, W.C.
Chłopicki, S.
Cho, K.H.
Cho, S.
Choi, C.U.
Choi, D.
Choi, S.Y.
Choudhury, R.P.
Chowienczyk, P.
Christodorescu, R.
Christoffersen, C.
Christoffersen, M.
Christogiannis, L.
Chrysochoou, C.
Chu, P.H.
Chumakova, G.
Chung, P.W.
Chung, W.Y.
Cianflone, D.
Cicha, I.
Ciechanowicz, A.
Cífková, R.
Cigliano, A.
Cinnamond, N.
Cintra, R.
Ciocoiu, M.
Cipollone, F.
Cirovic, S.
Citti, L.
155
34
131
119
102
81, 97
69
139
76, 111
132
56
35
96
100
96
37
102
76, 111
83
52, 59, 60, 61, 62
46
63, 65, 82
135
119
32
75
143
20, 60, 89
100
43
125
124
111, 137
124
99, 122
85, 88
75
113
94, 101
39
138
58
123
73
121
56
Civeira, F.
37, 48, 51, 57, 110, 112, 118
Cladellas, M.
92
Clapp, B.
75
Clarke, M.
8
Claudel, T.
35
Clausen, O.P.
111
Clemente-Postigo, M.
52
Cloyd, K.
69
Coca, I.
50
Coca-Prieto, I.
112
Cocci, F.
96
Coceani, M.
96
Coelho, O.
58, 91, 126
Cofán, M.
37, 110, 112, 138
Cogger, V.
40
Cohn, J.
47
Colak, A.
93
Colas, R.
64
Colberg, C.
78
Cole, J.
13
Collantes-Estevez, E.
71, 84
Collier, D.
131
Collier, E.
147
Collins, T.
103
Colquhoun, D.
120
Combes, G.
53
Comte, C.
90
Condorelli, G.
76
Contri, R.
85
Cordioli, S.
40
Cordova-Uscanga, R.
107
Corrêa-Giannella, M.L.
51
Corsini, A.
91, 132
Cosic, V.
98
Costa, A.P.
126
Costa, S.
20, 53
Costa-Mugica, A.
120
Côté, N.
60
Couvert, P.
33
Cox, B.
34
Cozma, A.
99
Creemers, E.
116
Croal, B.
120
Croizier, J.
137
Cromwell, W.
132
Crook, M.
Cross, A.
Crucet, M.
Cruickshank, K.
Cuadrado, M.J.
Cuccia, M.
Cuchel, M.
Cugnet-Anceau, C.
Cui, J.
Cullen, J.
Culmes, M.
Cuniberti, L.
Czarnecka, D.
Czech, U.
Czerwińska, M.
Czyżewska, M.
48
13
34
47
71, 84
86
3, 24
64
111
75
130
132
141
52
119
60, 61
D
da Silva, R.M.M.
Dąbek, J.
Dadd, T.
Dadoo, O.
Dadoush, G.
Daemen, M.
D'Agostino, M.
Dahl, T.
Dahlan, W.
Dahlbäck, B.
Dahlbom, I.
Dahlof, B.
Dalamaga, M.
Daleprene, J.
D'Alexandri, F.
Dallongeville, J.
Dambrova, M.
Damianidou, M.
Dan, A.
Danchin, N.
Dandamudi, S.
Danelon, M.R.G.
D'Angelo, P.
Daniel, W.
Dar, A.
Darabian, M.
156
108
142
132
78
93
22
38
46, 111
63
20, 60, 94
78
131
98
88
85
94
102
128
48
11, 95
104
108
132
75
48
137
Darakhshanian, H.
Dashkovsky, I.
Davaine, J.
Dàvalos, I.
Davey, Smith, G.
Davidovic, L.
Davies, A.
Davies, S.
Davoodpour, P.
Dawkins, L.
de Almeida, O.
De Backer, G.
De Boer, J.F.
De Caridi, G.
de Carvalho, G.
de Castro-Orós, I.
De Castro-Orós, I.
de Faria, E.
de Faria, E.C.
De Geest, B.
De Gendt, K.
de Groot, E.
de Groot, P.G.
de Haan, W.
de Jouvencel, T.
De Maistre, E.
De Meyer, G.
De Murtas, V.
De Nardis, V.
de Ronde, M.
de Souza, J.
de Vrese, M.
de Vries, M.
De Vries, R.
de Wal, J.
Deanfield, J.
Deans, K.
Debs, A.
deCampo, A.
Deckert, V.
Dedoussis, G.
Deedwania, P.
Deegan, P.B.
Deev, A.
Defesche, J.
Degirolamo, C.
54
Degroot, J.
147
Dehghan, manshadi, R.
113
Dehne, N.
88
Deiana, L.
66, 67, 125
Del, Turco, S.
96
Dela, F.
14
DelCore, M.
74
Delerive, P.
35
Delgado-Casado, N.
38
Delgado-Lista, J.
38, 82
Deljanin, Ilic, M.
98
Dembinska-Kiec, A.
52, 53
DeMicco, D.
94, 112, 134, 135
Demina, E.
62
Demonty, I.
117
Dencker, M.
103, 104, 107
Dengler, T.
147
Denisenko, A.
62, 104
Deniset, J.
81
Dennis, E.
15
Derdemezis, C.
99
Dergunov, A.
62
Derks, M.
56
Derlindati, E.
73
Déry, S.
9, 26
Descamps, O.
26, 107
Descamps, O.S.
26
Desrumaux, C.
80, 115
Deushi, M.
68
Devarakonda, M.
66
Dhar, K.
81
Dhawan, V.
84
Di Sciascio, G.
2
Di Filippo, M.
64
Di Leo, E.
109, 110
Di Santo, S.
91
Di Sciascio, G.
2
Di Taranto, M.
38
Diamant, M.
30
Diamantopoulos, E.
147
Diament, J.
130
Dias, K.C.
26
Dias, N.
139
Diaz-Ordoñez, A.
57, 103, 104
66
47, 58
8
109
105
97, 108, 127
13, 125
34
54
122
126
26
58
88
126
110
51
85, 126
108
8
73
141
11
35
79
115
79
67
73
116
56
112
70, 78, 81
58
9, 26
3, 12, 26, 118, 126
120
76
134
80, 115, 147
112
94, 112, 132, 134
53
92, 101
16, 30, 38, 110
157
Diaz-Zagoya, J.
107, 120
Dibrov, E.
81
Dilaveris, P.
124
Dimitriou, M.
112
Dionyssiou, -Asteriou, A.
98
Discacciati, A.
139, 141
Dizcfalusy, U.
86
Djian, J.
137
Djokovic, A.
87, 99, 144
Djordjevic, V.
98
Djuric, D.
107
Djuric, T.
97
Dobbs, B.
40
Dobordzhginidze, L.
101
Dobreńko, E.
135
Dodani, S.
62, 67, 103
Doddapattar, P.
50
Dogan, A.
142
Dogdu, O.
142
Doi, M.
97
Domani, E.
113
Doménech, M.
138
Donald, A.
75
Donati, A.
121
Doney, A.
110
Dong, L.
62, 103
Dong, Q.
41, 47
Donovan, J.
132
Doria, A.
88
Dorow, J.
64
dos, Santos, R.
52
Dragan, E.
83
Dragan, S.
143
Dragan, S. V.
99
Dragano, N.
72, 104
Dransfield, I.
84
Drapkina, O.
40, 128
Drexel, H.
39, 41, 59, 86, 103, 104, 105
106, 107, 113
Drexel, V.
39, 86, 106
Drier, Y.
113
Du, D.
125
Duarte, J.A.
115
Dudarev, A.
130
Duez, H.
90
Duhem, C.
90
Duivenvoorden, R.
141
Dullaart, R.
58, 94
Dumont, L.
115
Dunér, P.
88
Durrington, P.
47, 62, 63, 65, 112
Durukan, M.
93
Dusilova-Sulkova, S.
97
Duvnjak, L.
63, 77, 107
Dvořák, J.
50
Dwivedi, S.
104, 137
Dwyer, T.
105
Dziedzina, S.
109
E
Eckstein, H.H.
130
Edry, O.
140
Edsfeldt, A.
124, 139
Edvinsson, L.
67
Efstathiou, S.
120
Egashira, K.
68
Eggertsen, G.
89
Ehnholm, C.
51
Ehrenborg, E.
8, 112
Eilertsen, K.-E.
118
Eisele, S.
78
Eissing, L.
51
Ekberg, O.
139
Ekroos, K.
21, 43, 54, 95
Ekstrand, J.
130
El-Bistami, D.
119
Eldringhoff, D.
145
El-Gamal, D.
54
El-Hamamsy, I.
69
Elia, L.
76
Eligini, S.
92
Elisaf, M. 40, 43, 49, 65, 66, 99, 118, 124
128, 136
Elksne, K.
85
Eller, N.
103
Ellul, J.
115
Elmoktari, N.
112
Elmståhl, B.
139
El-Osta, A.
74
158
Elte, J.W.
47, 82
Elvevoll, E.
118
Emonnot, L.
60
Ena, J.
145
Enebakk, T.
138
Engelbertsen, D.
88
Englert, H.
106
Englinger, B.
58
Engström, G.
91, 96, 106
Enkhtaivan, O.
41
Enkhtamir, E.
136
Enklaar, D.
141
Epand, R.
34
Ephrem, G.
134
Erbel, C.
147
Erbel, R.
72, 104, 110
Erdmann, J.
110
Eremenko, N.
97
Ergin, A.
142
Erglis, A.
102
Ericson, U.
37
Eriksson, M.
16, 26, 46, 54
Eriksson, P.
69
Erlich, D.
33
Eryd, S.
91, 96
Escolà-Gil, J.C.
55, 58
Esis, C.
141, 142
Eskandarian, R.
137
Esmaeili Nadimi, A.
95
Estevanez, I.
80
Estrada, O.
128
Etxebarria, A.
143
Eussen, S.
126
Evangelopoulos, A.98, 118, 119, 121, 126
Evdokimova, M.
111, 114, 115, 146
Ewing, M.
78, 81
Ezhov, M.
70, 72, 101
Falasca, M.
Falcone, C.
Falcucci, G.
Falk, E.
Faludi, A.
Fancello, T.
Fang, L.
Fanton, N.
Farajian, P.
Faria, E.
Farnier, M.
Fasano, T.
Fatemi, F.
Fatorova, I.
Faulin, T.
Fava, A.
Favari, E.
Fayad, Z.A.
Fayyad, R.
Fazio, S.
Fearon, I.
Federici, M.
Fedorov, A.
Fedotova, O.
Feher, M.D.
Feki, M.
Feldmann, M.
Felicioni, L.
Fennessy, J.
Fenyo, I.
Feoktistov, A.
Ferin, R.
Fernandez, A.
Fernández-Cruz, A.
Fernández-Sender, L.
Ferns, G.
Ferraro, S.
Ferré, R.
Ferreira, C.
Ferreira, C.E.
Ferreira, T.
Ferretti, G.
Ferri, N.
Ferrières, J.
Ferroni, P.
F
Fabbi, P.
Fagerberg, B.
Faggin, E.
Fåk, F.
Fakhrzadeh, H.
70, 83
54
88
75
140, 145
159
91
86
92
19
105
109
147
50
120
91
17, 134
53
97
93
66
132
53, 55
32
134, 135
40, 47
72
83
74
104
53
114
13
73
104
71, 90
48
102
128
85
84, 85
100
127
96, 141, 143
101
79
137
65
132
53
91
Figg, N.
8
Figueiredo Neto, A.
86
Filimon, S.
95
Filipiak, K.
122
Filipovic, N.
72
Filipovský, J.
94
Filipowicz-Sosnowska, A.
93
Filippatos, T.
99
Finkov, B.
96, 97
Fioratti, C.
122
Fischer, K.
113
Fischer, S.
86, 101
Fisher, E.
26
Fistas, N.
129
Flavell, R.
13, 69
Fletcher, J.
87
Florea, I.
71
Florentin, M.
49
Floriano, E.
81
Floudaras, I.
128
Fogelstrand, P.
8, 44, 71
Folkersen, L.
130
Fonseca, F.
86, 99, 101, 117
Fonseca, H.
86, 99, 101
Foody, J.
40
Forfang, K.
70
Forghanifard, M.
113
Fóris, G.
76
Formato, M.
39
Fornieles, G.
103, 104
Fornieles-Gonzalez, G.
57
Foroughi, M.
115
Fortunato, G.
38
Fotiadis, D.
72
Fouchier, S.
38, 110
Fournier, N.
51
França, C.
79, 82, 99
France, M.
47, 62, 63, 112
Franczyk-Żarów, M.
83
Frandsen, M.
37
Frank, S.
34, 147
Franzini, L.
135
Fraser, R.
40
Fredrikson, G.
13, 96
Freidig, A.
26
Freise, H.
Freitas, F.
Fresa, R.
Frey, N.
Freyer, J.
Friedmann, P.
Frigerio, B.
Frigola, R.
Frikke-Schmidt, R.
Frisch, F.
Frochot, V.
Froehlich, H.
Froemming, G.
Frostegard, J.
Fruhwürth, S.
Fu, Y.
Fuchs, D.
Fuentes, F.
Fuhrman, B.
Fujimoto, S.
Fujioka, Y.
Fujita, M.
Furusawa, T.
20
62, 130, 133
109, 110
112
110
134
139, 141
55
5, 20, 33, 100, 110
9
89
140
78
78
58
56
85
82
58, 73
97
97
114
131
G
Gabrielsen, A.
Gadeau, A.P.
Gaetani, E.
Gafarov, V.
Gafarova, A.
Gåfvels, M.
Gagliardi, A.C.
Gagné, C.
Gagulin, I.
Gajda, M.
Galabova, G.
Galanopoulou, A.
Galdino, S.
Galletti, M.
Gallitz, I.
Gälman, C.
Gálvez-Godoy, M.
Gamba, P.
Gamezardashvili, T.
160
130
79
110
104, 107
104, 107
89
52
9
104, 107
83
131
42
81
20, 53
77
46
93
64
139
Gan, A.M.
72, 83
Garces, C.
114
García, A.
57
Garcia, C.
92
Garcia Calzado, C.
45
Garcia De, La, Torre, I.
64
Garcia, N.
57, 103, 104
García, R.
85
García-Anguita, A.
114
Garcia-Arellano, A.
100
Garcia-Arnés, J.A.
140
García-Casares, N.
140
García-Malpartida, K.
92
Garcia-Rios, A.
38, 82
Gargiulo, S.
64
Garibaldi, S.
70, 83
Garlaschelli, K.
85, 88
Garlichs, C.
75
Garnier, P.
115
Garssen, J.
126
Gąsior, Z.
142
Gaspar, I.
49
Gasperotti, S.
40
Gaudet, D.
9, 26
Gaudino, M.
23
Gauer, N.
52
Gauster, M.
54
Gautier, T.
35, 45, 63, 80, 147
Gavrisheva, N.
83
Gayral, S.
79
Gazi, I.
65, 99
Geerling, J.
9
Gegenava, T.
133, 137
Geiger, K.
113
Geis, T.
88
Geleijnse, J.
117
Geller-Rhomberg, S.
113
Gelpi-Méndez, J.-A.
93
Gelsinger, C.
64
Genis, A.
71
Genoux, A.
53
Genser, B.
26
Gentile, M.
38
Gentleman, E.
69
Genvigir, F.
56
George, J.
140
Gerdes, N.
45, 79
Gerotziafas, G.
124
Gertow, K.
130
Geshi, E.
101
Ghaderpanahi, M.
140, 145
Ghaffari, S.
145
Gharavi, A.
127
Ghayour-Mobarhan, M.
100, 113
Gheyle, L.
137
Ghigliotti, G.
70, 83
Ghorbanihaghjo, A.
62
Ghosh, M.
141
Gialernios, T.
42
Gianellini, S.
91
Giannakidou-Jordan, E.
52, 64, 123
Giannakopoulou, E.
115
Giannella-Neto, D.
51
Giarretta, I.
110
Gibney, J.
97
Gibson, C.
145
Gidlund, M.
13, 63, 86
Gilabert, R.
138
Gill, P.
101, 113
Ginanni, Corradini, S.
14
Ginghina, C.
68, 84, 95
Ginsberg, H.
26
Gioka, T.
98
Giotopoulou, A.
98, 118, 119, 121
Giral, P.
39
Girard, E.
50
Girona, J.
46, 96
Gisterå, A.
69
Gitt, A.
17
Giunta, G.
132
Gizurarson, S.
46
Glass, C.K.
35
Glatz, J.F.C.
14
Glieca, F.
23
Głogowska-Ligus, J.
142
Głowińska-Olszewska, B.
135, 136
Gluszko, P.
93
Goddard, M.
13
Godoi, E.
146
Goff, W.
56
161
Gogos, J.
Gojkovic-Bukarica, L.
Goland, S.
Goldhammer, E.
Golovanova, N.
Golpaie, A.
Gomaraschi, M.
Gomes, A.
Gomez, M.
Gomez, P.
Gómez-Garre, D.
Gomez-Luna, M.
Gomez-Luna, P.
Gonçalves, I.
Gonzalez, A.
Gonzalez, Anglada, I.
González, M.
Gonzalez, V.L.
González-Muñoz, M.J.
González-Quintela, A.
González-Santos, P.
González-Torres, L.
Goralczyk, R.
Goralska, J.
Gordon, A.
Gordts, S.
Gorshunova, N.
Goswami, B.
Gotenko, I.
Goueffic, Y.
Goumas, G.
Gozdzicka-Jozefiak, A.
Graaf, J.
Graaff, R.
Gracheva, E.
Gradinaru, D.
Græbe, M.
Græsdal, A.
Graham, L.
Graier, W.
Grammer, T.
Grammer, T.B.
Granata, A.
Grande, P.
Granér, M.
Gratsiansky, N.
Greber, S.
Green, B.
Green, N.
Greentree, S.
Greiderer-Kleinlercher, B.
Grigore, C.
Grigore, L.
Grigore, O.
Grinevich, E.
Grip, L.
Gritsenko, O.
Grivenco, A.
Grobbee, D.
Grober, J.
Gromova, E.
Gruca, A.
Gruenberger, R.B.
Grufman, H.
Grunstein, R.
Grynberg, A.
Guallar, E.
Guan, Y.Y.
Guardamagna, O.
Guardiola, M.
Guarino, A.
Guerci, A.
Guérin, M.
Gugliucci, A.
Guichardant, M.
Guido, V.
Guiffre, A.
Guijarro, C.
Guimarães, A.
Gullberg, B.
Gulliver, W.
Gun, C.
Guo, L.
Gupta, A.
Gupta, G.
Gupta, K.
Gupta, R.
Gurakan, F.
Guray, U.
Gurevich, V.
71
120, 121
140
115
53
40, 66, 80
54
49
88
74, 82, 95, 106
85
82
38
71, 124, 139
142
79, 139
43, 141
145
121
106
101, 112, 140
121
53
52
54, 55
8
130
85, 97
129
8
147
112
139
58
53
84, 95
87
38
27, 120
34
101
23, 69
132
26
141
162
101
39, 104
67
119
9, 26
80
122
88
122
73
51, 144
137
95
144, 146
35, 63, 80
104, 107
52
50
124
47
51
94
111
48
43
39
133
33
59
64
109
87
79, 139
129
37
111
128
34
131
74
67
35
53
93
83
Gustafsson, J.
Gustafsson, J.Å.
Gutiérrez, A.
Gutiérrez-González, F.
Gutiu, I.
Gutiu, L.
Guyton, J.
Guzik, T.
Guzik, T.J.
Gylling, H.
Harvey, D.
Hasegawa, H.
Hashemizadeh, H.
Hashimoto, T.
Hatakeyama, K.
Hattori, K.
Hatzitolios, A.
Hatzoudis, G.
Haugen, J.E.
Haupt, M.
Hauschildt, S.
Havekes, L.
Håversen, L.
Haviv, I.
He, B.
He, Q.
He, X.
Heczková, M.
Hedblad, B.
Hedin, U.
Heeren, J.
Heeringa, P.
Hegde, M.
Heigl, C.
Heijer, M.
Heinecke, J.
Heinecke, J.W.
Heinle, H.
Helal, O.
Helfenstein Fonseca, F.
Helfenstein, T.
Hellerstein, M.
Hellstrand, P.
Hellstrand, S.
Hellström, L.
Heltianu, C.
Helvind, M.
Helwig, U.
Hemantkumar, C.
Henein, M.
Henriksson, P.
Heras, M.
Heravifard, S.
Hering, V.
Hérisson, F.
54
89
140
106
85
85
40, 47, 134
75
82
10, 117
H
Haas, G.
27, 120
Haas, J.
147
Haase, C.
20, 33
Habib, S.
99
Hadi, N.
132, 135
Haeggström, J.
34, 130
Hafner, F.
140
Hag, A.M.
87, 138
Hagemeyer, C.
32
Hägg, S.
73
Hakkarainen, A.
37, 141
Halcox, J.
94, 135
Halis, S.
119
Hallén, J.
110
Halliani, A.
116
Hallikainen, M.
117
Halvorsen, B.
13, 46, 110, 111, 124
Hama, S.
62, 63
Hamamoto, Y.
97
Hamdan, A.
107
Hammami, M.
105, 108, 114
Hamsten, A.
21
Han, F.Y.
111
Hansen, B.
37
Hanson, M.
39, 48, 64
Hansson, G.
13, 44, 45, 69, 79, 87, 130
Harangi, J.
114
Harangi, M.
59, 61, 114
Hardersen, R.
138
Harigaya, H.
32
Harland, J.
121
Hartwich, J.
53
163
105
143
115
32
73
32
98
74
67
123
64
9, 54, 57, 61
43, 45, 89
56
81
111
124
41
71, 91, 96, 106
74, 130
14, 38, 44, 51
118
122, 123
135
139
60
20
120, 121
55, 58
79, 82
101, 117
104
126
37
38
74
94
112
96
135
49
96, 143
127
66
8
Hermo, R.
Hernández-Mijares, A.
Herová, M.
Herreros, B.
Hersberger, M.
Heymann, D.
Heymann, M.F.
Hietaniemi, M.
Higaki, J.
Higuchi, M.
Hildebrand, R.B.
Hilgendorf, I.
Hilling-Smith, R.
Hing, P.
Hinic, S.
Hirano, T.
Hirao, Y.
Hirata, K.I.
Hirata, M.
Hirata, R.
Hirata, Y.
Hirayama-Kuniyoshi, N.
Hirose, H.
Hisakawa, N.
Hishida, H.
Hitos, K.
Hlubik, J.
Hlubik, P.
Hnatiuk, A.
Hobbs, H.
Hoefer, I.
Hoefle, G.
Hoekstra, M.
Hoffmann, M.
Hofker, M.
Højgaard, L.
Hojlund, K.
Holewijn, S.
Hollaus, M.
Holm, S.
Holmäng, A.
Holme, I.
Holmes, E.
Holven, K.
Holzer, M.
Honda, A.
Hong, B.
Hoofnagle, A.
Hoppe, N.
Hornemann, T.
Horno, J.
Hornstrup, L.
Hoshina, S.
Hosseini, M.
Hosseiny, M.
Hosseinzadeh-Attar, M.J.
Hou, Y.
Houdebine, L.M.
Houiller, A.
Hounslow, N.
Hovatta, O.
Hovingh, G.
Hovland, A.
Howe, A.
Hozawa, S.
Hryniewicz, A.
Hsieh, F.I.
Hsieh, Y.C.
Hu, H.
Hu, J.
Hu, L.
Hu, M.
Hu, X.
Huang, P.H.
Huang, Z.
Hubacek, J.
Huber, K.
Huber, S.
Hueb, W.
Huelmos, A.
Hughes, E.
Huijgen, R.
Hulikova, K.
Hultén, L.
Hultgaardh-Nilsson, A.
Humphries, S.
Hunt, J.
Hurme, R.
Hurst, L.
Hurt-Camejo, E.
59
63, 92, 127
34, 84
79
34, 84
8
8
117
89
96
69
76, 78
84
48
87
56, 96, 101
94
20, 97
56
56
48
75
100
102
39
87
42
42
132
7
89
103
54
48
35, 90
87
45
139
58
46, 111, 124
73
134, 135
125
67
54
164
114
46, 124
60
78
101
118
33
98
66
80
40, 66, 80
127
80
89
65, 91
49
110, 112
138
138
100
135
96
96
40
65, 68, 87
81
41
89
90
89
113
105
82
62
79, 139
113, 134
38, 110
142
34, 45
69
33, 133
75
21, 95
96
34, 57
Husche, C.
Husmann, M.
Hussein, O.
Hussey, S.
Hutten, B.
Huuhilo, R.
Hyde, C.
Hyodo, T.
Hyńpler, R.
Hyttinen, L.
Ito, W.
Ito, Y.
Ittrich, H.
Iuliano, L.
Ivanova, M.
Ivanova, N.
Ivashkin, V.
Iwabuchi, H.
Izar, M.
Izar, M.C.
Izzotti, A.
119, 126
74
47, 58
138
38
95
112
56
48, 49
133
I
Iannuzzi, A.
Iborra, R.
Ide, M.
Idzior-Walus, B.
Ignjatovic, S.
Ihász, F.
Ikeda, Y.
Ikegaki, M.
Ikramova, Z.
Iliás, A.
Inazu, T.
Ingueneau, C.
Ionescu, C.
Ionova, V.
Irigoyen, L.
Irtyuga, O.
Isacoff, D.
Ishida, R.
Ishida, T.
Ishigaki, Y.
Ishihara, M.
Ishii, J.
Ishikawa, M.
Ishikawa, S.
Ishikawa, T.
Ishikawa, Y.
Ismail, K.
Issa, M.
Itakura, H.
Ito, H.
Ito, K.
Ito, T.
50, 83, 88
56, 94, 96, 101
14
81
97, 130
97
40, 128
82
86, 99, 101, 117
79, 82
111
J
38
51, 58
60
109, 141
86
136
102
88
142
80
131
61
95
130
143
77
122
80
20
66
82
32
32
38
114
39
125
56
39
97
98
75
Jabauri, A.
Jacob, S.
Jacobs, C.
Jacobs, F.
Jacomella, V.
Jahnel, H.
Jain, A.
Jain, P.
Jakovljevic, V.
James, V.
Jamialahmadi, K.
Jang, Y.
Jänis, M.
Jankovic, V.
Jansen, M.
Janssen, J.
Janssens, R.
Januszek, R.
Januzzi, J.
Japiassú, A.
Jarauta, E.
Jardini, M.
Jarman, A.
Jarrstrand Hall, C.
Jassal, D.
Jauhiainen, M.
Javadzadeh, A.
Javidi, D.
Jeannin, A.
Jelassi, A.
Jelic, S.
165
133
48
64
8
74
134
105
137
107
87
113
135
21, 95
41, 106
49
82
77
106
110, 111
91
112
86
132
86
45
50, 51, 55, 79
62
146
45
109
99
Jelic-Ivanovic, Z.
49
Jemaa, R.
114
Jensen, G.
26, 100
Jensen, I.
118
Jensen, J.
110, 111
Jern, C.
23
Jeyaseelan, K.
100
Jeziorska, M.
62
Jia, F.
32
Jiang, M.
21
Jiang, W.
124
Jiang, Z.-Y.
89
Jiménez, M.
50
Jiménez-Borreguero, L.J.
140
Jimenez-Gomez, Y.
82
Jin, S.
81
Jirholt, P.
44
Jirsa, M.
33, 41
Jöckel, K.-H.
72, 104, 110
Johansson, D.
69
Johansson, J.
54, 55
Johansson, L.
32
Johansson, M.
13, 27, 44, 74
Johnson-Levonas, A.
134
Jolivet, G.
80
Joost, A.
83, 88
Jorga, J.
127
Jorge, I.
57
Jourdil, J.F.
79
Joven, J.
57, 84, 85, 113
Jover, A.
63, 92, 127
Juarez-Oropeza, M.
107
Juarez-Rojop, I.
107, 120
Judstrom, I.
55
Jukema, J.
70, 78, 81
Jukema, W.
57
Jula, A.
21
Jullien, G.
98
Julve, J.
58
Jung, J.H.
133, 135
Junior, J.
81
Junker, N.
69, 89
Juonala, M.
21, 105
Jurka, A.
85
K
Kaabachi, N.
114
Kächele, M.
50
Kagiadaki, C.
93
Kagimoto, S.
97
Kähönen, M.
21
Kahri, J.
37
Kaiser, A.
83, 88
Kaizuka, T.
68
Kajinami, K.
80
Kalayi, A.
127
Kaliya, O.
53
Kallel, A.
114
Kallend, D.
56
Kalousova, M.
97
Kalra, P.
2
Kaltsas, T.
147
Kalvelis, A.
136
Kamstrup, P.
108
Kan, S.
32
Kanai, H.
143
Kanbara, T.
48
Kanbay, A.
142
Kang, T.S.
133
Kangas, A.
21
Kanjuh, V.
120, 121
Kanonidis, I.
93
Kansal, V.
71
Kapanadze, K.
138
Kapelak, B.
82
Kapelouzou, A.
73
Kaplan, D.
85
Kapłon-Cieślicka, A.
122
Kaprio, J.
51
Kapsokefalou, M.
147
Karabina, S.
78
Karadag, Z.
142
Karányi, Z.
76
Karbaschian, N.
80
Karbaschian, Z.
40, 80
Karlson, B.
134
Karlsson, H.
38
Karlsson, L.
51
Karlsson, M.
34, 94, 103, 104, 107
166
Karolina, D.
100
Karper, J.
78, 81
Karras, S.
147
Kashanian, M.
97
Kashtanova, E.
81, 97, 108
Kasmas, S.
117
Kassi, E.
98
Kassner, U.
52, 64, 123
Kaste, M.
23
Kastelein, J. 38, 54, 55, 59, 94, 110, 112
Katagiri, T.
101
Katano, H.
125
Kathiresan, S.
33, 110
Kato, M.
143
Katra, B.
109, 141
Katsagoni, C.
98, 119, 121, 126
Katsiki, N.
98
Katsilambros, N.
124
Katus, H.
106, 147
Kauhanen, D.
21
Kawahara, T.
131
Kawai, H.
32
Kawai, Y.
80
Kaya, M.
142
Kayaba, K.
38
Kazanis, K.
98
Kedenko, I.
21
Kedenko, L.
21
Kei, A.
128, 136
Keller, C.
132, 135
Kelly, E.
59
Kenjaev Latipovich, M.
93, 127
Kenjaev Rashidovich, S.
93, 127
Kenjaev, S.
93
Keryttopoulos, P.
137
Kesäniemi, Y.
117
Ketelhuth, D.
13, 69, 79
Khabbazi, A.
144
Khalil, A.
55, 58
Khamashta, M.
71, 84
Khan, J.
139
Khan, S.
123
Khanna, G.
96
Khateeb, J.
73
Khattak, S.
141
Khorchfi, H.
Kiec-Wilk, B.
Kiene, V.
Kikas, P.
Kim, B.K.
Kim, C.J.
Kim, E.J.
Kim, H.-S.
Kim, J.
Kim, J.Y.
Kim, M.A.
Kim, M.K.
Kim, S.
Kim, S.E.
Kim, S.H.
Kim, S.M.
Kim, Y.K.
Kimber, C.
Kinoshita, M.
Kipshidze, N.
Kirichenko, T.
Kısacık, H.
Kiss, A.
Kita, T.
Kitabatake, A.
Kitagawa, T.
Kitaichi, T.
Kitayama, M.
Kitlinska, J.
Kjær, A.
Kjaer, A.
Klapp, B.
Kleber, M.
Kleber, M.E.
Kleemann, R.
Klein, A.
Klingenberg, R.
Klingvall, M.
Klop, B.
Klukvina, N.
Klungel, O.
Klymas, I.
Klyueva, N.
Knapp, A.
Knippschield, U.
167
114
52, 53
39, 86, 106
98
133
102
63, 65, 72, 82, 138
91
72, 82
133
99, 102, 122
119, 135
138
72
99, 122
52
65
110
114
133, 137, 139
128, 143
93
119, 122
39
39
48
48
80
104
87
138
123
101
69
118
80, 115
79
124
47, 82
86
126
43
104
52
51
Knipse, A.
102
Knoblauch, H.
64
Ko, Y.G.
135
Koba, S.
101
Kobayashi, H.
60
Kobayashi, K.
60, 83
Kobayashi, Y.
101
Köbling, T.
114
Koenig, W.
3
Köfeler, H.
147
Kohler, M.
74
Koistinen, K.
43, 95
Kokoreli, M.
118
Kolakovic, A.
97, 108, 127
Kolomvotsou, A.
120
Kolovou, G.
112
Komarov, A.
104, 114, 118
Konavalov, G.
70
Koncar, I.
97, 108, 127
Koneru, J.
107
Konik, A.
106
Konnov, M.
101
Kono, S.
66
Konrad, T.
48
Konstantinides, S.
73, 98
Kontush, A.
54, 55, 56
Kónya, G.
76
Kooistra, T.
118
Koos, R.
99
Korbut, R.
75, 82
Kornic, D.
49
Koroleva, O.
114
Korth, R.M..
116
Kortz, L.
64
Korzhenevskaya, K.
83
Kosenkov, Y.
80
Koshiyama, H.
97
Kosmas, N.
42
Kostakis, A.
73
Kostapanos, M.
40, 43, 65, 118, 124
Kostareva, A.
74
Kostic, M.
49
Kostogrys, R.
83
Kostopoulos, C.
137
Kostyreva, M.
130
Kotani, K.
59, 122
Kotova, O.
88
Kotur-Stevuljevic, J.
49
Kougialis, S.
42
Koutelidakis, A.
147
Kovanen, P.
19, 22, 26, 28, 50, 54, 55
Kovář, J.
33, 41
Kozarenko, A.
111, 137
Kozarova, R.
96
Koziolova, N.
95, 143
Kralova Lesna, I.
113
Kraml, P.
142
Kratky, D.
50
Krauss, R.
37
Krettek, A.
73
Krievina, G.
85
Kriki, P.
98
Kristensen, J.
26
Kristiansen, J.
103
Krivmane, B.
102
Krogh-Sørensen, K.
111, 124
Kronenberg, F.
21
Krotin, M.
87, 98, 99, 144
Kroupa, O.
112
Kruglyakov, P.
136
Kruth, H.
43
Krutikov, A.
136
Krylov, A.
136
Kučinskienė, Z.
66
Kuharchuk, V.
80
Kühn, H.
130
Kühnast, S.
57
Kuiper, J.
78
Kuipers, F.
35
Kuivenhoven, J.A.
26
Kulikov, I.
108
Kumar, S.
97
Kumar, V.
96
Kume, N.
97
Kumon, Y.
89, 102
Kundalic, B.
98
Kundalic, S.
98
Kurata, M.
89
Kurdi, M.
99
Kurobe, H.
48
168
Kurochkin, I.
Kuryata, O.
Kusachi, S.
Kusano, J.
Kusano, K.
Kusters, D.
Kvien, T.
Kwok, S.
Kwon, B.
Larroque, P.
Larsson, L.
Larsson, M.
Larsson, T.
Laskar, A.
Lasunción, M.
Lati, Y.
Latkovskis, G.
Latysheva, N.
Laufs, U.
Laurindo, F.
Lauro, R.
Lazarev, I.
Lázaro, I.
Le Couteur, D.
Le Goff, W.
Le Guern, N.
Lebrun, S.
Lechleitner, M.
Lee, B.
Lee, H.L.
Lee, J.
Lee, K.J.
Lee, M.O.
Lee, S.P.
Lee, W.J.
Lee-Rueckert, M.
Lefrandt, J.
Lehtimäki, T.
Leiter, L.
Leitinger, N.
Leitner, E.
Lejnieks, A.
Lekakis, J.
Lemaire-Ewing, S.
Lenicek, M.
Leonarduzzi, G.
Lepedda, A.
Lepperdinger, G.
Leroux-Coyau, M.
Leroyer, A.
Lesná, J.
Lesnik, P.
Lettesjö, H.
Levin, M.
111, 146
78, 80, 136
97
114
97
38
134, 135
112
82
L
La Vallee, R.
45
Laaksonen, R.
21, 95, 108
Laatikainen, R.
21
Labbé, J.
80
Labbé, S.
9
Labrie, F.
94
Lachaux, A.
33, 64
Lacorte, J.M.
39, 89
Lacoste, E.
142
Laffargue, M.
53, 79
Lagarde, M.
64
Lagrost, L.
35, 45, 63, 80, 115, 147
Lahera, V.
119
Lahl, K.
79
Lahoz, C.
126
Lai, F.
124
Lai, N.
47
Lalloyer, F.
35, 90
Lamaze, C.
50
Lambert, G.
8, 44
Lamerichs, R.
147
Lamina, C.
21
Landmesser, U.
38
Landray, M.
17
Langslet, G.
38, 132
Lanigan, J.
118, 126
Lanska, M.
93
Lanska, V.
113
Lappalainen, J.
50
Lappegård, K.T.
138
Larina, V.
137
LaRosa, J.
94, 112, 134, 135
Larose, E.
25
169
61
54
44
43, 51
141
114
73
102
76
119, 125
46
83
143
46, 100
40
55
80
74, 75, 77
147
82
99, 122
82
135
22
91
72
50, 55
58, 100
21, 108
134
34
32
136
120
115
33
64
39
80
80
35
48
26
78
44, 89
Levine, M.
Levisianou, D.
Levula, M.
Levy, É.
Lévy, P.
Lewis, M.
Lhomme, M.
Li, C.
Li, D.
Li, K.
Li, L.
Li, M.
Li, N.
Li, S.
Li, W.
Li, Z.
Liakos, G.
Liangwei, Z.
Liao, D.
Libby, P.
Liberopoulos, E.
Licis, N.
Liebisch, G.
Liebscher, F.
Lien, L.M.
Liepins, E.
Liepold, E.
Lietz, M.
Lim, H.E.
Lim, S.Y.
Lima, A.
Lima, M.
Limuris, A.
Lin, J.
Lin, S.J.
Lin, S.Y.
Lindahl, M.
Lindén, C.
Ling, B.
Linsel-Nitschke, P.
Lip, G.
Lisii, D.
Littlewood, T.
Liu, B.
Liu, H.
Liu, J.C.
Liu, L.
Liu, M.L.
Liu, P.
Liu, Q.
Liu, Y.
Liu, Z.
Ljunggren, Ö.
Ljunggren, S.
Llaverias, G.
Lo, Nigro, A.
Lochner, A.
Locsey, L.
Lőcsey, L.
Lohmann, C.
Lohovinina, N.
Lomakovskyi, O.
Loncar, S.
Long, G.
Lookene, A.
Lopez Bescos, L.
Lopez, L.
Lopez-Juarez, E.
Lopez-Miranda, J.
Lopez-Pedrera, C.
Loppnow, H.
Loriga, G.
Loued, S.
Lourenço-Filho, D.
Louwe, M.
Low, S.
Lowe, R.
Löwik, C.
Lozano, T.
Lu, C.
Lu, E.
Lucas, A.
Łuczyński, W.
Lüdde, M.
Ludew, D.
Lugovaya, A.
Lund, S.
Lundberg, A.
Lundberg, J.
Lundbom, J.
134
42
108
60
79
125
55, 56
73
81
50
43, 89
69
124
111
141
54, 125
120
98
111
19, 25
40, 49, 65, 128, 136
102
9, 69
58
96
102
27, 120
74, 75, 77
63, 65, 82
63
102
81
129
39, 40, 64, 134
90
76, 111
38
103, 104, 107
129
110
101, 113
95
8
43, 89
13, 87
170
119
26
73
47
52, 124
62, 63, 73, 112
52
94
38
58
88
71
76
59, 61
79
83
86
122
129
44
79, 139
60, 64, 83
107
38, 82
71, 84
70
66
55
133
57
118, 126
39, 64
70
145
104
43, 89
118, 126
135, 136
112
75, 82
83
37
44, 45, 69
46
37, 141
Lundbom, N.
Lunde, K.
Lundman, P.
Lundqvist, A.
Luo, L.
Luo, X.
Lupu, S.
Lüscher, T.
Lütjohann, D.
Lyakishev, A.
Lyytikäinen, L.-P.
Mak, V.
Makarenkova, K.
Makarova, M.
Makharova, N.
Makita, S.
Makoveichuk, E.
Maksimenko, A.
Maksimov, V.
Maksimova, M.
Maksimovic, J.
Maksimovic, M.
Malchinkhuu, M.
Malecki, M.
Málek, F.
Maleki, S.
Malet, N.
Malgina, E.
Malli, R.
Mallika, V.
Malo, E.
Malynovska, I.
Malyutina, S.
Mancera, J.
Mandapathil, M.
Mandolini, C.
Mandrup-Poulsen, T.
Manduteanu, I.
Manea, A.
Manea, S.
Mangas, A.
Mangeri, E.
Mangili, L.
Mangili, O.
Mankeshwar, R.
Mann, G.
Mann, K.
Mann, N.
Manolopoulos, V.
Manolov, D.
Mansharipova, A.
Mantesso, A.
Marais, D.
Maranhão, R.
Maraslis, S.
Marçais, C.
37, 141
70
134
34
125, 127
65
65, 143
25, 79
119, 125, 126
101
108
M
Maas, M.C.E.
Maccubbin, D.
Machado-Lima, A.
Maciocia, P.
Mackness, B.
Mackness, M.
MacMahon, Z.
MacRae, C.
Madsen, M.
Madsen, Svarrer, E.
Maeda, T.
Mæhre, H.
Maerz, W.
Maffeis, C.
Magaña, T.
Magedanz, A.
Maggioli, E.
Maglio, C.
Magne, J.
Magnolo, A.
Magnussen, C.
Magnusson, L.
Magour, G.M.
Mahajan, N.
Mahjoub, S.
Mahmoud, M.
Mahnken, A.H.
Maierhofer, S.
Maiwald, S.
Majd, Z.
Majkic-Singh, N.
61
41
51, 58
84
57
57, 85
48
35
69
94
114
118
101
40
109
135
86
14, 131
112
109
21, 105
34
145
84
108
145
99
134
116
35
86
171
41
42
60
145
92
44
77
129
130
127
127
41
109
50
73
79
95
34
85, 97
117
129
42, 80, 105
101
83, 88
73
14
72, 83
71, 74, 90
74, 90
74, 95, 106, 114
91
52
52
92, 109
118
72
35
115
50
73
63
44
52, 62, 130, 133
128
33
Marchetti, A.
73
Marchioli, R.
10
Marenzi, G.
92
Margelli, M.
42
Marie, C.
115
Marimon, F.
141
Marìn, B.
109
Marin, C.
38, 82
Marinkovic, J.
122, 127
Marino, A.
83
Marino, F.
127
Markovic-Lipkovski, J.
121
Markwell, K.
27, 120
Marotta, G.
38
Marousi, S.
115
Marquart, J.
116
Marraccini, P.
96
Marsche, G.
54
Marsillach, J.
57
Martiadou, K.
93
Martin, C.
143
Martin, F.P.
75
Martínez, A.
108
Martìnez, E.
109
Martinez, L.
53, 79
Martinez, N.
118
Martín-Fuentes, P.
57, 112
Martin-Paredero, V.
85
Martirosyan, D.
60
Marx, N.
99
März, W.
23, 26, 69
Masana, L. 12, 26, 46, 96, 100, 107, 110
112, 143
Masenko, V.
80, 87
Maseri, A.
88
Mashimo, Y.
114
Masoudi, Kazemabad, A.
113
Masoura, K.
91, 125, 129
Massa, E.
98
Massaad, R.
48
Massó-González, E.
94
Masson, C.
117
Masson, D.
63, 80
Mata, K.
81
Mata, N.
140
Mata, P.
Mateescu, R.
Mateo-Gallego, R.
Mateuszuk, Ł.
Mathew, O.
Mathieu, P.
Matowicka-Karna, J.
Matsumoto, T.
Matsunami, Y.
Matsushita, K.
Matsushita, S.
Matsuura, E.
Matsuzaki, M.
Matsuzaki, Y.
Matsuzawa, Y.
Mattar, M.
Mattner, F.
Mattsson Hultén, L.
Matusik, P.
Maucci, R.
Maynes, L.
Mazer, N.
Mazzarisi, A.
McCartan, S.
McCarthy, M.
McEneny, J.
Mcginty, A.
McGinty, A.
Mcgown, A.
Mechmeche, R.
Medbury, H.
Medeiros, A.
Medvedeva, E.
Meguro, Y.
Mehri, S.
Meijer, L.
Meijers, J.
Meiler, S.
Melander, O.
Mellström, D.
Melo, E.S.
Mendes, M.
Mendez, P.
Méndez-Contreras, C.
Méndez-González, J.
172
140
143
37, 57, 118, 126
83
55
60
93
48
60, 83
82
38
60, 64, 83
39
114
39
119
131
22, 89
75
137
53
55
96
67
26
56, 67, 97, 117
56, 97
67
97
108, 114
87
39, 48
137
101
105, 108, 114
117
116
147
37, 91, 96, 106
94
122
42
132
133
58
Ménétrier, F.
Menghini, R.
Menini, T.
Mennander, A.
Menown, I.
Menrad, H.
Mensink, R.
Merantzi, G.
Mercer, C.
Mercer, J.
Merculov, E.
Merculov, U.
Merculova, D.
Mereuta, A.
Merino, J.
Merkel, M.
Merono, O.
Mesens, S.
Metaxa, V.
Metelskaya, V.
Méthot, J.
Metso, J.
Metspalu, A.
Meunier, N.
Meydani, S.
Meyer-Sabellek, W.
Mezzetti, A.
Miarka, P.
Miccoli, R.
Michelsen, A.
Michoel, T.
Mieno, M.
Miettinen, H.
Miettinen, T.
Miglietta, D.
Mijatovic, A.
Mika, P.
Mikelsone, I.
Mikhailidis, D.
Mikołajczyk, M.
Mikołajczyk, T.
Milani Moghaddam, N.
Milardo, C.
Milionis, H.
Miliou, A.
Millán, J.
Milovanovic, B.
Miltiadous, G.
Min, P.K.
Minami, M.
Mingpakanee, R.
Minichilli, F.
Minushkina, L.
Mirarefin, M.
Mirjafari, H.
Miron, A.
Mironova, D.
Miroshnichenko, A.
Miroshnikova, V.
Mistrik, E.
Mitjavila, M.
Mitra, A.
Mitrofanova, L.
Mitrogianni, Z.
Mitrousi, K.
Miura, S.I.
Miyazawa, T.
Miyoshi, T.
Mobini, R.
Mocan, T.
Moebus, S.
Moerland, P.
Mogensen, C.
Mohammad, B.
Mohammadpour, A.H.
Möhlenkamp, S.
Möhring, M.
Moiseeva, O.
Moisenovich, M.
Mojarrad, M.
Molin, D.G.M.
Molinaro, A.
Mollnes, T.E.
Mombelli, G.
Monaco, C.
Mondejar, D.
Monier, S.
Monteiro, A.
Monteiro, C.
Monteiro, L.
80
83
59
108
138
88
59, 117, 126
98
67
28, 96
87
128
128
84, 95
96, 126, 143
14, 38
92
137
91, 125, 129
92
9, 26
55
112
72
82
106
73
141
135
111, 124
73
38
117
117, 133
132
46
106
85, 146
105
53
75, 82
115
48
40, 43, 124
91, 129
173
45, 119
98
66
133, 135
132
63
41
108
140, 145
65
123
143
78, 136
62
97
118
13
130
43
98
57
61, 66
97
43
65, 143
72, 104, 110
116
8
132, 135
115
72, 104, 110
75
77
77
113
141
14
138
21
13, 125
120
115
63, 86
86
122
Monticolo, R.
Moohebati, M.
Moore, X.L.
Mora, S.
Morais, G.
Moreau, P.
Moreira, F.
Morelli, M.
Moreno, R.
Moreno, T.
Moret, M.
Moriarty, P.
Morozov, I.
Morris, A.
Morrone, D.
Morrow, D.
Mörtstedt, H.
Moser, M.
Mosimann, K.
Mossiat, C.
Mostashfi, A.
Motazacker, M.M.
Motevalli, M.
Motoki, T.
Motoyama, A.
Mouka, E.
Moulin, P.
Moura, F.
Mourali, M.S.
Moutzouri, E.
Mozos, I.
Mpilinis, H.
Mrazek, F.
Mrda, D.
Mudau, M.
Muendlein, A.
Mühleisen, T.
Muid, S.
Mukhamedova, N.
Mulder, D.
Mulders, T.
Muller, C.
Müller, M.
Müller-Nordhorn, J.
Müller-Werdan, U.
Muncy, I.
Munkhzol, M.
Muñoz-Pacheco, P.
Murata, K.
Murayama, T.
Murillo, S.
Musil, F.
Mutch, W.
Myarina, L.
Myasoedova, V.
Myhre, S.
Myhrstad, M.
Mysliwiec, M.
Mytrokhina, O.
81
100, 113
56
55
42
60
117
23
117
50, 101
64
65, 145
52, 53, 60
110
39, 64
75
38
76
74
115
140, 145
110
144
48
80
42
33, 64
58
114
40, 43, 128
143
42
115
144
71
103, 113
110
78
60
58, 100
116, 133, 144
61, 65
139
106
70
64
136
85
114
132
43
48
120
145
128, 143
45
67
74, 76
78
N
Na, J.O.
Na, T.Y.
Nabrozidis, A.
Nachabe, R.
Nachtigal, P.
Nadaraia, K.
Nadeem, N.
Nafi-Valencia, E.
Nagai, M.
Nagamine, T.
Nagao, M.
Nagy, E.
Nahum, S.
Nair, D.
Najah, M.
Nakagawa, K.
Nakahara, K.
Nakajima, K.
Nakajima, Y.
Nakamura, K.
Nakamura, M.
Nakamura, Y.
Nakandakare, E.
Nakanishi, N.
Nakano, K.
Nakano, T.
Nakaya, N.
Nakayama, T.
174
63, 65, 82
22
140
147
49, 84, 85
133, 137
117
43
92
49
61
87
113
105, 133
109
61, 66
38
49
61
97
92
97, 105
46, 51, 58, 59
56
68
49
39
48
Nakiri, K.
Napieralski, R.
Naruse, H.
Naruszewicz, M.
Nasonov, E.
Nathwani, R.
Naukkarinen, J.
Naumov, V.
Navarra, T.
Navin, T.
Navis, G.
Nawawi, H.
Nazemi, S.
Nedelcu, L.
Nederveen, A.
Neff, D.
Nefyodova, E.
Negrean, V.
Nègre-Salvayre, A.
Neil, A.
Nejatpour, S.
Nemati, M.
Nemes, A.
Netterstrøm, B.
Neureiter, D.
Neužil, P.
Newby, A.
Newby, A.
Newman, J.
Neyestani, T.
Ngo, J.
Nguyen, S.
Nicholls, S.
Nicholson, J.
Nicoll, R.
Niculescu, L.
Nie, P.
Nielsen, B.
Nielsen, L.
Nielsen, L.B.
Nielsen, M.
Nielsen, S.
Niemeier, A.
Nieminen, M.
Nienhaus, U.
Niesor, E.
56
Niessen, H.
70
Nikitin, A.
108, 114, 115
Nikitin, Y.
42, 80, 105
Nikolaev, K.
102
Nikooyeh, B.
127
Nikopensius, T.
112
Nilsson, A.
67
Nilsson, B.
70
Nilsson, J.
13, 31, 71, 88, 96, 124
Nilsson, M.
124
Nilsson, S.
44, 79
Ninio, E.
78
Ninkovic, N.
87, 144
Nishihira, K.
73
Nishikawa, M.
131
Nissen, S.
54, 55, 59
Nissilä, E.
9
Nissinen, M.
117
Nitulescu, M.
124, 139
Niżankowski, R.
106
Njo, T.
82
Nobili, E.
130
Noble, D.
120
Noda, K.
136
Nofer, J.R.
20, 53
Nohtomi, K.
56
Nolasco-Coleman, A.
107
Norata, D.
109
Norata, G.
76, 85, 88, 91
Nordestgaard, B. 15, 20, 26, 31, 100, 105
108, 110
Nordzell, M.
78
Northstone, K.
118
Nosalski, R.
75, 82
Nose, M.
89
Nosikov, V.
108, 111, 114, 115, 146
Nosratinia, H.
144
Nöthen, M.
110
Noto, D.
44, 109
Novakovic, R.
121
Noveanu, L.
143
Novials, A.
43
Novikov, A.
41, 142
Novikova, D.
41, 86, 142
42
130
32
119, 122
41, 86, 142
122
51
80
96
13
94
78, 120
115
123
141
40
8
102
61, 65
133
103
144
102
103
81
50
26
13, 19
130
127
87
54
4, 54, 55, 59, 134
125
135
55
81
37
14, 20, 60, 89
16, 69, 94
103
60
14
141
50
175
Novikova, I.
Nowak, W.
Nowobilski, R.
Ntzani, E.
Nucci da Silva, L.
Numakura, M.
Nunes, V.
Nuñez, E.
Núñez, I.
Nuñez-Cortes, J.
Nyman, K.
Olivecrona, G.
44, 112
Oliveira, E.
51
Oliveira, J.
115
Olivero, R.
121
Olkkonen, V.M.
9, 69
Olofsson, S.O. 14, 24, 37, 43, 44, 45, 51
73, 89
Olsson, C.
51
Olvera-Hernandez, V.
120
Omar, E.
120
Omata, K.
143
Omerovic, E.
46, 144
Ong, T.
88
Oniki, K.
57
Öörni, K.
22, 54, 79
Opolski, G.
122
Opstad, T.
91, 116
Ordonez, F.
103, 104
Ordoñez, F.J.
57
Ordovas, J.
82
Oregon-Miranda, A.
64
Orekhov, A.
48, 52, 53, 60, 71, 77, 128
Orekhova, E.
48
Orellana, R.
63
Orho-Melander, M.
37
Origasa, H.
39
Orlova, E.
80
Ortega-Alonso, A.
51
Ortega-Hernández, A.
85
Ortmann, J.
59, 107
Orwoll, E.
94
Osada, K.
68
Ose, L.
30, 38, 132
Oskolkova, O.
67
Osmolovskaya, V.
115
Ostanek, L.
113
Ostanek, M.
113
Öste, R.
126
76
112
106
118
128
114
58
57
138
80
141
O
Obeid, O.
Odkhuu, E.
Offerman, E.
Offidani, A.
Oguma, K.
Ogunleye, O.
Ogura, M.
Oh, D.J.
Ohguro, T.
Ohlsson, C.
Ohno, M.
Ohno, S.
Ohota, M.
Ohro-Melander, M.
Ohwaki, K.
119
136
61
65
83
129
82
63, 65, 82
102
73, 94
125
60
32
37
21
Ø
Øie, E.
124
O
Oikawa, S.
Oikonomou, E.
Oka, Y.
Okajima, F.
Oksala, N.
Okuda, L.
Okumura, M.
Okura, T.
Oleaga, A.
39, 61, 66
91, 125, 129
66
61, 66
108
46, 59
32
89
143
Ø
Østerud, B.
176
118
Park, A.
53
Park, C.G.
65
Park, H.E.
119
Park, J.
60, 82
Park, K.H.
60, 61, 135
Park, K.Y.
124
Parl, C.G.
63, 82
Parlevliet, E.
9
Parnell, L.
82
Parra, E.
85
Parra, S.
141
Partigulova, A.
80
Parving, H.H.
37
Parzonko, A.
119
Passarelli, M.
46, 51, 58, 59
Pasterkamp, G.
21, 22, 89
Pastori, D.
91
Patel, J.
113, 134
Patiakas, S.
41, 42, 123
Paul, J.L.
50, 51
Pauletto, P.
88
Paulsson-Berne, G.
45
Paulweber, B.
21
Pavão, M.L.
102
Pavlov, L.
145
Pavone, N.
23
Pawlak, D.
74, 76
Pawlak, K.
74, 76
Paximadas, S.
103, 124
Paydar, R.
100
Peake, R.
120
Pechlivanis, S.
72, 110
Peco-Antic, A.
49
Pedersen, O.
37
Pedersen, S.
87, 138
Pedersen, T.
31, 69, 89, 112, 130, 134
135
Pederson, K.
133
Pedrelli, M.
54
Pedron, I.
128
Pego, L.
91
Pelegatta, F.
88
Pelisek, J.
130
Pello, E.
80
Peltonen, M.
131
O
Östling, G.
Ostojic, M.
Ostolaza, H.
Othman, A.
Ottestad, I.
Ozaki, Y.
Ozdogru, I.
71
122
143
101
67
32
142
P
Packard, C.
3
Pacurari, A.
143
Padra, J.T.
59, 76
Paim, B.
51
Pais de Barros, J.P.
45, 80, 115
Palacio-Olmos, L.
93
Palacios, L.
143, 145
Palasz, A.
41, 68
Palini, A.
85, 88
Palmer, C.
110
Palmer, M.
134
Palmer, T.
105
Palmieri, D.
83
Palombo, D.
83
Panafidina, T.
86
Panagiotakos, D. 98, 118, 119, 121, 126
Panagoutsos, S.
98
Panáková, D.
35
Panchenko, E.
104, 114, 118
Pane, B.
83
Pang, J.
9
Pankajakshan, D.
71, 81
Panov, A.
83, 130
Pantea, I.
123
Panzoldo, N.
85
Papadaki, H.
137
Paragh, G.
59, 61, 76, 114
Pardo, P.
84, 113
Paredes, C.
80
Parhofer, K.
18
Parhofer, K.G.
131
Parini, P.
46, 54, 89
Parizadeh, S.M.R.
100
177
Pemberger, E.
Pena, C.
Pendleton, S.
Peng, C.
Peng, Q.
Pentikäinen, M.
Pépin, J.L.
Peppes, V.
Peralta, M.L.
Peretti, N.
Pereyra, A.
Perez-Calahorra, S.
Perez-Jimenez, F.
Perez-Martinez, P.
Perez-Sanchez, C.
Perisa, D.
Perk, J.
Perkins, R.
Perman, J.
Perret, B.
Persaud, J.
Persson, A.
Persson, L.
Perttilä, J.
Peter, J.
Peter, K.
Petersen, C.
Petrek, M.
Petrischev, N.
Petrkova, J.
Petrova, S.
Petrus, J.
Pettersen, A.Å.
Pettersson, K.
Pfaffelhuber, P.
Pfister, P.
Phillips, C.
Phrawisat, Y.
Pierce, G.
Pieterman, E.
Pietiläinen, K.
Piffaretti, G.
Pignatelli, P.
Pijl, H.
Pikhart, H.
Pikkemaat, J.
147
Pilipcincova, A.
104
Pillai, K.K.
96
Pillois, X.
45
Pilz, S.
101
Pinelli, L.
40
Pinheiro, L.
86
Pinheiro, L.F.
82
Pinna, C.
76
Pinna, M.
67
Pinotti, E.
44, 109
Pintio, R.
51
Pinto, A.L.
56
Pinto, R.
51
Pinto-Sietsma, S.
116, 133, 144
Piotrowska-Jastrzębska, D.
135
Pirazzi, C.
14, 131
Piredda, F.
39, 125
Pirro, M.
48
Pirvulescu, M.M.
72
Pisanu, E.
67
Pisciotta, L.
109, 110
Pitha, J.
104
Pitkälä, K.
133
Pitsavos, C.
91, 125, 129
Pitta, I.
81
Plana, N.
96, 110, 112, 126, 143
Plat, J.
59, 126
Plihtari, R.
22
Plomgaard, P.
60
Ploug, T.
14
Plovie, E.
35
Pock, K.
94
Pocoví, M.
51, 110
Pokrovsky, S.
70, 72, 101
Pola, R.
110
Poledne, R.
33, 41, 104
Polek, A.
93
Poli, G.
64
Polikarpov, L.
102
Politi, M.
66
Polonskaja, Y.
81, 97
Polonskaya, Y.
108
Polus, A.
53
Polydorou, A.
42
58
68, 95
48
131
65
141
79
112
79, 139
33, 64
132
118
38, 82
38, 82
71, 84
62
10, 38, 94
43, 45
14, 51, 87
53
105
124, 139
46, 49
9
110
32
42
115
83
115
145
50
91, 116
78, 81
49
132, 137
47
63
45, 81
61
51
127
91
9
104
178
Polyntsev, D.
Ponde, C.
Pons, V.
Poon, E.
Pop, D.
Pope, A.
Popkova, T.
Popovic, M.
Popovic-Lisulov, D.
Porcu, P.
Postadzhiyan, A.
Postnov, A.
Poti, F.
Potluri, R.
Potockova, J.
Pott, A.
Potteaux, S.
Poulter, N.
Pounis, G.
Pourghadamyari, H.
Povoa, R.
Powell, L.
Powell, S.
Prada, G.
Prada, S.
Pragliola, C.
Pramfalk, C.
Prat, A.
Preston, G.
Princen, H.
Priscu, O.
Prkačin, I.
Profumo, E.
Prokazova, N.
Prokop, M.
Protic, D.
Prudente, P.
Prüfer, J.
Prusikova, M.
Pshenichnaya, A.
Pshezhetsky, A.
Puato, M.
Puntoni, M.
Puras, E.
Pushkov, A.
Pustovalova, O.
Pütz, G.
Pysz, P.
136
92
53
41
99
111
41, 86, 142
127
87
125
96, 97
71
20, 53
92
142
50
8
131
147
100
101
67
145
68, 95
68, 95
23
46
33, 95
94
54, 57, 61
95
63, 77, 107
81
53
144, 146
120
81
82
113
104
48
88
41, 42, 55, 56
79, 139
114, 115
77
48, 49, 52
142
Q
Qayyum, A.
Qiu, J.
Quan, N.
Quax, P.
Quinaglia e Silva, J.
Quintero, P.
20
65, 68, 87
60, 83
70, 78, 81, 89
91, 126
35
R
Rabès, J.P.
Rached, F.
Radak, D.
Radermacher, M.
Radke, P.
Radovanovic, S.
Radovic, B.
Radulescu, F.
Radunovic, N.
Ragia, G.
Ragino, Y.
Rahim, A.
Rahsepar, A.
Raicu, M.
Raiko, J.
Raitakari, O.
Raitoharju, E.
Raivio, T.
Rajani, R.
Rajappa, M.
Rallidis, L.
Ramey, D.
Ramires, J.
Ramìrez, L.
Ramonda, R.
Ramos, S.
Råmunddal, T.
Randell, E.
Ranganna, K.
Ranheim, T.
179
33
55, 56
97, 127
50
83, 88
87, 98, 99, 144
50
85
120
115
81, 97, 108, 130
43
100
71, 90
21
21, 105
108
51
92
97
120
40
91
109
88
81, 117
46
111
55
46, 124
Ras, R.
117
Rashedi, N.
59
Rashtchizadeh, N.
62
Rathcke, C.
124
Rathke, N.
50
Rathouska, J.
49, 84, 85
Ratnikova, L.
92
Rato, Q.
49
Rattazzi, M.
88
Räty, J.
108
Raud, J.
74
Rausche, T.
112
Ravani, A.
139, 141
Ravn-Haren, G.
67
Ray, K.
26
Raz, O.
84
Razuvaev, A.
74
Reboulleau, A.
51
Recarte, C.
45, 119
Recasens, L.
92
Reddy, S.
62
Redmond, E.
75
Rehan, M.
120
Reihmane, D.
85
Rein, P. 39, 41, 59, 86, 103, 104, 105, 106
107, 113
Reiner, Z.
26, 31
Reinhardt, C.
75
Reis de Azevedo, F.
122
Reitinger, S.
80
Relvas, M.
42
Remer, I.
78
Renouf, J.
111
Rensen, P.
9, 35, 54, 57
Resende, E.
76
Resende, L.
76
Retterstøl, K.
38, 67, 132
Revnic, C.
84
Revnic, C.R.
68, 95
Revnic, F.
68, 84, 95
Reyland, M.E.
61
Rezende, V.
117
Rha, S.W.
63, 65, 82
Ribalta, J.
43, 141
Ribas, N.
92
Ribeiro, F.
Ribeiro-Pillet, A.
Riccardi, G.
Richards, C.
Richter, D.
Rico, M.
Riederer, M.
Riestra, P.
Rietveld, A.
Rietzschel, E.R.
Riganò, R.
Rikk, J.
Rioja, J.
Rios, F.
Ripoll, P.J.
Rissanen, A.
Ristic, T.
Ritsema, T.
Rivas, G.
Rivellese, A.
Rivlin, Y.
Rizos, C.
Rizos, E.
Robciuc, M.
Robenek, H.
Robert, V.
Robertson, A.K.
Robertson, I.
Robertson, L.
Rocchiccioli, S.
Rocco, D.
Rocha, M.
Röcker, C.
Rodrigues, R.
Rodriguez, Artalejo, F.
Rodriguez, C.
Rodríguez, E.
Rodriguez, Leal, C.
Rodriguez, M.A.
Rodriguez-Ariza, A.
Rodriguez-Cantalejo, F.
Rodriguez-Hernandez, A.
Rodriguez-San, Pedro, I.
Roever, L.
Rogava, M.
180
115
89
31
78
147
49
34, 147
114
82
26
81
136
101, 140
13
80
51
98
108
92
135
115
49, 128, 136
118
51, 55
43, 52
51
69
119
105
56
59
63, 92, 127
50
108
94
95, 106
113
74
80
71, 84
82
120
140
76
138
Rogero, M.
68, 122
Roggenbuck, U.
104
Rogowski, O.
84, 102
Rohde, C.
56
Rohrer, L.
62
Röhrl, C.
58
Romano, M.
38
Romaschenko, A.
129
Romeo, S.
14, 131
Romero, C.
80
Romero, P.
80
Romero-Mateos, I.
93
Romijn, J.
9, 54
Romosan, I.
143
Rompelberg, C.
126
Rompolas, G.
93
Ros, E.
16, 37, 51, 110, 112, 118, 138
Rosado, P.
140
Rosengren, A.
27
Rosengren, B.
57
Rosenschein, U.
115
Rosenzweig, A.
35
Rosety, I.
57, 103, 104
Rosety, J.
57
Rosety, M.
103, 104
Rosety, M.A.
57
Rosety-Rodriguez, M.
57, 103, 104
Rosic, M.
72
Rosinger, S.
23
Rothenberg, E.
5
Rotllan, N.
55
Roughton, M.
133
Rouleau, A.
55
Rousset, M.
89
Rovella, V.
83
Roy, J.
74
Rozikhodjaeva, F.
142
Rozikhodjaeva, G.
129, 145
Ruan, C.
125
Rubba, P.
38
Rubin, D.
112
Rubio, J.S.
80
Rubtsov, P.
52, 53, 60
Rudd, J.
19
Rudel, L.
54
Rudling, M.
26, 37, 40, 46, 49, 79, 121
Rudnicki, M.
81, 88
Rudymov, E.
52, 60
Ruebel, A.
43
Ruidavets, J.B.
53
Ruilope, L.M.
106
Ruilope-Urioste, L-M.
93
Ruisinger, J.
145
Ruiterkamp, G.
26
Ruiz, M.
128
Ruiz-Limón, P.
71, 84
Ruland, H.
50
Rull, A.
57, 84, 85, 113
Rupinski, R.
93
Russell, D.
111
Rutberg, M.
43
Rutten, A.
144, 146
Rutter, M.
112
Rütti, M.
101
Rye, K.A.
44
S
Saad, A.
65
Saadat, S.
104
Sabbadini, M.
85
Sabour, S.
144, 146
Saely, C.
39, 41, 59, 86, 103, 104, 105
106, 107, 113
Safarova, M.
70, 72, 101
Saffarian, N.
146
Sagan, A.
75
Sagiv, M.
115
Sahebkar, A.
100
Sahlawi, M.
132
Saiid, T.
55
Saint-Just, S.
89
Sainz, A.
92
Sainz-Gutiérrez, J.C.
93, 106
Saito, C.
81
Saito, I.
100
Saito, R.
80
Saito, Y.
21, 29, 39
Sajjan, S.
40
Sakantamis, G.
93
181
Sakata, T.
Saku, K.
Salas-Salvadó, J.
Sala-Vila, A.
Salekzamani, S.
Salomaa, V.
Salvayre, R.
Samokhin, A.
Samovilova, N.
Sampietro, A.
Sampietro, M.
Sampietro, T.
Samson-Bouma, M.E.
Samuel, A.
Samuel, N.
Sanak, M.
Sanchez, C.
Sanchez, G.
Sanchez, R.
Sánchez-Chaparro, M.Á.
Sánchez-Muniz, F.J.
Sánchez-Pérez, M.R.
Sánchez-Reus, M.I.
Sanda, G.
Sandstedt, K.
Sanna, M.
Sansaro, D.
Santaniemi, M.
Santos, A.
Santos, C.
Santos, D.
Santos, S.
Santos, T.
Santovito, D.
Sanz-Martín, C.
Saougos, V.
Saponjski, J.
Sartori, C.
Sasaki, J.
Sassolas, A.
Sata, M.
Sato, H.
Sato, T.
Sato, Y.
Satsoglou, E.
Satta, A.
Saukko, M.
Savic-Radojevic, A.
Savolainen, M.
Savopoulos, C.
Sawabe, M.
Sawant, A.
Sawayama, Y.
Sawicki, M.
Sazonova, M.
Sberna, A.L.
Sbrana, F.
Scanu, B.
Scarneciu, C.
Scharin Täng, M.
Scharnagl, H.
Scheja, L.
Schembri, L.
Schepers, A.
Scherag, A.
Scherer, T.
Schewe, T.
Schillizzi, M.
Schirmer, S.
Schlitt, A.
Schlueter, M.
Schmermund, A.
Schmid, M.
Schmid, T.
Schmidt, A.
Schmidt, C.
Schmidt, W.
Schmiedtová, M.
Schmitz, G.
Schneider, W.
Schnohr, P.
Schou, J.
Schreier, S.
Schrezenmeir, J.
Schröder-Van derElst, J.
Schuchardt, M.
Schueller, J.
Schultz, A.
Schunkert, H.
Schvarzman, A.
39
57, 136
100
37, 138
127
133
61, 65
120
53
44
81
41, 42, 55, 56
33
107
139
109, 141
79, 139
128
132
93, 101, 106
121
101
121
63, 66
86
67
139, 141
117
86
46
58
91, 126
39, 49
73
106
99
144
51
39, 66
33, 64
48
82
101
73, 82
98, 128
182
66
117
87, 99
21
98
38
109
144
113
71
63
41, 42, 55, 56
67
123
144
58, 140
51
127
78
110
51
48
91
125
70
96
135
84
88
58
103
131
41
9, 52, 69
21
100
20, 110
58
112
9
82
74
121
110
62
Schwandt, P.
27, 120
Schweitzer, P.
134
Schwerz, V.
99
Seabra, M.
42
Sediri, Y.
114
Seed, M.
133
Seferovic, J.
86
Segre, C.
62
Seidah, N.
33, 95
Seidlerová, J.
94
Sekita, Y.
73
Seleznev, E.
137
Seljeflot, I.
70, 91, 116
Semb, A.
134, 135
Semenova, A.
87
Senchik, I.
136
Seng, K.
147
Seo, H.S.
65, 63
Seo, J.
62
Seo, J.B.
99, 122
Seog, H.S.
72, 82, 138
Seong, J.H.
133
Serban, C.
143
Seres, I.
59, 61, 76, 114
Sereti, S.
128
Sergienko, I.
87
Serrano, F.
80
Serrano, Jr, C.V.
56
Ses, T.
83
Sever, P.
131
Severs, N.
43
Sexton, D.
78
Shabalina, A.
130
Shah, A.
39, 40, 41, 47, 64, 134
Shah, S.
92
Shahin, Y.
139
Shakeri, Bavil, A.
144
Shakeri, Bavil, M.
128
Shakhmatova, O.
104, 114, 118
Shakhtshneider, E.
108, 129
Shalhoub, J.
125
Shalnova, S.
92
Shamoon, F.
107
Shams, I.
47, 58
Shand, J.
138
Shang, M.
Shao, Y.
Shapira, I.
Sharashkina, N.
Shariatzadeh, N.
Sharifi, F.
Sharifzadeh, F.
Sharma, I.
Sharma, P.
Sharma, S.
Shatunova, I.
Shchelkunova, T.
Shchukin, Y.
Sheludchenko, O.
Shen, J.
Shen, L.
Shenoy, A.
Shepherd, J.
Sheu, W.H.H.
Shibata, Y.
Shimada, K.
Shimomura, Y.
Shimoni, S.
Shiomi, M.
Shirato, K.
Shiri-Sverdlov, R.
Shishkin, S.
Shkolnikova, M.
Shlyakhto, E.
Shoenfeld, Y.
Shoji, M.
Shtegman, O.
Shulman, V.
Shumakov, V.
Shuumarjav, U.
Shyu, K.G.
Si, S.
Sialvera, T.E.
Siddiqi, S.
Siegrist, J.
Silbernagel, G.
Sillesen, H.
Silva, E.
Silva, F.
Silva, J.
183
73
46
84, 102
76
127
140, 145
97
84
77
77
143
52, 53, 60
137
128
82
60, 81, 83
74
132, 134
76, 111
73
39
49
140
75
39
54, 90
129
92
77, 136
83
101
102
102
129
122
96
46, 124
147
43
104
23, 26, 69, 101
87
141, 142
117
49
Silva, J.C.
Silva, N.
Silva, U.
Silvennoinen, R.
Silverman, S.
Sima, A.
Simic, D.
Simic, T.
Siminiak, T.
Simion, V.
Simionescu, M.
Simone, J.L.
Simonen, P.
Simonetti, O.
Simoni, M.
Simonova, G.
Simpson, W.
Simsone, Z.
Singh, B.
Singh, M.
Singh, N.
Singhal, A.
Sio, C.
Siow, R.
Sirén, R.
Sirtori, C.
Sisk, C.
Sitar-Taut, A.V.
Sivapalaratnam, S.
Sjöberg, B.
Sjöström, L.
Skålén, K.
Skalníková, V.
Skiba, D.
Skjelland, M.
Skogsberg, J.
Skopelitis, E.
Skoumas, I.
Skuja, I.
Slagman, M.
Slanarova, M.
Slimene, N.
Sliwa, A.
Slomiany, U.
Smagina, L.
Ńmahelová, A.
48
Smedbakken, L.
110
Smirnov, A.
52, 53, 60
Smirnova, N.
79
Smit, A.
58, 100
Smit, J.
9, 54, 57
Smith, J.G.
91, 96, 106
Smutova, V.
48
Sobenin, I.
48, 52, 53, 60, 71, 128, 143
Sobiczewski, W.
93
Sobotka, L.
48, 97
Sobotova, D.
42
Söderberg, I.
88
Söderlund, S.
37
Soininen, P.
21
Solá, E.
63, 92
Solanas-Barca, M.
110, 112
Solheim, S.
70
Solivera, J.
82
Somerset, S.
27, 120
Sondermeijer, B.
116
Sonestedt, E.
37
Sonntag, F.
106
Soon, C.C.
102
Soran, H.
47, 62, 63, 112
Sormaz, L.
122
Soska, V.
42
Sosnowski, M.
142
Soto, Y.
120
Sottero, B.
64
Sousa Soares, A.
91
Soya, O.
136
Spallarossa, P.
70, 83
Sparwasser, T.
79
Spasic, S.
49
Spasojevic-Kalimanovska, V.
49
Spence, J.
123
Spengos, K.
124
Spiegelman, B.
35
Spinella, G.
83
Spinelli, F.
88
Spirito, R.
39
Spiroglou, S.
137
Sposito, A.
58, 91, 126
Sprandel, M.
62
58
76
126
55
101
55, 63, 66
99
87, 99
112
72
72, 83
128
117
65
20, 53
42, 80, 105
120
146
97
77
104
118, 126
147
118
141
21
41
99
116, 133
40
131
8, 34
50
75
111, 124
73
42
91, 125, 129
136
94
49, 84, 85
109
52
72, 104
77
184
Sprecher, E.
113
Spremovic-Radjenovic, S.
120
Springer, L.
134
Spuler, S.
64
Spyrou, A.
65
Squadrito, F.
88
Squellerio, I.
92
Staels, B.
28, 35, 90
Staempfli, A.
56
Stahelova, A.
115
Ståhlman, M.
43, 44, 45, 51, 54, 56
Stakos, D.
73, 98
Stalenhoef, A.
139
Stålstrøm, Y.
38
Stan, D.
72, 83
Stančic, O.
108
Stancu, C.
55, 63, 66
Stangl, H.
58
Stanke-Labesque, F.
79
Stankovic, A.
97, 108, 127
Stankovic-Ferlez, D.
98
Stanojlovic, O.
107
Stark, N.
113
Starzyk, J.
109
Stavek, P.
104
Stef, M.
143, 145
Stefanadis, C.
91, 124, 125, 129
Stefano, J.
51
Stefanovic, A.
49
Steffen, Y.
74, 75, 77
Steffensen, K.
54, 89
Steg, P.G.
94
Steinbach, O.
147
Steinhagen-Thiessen, E. 52, 64, 123, 132
Stenvinkel, P.
16
Steptoe, A.
27
Sternak, M.
83
Stevens, M.
69
Stojakovic, T.
134, 140
Stojanovic, L.
98, 99
Stojanovich, L.
144
Stojkovic, L.
127
Stolf, N.
133
Stolle, K.
74, 75, 77
Størling, J.
14
Strandberg, A.
Strandberg, T.
Straniero, S.
Strasky, Z.
Strijdom, H.
Stritecka, H.
Strobl, W.
Strodthoff, D.
Stroes, E.
Stübiger, G.
Stukena, I.
Sturzu, D.
Su, B.
Suchanek, P.
Sugano, M.
Sugihara, H.
Suh, J.W.
Suhorutńenko, J.
Sukoyan, G.
Sulimov, A.
Sullivan, D.
Sun, L.
Sun, S.
Sun, X.
Suokonina, V.
Suomalainen, A.
Surano, M.G.
Susan, L.
Sussex, B.
Suwa, J.
Suzuki, G.
Suzuki, H.
Svensson, M.
Sviridov, D.
Swedberg, K.
Swedenborg, J.
Swinkels, D.
Sylvänne, T.
Symmons, D.
Syrovatka, P.
Szabo, L.
Szabo, Z.
Szafarz, M.
Szczeklik, A.
Széll, A.
185
133
133
40, 121
49, 84, 85
71
42
58
45, 79
18, 25, 133, 141, 144
94
136
102
111
113
48
66
91
112
138
111
47
20
111
131
44
51
40
143
111
124
131
101
37
56
11
130
139
21
65
142
76
136
83
106
136
Sztanek, F.
Szutowicz, A.
Szvalb, S.
Szymura-Oleksiak, J.
Tayal, D.
Tayebinejad, N.
Tedesco, C.
Tejedor, D.
Tellis, C.
Tellis, K.
Teng, Y.
Tenneti, V.
Tentolouris, N.
Teramoto, T.
Tereshina, E.
Tereshkevysh,, L.
Tershakovec, A.
Tesauro, M.
Thalhammer, C.
Theodoraki, E.
Thiery, J.
Thies, F.
Tholstrup, T.
Thomaidi, A.
Thomson, R.
Thorpe, G.
Thorsson, O.
Thuhairah, A.
Tian, Y.
Tibolla, G.
Ticha, A.
Tichá, A.
Tietge, U.
Tijsen, A.
Tilan, J.
Tilling, L.
Tilvis, R.
Timpson, N.
Tinahones, F.J.
Tinoco, I.
Tio, R.
Tipping, P.
Tischenko, E.
Tivesten, Å.
Tkacheva, O.
To, F.
To, K.
Tocchetti, P.
Toedter, K.
59, 61, 76
60, 61
47, 58
83
T
Tabas, I.
19
Taborelli, A.
125
Taborsky, M.
115
Tada, N.
98
Tafalla, M.
95
Tagawa, M.
89
Tailleux, A.
35, 90
Taira, T.
56
Tajik, N.
40
Takayama, T.
100
Takeda, K.
97
Talaeva, T.
129
Talebpor, M.
80
Talebpour, M.
66
Tamisier, R.
79
Tamura, Y.
132
Tanaka, A.
49
Tanaka, N.
38
Tanaskovic, I.
72
Tancredi, L.
44
Tang, C.
52, 65, 68, 127, 129
Tang, C.H.
124
Tang, C.K.
88
Tangirala, R.
72
Tanigawa, H.
57
Taniguchi, A.
97
Tanus-Santos, J.E.
108
Tanzilli, G.
91
Tarasov, K.
21, 95
Tarasova, V.
145
Tardif, J.C.
21
Tarmure, S.
102
Tarnow, L.
37
Tarugi, P.
44, 109, 110
Taskinen, M.R.
9, 17, 26, 30, 37, 141
Tavallaie, S.
100
Tavares, E.
130, 133
Tavridou, A.
115
186
85
127
139, 141
108, 143, 145
49, 65
136
68, 87, 129
9
103, 124
29, 114
130
129
39, 40, 47, 64
83
74
112
64
56, 97
10
98
21
134
103, 104, 107
120
131
91
49
48
35, 53, 58
116
104
75
133
105
52
74, 95, 106
53
13
77
71, 73, 94
76
88
13
137
51
Toh, B.H.
13
Tokgözoglu, L.
23, 26
Tokita, Y.
49
Tölle, M.
82
Tołwińska, J.
136
Toma, L.
63
Tomaschitz, A.
101
Tomassini, J.
40, 47
Tomesc, F.
102
Tomlinson, B.
41
Tomono, Y.
98
Tomskij, M.
145
Tonkin, A.
4
Toplak, H.
134
Tornvall, P.
2
Toro, R.
74, 95, 106
Torres, A.
119
Torres, B.
143
Torzewski, J.
50
Tosolini, L.
33
Toth, P.
39, 40, 64
Toulmin, E.
147
Tozzi, M.
127
Tramontana, S.
85, 88
Trautwein, E.
117
Tremblay, K.
9, 26
Tremoli, E.
91, 92, 100, 139, 140, 141
Trentadue, G.
132
Tretjakovs, P.
85, 146
Trevisan, D.
125
Trigatti, B.
78
Trip, M.
116, 144
Tripathi, C.D.
96
Tripoten, M.
72
Triscari, J.
48
Tritscher, M.
147
Trovati, M.
135
Trukhacheva, E.
72
Tselepis, A.
43, 49, 65, 99, 136
Tserenkhuu, L.
41
Tsetsekou, E.
125
Tsigalou, C.
98
Tsikunov, S.
104
Tsimihodimos, V.
99
Tsimikas, S.
15, 18, 132
Tsiopoulos, V.
23
Tsoy, N.
77
Tsukinoki-Murakami, R.
82
Tsunoda, F.
101
Tsuruda, T.
73
Tubach, F.
94
Tunceli, K.
40
Tuo, Q.
111
Tutunaru, D.
123
Twisk, J.
9
Tyagi, S.
85
Tybjærg-Hansen, A. 20, 26, 33, 100, 105
108, 110
Tynkkynen, T.
21
Tyynismaa, H.
51
Tziakas, D.
73, 98
Tziomalos, K.
98, 147
Tzotzas, T.
147
U
Ucchino, S.
Udachkina, E.
Uehara, Y.
Ueland, T.
Ukkola, O.
Ukraintzeva, D.
Ulleryd, M.
Ullström, C.
Ulrich, C.
Ulven, S.
Umaerus, M.
Uporov, I.
Urbanski, K.
Uren, N.
Urschel, K.
Urtane, I.
Usova, E.
Uspensky, V.
Usui, S.
73
142
57, 136
110, 111
117
130
27, 74
89
125
67
57
111, 146
82
84
75
102
130
77
97
V
Vaag, A.
Vaca, G.
187
37
109
Vaccaro, O.
135
Vacchio, V.
88
Vacek, J.
67
Vagionas, I.
98
Vâlcu, M.
123
Valdeperez, M.
80
Valdivielso, P.
50, 101, 106, 112
Valdivielso-Felices, P.
93
Valenti, C.
109
Valenti, V.
44
Valles, E.
92
Vallez, E.
35, 90
Vallianou, N.
98, 118, 119, 121, 126
Vamvakou, G.
120
Van Berkel, T.
35, 54
Van Brussel, I.
79
Van Craeyveld, E.
8
van de Geijn, G.J.
82
van de Molengraaf, R.
147
Van de Werf, F.
95
van den Bulk, N.
9, 26
van den Hoek, A.M.
61
van den Hoogen, C.M.
61
van der Geest, R.
141
van der Giet, M.
82
van der Graaf, A.
38
van der Hoorn, J.
57, 61, 147
van der Knaap, H.
117
van der Made, S.
59
van der Meulen, N.
82
van der Schouw, Y.
144, 146
Van Eck, M.
35, 69
van Ee, J.
123
van Kampen, E.
69
van Meijl, L.
117
van Nieuwkoop, A.
61
van Oostrom, A.
47
van Stijn, C.
72
Van Vré, E.
79
van Wijk, D.
141
van Wijk, J.
47
Vandenput, L.
94
Vandroux, D.
115
Vanhoutte, J.
90
Vanmierlo, T.
125
Varakis, J.
137
Varga, G.
20, 53
Vargemezis, V.
98
Varisxanova, S.
93
Varret, M.
33
Vasic, D.
49
Vasina, L.
83
Vataman, E.
95
Vavaev, A.
77
Vavilov, V.
136
Vàzquez, A.
109
Vázquez, A.M.
120
Vazquez, J.
57
Vázquez-Sanchez, M.
120
Vázquez-Velasco, M.
121
vd Bogaard, B.
144
vd Born, B.
144
Večeřová, L.
49, 84, 85
Védie, B.
50, 51
Veglia, F.
92, 139, 140, 141
Velasco, F.
71, 84
Vemmos, K.
124
Vemmou, A.
124
Venn, A.
105
Verbovenko, J.
85
Vercesi, A.
51
Verdu, G.
145
Verhoeven, G.
73
Verstappen, S.
65
Veselovskaya, N.
111, 137
Vestergaard, H.
124
Vianello, D.
40, 50
Víctor, V.
92, 127
Vidal, A.
120
Vidale, S.
44, 125
Viglietta, C.
80
Vihervaara, T.
69
Viikari, J.
21, 105
Villalba, J.M.
71, 84
Villasmil, J.
141, 142
Vind, B.
45
Vindis, C.
61, 65
Vink, A.
22, 89
Violi, F.
91
Virseda, M.
74, 95, 106
188
Vissers, M.
38
Vitek, L.
33
Vives, G.
141
Vlahovic, P.
98
Vlajinac, H.
127
Vlaming, M.
147
Voevoda, M.
102, 108, 129, 130, 145
Vogiatzakis, E.
98, 118, 119, 121, 126
Vogt, A.
131, 132, 135
Vogt, G.
67
Vogt, K.
50
Volkov, A.
81, 142
Volkova, N.
58
Völler, H.
106
von Eckardstein, A.
20, 38, 62, 101
Vonbank, A. 39, 41, 59, 86, 103, 104, 105
106, 107, 113
Vorkas, P.
125
Voronkina, I.
77
Vossen, M.
51
Voulgari, C.
103, 124
Vrablik, M.
113
Vrints, C.
79
Vtyurina, D.
111
Vujovic, A.
49
Vulic, B.
122
Vulic, D.
122
Wang, T.D.
Wang, X.
Wang, Y.
Wang, Z.
Wangler, S.
Wanko, B.
Want, E.
Watanabe, H.
Watanabe, M.
Watanabe, T.
Waters, D.
Watts, G.
Weber, C.
Wegscheider, K.
Wei, C.
Weiler, H.
Weingärtner, O.
Weintraub, W.
Weiss, D.
Weiss, N.
Weiss, T.
Weissen-Plenz, G.
Werdan, K.
Westcott, C.
Wester, P.
Westerbacka, J.
Westerlund, E.
Westheim, A.
Westzaan, A.
Wezel, A.
Wheelock, C.
Wichterle, D.
Wicks, E.
Wickström, Y.
Widdowson, M.
Widhalm, K.
Wiegman, A.
Wiehe, J.
Wielinga, P.
Wierzbicki, A.
Wigren, M.
Wijburg, F.
Wiklund, O.
Wiklund, U.
Wikstrand, J.
W
Wachter, D.
81
Wade, L.
56, 97
Wagh, U.
123
Wagner, S.
77
Wågsäter, D.
69
Waksman, I.
47, 58
Walecka, A.
113
Walewska, E.
93
Wallentin, L.
11
Wallerath, T.
74
Walus-Miarka, M.
109, 141
Wang, G.
65, 68, 87, 125, 127, 129
Wang, G.L.
111
Wang, L.
46
Wang, T.
133
189
72
32
9, 13, 54, 125
52, 89
147
131
125
89
80
56
2, 94, 112
9, 26
13, 83, 88, 141
106
127, 129
75
119, 125
39, 64
74
132, 135
116
43
70
71
23
37
49
70
82
78
130
94
84
45
97
30, 94
30, 38
50
118
48
13, 96
38
4, 5, 7, 28, 34, 45
135
71
Wildemann, B.
Wilhelmson, A.
Willecke, F.
Willems, S.
Willemsen, H.
Willenheimer, R.
Williams, K.
Williams, K.J.
Willich, S.
Wilson, D.
Windler, E.
Winkelmann, B.
Winkelmann, B.R.
Winkler, K.
Winsauer, G.
Wirfält, E.
Witztum, J.
Wohlfahrt, P.
Wojcik, M.
Wojciuk, M.
Wolf, A.
Wolf, D.
Wollmer, P.
Wołoszyn, K.
Wolska, A.
Wolski, K.
Wong, N.
Wood, D.
Woodside, J.
Worrsjö, E.
Wouters, K.
Wozniakiewicz, E.
Wramstedt, A.
Wróblewska, M.
Wu, C.L.
Wu, J.
Wu, L.
Wu, Y.
Würtz, P.
Wüst, S.
Wymann, M.
Wysocki, H.
X
147
71, 73
76, 78
89
53
17
73
9
106
132, 134
106
101
23, 69
48, 49, 52
131
37
132
94, 101
109
135
51
76
104, 107
60, 61
60, 61
54, 55
54, 55
4
117
44
90
141
44
60, 61
26
35, 131
129
76
21
34
43, 79
41, 68
Xenophontos, S.
Xiao, C.
Xiao, H.
Xiao, J.
Xie, Y.G.
Xu, C.B.
Xu, G.
Xu, Q.
Xu, Y.
66
35
81
88
111
67
111
43
46, 124
Y
Yacoub, M.
Yadav, R.
Yahiro, E.
Yakala, G.
Yamada, K.
Yamada, S.
Yamagishi, T.
Yamamoto, T.
Yan, Z.Q.
Yang, J.
Yang, L.
Yang, Y.
Yannakoulia, M.
Yanus, O.
Yarlioglues, M.
Yasuda, T.
Yatsu, F.
Yatsuzuka, S.
Ye, D.
Ye, L.
Yee, B.
Yeo, J.S.
Yeom, B.W.
Yeung, N.
Yfanti, G.
Yi, G.
Yi, J.
Yildiz, H.
Yilmaz, A.
Yin, K.
Yin, T.
190
69
62, 63
57
118
125
75
143
97
13, 44
89
76, 98, 131
46, 52
112
129
142
20
55
49
35
87
47
72, 138
82
50
147
52
81
142
81
88
68, 125, 127, 129
Yla-Herttuala, S.
Yokode, M.
Yokota, Y.
Yokoyama, M.
Yoon, J.H.
Yoshida, H.
Yoshida, M.
Yoshimura, N.
Young, I.
Young, S.
Younis, N.
Yu, B.L.
Yu, D.
Yu, H.
Yu, Y.M.
Yuan, X.
Yuan, Z.
Yubero-Serrano, E.
Yunfei, W.
Zdrenghea, D.T.
99
Żelazowska-Rutkowska, B.
135
Zelcer, N.
110
Zelinsky, V.
75
Zencir, C.
142
Zeppetzauer, M.
105
Zervou, A.
42
Zeschky, K.
76, 78
Zhang, B.
136
Zhang, D.
87, 125
Zhang, J.
129
Zhang, W.
67
Zhang, Y.
67
Zhang, Z.
131
Zhao, P.
124
Zhao, S.P.
26
Zhao, Y.
135
Zheng, X.Y.
26
Zheng, Y.
60, 65, 68, 87
Zhong, L.
76
Zhou, X.
69
Zhou, Y.
9
Zhu, B.
111
Zidek, W.
82
Zilberman, L.
140
Zimetti, F.
55
Zimmermann, O.
50
Zimolová, M.
33, 41
Zinellu, A.
66, 67, 125
Zinellu, E.
39
Zirlik, A.
76, 78
Zis, P.
124
Zivanovic, I.
99
Zivkovic, M.
97, 108, 127
Zlatkovic, M.
107
Zlatohlavek, L.
113
Zo, J.H.
99, 122
Zock, P.
117
Zomer, G.
22
Zuchowski, B.
41, 68
Zukowska, Z.
104
Zurawski, J.
41
Zwaginga, J.
110
83, 88
132
101
39
59
98
68
114
56, 97, 117
7
47
26
73
8
77, 121
141
52
82
98
Z
Zabunova, M.
102
Zacho, J.
105
Zadeh, R.
62
Zago, V.H.d.S.
108
Zahedirad, M.
127
Zakopoulos, N.
112
Zaldivar, C.
120
Zambon, A.
4, 40, 50
Zampelas, A.
120, 147
Zanardo, M.
88
Zandvoort, M.A.M.J.
141
Zanon, M.
88
Zanoni, P.
53
Zanwar, A.
122, 123
Zappella, F.
76
Zaragozá, M.
118
Zaritskey, A.
136
Zaroui, A.
108
Zateyshchikov, D. 108, 111, 114, 115, 146
Zatz, H.
105
Zavaroni, I.
73, 110, 135
Zdravkovic, M.
98
191
NOTES
NOTES
NOTES
NOTES
NOTES
NOTES

79th EAS CONGRESS

Transcription

Similar documents

Stakeholder mapping - Service Design Toolkit

Le nuove Linee guida neLLa prevenzione cardiovascoLare: aLLa

16th Bandung Scientific Meeting Of Indonesian Society

Program - NanotechItaly 2010

final programme

PHYTOBALNEOTHERAPY (“HAY BATHS”) : BETWEEN TRADITION

Tentative Program 2016/4/25 2016/7/11

Convegno - Archeologia Sperimentale